Patient: Patient ID,Specimen: Lab ID,Heme Malignancy: Diagnosis,Heme Malignancy: Specific Diagnosis,Inhibitor Panel Run: Inhibitor Panel,Inhibitor Panel Run: Run Type,Inhibitor Interpreted Result: Drug,Inhibitor Interpreted Result: Replicant,Inhibitor Interpreted Result: IC10,Inhibitor Interpreted Result: IC25,Inhibitor Interpreted Result: IC50,Inhibitor Interpreted Result: IC75,Inhibitor Interpreted Result: IC90,Inhibitor Interpreted Result: Area under the curve,Inhibitor Interpreted Result: Model Curve624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Gefitinib,1,1.510211441,2.714997847,6.182031082,10,10,628.1399907,0.40237311x^3 - 18.65308633x^2 - 47.57458751x + 99.11325388
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Ponatinib (AP24534),1,0.000464,0.012805163,0.034319881,0.091531262,0.183545871,3.897195055,11.03459899x^3 + 48.15969168x^2 + 9.51116771x - 4.69942518
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Ponatinib (AP24534),2,0.000807,0.004141988,0.045585871,0.229673862,0.481079665,13.598496,-2.03930908x^3 - 15.54735628x^2 - 60.13496087x - 7.6052472
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Ponatinib (AP24534),3,0.002282689,0.005524018,0.018526167,0.06241791,0.153160352,4.488300813,6.61582499x^3 + 34.53758447x^2 + 10.78394433x - 0.56564825
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Barasertib (AZD1152-HQPA),1,0.022870687,0.088582132,10,10,10,603.7379703,5.1081631x^3 + 17.212002x^2 - 7.38254557x + 54.11474525
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,CI-1040 (PD184352),1,0.094562221,0.324506802,1.504966991,5.298118904,10,313.4874469,0.65077049x^3 - 7.04359058x^2 - 39.83228202x + 57.28964809
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Bosutinib (SKI-606),1,0.034344087,0.066847019,0.166097403,0.40358514,0.740408459,-14.50917901,13.63625577x^3 + 29.9869462x^2 - 44.23848966x + 3.74502717
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,KN92,1,0.113994362,0.427734202,10,10,10,703.9644427,7.859044x^3 + 16.81065905x^2 - 14.85775882x + 67.6275806
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Imatinib,1,0.336445783,0.945584288,2.77361493,6.012203918,8.857071799,368.8022765,-3.29570916x^3 - 22.08643076x^2 - 43.63157366x + 73.95275782
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Staurosporine,1,0.009086103,0.019330164,0.061259861,0.203128242,0.481521248,-8.058278359,5.0816734x^3 + 20.23402482x^2 - 23.65136207x + 0.61765684
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PD98059,1,0.505396853,10,10,10,10,852.6181014,4.88492428x^3 + 9.18733739x^2 - 11.99795422x + 85.76439878
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Canertinib (CI-1033),1,0.145198802,0.893849262,2.602847238,5.145169346,7.142170253,310.2306827,-8.04870503x^3 - 31.59901695x^2 - 41.02479733x + 73.07474856
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Vatalanib (PTK787),1,0.211395582,0.541613429,2.293798342,10,10,426.9960769,4.21913223x^3 - 0.61121818x^2 - 40.26593373x + 64.39979154
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,JNJ-28312141,1,0.005238181,0.006750207,0.01114702,0.022011805,0.040694384,15.78973683,-10.57936969x^3 - 2.40729237x^2 + 10.35109499x + 0.60637392
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PP2,1,0.007513958,2.907227135,4.636893963,6.638759895,7.985651293,482.2054051,-20.81616173x^3 - 62.81255431x^2 - 32.20725699x + 105.49280543
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GSK-1838705A,1,0.006413321,0.009915399,6.788702318,8.825480146,10,737.4467707,-30.16819233x^3 - 78.21803197x^2 - 8.76952263x + 128.77244439
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,CYT387,1,0.012060747,0.043058501,0.249712906,1.285666618,3.539634454,97.58580037,1.30641851x^3 + 0.81645941x^2 - 35.12890111x + 28.82213859
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Vargetef,1,0.008594897,0.014888205,0.039127727,0.118551065,0.272328761,-15.47744947,3.05666364x^3 + 21.20241411x^2 - 15.11289752x - 4.75244167
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Masitinib (AB-1010),1,0.076754048,0.170392678,0.531097559,1.739232079,4.542837561,155.1923885,7.97799367x^3 + 8.49706369x^2 - 48.77002205x + 36.12057076
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GW-2580,1,0.036589218,0.117929531,1.212214271,10,10,522.5089598,5.58371252x^3 + 15.9011556x^2 - 15.68960938x + 51.19699024
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Doramapimod (BIRB 796),1,0.005822803,0.009712097,0.040538789,5.442214901,10,268.9587058,-7.38011427x^3 - 9.31467679x^2 - 7.12360042x + 38.22369547
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Lestaurtinib (CEP-701),1,0.00132075,0.003128412,0.010097175,0.032159943,0.073332859,0.374825282,7.00834805x^3 + 41.4463197x^2 + 30.48476152x + 1.46607473
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Crenolanib,1,0.009005386,0.02306674,0.102746329,0.550171385,2.586178282,105.9617401,2.67838895x^3 + 10.79555012x^2 - 24.31915196x + 18.00895052
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Crenolanib,2,0.006227764,0.007471083,0.010971715,0.021876672,10,604.4299872,-36.96738546x^3 - 70.15644119x^2 + 26.74211174x + 93.61436989
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,KW-2449,1,0.009322111,0.033664252,0.148915045,0.610465036,1.657325628,37.99777927,4.49235589x^3 + 9.63567357x^2 - 34.84258805x + 17.13342838
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Crizotinib (PF-2341066),1,0.072675189,0.14149369,0.376110266,1.026911163,2.146279742,64.61757315,10.16277572x^3 + 14.65486252x^2 - 53.04065617x + 25.60974646
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,R547,1,0.181976626,0.37350003,1.032519236,2.64086626,4.639419461,158.5004226,5.04453437x^3 - 5.55644538x^2 - 59.80448667x + 50.83223153
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Selumetinib (AZD6244),1,0.007328294,0.023056276,3.224866528,10,10,442.7697409,-6.46787996x^3 - 14.11760647x^2 - 13.96101052x + 61.6004093
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SB-203580,1,0.013822594,0.054416169,2.060993239,10,10,524.4466743,2.04296483x^3 + 10.04861585x^2 - 8.94694207x + 51.75549356
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,H-89,1,1.566670058,3.627440856,9.020165674,10,10,699.8502097,-4.93478025x^3 - 20.57255511x^2 - 23.34343693x + 95.37011536
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Roscovitine (CYC-202),1,1.789988481,3.459393048,10,10,10,742.2687473,8.90690803x^3 - 4.37058737x^2 - 53.33024883x + 103.6200069
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,BI-2536,1,0.022161786,0.048289559,0.136356159,0.37510878,0.758717429,-3.382912353,10.15060486x^3 + 24.85876161x^2 - 37.9700546x + 5.10664983
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SU14813,1,0.006656091,3.377472644,6.383523184,10,10,619.8984531,-15.33977683x^3 - 41.39959316x^2 - 14.45757481x + 96.47517403
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,RAF265 (CHIR-265),1,0.012504133,0.034846799,0.132386229,0.504930054,1.427331458,64.16930853,5.79560079x^3 + 15.36759811x^2 - 31.43487675x + 14.46913864
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,BEZ235,1,0.023219247,0.046199321,0.118243361,0.294622495,0.546637434,-21.8278336,12.1389903x^3 + 31.67091111x^2 - 36.70800496x - 1.58847406
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Axitinib (AG-013736),1,0.015199478,0.03693839,0.120263677,0.394268668,0.981052194,67.10005649,7.96592845x^3 + 22.23485501x^2 - 30.04494989x + 9.74885986
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Go6976,1,0.014292861,0.043761672,0.212363466,1.633838625,10,247.9201938,4.85666141x^3 + 14.06822755x^2 - 23.46844326x + 29.3171003
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,NVP-TAE684,1,0.011276231,0.022101875,0.060662642,0.169605284,0.347108193,-2.739859187,7.59786294x^3 + 28.83853951x^2 - 21.55958984x - 5.25999096
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Afatinib (BIBW-2992),1,0.02747131,0.067356593,0.212440406,0.651361939,1.457486696,33.83386135,8.56720872x^3 + 16.11366603x^2 - 42.78541042x + 16.53106724
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,NF-kB Activation Inhibitor,1,0.011069491,0.09173723,2.237361834,10,10,448.6504348,-0.52536315x^3 - 2.12166836x^2 - 19.04205246x + 56.94168238
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GDC-0941,1,0.01040969,0.032572253,0.148678779,0.669222744,2.004907394,59.28744889,3.50799352x^3 + 8.46380751x^2 - 32.80053478x + 19.03972647
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GDC-0941,2,0.041879345,0.081549548,0.212379182,0.559605863,1.124126889,22.89677783,11.24295653x^3 + 23.50667412x^2 - 45.38356941x + 12.24400719
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,VX-745,1,0.066140613,0.222681537,1.777670826,10,10,459.5085883,3.9502247x^3 + 6.76714612x^2 - 26.27117936x + 56.07983348
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Tandutinib (MLN518),1,0.108724938,0.404543847,2.556762019,10,10,452.0876719,2.47720009x^3 - 1.24791685x^2 - 31.60089695x + 62.9229354
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,INK-128,1,0.002654276,0.00362643,0.006823115,0.017000796,0.04486425,9.440254334,-7.4922742x^3 - 6.01245996x^2 + 0.61157158x + 3.39527355
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,MEK1/2 Inhibitor,1,1.231291718,4.332915222,10,10,10,767.2514448,2.90200147x^3 - 3.35677076x^2 - 26.37800957x + 92.40880948
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,JNJ-7706621,1,0.479747958,0.853244482,1.922935704,3.909594937,5.801553784,242.9913486,2.69417584x^3 - 17.72774188x^2 - 67.20852197x + 70.45265534
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,JAK Inhibitor I,1,0.079066483,0.195375072,0.854887217,10,10,390.8377964,7.8685683x^3 + 13.9944885x^2 - 32.49558165x + 47.72493754
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sorafenib,1,0.006189119,0.015303624,0.057527701,0.222985014,0.597537645,0.494201032,4.07296325x^3 + 15.94426149x^2 - 23.6097356x + 3.9681851
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sorafenib,2,0.006054067,0.013338365,0.055473937,0.302433779,1.157854061,27.11303896,0.75812477x^3 + 7.52276829x^2 - 22.48221333x + 11.40040248
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sorafenib,3,0.00629211,0.01212913,0.041343363,0.19385352,0.753436818,41.25327742,0.73678926x^3 + 11.00476164x^2 - 16.69763305x + 7.78197847
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GSK690693,1,0.041901018,0.088076794,0.308544958,10,10,499.046595,11.72173654x^3 + 35.16669685x^2 - 13.27572023x + 35.61015557
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,BMS-345541,1,2.004683372,2.930541694,4.74036749,6.931456234,8.447552845,512.6479162,-15.23140319x^3 - 54.86515707x^2 - 41.91321519x + 108.08486802
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,TG101348,1,0.03436723,0.080726189,0.257222904,0.817386735,1.904339275,55.46091952,7.58535792x^3 + 13.31213443x^2 - 43.86086169x + 21.06200287
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sunitinib,1,0.003069043,0.008302538,0.032850611,0.152786296,1,19.32768844,6.14125058x^3 + 30.37973537x^2 + 7.36716821x + 14.12238539
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sunitinib,2,0.002293503,0.007086685,0.031140656,0.141450985,0.500452455,14.93754271,4.44475981x^3 + 20.68139521x^2 - 8.29376356x + 5.75812058
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sunitinib,3,0.000709,0.001059573,0.512141328,0.687105626,0.800474673,52.44011528,-31.20571036x^3 - 173.33399594x^2 - 269.55274641x - 14.4618646
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PLX-4720,1,0.442170471,1.561606742,5.618785997,10,10,563.4962791,-2.20906772x^3 - 14.62709788x^2 - 29.51706982x + 81.27776857
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Neratinib (HKI-272),1,0.047564291,0.085060638,0.195458487,0.446197976,0.785168406,-14.70991185,15.58775138x^3 + 32.43208696x^2 - 49.00325686x + 4.51308278
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SB-431542,1,0.006575331,0.005015916,9.50954635,10,10,1268.901286,-12.8619261x^3 - 87.84848773x^2 - 72.32475942x + 216.83578214
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PP242,1,0.007733303,0.015664422,0.050023456,0.177989118,0.458059463,-5.10962427,3.52291636x^3 + 17.58436265x^2 - 20.67449236x + 1.10532881
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,YM-155,1,0.03391082,0.079176521,0.255381562,0.713210185,1,39.87628025,1.80137838x^3 - 3.9065201x^2 - 59.76813207x + 16.31694941
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,R406,1,0.048162399,0.079268946,0.172955698,0.400036926,0.764417335,148.4559358,16.68867897x^3 + 45.0320589x^2 - 33.80904381x + 5.46905376
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Ibrutinib (PCI-32765),1,0.013491898,0.155465322,1.623615322,4.727484861,7.557997798,273.27983,-5.80511794x^3 - 19.32847053x^2 - 33.03079857x + 57.86287153
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,A-674563,1,0.099570301,0.167063828,0.382785486,0.947110126,1.92806908,82.91984335,12.69141378x^3 + 23.27056178x^2 - 55.62659171x + 23.6744457
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,LY294002,1,0.292386919,0.587048179,1.578221559,4.294170978,8.914514253,250.0178256,10.82409939x^3 - 5.68309542x^2 - 58.90453514x + 61.81193558
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AT7519,1,0.034603476,0.061027836,0.137195624,0.303323568,0.514353952,-36.94830446,15.78428383x^3 + 38.81775983x^2 - 41.99512241x - 4.98184616
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SGX-523,1,0.234063124,10,10,10,10,823.7663992,6.43166431x^3 + 14.19594123x^2 - 10.82202222x + 79.14193351
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AMPK Inhibitor,1,0.010690545,0.035836849,0.303143691,5.336507502,10,282.6273402,0.76828038x^3 + 4.12053038x^2 - 21.25446369x + 37.98258174
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,STO609,1,6.656494907,10,10,10,10,936.5158003,-1.16736487x^3 - 6.27901948x^2 - 9.24331649x + 102.51634112
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PD153035,1,0.000897,1,1,1,1,106.9395914,-17.10714308x^3 - 94.96437716x^2 - 135.21842405x + 75.70976067
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Lapatinib,1,10,10,10,10,10,932.2399177,2.97454716x^3 + 1.93970655x^2 - 13.10189615x + 98.6832087
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,LY-333531,1,0.144859304,0.489167866,1.844183678,4.916434406,8.086588462,300.4138553,-1.12656738x^3 - 14.56763062x^2 - 43.93318228x + 62.72800985
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Trametinib (GSK1120212),1,0.004765416,0.006732133,0.01383632,0.043553459,4.021299194,89.2437893,-6.9710761x^3 - 0.95277827x^2 + 1.37144008x + 11.05802403
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PD173955,1,0.109830385,0.177246824,0.378390381,0.858998602,1.616331317,80.8534213,17.08510311x^3 + 29.47837888x^2 - 59.42081621x + 20.95425433
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,p38 MAP Kinase Inhibitor,1,0.511164718,2.116572892,10,10,10,685.9909614,2.25991501x^3 - 2.94820398x^2 - 24.42463458x + 83.18805836
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Tozasertib (VX-680),1,0.090043846,0.264827278,1.347971425,10,10,384.9886131,4.77156175x^3 + 4.26589371x^2 - 34.77839622x + 54.42794033
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Dasatinib,1,0.000834,0.001741678,0.007372222,0.069555109,1,21.77941072,0.77606013x^3 + 13.5917834x^2 + 12.58511676x + 22.55775556
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Dasatinib,2,0.000772,0.001475501,0.004529213,0.016797736,0.050901665,8.851527842,3.34065645x^3 + 30.2288071x^2 + 37.81150634x + 15.56744865
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Dasatinib,3,0.000842,0.001645494,0.007887239,0.290381649,1,24.20030768,-2.38315293x^3 - 3.6823443x^2 - 11.7661859x + 19.37408658
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,MLN120B,1,2.912330872,5,5,5,5,463.5404582,2.19739921x^3 + 0.50610018x^2 - 14.69275779x + 96.49204578
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AKT Inhibitor X,1,1.508339276,50,50,50,50,4510.575624,4.318466x^3 + 1.75428382x^2 - 12.82016034x + 92.20793098
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SYK Inhibitor,1,0.008228837,0.029238248,0.312338131,6.210024488,10,291.9542158,0.1073045x^3 + 2.30364559x^2 - 19.96814673x + 39.33408826
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Rapamycin,1,0.050070376,0.140764482,1.375233414,10,10,594.4041418,9.45812269x^3 + 24.71483818x^2 - 13.55500954x + 51.37739253
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AKT Inhibitor IV,1,0.130757734,0.211330913,0.427297536,0.854523299,1.347963059,-122.3119552,20.79511873x^3 + 20.9991049x^2 - 77.32705329x + 19.6291397
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Erlotinib,1,1.780267921,10,10,10,10,855.3081988,3.15228036x^3 + 0.39067853x^2 - 17.83895258x + 94.39434244
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Foretinib (XL880),1,0.005167085,0.006554261,0.010464662,0.019579723,0.033946162,19.29425908,-11.97856439x^3 - 4.80528526x^2 + 12.83771969x + 1.24505169
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PI-103,1,0.040562954,0.101478774,0.344225292,1.186978696,3.148769375,113.8737743,7.3482468x^3 + 10.74319184x^2 - 43.69060105x + 28.18988855
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,KN93,1,0.155342434,0.424512538,1.496645964,4.251358684,7.523952646,269.5246164,1.43850242x^3 - 10.06789323x^2 - 47.8175878x + 58.67479569
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Cediranib (AZD2171),1,0.036398292,0.102182639,0.393302221,1.45386707,3.620554145,114.1205518,4.87284971x^3 + 4.86518856x^2 - 43.45680284x + 31.91337439
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SB-202190,1,0.007847311,0.019388332,1.665962204,10,10,445.2756797,-3.93377089x^3 - 3.2908092x^2 - 7.59575358x + 51.88825427
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PHA-665752,1,0.103944958,0.247733197,0.936907929,5.141515745,10,308.7897849,6.40704377x^3 + 6.69253192x^2 - 41.49695167x + 48.82029233
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Pelitinib (EKB-569),1,0.048234449,0.095048977,0.24880906,0.658728158,1.339541268,38.05389029,11.733862x^3 + 22.03681762x^2 - 47.76910759x + 15.68538282
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GS-1101 (CAL-101),1,0.017641709,0.119012587,1.53046737,10,10,399.1629029,0.14503923x^3 - 1.93177235x^2 - 24.07095353x + 54.51396522
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,JNK Inhibitor II,1,0.063817804,0.405166488,5.140950102,33.7513389,50,1643.394216,-0.7519597x^3 - 2.74174282x^2 - 21.49715425x + 66.94191007
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Linifanib (ABT-869),1,0.008399978,0.016852921,0.0767933,0.752981255,3.863011019,102.2960359,-2.25238405x^3 + 0.93902068x^2 - 20.91076319x + 22.40499302
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Velcade,1,0.008620493,0.014496098,0.037495541,0.117595058,0.289492819,-3.79986366,1.77879918x^3 + 18.69231465x^2 - 13.84195107x - 2.59209307
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,TG100-115,1,0.315495248,1.104010124,3.690373949,8.540912822,10,460.363079,-3.26458285x^3 - 18.48774219x^2 - 35.28736824x + 76.55080613
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Nilotinib,1,0.346777226,0.644205632,2.280202294,10,10,501.2185265,14.11891218x^3 + 16.63843665x^2 - 49.67914638x + 65.00401093
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Nilotinib,2,0.477109772,0.922314131,2.723402856,9.876663214,10,442.4824223,7.02815809x^3 - 1.5641374x^2 - 53.77134455x + 73.11372304
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Nilotinib,3,0.18579764,0.347951218,0.892383777,2.288534644,4.285248386,149.4299915,8.16202065x^3 + 1.20599921x^2 - 62.42785479x + 46.91108465
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Alisertib (MLN8237),1,0.326134547,0.970256075,3.175037588,7.56309022,10,425.9086177,-2.08327884x^3 - 17.07163425x^2 - 39.70373103x + 74.48227105
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AST-487,1,0.381129995,10,10,10,10,871.2978522,-2.40443023x^3 - 5.99371625x^2 + 0.16194327x + 90.94296049
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Tofacitinib (CP-690550),1,0.004576669,0.010707476,0.154806632,10,10,332.2823565,-2.92821652x^3 - 2.5120547x^2 - 10.57020883x + 41.52753455
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Vandetanib (ZD6474),1,0.00479863,0.493391046,1.139515769,2.628613317,4.526682424,166.7528575,9.37487251x^3 - 1.72663619x^2 - 69.95159004x + 53.97152212
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Quizartinib (AC220),1,0.005643516,0.008305297,0.019318199,0.098325532,3.450436466,74.11422923,-7.32339083x^3 - 4.5921137x^2 - 6.28127569x + 15.84667649
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Quizartinib (AC220),2,0.005833218,0.008857391,0.020257186,0.062635048,0.177364935,-1.353060841,-2.28791577x^3 + 10.55875522x^2 - 5.87637158x - 1.34077046
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Motesanib (AMG-706),1,0.016315355,0.042347848,0.190496406,1.339068141,10,229.8508987,4.06520587x^3 + 13.83606696x^2 - 23.112012x + 27.69990766
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,KI20227,1,0.009841549,0.023062307,0.130820916,1.332562759,7.331541903,162.0137457,-0.8587163x^3 + 2.69082323x^2 - 22.17118301x + 27.72430356
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Pazopanib (GW786034),1,0.144237074,0.242494159,0.556919701,1.393383091,2.948281403,124.6692239,13.40511355x^3 + 18.23731537x^2 - 61.41518387x + 33.42949262
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Midostaurin (PKC412),1,0.014501695,0.049840716,0.216851886,1.020965177,10,163.794445,5.97069914x^3 + 13.20652016x^2 - 31.10347127x + 25.27919449
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Dovitinib (CHIR-258),1,0.060793703,0.094689261,0.191008648,0.39750855,0.661586276,0,16.95211065x^3 + 41.93490698x^2 - 47.9600587x + 0.14336743
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SNS-032 (BMS-387032),1,0.024986644,0.047671211,0.117412149,0.282996088,0.511619766,-28.42233732,12.75338378x^3 + 33.68366409x^2 - 37.00638113x - 3.3097641
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AZD1480,1,0.486999655,1.700172862,5.252489434,10,10,547.8600245,-4.52874751x^3 - 19.77232759x^2 - 28.89041361x + 82.76494245
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Flavopiridol,1,0.009255464,0.018312327,0.063035546,0.305562041,10,145.2125992,2.24139527x^3 + 16.00102052x^2 - 14.23167703x + 13.7358453
624,11-00466,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GDC-0879,1,10,10,10,10,10,1476.316415,3.16668834x^3 - 1.33813384x^2 + 0.71080605x + 146.87002059
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,STO609,1,0.007698073,10,10,10,10,1049.212512,-17.21993518x^3 - 37.87623411x^2 + 12.49169683x + 123.0138166
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Vatalanib (PTK787),1,0.120079196,0.249891021,0.813459826,3.978310162,10,291.3467031,8.14665458x^3 + 11.15682107x^2 - 44.51304491x + 45.9249633
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Neratinib (HKI-272),1,0.051681954,0.090385275,0.200379962,0.438878479,0.745325694,-25.28333286,17.47895986x^3 + 35.07090644x^2 - 51.51534784x + 2.88872543
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,GSK690693,1,0.008173108,0.022270616,10,10,10,648.851728,-0.19500509x^3 + 10.33180783x^2 + 6.23914504x + 56.22341445
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,LY294002,1,0.022862333,0.084049757,0.461228834,2.298998769,7.123321489,142.9459407,3.04057009x^3 + 1.78420763x^2 - 36.2528497x + 37.72990763
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,R547,1,0.096906608,0.214710648,0.647247868,1.87774807,3.790656414,119.7979908,6.69592774x^3 + 1.91275169x^2 - 54.60249865x + 39.66086526
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Afatinib (BIBW-2992),1,0.008451553,0.203675576,0.68072588,1.974198739,3.754427496,106.5946575,5.44277042x^3 - 3.38134513x^2 - 53.98774721x + 41.1022445
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,KI20227,1,0.020525645,0.052729027,0.267963825,10,10,457.0511095,6.05083646x^3 + 22.4789768x^2 - 10.10983549x + 37.99709841
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Trametinib (GSK1120212),1,0.004945528,0.009181934,0.034599927,0.409812923,10,208.0413974,-1.31512476x^3 + 7.0770675x^2 - 6.4586633x + 21.35915442
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,JNK Inhibitor II,1,0.02855497,0.049798354,0.20895376,50,50,3256.718959,-2.51992091x^3 + 16.52281197x^2 + 0.29551573x + 41.76974705
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,SNS-032 (BMS-387032),1,0.007745154,0.016027079,0.122713515,2.224055409,6.026650081,158.9459449,-4.91789432x^3 - 7.67589967x^2 - 21.07811282x + 33.44793523
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Lapatinib,1,0.007530022,0.015940481,10,10,10,990.3867578,-5.86421712x^3 + 1.35124901x^2 + 27.00760324x + 85.12251068
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Lestaurtinib (CEP-701),1,0.000629,0.001073282,0.341861128,0.711109188,0.975595031,39.5207025,-14.51204926x^3 - 76.32228423x^2 - 120.99999318x + 8.71038918
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,R406,1,0.113051757,0.236595082,0.822005157,10,10,383.5607576,10.87029395x^3 + 18.65565593x^2 - 37.87327874x + 46.64753984
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,NVP-TAE684,1,0.013561644,0.03623975,0.154242401,0.904325293,10,222.7583342,5.21543173x^3 + 17.127718x^2 - 21.52658632x + 24.02758222
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Velcade,1,0.141607916,0.230647372,0.496635956,1.117153382,2.012540554,52.52231533,15.28676015x^3 + 19.55646098x^2 - 67.22837996x + 28.18757326
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Erlotinib,1,0.010781392,0.079199236,10,10,10,656.794096,1.84510394x^3 + 8.79798152x^2 - 3.6991267x + 62.72031121
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,p38 MAP Kinase Inhibitor,1,0.018855042,0.092255127,10,10,10,669.4786173,4.34620827x^3 + 15.84765407x^2 - 3.35989515x + 59.36461348
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,PLX-4720,1,0.073994528,6.188720393,10,10,10,810.4303334,-8.01673196x^3 - 25.11592578x^2 - 8.22355803x + 101.22485525
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Cediranib (AZD2171),1,0.053009796,0.358937985,1.826038848,5.087692309,8.270678944,301.7611072,-3.42233951x^3 - 16.26657282x^2 - 37.85716485x + 61.07366286
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,GSK-1838705A,1,0.006142545,0.012840832,3.396186823,6.621808779,8.957834897,386.8693032,-13.61678069x^3 - 35.32486346x^2 - 19.50023347x + 72.35300223
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,A-674563,1,0.307933633,0.578005149,1.489930179,3.742001908,6.673463583,253.9771688,6.05052938x^3 - 5.19166183x^2 - 61.40448065x + 60.75742448
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Alisertib (MLN8237),1,0.015077094,0.115866048,10,10,10,576.9906559,-0.60632961x^3 + 0.93173234x^2 - 10.79019808x + 63.58626275
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,RAF265 (CHIR-265),1,0.005047504,0.014841774,0.064301536,0.276314388,0.793109148,5.948521406,3.66858548x^3 + 12.95595338x^2 - 25.60292778x + 7.29507779
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,CI-1040 (PD184352),1,0.089950373,1.20979528,10,10,10,654.2349658,-0.08124065x^3 - 3.23185253x^2 - 16.32030246x + 76.37203889
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,GS-1101 (CAL-101),1,0.01817815,0.326009078,10,10,10,737.5951812,-0.17857891x^3 + 4.09535957x^2 - 2.10895542x + 72.98244987
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,AST-487,1,0.120937464,0.286802845,10,10,10,770.7082592,14.52148704x^3 + 35.74093999x^2 - 11.54246981x + 60.54107478
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Go6976,1,0.00786541,0.017911064,10,10,10,886.8238483,-5.19858829x^3 + 0.96854301x^2 + 19.75304841x + 78.83822018
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Masitinib (AB-1010),1,0.089847102,0.175596957,0.552286169,10,10,456.7676588,15.20091399x^3 + 32.96920851x^2 - 29.47560672x + 40.46891703
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,PD173955,1,0.368339247,1.160525715,10,10,10,677.497431,6.63917264x^3 + 8.95109378x^2 - 27.88273799x + 76.76353986
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,SU14813,1,0.004572222,0.006636989,1.709148562,4.629598068,6.790639844,243.0450884,-12.4251973x^3 - 32.56917764x^2 - 20.40866562x + 56.67225858
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Sorafenib,1,0.006170368,0.048571998,0.193940522,0.688350798,1.655985483,31.10901953,6.46211799x^3 + 10.7832025x^2 - 40.20829214x + 18.22252142
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Sorafenib,2,0.007324027,0.016650056,0.058217471,0.214984493,0.559103091,-0.681655108,4.15343634x^3 + 17.01956891x^2 - 23.29356043x + 3.09988393
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Sorafenib,3,0.037853375,0.074352186,0.265002885,1.675075665,10,225.8879954,2.10259812x^3 + 13.51888433x^2 - 26.98435889x + 30.34325048
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Quizartinib (AC220),1,0.03891045,0.101282688,0.361894029,1.273738398,3.165943341,102.2010611,5.8769741x^3 + 7.32855325x^2 - 44.21830271x + 29.55873014
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Quizartinib (AC220),2,0.041423847,0.066078879,0.134338125,0.274297852,0.441633059,-16.38801115,18.07232713x^3 + 48.0309682x^2 - 40.07320776x - 9.4664094
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,CYT387,1,0.004572222,0.010926303,0.070672386,0.461572733,1.910709932,66.14338926,1.93738229x^3 + 6.77822997x^2 - 24.13180086x + 16.20670183
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,SB-203580,1,0.112153048,0.205811067,0.620153221,10,10,507.8890229,17.15554759x^3 + 37.97128704x^2 - 29.50962347x + 42.39507961
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Tozasertib (VX-680),1,0.071691649,0.598843428,3.124492248,8.831922961,10,434.6033469,-2.99259864x^3 - 13.94069752x^2 - 30.50040387x + 68.86622882
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Canertinib (CI-1033),1,0.017624653,0.12155439,1.004488802,3.720564353,6.818997784,225.2335235,-2.54049626x^3 - 12.1134354x^2 - 36.19711742x + 50.07045285
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,AZD1480,1,0.006780699,0.01647495,5.543296911,10,10,540.5483967,-12.17394772x^3 - 29.09438163x^2 - 10.83601496x + 79.16315475
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,PP242,1,0.00629211,0.019510214,0.345683436,4.217370794,10,253.4810507,-2.58710178x^3 - 5.27913772x^2 - 21.33293499x + 41.02815806
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Barasertib (AZD1152-HQPA),1,0.024596975,0.112744355,10,10,10,605.1812135,4.56885116x^3 + 14.11639823x^2 - 9.49361913x + 57.20838564
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Dasatinib,1,0.000457,0.002958063,0.013299664,0.050438948,0.126447799,1.473906894,5.94626015x^3 + 29.93887616x^2 + 6.4151151x - 4.07899248
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Dasatinib,2,0.00209426,0.00473789,0.015955147,0.069890556,1,26.1754134,8.53861472x^3 + 52.27981367x^2 + 58.68520119x + 36.17888002
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Dasatinib,3,0.00643911,0.204134754,1,1,1,67.66070204,-3.53881093x^3 - 17.93454195x^2 - 37.6398223x + 56.40313655
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Flavopiridol,1,0.097654116,0.165365934,0.380106857,0.963638553,2.245622925,144.1794776,15.69215058x^3 + 28.62476887x^2 - 52.27377621x + 24.1517913
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Foretinib (XL880),1,0.005492101,0.014541841,0.055608804,0.225063083,0.741716374,124.4157771,5.50019485x^3 + 22.03412033x^2 - 14.69291135x + 7.73441902
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,JNJ-7706621,1,0.453215017,1.141885527,3.071906986,6.279463008,8.982971366,389.8119561,-4.52340005x^3 - 24.10629593x^2 - 43.81321174x + 77.60553684
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,AT7519,1,0.033280633,0.169923621,1.02775806,3.346516311,5.848884435,195.4172309,-2.8527831x^3 - 13.62736064x^2 - 40.64712659x + 50.48526218
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,H-89,1,0.227985963,0.652494672,7.216026128,10,10,562.6440268,4.48142739x^3 + 5.78970564x^2 - 30.59073312x + 69.15728346
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Sunitinib,1,0.002296945,0.008715015,0.042981916,0.261581111,1,24.18494222,5.27074297x^3 + 23.97210681x^2 - 0.97883378x + 17.3401885
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Sunitinib,2,0.000484,0.001448028,0.006920334,0.033858672,0.108134463,1.973173482,2.6995556x^3 + 17.8619508x^2 + 1.58389819x - 2.70539404
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Sunitinib,3,0.01517524,0.040918875,0.198907258,1,1,42.35657161,4.03827249x^3 + 14.36471035x^2 - 20.08909647x + 30.23780714
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,JAK Inhibitor I,1,0.010297664,0.035805624,0.550050226,10,10,585.9305114,3.71592535x^3 + 17.56839883x^2 - 0.52132308x + 48.74572319
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Linifanib (ABT-869),1,0.021071507,0.051216632,10,10,10,1069.056462,11.35531226x^3 + 49.61380786x^2 + 32.9217722x + 59.26045773
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,GDC-0879,1,10,10,10,10,10,1613.541399,1.39945318x^3 - 0.51201496x^2 + 14.40249532x + 153.0300411
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,PD98059,1,10,10,10,10,10,930.8140127,4.90920303x^3 + 9.61167527x^2 - 15.08425822x + 95.11536983
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Nilotinib,1,10,10,10,10,10,1004.402867,17.24527041x^3 + 24.88527965x^2 - 34.88660682x + 101.69979696
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Nilotinib,2,1.460596398,3.148468662,10,10,10,755.9860176,12.25508282x^3 + 6.12275108x^2 - 53.40190702x + 98.56590124
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Nilotinib,3,0.559918006,0.844175423,1.796231087,7.972198337,10,389.4428463,19.92774526x^3 + 16.99823606x^2 - 80.33336886x + 69.00602871
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Axitinib (AG-013736),1,0.019319934,0.066697224,0.606064101,10,10,481.0937117,4.34218244x^3 + 14.68947553x^2 - 12.93677721x + 46.53637142
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Doramapimod (BIRB 796),1,0.005703858,0.00784641,0.016626591,10,10,431.4391463,-14.09070782x^3 - 18.24476081x^2 + 12.31313344x + 50.30146115
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,SGX-523,1,0.024925409,10,10,10,10,887.3615991,1.15275379x^3 + 6.52872148x^2 + 3.2752067x + 83.21904661
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,BMS-345541,1,0.011193113,1.408289201,3.758638075,6.8835906,9.192664888,422.9561249,-11.68034275x^3 - 34.72097653x^2 - 28.39131884x + 80.02761175
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,KN93,1,0.00677779,0.009509611,10,9.354443692,10,576.1417936,-23.43301356x^3 - 48.28733872x^2 + 4.43214437x + 87.67935774
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,MEK1/2 Inhibitor,1,0.009495282,10,10,10,10,916.4511297,-9.29575696x^3 - 16.5322662x^2 + 8.70895531x + 98.33525196
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Crenolanib,1,0.009864417,0.027209273,0.101487448,0.370604603,0.954137596,24.48796903,5.67684109x^3 + 16.34313766x^2 - 30.25165021x + 9.37645346
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Crenolanib,2,0.034433328,0.076637551,0.230245589,0.70054392,1.621819035,60.33318457,8.95522539x^3 + 17.70506993x^2 - 42.44442669x + 18.04968263
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Ibrutinib (PCI-32765),1,0.004572222,0.014382926,4.506434076,10,10,500.0321472,-3.76425512x^3 - 10.71938487x^2 - 12.90472449x + 64.07220125
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,SB-431542,1,10,10,10,10,10,1035.53327,9.66995799x^3 + 18.83928572x^2 - 9.30611467x + 95.99533066
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,KN92,1,0.006783391,0.015510654,10,10,10,658.1906589,-4.88352484x^3 - 2.60100807x^2 + 6.00668542x + 65.45574144
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Vargetef,1,0.088188977,0.163887679,0.413428991,1.10894212,2.489169993,112.7619141,13.01760657x^3 + 19.29376935x^2 - 53.52488176x + 27.36365159
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Motesanib (AMG-706),1,0.032040892,0.06701578,0.201652515,0.789149842,10,297.0666991,11.65524923x^3 + 32.38230099x^2 - 22.93436239x + 22.3116142
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Dovitinib (CHIR-258),1,0.005130288,0.019302751,0.100255939,0.48886694,1.494557153,30.20453375,2.9729239x^3 + 7.99866859x^2 - 30.03361039x + 14.98184459
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,LY-333531,1,0.182601769,0.542382393,1.871202361,4.754342747,7.660057514,293.1021547,-1.10946437x^3 - 15.41569963x^2 - 46.30504314x + 63.76444764
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,BI-2536,1,0.005990017,0.011513869,2.86647713,5.850735923,8.009067096,335.49968,-13.97745951x^3 - 35.94301091x^2 - 20.61135825x + 68.28180662
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Pazopanib (GW786034),1,0.01640207,0.06638091,0.35044473,1.523966857,3.704516708,103.3274838,2.07589907x^3 - 0.34327847x^2 - 39.58362372x + 32.24161018
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Crizotinib (PF-2341066),1,0.00656651,0.254659438,0.709320739,1.881895529,3.532793069,104.4356025,8.04358132x^3 + 0.54338955x^2 - 59.52082685x + 41.13663451
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Rapamycin,1,0.005980975,0.008036764,0.024939118,9.301330633,10,678.5427495,-29.17745194x^3 - 66.21942331x^2 + 5.31046979x + 108.48548557
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,SB-202190,1,0.005874424,0.011085473,0.095151179,10,10,570.4230089,-3.73543065x^3 + 3.37749652x^2 + 8.91816996x + 51.60320684
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Gefitinib,1,0.221830644,0.443356014,10,10,10,592.7861583,14.67893337x^3 + 26.80349627x^2 - 34.38204195x + 60.15703358
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,INK-128,1,0.025103775,0.050703772,0.137436962,0.380759635,0.819900601,30.96771792,11.05544209x^3 + 29.8939929x^2 - 32.34225996x + 6.99560759
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,TG101348,1,0.055749429,0.18170507,0.724916326,2.274499677,4.290412653,126.4865017,1.9499889x^3 - 6.94241565x^2 - 49.02401926x + 43.29158051
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,SYK Inhibitor,1,0.004728983,0.012516479,10,10,10,528.3245364,-1.05667182x^3 + 5.19150063x^2 + 0.67573207x + 50.21800783
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,KW-2449,1,0.00585821,0.482922699,1.184049344,3.068673586,6.257427553,228.419587,10.70137636x^3 + 2.04195419x^2 - 64.56927636x + 54.72221629
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,GW-2580,1,0.026162524,0.107160868,0.712051269,3.377041912,7.71810979,225.8849697,-0.13355679x^3 - 4.47292169x^2 - 35.24667086x + 44.89838374
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,MLN120B,1,0.003005119,0.008609486,5,5,5,343.6372942,-4.37179997x^3 - 7.86028638x^2 + 0.35123834x + 70.74638139
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,AKT Inhibitor IV,1,0.011431446,0.034911213,0.164087973,0.767319967,2.354956517,34.78091264,3.13066009x^3 + 7.28738586x^2 - 33.01364173x + 21.11100455
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,PP2,1,0.006731352,0.012101718,10,10,10,645.4124169,-10.82655469x^3 - 17.43156356x^2 + 5.78235368x + 73.86617873
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,VX-745,1,2.816193321,10,10,10,10,904.4153279,7.0250877x^3 + 6.11696272x^2 - 27.02278372x + 100.27558241
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,YM-155,1,1,1,1,1,1,107.5814563,-2.03327328x^3 - 21.14017998x^2 - 53.07940017x + 91.55071939
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,PD153035,1,0.000511,0.001282929,1,1,1,77.1757973,-3.67214252x^3 - 10.78712486x^2 + 1.2583447x + 80.04405255
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Tofacitinib (CP-690550),1,0.050996439,0.256548597,10,10,10,758.6430055,5.97686982x^3 + 17.80292778x^2 - 4.48528641x + 67.36801515
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Pelitinib (EKB-569),1,0.06268733,0.111053856,0.255771771,0.592914826,1.067338314,1.660985052,15.18662779x^3 + 27.66805783x^2 - 53.95155439x + 11.50443561
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,AMPK Inhibitor,1,0.007777842,0.018634102,0.153931928,10,10,349.1182874,-0.96648336x^3 + 4.96760288x^2 - 9.74435028x + 38.28154201
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,AKT Inhibitor X,1,0.197073029,1.245616576,50,50,50,3363.51989,4.25621706x^3 + 2.18463014x^2 - 19.26971427x + 76.81445992
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Roscovitine (CYC-202),1,0.008746377,0.031149273,4.48071466,10,10,487.2053117,-9.430867x^3 - 21.71549228x^2 - 14.00462905x + 70.94083642
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Imatinib,1,0.018434388,0.777361766,3.423630265,8.553484692,10,443.0607757,-3.76405319x^3 - 17.97314643x^2 - 30.28724734x + 71.89736975
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Tandutinib (MLN518),1,0.004986471,0.013134271,0.111791028,1.214827899,3.831880173,93.62894519,-2.13723297x^3 - 4.47436147x^2 - 26.2296762x + 27.25004411
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,PI-103,1,0.004879618,0.014377045,1.03888543,3.286164176,5.188824518,152.7430092,-8.28819335x^3 - 26.33892156x^2 - 33.65652552x + 50.56487711
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,PHA-665752,1,0.068369412,0.261603783,10,10,10,677.2804529,7.28456112x^3 + 17.59272963x^2 - 12.29777948x + 63.31063876
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Bosutinib (SKI-606),1,0.007381303,0.040474249,0.290533275,1.45421246,3.523055095,87.07178671,0.60215431x^3 - 3.13945299x^2 - 37.05487255x + 31.10659642
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,BEZ235,1,0.033832923,0.079224801,0.266721224,10,10,426.9397156,13.56824624x^3 + 35.0681744x^2 - 18.17471862x + 30.582198
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Vandetanib (ZD6474),1,0.053558841,0.095690298,0.220667271,0.508447197,0.906533025,-4.041598094,15.50986917x^3 + 30.44636513x^2 - 51.04761427x + 7.7704411
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,GDC-0941,1,0.033143036,0.075367906,0.232867253,0.775293009,2.634633941,145.7681134,10.03939601x^3 + 21.86606506x^2 - 36.45042661x + 20.71738668
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,GDC-0941,2,0.334723346,1.661123169,4.78549447,9.449491804,10,516.2831473,-7.97841152x^3 - 25.03904323x^2 - 26.58902578x + 82.16201141
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Selumetinib (AZD6244),1,0.314701717,2.182418991,10,10,10,745.7896117,3.94345933x^3 + 6.18069974x^2 - 17.60270764x + 80.10264983
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,JNJ-28312141,1,0.005108759,0.006890607,0.013027407,0.040152929,7.521139497,153.984942,-11.5663958x^3 - 11.68982711x^2 + 4.60032095x + 22.72785051
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,TG100-115,1,0.083669331,0.321170921,10,10,10,559.732839,5.40515443x^3 + 8.71272769x^2 - 22.45478856x + 62.45268243
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Ponatinib (AP24534),1,0.000545,0.001964746,0.01084704,0.057282387,0.182117966,4.139749426,2.27562901x^3 + 12.8424872x^2 - 11.25732345x - 4.43146877
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Ponatinib (AP24534),2,0.000505,0.00134536,0.006807714,0.040014911,0.146681818,3.154348614,1.17586017x^3 + 9.60573998x^2 - 9.63885065x - 4.02929072
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Ponatinib (AP24534),3,0.007312898,0.015309172,0.046717883,0.164453419,1,18.43910236,8.65224384x^3 + 39.67819988x^2 + 8.49856339x + 11.44548268
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,NF-kB Activation Inhibitor,1,0.00590972,0.00847413,0.017881273,0.056643772,0.273070449,36.32505548,-6.1665467x^3 + 1.68138138x^2 - 3.03304986x + 6.65117265
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Midostaurin (PKC412),1,0.029605471,0.069577002,0.211852006,0.630728345,1.381387633,30.84981057,9.09615478x^3 + 17.36825601x^2 - 43.30501802x + 15.70928483
523,11-00473,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123,Standard,Staurosporine,1,0.005475643,0.007878845,0.017671351,0.118082794,8.628433525,168.4599193,-8.73775578x^3 - 6.96560831x^2 - 0.40357645x + 23.64299762
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Sunitinib,1,0.000615,0.000934,0.620499264,0.952392243,1,59.31679383,-20.76895874x^3 - 109.38298892x^2 - 158.34983199x + 21.69438352
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Sunitinib,2,0.005541844,0.012756242,0.045746791,1,1,35.56475818,10.67912943x^3 + 54.65413361x^2 + 47.08768174x + 40.67072151
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Sunitinib,3,0.004644511,0.011488642,0.050012161,1,1,44.71344148,9.65264067x^3 + 52.8327788x^2 + 55.0647082x + 53.47272439
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Flavopiridol,1,0.014214097,0.032894859,0.100110606,0.296667768,0.635364458,1.744649391,8.43377x^3 + 24.05963132x^2 - 31.46766615x + 2.93253473
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Bosutinib (SKI-606),1,0.049050998,0.136460378,0.61210029,10,10,312.04917,6.14899637x^3 + 10.48640183x^2 - 33.06230705x + 42.53488245
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,AKT Inhibitor IV,1,0.01179258,0.153555767,0.478676198,1.404896132,2.983398045,32.4554617,9.71257671x^3 + 6.62926414x^2 - 53.06912098x + 32.65957908
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,JNK Inhibitor II,1,0.034555478,0.079889281,50,50,50,3220.034544,-7.99660529x^3 + 3.70844069x^2 + 7.81675917x + 68.54064021
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Vargetef,1,0.014983382,0.041611026,0.233441301,10,10,336.5804801,3.52816887x^3 + 13.90248256x^2 - 16.61210271x + 34.84412562
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PD173955,1,0.094944409,0.246665053,1.3099089,10,10,450.4746264,7.41512985x^3 + 12.71170608x^2 - 30.55298144x + 53.39538678
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Tozasertib (VX-680),1,0.004758293,0.382447534,1.415345763,10,10,415.4806625,10.16235667x^3 + 11.70897747x^2 - 42.23243632x + 56.06990939
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,SB-203580,1,0.022059047,0.093607751,1.03281139,10,10,481.3811424,4.38167714x^3 + 11.65580515x^2 - 16.72359243x + 50.23217833
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,STO609,1,0.006630025,0.022430247,10,10,10,677.2411086,-7.61824854x^3 - 15.04732514x^2 - 1.68988404x + 78.96778377
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Rapamycin,1,0.032471508,0.612901214,10,10,10,705.089656,1.2373443x^3 + 3.78017271x^2 - 8.5150422x + 73.03063811
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,INK-128,1,0.002782468,0.004375973,0.01336123,0.901216026,3.067350862,72.95033264,-7.91919324x^3 - 17.49918319x^2 - 18.75305506x + 24.18787991
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Barasertib (AZD1152-HQPA),1,0.224153726,0.845299145,10,10,10,811.0363098,10.83205988x^3 + 23.18702504x^2 - 14.40941062x + 73.82894701
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,AT7519,1,0.093840115,0.155952351,0.338621429,0.757476041,1.351752228,29.38074771,16.77491975x^3 + 27.45072189x^2 - 60.18391923x + 17.36993537
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,KN93,1,0.027666648,2.780022873,10,10,10,712.0012719,-3.42207236x^3 - 6.21555179x^2 - 7.8019681x + 79.98965358
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,BMS-345541,1,1.287581239,2.260343973,4.236703714,6.747686561,8.542435563,459.7892061,-12.53540121x^3 - 44.80500492x^2 - 38.37671517x + 94.76929382
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Crenolanib,1,0.00623817,0.007018576,0.008905588,0.012680815,10,1548.794513,-79.90780622x^3 - 180.52403179x^2 + 58.7664487x + 240.63733109
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Crenolanib,2,0.005963775,0.006835713,0.009131473,0.016128974,9.195996032,1164.523572,-73.4868236x^3 - 178.8963807x^2 + 23.68971779x + 219.03231829
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PP2,1,0.005697295,0.805248216,10,10,10,706.8831604,-0.94305756x^3 - 1.28044003x^2 - 5.01242932x + 74.53902546
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,SB-431542,1,10,10,10,10,10,977.1778129,-1.49200523x^3 - 6.29875675x^2 - 5.07010624x + 104.34007379
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Doramapimod (BIRB 796),1,0.005884177,0.010174741,0.041109537,10,10,362.0513706,-4.43659135x^3 + 0.98785556x^2 + 0.50085882x + 36.98250073
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,TG101348,1,0.032813414,0.075537057,0.231491144,0.708202264,1.621452338,52.57894618,8.75227806x^3 + 16.61006941x^2 - 43.00046444x + 18.21319779
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,SYK Inhibitor,1,0.006738076,0.016325796,4.109756817,10,10,489.2096246,-4.80281966x^3 - 5.79050713x^2 - 5.32627888x + 56.56178338
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,AST-487,1,0.006259775,9.198711531,10,10,10,849.9834937,-6.23765045x^3 - 15.08107511x^2 - 0.59997475x + 95.168257
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Afatinib (BIBW-2992),1,0.04811641,0.133995579,0.501571591,1.710025464,3.742701324,111.5431934,4.32666531x^3 + 1.06151093x^2 - 47.18396933x + 35.88162557
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Quizartinib (AC220),1,0.00574007,0.013334813,0.062080984,0.455066017,10,140.269006,1.12206361x^3 + 9.40512404x^2 - 16.55870782x + 18.2834268
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Quizartinib (AC220),2,0.004889382,0.008856077,0.035094555,1.26743467,10,213.3912228,-2.95667184x^3 + 1.88200001x^2 - 7.65939737x + 25.77163448
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Ibrutinib (PCI-32765),1,0.010675493,0.099987884,1.793730273,7.616262758,10,366.4860342,-2.99199506x^3 - 10.15416174x^2 - 25.09154163x + 57.06990103
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Pazopanib (GW786034),1,0.112505917,0.292848843,1.447308453,10,10,425.7154452,6.62510394x^3 + 8.82484294x^2 - 34.22555481x + 55.24036649
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,CYT387,1,0.004784881,0.120035431,0.541831001,2.170545281,5.471659271,169.0386254,4.05132129x^3 + 0.83125342x^2 - 41.92119713x + 38.86074505
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Dasatinib,1,0.001106385,0.003318831,0.021185042,1,1,36.71265207,3.33660132x^3 + 24.02212394x^2 + 25.00823452x + 40.19999612
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Dasatinib,2,0.000691,0.001693645,0.034647925,1,1,41.70797858,-2.42226229x^3 - 6.4786229x^2 - 12.91621515x + 37.41068576
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Dasatinib,3,0.001050482,0.003782279,1,1,1,59.9005719,-0.02302273x^3 + 7.21678595x^2 + 12.521568x + 62.66023688
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Crizotinib (PF-2341066),1,0.060909394,0.35052081,1.534477014,4.019604142,6.391802846,235.8341627,-3.23460846x^3 - 18.54006006x^2 - 43.47139369x + 58.74589689
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Lestaurtinib (CEP-701),1,0.001380168,0.003895698,0.015131584,0.076594412,1,26.81897213,8.10800652x^3 + 48.69529961x^2 + 54.04839074x + 35.94450083
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,LY-333531,1,0.12313507,0.351293058,1.47807083,5.832081861,10,331.4213887,3.0181745x^3 - 2.98885632x^2 - 41.390406x + 57.09507498
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,KI20227,1,0.021592518,0.165313896,9.291873613,10,10,555.1929184,-0.23480318x^3 + 0.67050913x^2 - 14.22653971x + 63.35738659
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Neratinib (HKI-272),1,0.018877018,0.040753092,0.113817976,0.308438634,0.612272925,-11.83396676,10.20784542x^3 + 27.10767651x^2 - 34.98856789x + 1.4137507
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,SU14813,1,0.006252867,0.009252813,7.901167213,9.776581966,10,917.6310753,-35.13577984x^3 - 91.68591359x^2 - 3.19540068x + 152.17090674
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Axitinib (AG-013736),1,0.03717549,0.10099512,0.606255576,10,10,572.669904,9.56879743x^3 + 27.30060885x^2 - 11.01164015x + 46.41528585
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PD153035,1,0.000647,0.887902475,1,1,1,88.39222148,-7.06060259x^3 - 41.68280992x^2 - 66.87336106x + 71.65717226
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,MLN120B,1,0.035556308,5,5,5,5,458.6682399,-0.10483176x^3 + 3.09966083x^2 + 4.55719306x + 89.77596591
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Pelitinib (EKB-569),1,0.032970229,0.068589263,0.191751218,0.571409148,1.558945331,153.9841828,12.20651135x^3 + 29.4832987x^2 - 33.53502499x + 15.28276612
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Cediranib (AZD2171),1,0.33145161,0.500815794,1.051828677,2.893976506,10,284.2580951,15.94132761x^3 + 24.25152474x^2 - 72.16477827x + 51.57180898
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Dovitinib (CHIR-258),1,0.016046285,0.037647409,0.126130382,0.43191308,1.079090443,33.11207977,6.11062037x^3 + 17.22344354x^2 - 32.755511x + 11.06378375
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,p38 MAP Kinase Inhibitor,1,0.114969005,0.746985023,10,10,10,683.3107927,2.87495416x^3 + 5.85286901x^2 - 15.14197362x + 72.99359995
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Vatalanib (PTK787),1,0.19711068,0.448987489,1.975091694,10,10,461.3431326,8.65755158x^3 + 9.65140917x^2 - 39.26884343x + 60.54051873
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,SNS-032 (BMS-387032),1,0.020951233,0.043573677,0.117224164,0.306869663,0.592840289,-15.15310107,10.94839963x^3 + 28.76161878x^2 - 35.88550082x + 0.49705487
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,BEZ235,1,0.029410521,0.085452988,0.402126725,3.61103658,10,278.4985184,5.23793091x^3 + 11.47661329x^2 - 29.37774628x + 36.90503303
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,YM-155,1,0.489714247,0.573046377,0.723291601,0.888700374,0.995633484,91.0540583,-28.86558186x^3 - 181.95709071x^2 - 313.57894002x + 9.40469834
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,SGX-523,1,0.487213727,1.01372133,10,10,10,837.0935789,19.47942534x^3 + 43.52596737x^2 - 35.66989876x + 75.20958657
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,KN92,1,5.157405787,7.788198297,10,10,10,952.9593416,-2.67203859x^3 - 26.5077344x^2 - 36.10474434x + 130.14258271
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,AKT Inhibitor X,1,0.157621682,50,50,50,50,4091.607596,1.05602399x^3 + 2.58206956x^2 - 6.93811017x + 83.3161152
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,GDC-0941,1,0.00939303,0.023490636,0.364854526,6.601151289,10,305.4659444,-3.53086201x^3 - 3.95257888x^2 - 16.59011679x + 43.19693246
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,GDC-0941,2,0.044552297,0.118782434,0.516221139,10,10,356.3177388,7.96535122x^3 + 16.69870788x^2 - 28.52634015x + 40.61984912
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Nilotinib,1,0.449477793,0.71587863,2.291266377,10,10,595.4437115,25.39786694x^3 + 38.31907805x^2 - 60.21775601x + 65.52899614
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Nilotinib,2,0.004681231,3.321044809,6.77129432,10,10,681.7535889,3.28241412x^3 - 20.69378917x^2 - 57.40360238x + 110.08117989
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Nilotinib,3,0.17360875,0.605735835,2.819777039,10,10,437.6512147,1.01930962x^3 - 7.54848752x^2 - 35.8289903x + 67.56775111
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,SB-202190,1,0.019162518,0.082333299,0.66761027,10,10,420.3637097,4.54374372x^3 + 11.05659618x^2 - 19.92200064x + 46.18824193
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Tofacitinib (CP-690550),1,0.030907484,0.227865614,10,10,10,620.0973897,2.45686743x^3 + 6.42708919x^2 - 12.45392491x + 64.99999997
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Vandetanib (ZD6474),1,0.095862693,0.371529029,1.659546733,5.013670978,8.777198758,302.265405,-0.91126415x^3 - 11.59016493x^2 - 40.76947575x + 59.53946816
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,GSK690693,1,0.025622361,0.106338758,10,10,10,783.2440014,8.09553983x^3 + 26.55547621x^2 + 3.12728769x + 60.35147573
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,NF-kB Activation Inhibitor,1,0.007628031,10,10,10,10,986.9800292,-13.93930449x^3 - 29.78348227x^2 + 10.22449028x + 112.84307787
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,JAK Inhibitor I,1,0.017070784,0.131140906,2.200164228,10,10,433.8612159,-0.86492107x^3 - 3.64166843x^2 - 21.86532403x + 57.94970679
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,R547,1,0.134129103,0.319952856,1.028956926,2.947276268,5.502028739,191.7285841,3.85325374x^3 - 5.5724269x^2 - 52.8889718x + 50.65652398
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Staurosporine,1,0.004670119,0.286232596,0.431246213,0.670580708,0.906548126,16.58669839,43.74827397x^3 + 74.52195594x^2 - 100.16852872x + 5.59999239
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,JNJ-28312141,1,0.007186852,0.014723474,0.064935802,10,10,362.5364487,0.90120652x^3 + 14.45173896x^2 - 1.41030803x + 29.4546699
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PLX-4720,1,0.882738036,4.461625288,10,10,10,746.4331313,-4.24031007x^3 - 12.28370961x^2 - 12.35227906x + 89.36626855
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PI-103,1,0.046605164,0.149663332,0.783065672,4.658901904,10,287.939856,2.95375164x^3 + 2.45480826x^2 - 34.80213442x + 46.27980093
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PHA-665752,1,0.139278042,0.546036158,10,10,10,600.5509512,4.6284018x^3 + 6.0929124x^2 - 23.2165112x + 68.56245122
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,TG100-115,1,1.015762554,3.728271488,10,10,10,713.8613253,-4.96807318x^3 - 15.93553194x^2 - 15.70435123x + 90.1074038
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,GDC-0879,1,10,10,10,10,10,1443.420505,-4.61314694x^3 - 13.57188924x^2 + 12.09277021x + 146.01096564
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PP242,1,0.090139018,0.154300457,0.354479294,0.867803744,1.767961849,94.97546499,15.13624638x^3 + 26.58597664x^2 - 54.23152545x + 21.56322776
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Midostaurin (PKC412),1,0.004870667,0.553601321,1.669786432,10,10,428.5617676,13.5179812x^3 + 14.03104537x^2 - 52.45124665x + 60.83398786
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,RAF265 (CHIR-265),1,0.01814872,0.036140819,0.095336984,0.251371562,0.49992913,53.16808001,11.16141399x^3 + 34.14606753x^2 - 26.5188132x - 0.77548131
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Selumetinib (AZD6244),1,0.008168483,0.029704572,10,10,10,562.5988185,-2.34703237x^3 - 0.36074718x^2 - 4.86868612x + 60.04638734
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Gefitinib,1,0.417819128,1.483590252,10,10,10,635.352152,2.85034795x^3 - 2.68749598x^2 - 28.12280789x + 79.88237282
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Motesanib (AMG-706),1,0.010685842,0.054359205,2.793502601,10,10,436.5182191,-4.56974127x^3 - 10.00993597x^2 - 17.16575688x + 60.05677269
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,LY294002,1,0.357912004,0.986285391,3.584830441,11.49396202,23.39564423,755.3657874,3.99752142x^3 - 10.93380503x^2 - 39.82469031x + 74.76154956
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,AMPK Inhibitor,1,0.030458281,0.067877633,0.256399441,10,10,329.8082358,6.79509736x^3 + 22.02873776x^2 - 20.897636x + 31.35465425
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,GW-2580,1,0.022704517,0.113664265,10,10,10,565.2816708,3.7824276x^3 + 11.03064928x^2 - 12.360174x + 56.67541052
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Roscovitine (CYC-202),1,2.532633575,7.270917166,10,10,10,822.9514877,-5.06097581x^3 - 14.16098352x^2 - 8.49295707x + 96.06658972
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Go6976,1,0.008694902,0.025042702,0.391138654,10,10,464.4904335,0.09561611x^3 + 7.47048245x^2 - 6.25955151x + 46.21310039
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,H-89,1,0.01018156,4.459575111,10,10,10,741.8512978,-4.53871573x^3 - 9.18889442x^2 - 3.96250663x + 82.68908723
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,KW-2449,1,0.007400973,0.682379774,6.557345618,10,10,566.159104,-5.28172789x^3 - 13.85772164x^2 - 13.4694142x + 73.12202373
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,A-674563,1,0.090163526,0.173057624,0.462540659,1.358749049,3.717458744,150.57952,11.53884716x^3 + 16.85409215x^2 - 51.0042729x + 31.46468206
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Lapatinib,1,1.580237909,10,10,10,10,833.6942986,2.59230907x^3 - 1.04358273x^2 - 18.9633384x + 93.7893097
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,R406,1,0.021540841,0.064528138,0.306451114,10,10,390.8831743,7.7414544x^3 + 21.35123507x^2 - 18.3111371x + 36.0107536
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Foretinib (XL880),1,0.00645812,0.010163327,0.031537817,10,10,323.082369,-7.21618802x^3 - 4.23143794x^2 + 0.89363757x + 36.46548381
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,GS-1101 (CAL-101),1,0.106531172,0.581154145,3.258797002,10,10,461.894676,0.0293596x^3 - 8.75081902x^2 - 30.96705068x + 68.18736547
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,JNJ-7706621,1,0.166070397,0.610041268,2.100744534,4.885001107,7.382444693,296.1374736,-3.96245175x^3 - 20.81759062x^2 - 43.9908196x + 66.47767295
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Trametinib (GSK1120212),1,0.005049774,0.009213529,0.03600239,10,10,430.9572323,-1.14008148x^3 + 11.23417161x^2 + 7.30040779x + 33.69499257
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,VX-745,1,0.028978681,0.106668811,0.887669468,10,10,432.3065285,4.00351924x^3 + 9.80882453x^2 - 21.12045343x + 48.88133108
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Ponatinib (AP24534),1,0.012430084,0.02483592,0.070028307,0.210936061,0.513061378,17.65274975,9.01229872x^3 + 34.54189317x^2 - 12.14079359x + 3.79905981
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Ponatinib (AP24534),2,0.004275304,0.015975302,0.08938959,0.438166531,1,27.66240305,1.76005316x^3 + 3.70299886x^2 - 33.82619793x + 12.48346887
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Ponatinib (AP24534),3,0.002069744,0.014098626,0.087275481,0.320461825,0.616237283,20.06254088,-0.45325954x^3 - 10.88976935x^2 - 60.31590164x - 2.2043613
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Canertinib (CI-1033),1,0.701989893,1.338762402,3.150778575,6.37469241,9.287838234,408.2153239,-0.20815914x^3 - 20.99676903x^2 - 54.0622128x + 82.18737285
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,GSK-1838705A,1,0.041382476,10,10,10,10,899.9966444,3.16117056x^3 + 11.99391623x^2 + 3.8258221x + 80.71050589
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Tandutinib (MLN518),1,0.019949962,0.114323678,1.582315124,10,10,424.8690689,0.74389043x^3 + 0.6989069x^2 - 21.93842943x + 54.33852776
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Linifanib (ABT-869),1,0.008385856,0.021305592,0.246693892,3.815343517,10,241.3153571,-3.05338153x^3 - 4.0814729x^2 - 20.04539017x + 38.63783675
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,BI-2536,1,0.045025317,0.11510881,0.392013535,1.282015094,2.911404763,85.28122827,6.39150439x^3 + 6.37586908x^2 - 47.52814806x + 30.04571244
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Alisertib (MLN8237),1,0.005258698,2.045091453,10,10,10,692.3145409,8.9855478x^3 + 3.78091073x^2 - 39.52834097x + 86.64740161
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Erlotinib,1,0.622046897,1.630925482,6.299157248,10,10,591.0265491,1.6244648x^3 - 8.03947885x^2 - 35.85369924x + 82.96378324
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,NVP-TAE684,1,0.008551,0.022240668,0.315321194,9.622485752,10,329.7235284,-2.41203975x^3 - 0.9772051x^2 - 14.61995782x + 42.61354743
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Imatinib,1,0.176911825,0.645574072,10,10,10,593.189172,4.22482332x^3 + 4.59583177x^2 - 25.49808118x + 70.01698874
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Velcade,1,0.051517321,0.091622626,0.20941008,0.479282972,0.855385672,17.88114301,16.52557726x^3 + 33.81439661x^2 - 48.65115821x + 6.54914667
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,CI-1040 (PD184352),1,0.026484701,0.441471319,5.235143774,10,10,531.4779408,-1.70218655x^3 - 6.8565685x^2 - 20.12239396x + 68.6429452
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,MEK1/2 Inhibitor,1,0.005581204,4.145869793,8.029257557,10,10,698.9886771,-12.25268518x^3 - 34.87997201x^2 - 12.44450006x + 98.87744917
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Sorafenib,1,0.072069664,0.10995263,0.217690383,0.450177066,0.752958192,13.70825014,16.95227926x^3 + 41.60541684x^2 - 50.61797924x + 3.16231692
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Sorafenib,2,0.011501529,0.041604804,0.218367716,1.495354072,10,216.1914883,4.36678651x^3 + 11.2379831x^2 - 25.99374187x + 29.17579351
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Sorafenib,3,0.005153853,0.287885115,0.856926733,2.532488203,5.358449317,184.9693834,7.25508503x^3 + 1.11154894x^2 - 54.51506786x + 46.34161021
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,AZD1480,1,0.291047561,1.627311065,10,10,10,671.0766781,1.40986235x^3 - 1.892818x^2 - 20.98939033x + 79.50995199
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PD98059,1,0.583071992,2.719622894,10,10,10,754.7150006,6.62652627x^3 + 6.36481658x^2 - 24.64334042x + 83.96247981
628,11-00476,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Masitinib (AB-1010),1,0.099754824,0.513368596,5.63065482,10,10,543.6460442,1.51638961x^3 - 0.86695683x^2 - 24.2876294x + 68.07652869
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,AMPK Inhibitor,1,0.057618137,0.304660206,3.511460943,10,10,500.5053389,2.11850651x^3 + 0.99038239x^2 - 24.17511348x + 62.54867262
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Vargetef,1,0.008587895,0.016283311,0.054028399,0.2580087,1.431217357,110.7410202,1.22979025x^3 + 13.7968388x^2 - 14.53289243x + 11.92371648
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Vandetanib (ZD6474),1,0.004572222,0.013137969,3.240424403,6.186400358,8.373119991,372.1933284,-11.22098028x^3 - 35.89623932x^2 - 27.79303971x + 75.04359191
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Tandutinib (MLN518),1,0.101283689,0.253713696,1.376459419,10,10,478.9232971,8.55436894x^3 + 15.56742018x^2 - 29.4206463x + 53.75989749
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Bosutinib (SKI-606),1,0.0415264,0.087043607,0.244910593,0.693797747,1.482752176,39.41492772,9.85443696x^3 + 18.43713162x^2 - 45.9731316x + 17.2756717
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Nilotinib,1,0.360451923,0.677713377,10,10,10,590.3680481,15.26067224x^3 + 24.06923459x^2 - 44.5470967x + 66.86012579
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Nilotinib,2,0.269725322,0.576917198,2.024953865,10,10,412.5696011,6.89151146x^3 + 2.97894691x^2 - 46.58322279x + 63.79584582
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Nilotinib,3,0.225465479,0.369300203,0.814358571,1.909758762,3.610689995,137.0184013,13.34465093x^3 + 10.57907903x^2 - 70.39213455x + 43.64744653
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,SB-203580,1,0.022134102,0.068124146,10,10,10,641.5573291,6.39614043x^3 + 24.01948265x^2 - 1.52236487x + 50.68654243
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Erlotinib,1,0.020311968,5.812269724,10,10,10,799.0588883,-9.94529025x^3 - 26.66437331x^2 - 9.42116617x + 102.22007114
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Sunitinib,1,0.019979095,0.03259725,0.080963485,1,1,42.06790485,18.17716793x^3 + 89.73963047x^2 + 76.77061599x + 50.50767929
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Sunitinib,2,0.004730791,0.012362543,0.047086586,0.241406442,1,24.96277913,7.70982421x^3 + 35.76397806x^2 + 11.48766718x + 20.27787189
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Sunitinib,3,0.013553575,0.022775909,0.053150143,0.149950432,1,22.81034707,16.78645154x^3 + 77.9844484x^2 + 51.85729459x + 24.17024209
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Linifanib (ABT-869),1,0.016750325,0.045462225,0.364262413,10,10,399.9980249,1.3044362x^3 + 9.82135062x^2 - 13.54026327x + 42.28227486
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,VX-745,1,0.093625355,0.314463729,4.519530265,10,10,531.072929,4.91612602x^3 + 8.41010259x^2 - 24.61442773x + 61.13349667
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,AZD1480,1,0.659447634,2.983556088,9.359428734,10,10,673.2829443,-5.29450116x^3 - 17.14522782x^2 - 16.93032633x + 87.46793866
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,TG100-115,1,0.353324223,1.358573021,4.274346597,9.213417783,10,492.3658996,-4.97484863x^3 - 21.147324x^2 - 31.58099203x + 79.58916063
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,GSK690693,1,0.04167319,0.079457793,0.34170404,10,10,1619.348411,30.39885196x^3 + 104.94735331x^2 + 65.93059026x + 61.00567716
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,BMS-345541,1,0.010691484,3.02818648,5.12260028,7.643271981,9.382927203,543.8865541,-16.41808298x^3 - 51.38052161x^2 - 30.65295393x + 103.47530776
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Flavopiridol,1,0.127334479,0.241023528,0.646085144,1.930750133,5.408922755,181.466327,10.53571204x^3 + 11.91329555x^2 - 54.3953619x + 39.32381769
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Staurosporine,1,0.140520667,0.180527885,0.273234479,0.420665703,0.55719055,-93.01384419,38.9064979x^3 + 80.42846208x^2 - 83.93760724x - 15.87107284
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Dasatinib,1,0.001024822,0.002884269,0.014853856,1,1,39.69125399,5.11742915x^3 + 36.15009514x^2 + 48.90548382x + 49.85488999
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Dasatinib,2,0.000998,0.002438152,0.009566894,0.050445644,1,23.81454766,5.39141575x^3 + 37.65594935x^2 + 45.08286896x + 31.88595307
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Dasatinib,3,0.000768,0.001374692,0.004890253,0.10120108,1,26.86065659,-1.49330316x^3 + 4.91084049x^2 + 10.11715578x + 28.73445677
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,KI20227,1,0.012350704,0.032466078,0.15167285,1.652863492,10,284.5527876,4.34171802x^3 + 16.83014144x^2 - 16.33146328x + 27.7174257
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,LY-333531,1,0.255359018,1.035258286,6.43784362,10,10,573.0397784,1.03730475x^3 - 5.10771818x^2 - 27.98201352x + 75.42224653
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Midostaurin (PKC412),1,0.16339292,0.397056733,2.153164731,10,10,491.8987671,8.59361421x^3 + 11.67615484x^2 - 34.44276259x + 59.85919389
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,AKT Inhibitor IV,1,0.116898004,0.239969088,0.648451144,1.765131551,3.703400421,130.7855875,11.68170148x^3 + 7.04391869x^2 - 58.48016443x + 38.82703904
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,p38 MAP Kinase Inhibitor,1,0.250350173,10,10,10,10,783.2937227,3.60828866x^3 + 6.69954294x^2 - 12.52442228x + 80.828699
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,LY294002,1,0.386701445,1.16650142,5.176433081,22.32085054,50,1425.420342,3.36741616x^3 - 7.76324614x^2 - 34.46148524x + 77.33868817
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Motesanib (AMG-706),1,0.02377639,0.065713645,0.33001001,10,10,344.3330287,5.18934494x^3 + 15.57665358x^2 - 21.16464772x + 36.77807558
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PD98059,1,10,10,10,10,10,914.1563797,2.68888696x^3 + 4.59186258x^2 - 7.78973031x + 92.62017465
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,BEZ235,1,0.019461513,0.042448561,0.131866564,0.426176055,1.040962518,49.20845969,7.10797609x^3 + 20.3499504x^2 - 32.42359923x + 10.55908475
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Dovitinib (CHIR-258),1,0.078629204,0.162860464,0.495094287,2.002372534,10,248.0480536,10.76681875x^3 + 18.2334848x^2 - 42.11858287x + 35.74746642
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Quizartinib (AC220),1,0.049147077,0.119488258,0.441720103,2.46542274,10,263.7977479,7.8955892x^3 + 15.01748927x^2 - 35.14371325x + 35.9909441
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Quizartinib (AC220),2,0.020686422,0.04663865,0.136693078,0.413066282,1.057495361,151.644437,11.56112723x^3 + 31.38355639x^2 - 27.05630465x + 10.6382214
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,KN92,1,10,10,10,10,10,914.2281365,-1.22966536x^3 - 1.05525681x^2 + 0.76216873x + 91.99343278
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Neratinib (HKI-272),1,0.082027233,0.131826624,0.279284849,0.64492111,1.35852819,201.1638037,20.9192736x^3 + 45.42982645x^2 - 44.34942116x + 15.04778804
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,RAF265 (CHIR-265),1,0.03737106,0.103480313,0.461568751,3.606240845,10,277.8861525,5.54681829x^3 + 11.04354588x^2 - 31.75415201x + 38.30305713
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,JNJ-28312141,1,0.004660959,0.00613156,0.010752841,0.025084286,0.080458609,124.7964285,-11.2509229x^3 - 8.62341428x^2 + 9.13402655x + 15.5768667
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Ponatinib (AP24534),1,0.010550301,0.027798054,0.106111007,0.400385697,1,27.0406231,4.42104666x^3 + 12.62029775x^2 - 32.64372172x + 10.30683923
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Ponatinib (AP24534),2,0.010448615,0.02634546,0.097790794,0.386373194,1,26.93377062,5.38845331x^3 + 17.88625766x^2 - 25.10935234x + 11.95884544
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Ponatinib (AP24534),3,0.022953585,0.03986088,0.0952722,0.2403077,0.47269728,17.72334945,10.35940677x^3 + 36.41714341x^2 - 23.80786709x - 1.24692848
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Crizotinib (PF-2341066),1,0.10091474,0.180406417,0.429326631,1.046865423,1.988274656,49.78185521,13.20111026x^3 + 16.77676613x^2 - 60.44426236x + 26.19554654
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Imatinib,1,0.227775611,0.649814802,2.755597406,10,10,440.3799321,2.54749241x^3 - 5.3795261x^2 - 38.8572925x + 67.93076578
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Vatalanib (PTK787),1,0.187455071,0.746748455,7.906111353,10,10,575.7684305,3.20921273x^3 + 0.22370464x^2 - 26.84162972x + 71.59874084
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Go6976,1,0.016683251,1.242414289,10,10,10,679.5112639,-1.95732163x^3 - 4.12128282x^2 - 9.07578419x + 75.89380381
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PLX-4720,1,1.039233785,3.675075975,10,10,10,709.7322135,-5.24879839x^3 - 16.60580183x^2 - 15.95224632x + 90.27127705
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Alisertib (MLN8237),1,1.894470252,5.866938501,10,10,10,788.9696038,-4.82867723x^3 - 14.92393114x^2 - 10.69319163x + 94.21953647
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Canertinib (CI-1033),1,1.949948828,2.931547941,4.920946021,7.41369802,9.177966569,538.6927453,-12.15484663x^3 - 48.11418067x^2 - 42.96129992x + 106.80334049
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,AT7519,1,0.055254734,0.093969415,0.204460508,0.444168299,0.752597754,-23.27463775,17.25924565x^3 + 35.48380551x^2 - 51.76925959x + 3.10155785
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Selumetinib (AZD6244),1,0.010160565,0.026524746,0.246013369,10,10,386.6961842,-0.10118982x^3 + 6.91027466x^2 - 10.35716368x + 41.10596248
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,SYK Inhibitor,1,0.006793164,0.015901328,10,10,10,742.0925196,-10.07461114x^3 - 18.72680195x^2 + 4.33169809x + 84.7542116
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,SGX-523,1,10,10,10,10,10,964.9384713,0.64884874x^3 + 0.17802442x^2 - 1.78107969x + 97.23251357
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,AST-487,1,10,10,10,10,10,936.2781402,-1.00356193x^3 - 2.08271989x^2 + 0.23012092x + 94.94168598
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Foretinib (XL880),1,0.00593739,0.008576406,0.018549764,0.064797064,2.969916264,88.16784595,-6.21421717x^3 + 1.57270479x^2 - 1.22966557x + 10.88638393
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Barasertib (AZD1152-HQPA),1,0.663665139,5.909321329,10,10,10,780.0364327,-1.73768991x^3 - 6.63967218x^2 - 11.00498583x + 88.24123469
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,NVP-TAE684,1,0.009620503,0.025370133,0.41807326,4.221722633,9.545405286,249.4597895,-4.22440208x^3 - 7.657329x^2 - 21.747168x + 42.632237
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,TG101348,1,0.080981636,0.141149979,0.324106424,0.760921444,1.40042605,23.29089321,14.62343346x^3 + 23.78825173x^2 - 57.54227911x + 17.86151105
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,A-674563,1,0.229723162,0.44898894,1.189304268,2.953163298,5.097967933,185.1761467,4.90907051x^3 - 6.10325908x^2 - 61.24960138x + 54.64416905
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PD153035,1,0.064269675,1,1,1,1,88.43614472,0.02333209x^3 + 0.84698287x^2 - 0.87279778x + 87.79571148
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,R406,1,0.056254223,0.154859912,0.836282921,10,10,441.9658472,7.4839518x^3 + 15.97513661x^2 - 25.37924876x + 47.9365723
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Afatinib (BIBW-2992),1,0.078498187,0.149552008,0.383353103,1.00328064,2.018450621,56.10283053,11.37443148x^3 + 15.70290443x^2 - 55.28301192x + 25.0786045
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,GDC-0879,1,10,10,10,10,10,2146.481568,-2.61973967x^3 - 12.22416832x^2 + 29.53882999x + 205.07905662
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,GDC-0941,1,0.017884406,0.050031684,0.214783479,1.316630429,10,238.3148099,5.87238394x^3 + 16.3252327x^2 - 25.02813093x + 27.74695822
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,GDC-0941,2,0.014217336,0.034907229,0.127162682,0.498599408,1.580871925,90.62219626,5.47687797x^3 + 16.61688993x^2 - 28.60183032x + 14.98835302
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Tozasertib (VX-680),1,0.291628942,1.468185253,5.595396693,10,10,558.1596914,-3.22096659x^3 - 15.65741947x^2 - 26.41244148x + 79.8555567
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,AKT Inhibitor X,1,50,50,50,50,50,4856.628873,3.21500214x^3 + 0.5056402x^2 - 8.48588412x + 98.72248723
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Pazopanib (GW786034),1,0.0581921,0.138136594,0.528807181,10,10,312.9849406,7.84688511x^3 + 15.55219097x^2 - 33.47585979x + 39.71263782
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,MLN120B,1,0.011513365,0.316384885,5,5,5,391.1132529,2.29965922x^3 + 10.51062832x^2 + 3.7602038x + 74.54098608
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,STO609,1,6.749884953,10,10,10,10,940.4611667,-3.13735018x^3 - 10.28608132x^2 - 5.78005931x + 103.65679192
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,H-89,1,6.096223885,10,10,10,10,920.5376733,-0.5757563x^3 - 3.70566741x^2 - 7.37337159x + 98.35100432
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Doramapimod (BIRB 796),1,0.006038536,0.010944182,0.05004794,10,10,395.2716285,-3.32897793x^3 + 3.76615051x^2 + 1.33621679x + 38.04296702
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,SU14813,1,0.014300251,4.421359093,9.024783802,10,10,729.7787602,-9.1848182x^3 - 28.89874265x^2 - 16.53221888x + 100.18679261
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Velcade,1,0.004827597,0.259937621,0.397823054,0.624580883,0.845145353,-40.19117905,40.8023266x^3 + 68.64017835x^2 - 97.69091836x + 2.5113085
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Masitinib (AB-1010),1,0.119879528,0.212331268,0.539891773,1.830933872,10,263.7657613,14.76702325x^3 + 25.55898686x^2 - 48.0476681x + 35.58968551
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,R547,1,0.549885417,1.10090805,2.52198026,4.756120167,6.588003887,296.2923163,-3.98975126x^3 - 29.03617297x^2 - 55.85111249x + 77.38274722
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Sorafenib,1,0.064203378,0.151716731,0.52049232,1.959303686,6.905063538,186.3082044,6.82373017x^3 + 8.47285729x^2 - 44.06424346x + 36.97824089
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Sorafenib,2,0.085187419,0.184091127,0.583653309,2.277435107,10,231.0009612,9.12751729x^3 + 12.54436017x^2 - 44.73324146x + 38.97010124
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Sorafenib,3,0.078109441,0.148398351,0.391887642,1.111442752,2.618848388,112.0052276,10.78739443x^3 + 17.47264834x^2 - 50.52115143x + 27.28043588
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,GS-1101 (CAL-101),1,0.055060618,0.35882185,7.687999412,10,10,555.7592725,1.48429584x^3 + 1.04834933x^2 - 20.11930818x + 65.96766327
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Gefitinib,1,0.388571865,2.424176265,10,10,10,727.2229725,2.24881093x^3 + 1.69046731x^2 - 19.17837546x + 81.99741721
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,SB-202190,1,0.008712884,0.021511093,0.200084337,10,10,745.5256991,3.54453012x^3 + 24.80204765x^2 + 17.15853619x + 51.08870667
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,GSK-1838705A,1,0.126265421,0.358993877,10,10,10,1379.292303,22.60261299x^3 + 71.22132273x^2 + 30.87329389x + 76.628442
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Cediranib (AZD2171),1,0.195409501,0.345888286,0.84458226,2.173287881,4.35796831,160.9629409,10.29139207x^3 + 6.51176535x^2 - 63.59301207x + 45.30396127
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,CI-1040 (PD184352),1,0.02077344,0.066385046,0.396134398,3.144948714,10,247.366738,2.11043208x^3 + 4.93503269x^2 - 28.69749375x + 37.79820839
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Roscovitine (CYC-202),1,10,10,10,10,10,986.8558878,-0.18734547x^3 + 3.08551504x^2 + 5.82511193x + 93.93274273
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,INK-128,1,0.002945827,0.004592178,0.012721184,1.581718556,5,117.1130851,-5.84744969x^3 - 6.02698308x^2 - 3.12568446x + 25.9075709
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,JNK Inhibitor II,1,0.426546233,9.830923012,50,50,50,3444.89939,-1.00845057x^3 - 2.61548591x^2 - 8.61858658x + 87.11786142
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Crenolanib,1,0.006778185,0.011014465,6.189319893,8.166951506,9.453374623,665.9093618,-29.25301546x^3 - 76.60837313x^2 - 13.30541778x + 123.05654329
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Crenolanib,2,0.00672085,0.008765891,6.859876678,8.09090259,8.864213689,889.0801121,-50.33008902x^3 - 130.45474522x^2 - 6.29865983x + 175.95108566
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Ibrutinib (PCI-32765),1,3.06031509,4.018244466,5.876374955,8.095100667,9.614978257,664.470706,-14.25239834x^3 - 60.39637973x^2 - 48.26289689x + 129.32982943
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Tofacitinib (CP-690550),1,0.052683106,0.705329423,6.971735615,10,10,571.1060167,-1.24138548x^3 - 6.29642262x^2 - 20.01875949x + 72.10539324
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,JAK Inhibitor I,1,0.200499156,0.810022395,10,10,10,673.462636,5.16195336x^3 + 8.62771276x^2 - 20.81311646x + 73.02725464
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Pelitinib (EKB-569),1,0.071655021,0.124358392,0.293894826,0.767328305,1.895817585,160.9652529,15.32346341x^3 + 32.57718215x^2 - 44.38435571x + 19.48730802
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,SNS-032 (BMS-387032),1,0.019164523,0.04018567,0.112169715,0.309520971,0.629294798,0,9.58140744x^3 + 26.64242076x^2 - 33.60172679x + 2.24118493
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PI-103,1,0.009201016,0.020931986,0.095465936,0.942558857,10,239.2550409,1.84867174x^3 + 12.77571571x^2 - 13.7514788x + 24.63830227
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PD173955,1,0.067616365,0.152394154,10,10,10,802.9681343,14.18005448x^3 + 42.59054053x^2 - 0.30604568x + 54.05285783
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Axitinib (AG-013736),1,0.022274478,0.050701767,0.16437221,0.630635017,10,225.4047663,9.37177208x^3 + 26.96154945x^2 - 23.88122047x + 19.21282365
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PP2,1,0.415738245,1.594705256,4.793882022,9.999273853,10,521.6115169,-5.46788941x^3 - 22.31318107x^2 - 29.07730928x + 81.85553805
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,CYT387,1,0.092020559,0.383371372,6.002978695,10,10,541.8344216,3.79508124x^3 + 4.36548439x^2 - 24.23243487x + 64.42719857
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,GW-2580,1,0.064169099,0.163125391,0.793238686,10,10,446.2791841,8.56916624x^3 + 18.40058793x^2 - 26.13471575x + 47.19346631
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,BI-2536,1,0.043973085,0.080221057,0.191612071,0.45946677,0.84641855,0.853846696,13.68414588x^3 + 29.82472017x^2 - 46.26764242x + 6.49833496
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Rapamycin,1,0.014601864,0.075812571,1.70241471,10,10,456.0290486,0.46637106x^3 + 2.46538811x^2 - 16.7976305x + 53.743967
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Trametinib (GSK1120212),1,0.004763996,0.006326786,0.01137846,0.028540447,10,196.6021862,-10.74854317x^3 - 6.90200903x^2 + 11.85567306x + 20.17232144
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PHA-665752,1,0.008361114,0.013276428,10,10,10,2272.355178,-9.52157192x^3 + 19.24893106x^2 + 113.20703359x + 156.71265678
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PP242,1,0.008753093,0.020912394,0.086764227,0.416943472,1.418116336,46.06414972,2.2148259x^3 + 9.82601448x^2 - 26.2154679x + 13.74330315
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,YM-155,1,0.056191306,0.126886445,0.389758741,1,1,49.49223571,1.73767803x^3 - 6.129009x^2 - 61.62316102x + 25.92890448
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,JNJ-7706621,1,2.857297864,3.948553507,6.023215361,8.461502324,10,647.3388255,-18.17238863x^3 - 57.9324546x^2 - 30.62257733x + 117.72900595
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,KW-2449,1,0.191688473,0.436050819,1.767910814,10,10,426.3403133,7.66223064x^3 + 7.29567129x^2 - 41.08049958x + 59.60292195
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,SB-431542,1,10,10,10,10,10,988.1522599,0.05007614x^3 + 0.18836977x^2 - 0.43946296x + 98.99709769
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,NF-kB Activation Inhibitor,1,10,10,10,10,10,1137.36254,-1.58372281x^3 - 4.5868281x^2 + 4.20702163x + 114.27043781
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,KN93,1,4.722236308,10,10,10,10,892.8097355,-5.24656588x^3 - 12.82764046x^2 - 1.79321892x + 98.64619876
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Lapatinib,1,0.011117878,10,10,10,10,934.3281234,-12.84832933x^3 - 30.57832366x^2 + 0.99202478x + 112.83435925
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Lestaurtinib (CEP-701),1,0.00652609,0.014680463,0.047622339,0.176873283,1,19.2602948,8.3619607x^3 + 37.34482179x^2 + 5.93262646x + 11.88651039
629,11-00478,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,MEK1/2 Inhibitor,1,0.216504855,2.286822397,10,10,10,698.6252183,-0.50202209x^3 - 4.41457553x^2 - 15.83293644x + 81.28066908
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,AZD1480,1,0.004572222,4.967607721,10,10,10,751.2794459,-7.39409629x^3 - 17.4918387x^2 - 4.67063185x + 89.22288981
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,GSK690693,1,0.009677075,10,10,10,10,965.6684069,1.76537866x^3 + 12.34371281x^2 + 13.71839267x + 81.97830226
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Erlotinib,1,0.021384587,0.08232471,10,10,10,598.8567501,4.57151426x^3 + 16.35185372x^2 - 6.98638869x + 54.02305996
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Axitinib (AG-013736),1,0.209077877,10,10,10,10,819.9191078,6.2687707x^3 + 14.17364441x^2 - 10.21239713x + 78.47918456
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Ibrutinib (PCI-32765),1,0.053203057,0.361866785,10,10,10,819.7755726,6.50575395x^3 + 18.61288734x^2 - 1.57220664x + 71.23837016
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,PI-103,1,0.005798633,0.019324961,0.108001359,10,10,695.0562152,7.78187621x^3 + 34.51576018x^2 + 16.04450196x + 40.28873303
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Doramapimod (BIRB 796),1,0.020620188,10,10,10,10,848.6838434,1.64034728x^3 + 9.10400766x^2 + 3.43950603x + 77.7854305
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,YM-155,1,0.114414743,0.290811711,0.931634339,1,1,68.00127932,-0.6942205x^3 - 14.68178907x^2 - 57.55774096x + 48.24370619
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,PD173955,1,1.054302901,10,10,10,10,894.0056209,7.04821957x^3 + 10.85909209x^2 - 15.60322658x + 90.35252181
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,SB-431542,1,10,10,10,10,10,1419.377151,9.46460243x^3 + 34.70628052x^2 + 32.78247846x + 102.57773759
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,BI-2536,1,0.038842153,0.151112753,0.761642145,2.970355474,6.404792859,201.9476462,1.42300174x^3 - 4.52207508x^2 - 40.95217571x + 45.22302914
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,SNS-032 (BMS-387032),1,0.014472825,0.034118918,0.115763155,0.417620918,1.218251101,94.58162734,6.60831197x^3 + 20.45930257x^2 - 27.04083753x + 12.16383817
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Dovitinib (CHIR-258),1,0.160400036,0.603362656,2.208401773,5.427296616,8.450296319,327.5145916,-2.96650708x^3 - 18.0526148x^2 - 41.84515995x + 66.65608838
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,PD98059,1,0.004572222,0.012643963,10,10,10,725.0240667,-2.19242251x^3 + 3.08706999x^2 + 9.27016621x + 66.48046118
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,MLN120B,1,0.009533449,5,5,5,5,489.9657809,-0.24141994x^3 + 4.29552124x^2 + 11.57977011x + 93.86725908
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Crizotinib (PF-2341066),1,0.166911748,0.831195277,2.758661539,6.029996372,8.803091675,363.2397932,-5.16623892x^3 - 23.884246x^2 - 38.52330001x + 72.05801848
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Lapatinib,1,10,10,10,10,10,1035.787842,0.10662634x^3 + 0.70896218x^2 + 1.61590546x + 102.31424112
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Tozasertib (VX-680),1,2.215942929,6.398275769,10,10,10,808.3510651,-3.13554795x^3 - 12.81879084x^2 - 14.52550161x + 96.67949607
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Tandutinib (MLN518),1,9.045135489,10,10,10,10,994.5506423,-5.15268724x^3 - 14.2730898x^2 - 2.41922992x + 109.87769556
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,CI-1040 (PD184352),1,0.011697051,10,10,10,10,795.826761,-0.86818108x^3 + 1.19815972x^2 + 0.01914617x + 79.30497895
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Staurosporine,1,0.341061166,0.457754468,0.768854118,1.442644245,2.661201739,216.8825669,33.78938864x^3 + 49.13664691x^2 - 94.36310671x + 38.63781692
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Gefitinib,1,5.490201495,10,10,10,10,910.3170626,-1.92396124x^3 - 5.65580368x^2 - 4.22715716x + 96.99836335
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,INK-128,1,0.005105243,0.021831207,5,5,5,296.8001841,0.02574034x^3 + 5.99630059x^2 - 0.37088562x + 57.96015717
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,SU14813,1,0.568271328,6.66287867,10,10,10,786.3485905,0.03743684x^3 - 3.04490501x^2 - 12.28987909x + 87.16750718
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Nilotinib,1,10,10,10,10,10,994.9332962,5.87088926x^3 + 6.75393961x^2 - 15.05106696x + 102.62061072
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Nilotinib,2,10,10,10,10,10,1067.551083,6.96840535x^3 + 9.33878413x^2 - 17.23354732x + 109.43570729
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Nilotinib,3,1.597446087,4.322694245,10,10,10,755.0955744,-0.52589924x^3 - 11.12823142x^2 - 25.05492006x + 95.56176551
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,AMPK Inhibitor,1,0.013091103,0.079790455,10,10,10,680.5839635,-3.48973732x^3 - 2.08327809x^2 - 1.52228336x + 71.2201209
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Flavopiridol,1,0.045384092,0.095514228,0.2950798,1.35688511,10,300.1392999,11.67183735x^3 + 28.08796118x^2 - 29.2288946x + 28.35347011
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,GSK-1838705A,1,0.047952475,10,10,10,10,854.2193673,-1.95842472x^3 - 1.60313945x^2 - 0.71101691x + 87.3558963
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,KI20227,1,0.027937983,8.509289893,10,10,10,794.7425447,-2.88016675x^3 - 4.98990711x^2 - 3.87001714x + 85.2293688
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,AKT Inhibitor X,1,1.550361575,50,50,50,50,5383.789819,8.0409502x^3 + 6.18581253x^2 - 12.82470006x + 92.16238845
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,AST-487,1,0.325181161,10,10,10,10,1074.611869,14.03802074x^3 + 38.26382778x^2 + 0.72889585x + 82.87815173
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Motesanib (AMG-706),1,0.110339073,4.254392303,10,10,10,750.5361287,-1.58850002x^3 - 2.9843021x^2 - 9.30967927x + 82.42938317
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,KN92,1,10,10,10,10,10,923.1898829,2.53978937x^3 + 3.26581942x^2 - 7.20121982x + 93.91200247
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,RAF265 (CHIR-265),1,0.137582922,0.242440533,0.759738016,10,10,544.2629519,15.37039035x^3 + 38.77472375x^2 - 29.07688734x + 46.00400283
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Crenolanib,1,3.156292831,4.283149738,6.503852121,9.200690183,10,707.0515724,-13.21947651x^3 - 52.89137847x^2 - 40.5779968x + 125.07927164
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Crenolanib,2,1.968069464,3.497227169,6.807517701,10,10,656.0656775,-9.34828256x^3 - 33.27262791x^2 - 27.1349476x + 101.09317352
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,A-674563,1,0.047977054,0.497856799,3.085809055,9.81102095,10,441.5269206,-2.06911228x^3 - 11.62934406x^2 - 29.00790193x + 67.22307857
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Roscovitine (CYC-202),1,0.689035178,10,10,10,10,848.0312036,8.47154211x^3 + 13.71585804x^2 - 20.18324221x + 86.41215609
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Vandetanib (ZD6474),1,0.005375263,0.00742967,0.016914592,6.175284216,8.764502015,318.6090299,-17.37357114x^3 - 33.41021544x^2 - 1.47466719x + 55.6392005
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Pazopanib (GW786034),1,0.042825933,0.167746707,10,10,10,756.9689165,6.83180053x^3 + 22.12374897x^2 - 2.01758088x + 63.32009008
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Pelitinib (EKB-569),1,0.090349144,0.238638078,1.183553528,10,10,392.6626784,5.20485766x^3 + 7.9452912x^2 - 33.39170467x + 52.39926973
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,LY-333531,1,0.24026392,10,10,10,10,845.3076551,6.88144352x^3 + 16.1895916x^2 - 9.63345997x + 79.45900678
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Bosutinib (SKI-606),1,0.011164595,0.760205252,5.73287961,10,10,546.6375126,-4.80796556x^3 - 13.80478448x^2 - 17.26725024x + 73.13160391
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,PP2,1,10,10,10,10,10,971.1229918,5.02059663x^3 + 10.29349702x^2 - 10.57948556x + 96.20959009
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,JAK Inhibitor I,1,0.006302531,0.015189372,10,10,10,552.2650448,-3.88237994x^3 - 2.05079213x^2 - 0.33391329x + 57.82851059
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,R547,1,0.303926838,0.635927043,1.817105272,4.748147657,8.364195193,306.7563449,3.78254801x^3 - 8.64162294x^2 - 54.49303997x + 64.64979323
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,SB-203580,1,10,10,10,10,10,966.294704,-4.85825723x^3 - 11.0938888x^2 + 0.76554489x + 103.53550527
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Alisertib (MLN8237),1,1.143602008,10,10,10,10,849.4736852,3.6138693x^3 + 3.3949728x^2 - 15.66842027x + 90.90083138
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,VX-745,1,0.010740908,0.059561814,10,10,10,670.4265364,5.08593249x^3 + 18.62864269x^2 - 0.28063214x + 56.05017476
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,PP242,1,0.01014285,0.074277213,1.559219849,9.108942157,10,377.0794805,-1.97954985x^3 - 6.51492781x^2 - 22.84317744x + 54.66326917
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Barasertib (AZD1152-HQPA),1,0.02025366,10,10,10,10,975.6248285,1.11263572x^3 + 9.89612406x^2 + 11.1456394x + 85.8975892
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,BMS-345541,1,1.218198727,2.225211308,4.426170313,7.399725868,9.608535612,491.2245626,-9.13766181x^3 - 37.22099841x^2 - 39.7659541x + 93.68790379
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,GW-2580,1,0.013623796,10,10,10,10,956.9312402,-3.52259727x^3 - 1.53996899x^2 + 10.38130088x + 91.85229529
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,PHA-665752,1,0.924572448,3.999947819,10,10,10,727.3460607,-4.97118981x^3 - 14.44676992x^2 - 13.66927026x + 89.55099973
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,JNJ-28312141,1,0.008314451,0.025923877,10,10,10,693.662823,-11.10736918x^3 - 22.87555044x^2 - 1.58066634x + 85.7183374
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Go6976,1,0.915512647,10,10,10,10,904.3124225,8.0953688x^3 + 14.9403096x^2 - 16.30203204x + 89.35355044
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,TG100-115,1,0.007030432,7.121540823,10,10,10,841.176936,-9.39041277x^3 - 24.68501199x^2 - 3.97442491x + 102.15102714
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Quizartinib (AC220),1,0.068255935,0.296603584,3.220874014,10,10,502.2305433,3.57022545x^3 + 3.85904953x^2 - 25.01805134x + 61.24476274
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Quizartinib (AC220),2,0.137972832,0.431886012,3.393026102,10,10,509.8343291,4.86940343x^3 + 5.06428408x^2 - 29.8427936x + 63.68113861
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Foretinib (XL880),1,0.009333363,3.068757917,10,10,10,715.247288,-5.0080862x^3 - 8.04632923x^2 - 1.50107834x + 78.21732338
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,TG101348,1,0.059407379,0.217952394,1.131406217,6.206669312,10,326.2885591,3.62980419x^3 + 0.10869581x^2 - 36.35705306x + 51.94854083
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,p38 MAP Kinase Inhibitor,1,7.687431028,10,10,10,10,948.5175151,3.26485163x^3 - 1.31641251x^2 - 17.7688025x + 104.50309631
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Midostaurin (PKC412),1,0.513201271,5.866694878,10,10,10,777.8619888,0.92063697x^3 - 1.46605647x^2 - 13.89039931x + 86.12121825
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,NF-kB Activation Inhibitor,1,0.414876042,10,10,10,10,905.0692999,6.06722242x^3 + 13.75819076x^2 - 7.21001044x + 85.57510074
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Linifanib (ABT-869),1,0.544212217,2.51259988,10,10,10,701.2198544,1.13117833x^3 - 4.25058742x^2 - 22.14115247x + 84.46724281
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,LY294002,1,0.585857829,2.029762712,20.16133032,50,50,2582.347528,1.85842363x^3 - 0.79269925x^2 - 27.87919167x + 83.59224684
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,SYK Inhibitor,1,10,10,10,10,10,1134.10035,-3.24456188x^3 - 8.67225237x^2 + 4.10314737x + 116.64539199
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,KW-2449,1,3.815975509,8.864515528,10,10,10,870.3032337,-4.07587288x^3 - 14.80354126x^2 - 11.05407355x + 102.23850581
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Dasatinib,1,0.002489419,1,1,1,1,88.86100834,-0.18101875x^3 + 3.13518294x^2 + 10.18279845x + 92.06157945
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Dasatinib,2,0.003925393,0.023253362,1,1,1,65.65530156,3.0995791x^3 + 18.81644152x^2 + 18.19840189x + 68.02864591
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Dasatinib,3,0.00529869,0.040276126,1,1,1,73.48416455,3.99383396x^3 + 23.25315595x^2 + 27.19246759x + 78.52503519
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Tofacitinib (CP-690550),1,0.028592999,0.898987597,10,10,10,695.3073342,0.17490149x^3 + 0.61567889x^2 - 9.4674879x + 74.56086425
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,SGX-523,1,10,10,10,10,10,954.3034095,1.35460155x^3 + 4.58740393x^2 - 0.4224886x + 92.92452587
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Afatinib (BIBW-2992),1,0.011931345,0.43865077,2.430810054,6.265724822,9.70967418,357.3117006,-4.82382873x^3 - 19.55302439x^2 - 32.40414131x + 65.6863898
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,PLX-4720,1,0.019237139,6.473276294,10,10,10,814.0031051,-7.4626247x^3 - 20.43143072x^2 - 7.92617145x + 98.85388435
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,NVP-TAE684,1,0.009546976,0.053704804,10,10,10,621.2469158,-2.09009562x^3 - 0.57053134x^2 - 4.61035242x + 65.78392041
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Masitinib (AB-1010),1,0.007809161,6.424748795,10,10,10,785.4322161,-6.5409014x^3 - 14.14210257x^2 - 1.34157572x + 88.76195797
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,MEK1/2 Inhibitor,1,2.287537258,10,10,10,10,865.9948058,4.1644012x^3 + 0.0316371x^2 - 22.26845532x + 97.80521529
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,SB-202190,1,10,10,10,10,10,984.2877981,4.06089923x^3 + 2.91999566x^2 - 14.31409378x + 103.70460338
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,BEZ235,1,0.033895707,0.11914369,0.9805666,10,10,506.7407175,6.921868x^3 + 16.7420131x^2 - 17.66298915x + 49.84824819
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,GDC-0941,1,0.075573667,0.235826875,10,10,10,603.7692945,7.4278597x^3 + 17.32967198x^2 - 17.53611362x + 59.0105593
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,GDC-0941,2,0.021180052,0.359479636,10,10,10,757.89551,1.39145308x^3 + 7.27379203x^2 - 1.99813011x + 72.79820847
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Ponatinib (AP24534),1,0.000766,0.001531857,0.877359787,1,1,61.53212713,-10.43869658x^3 - 49.18895049x^2 - 65.90681194x + 46.41192972
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Ponatinib (AP24534),2,0.000743,0.248398769,0.926034165,1,1,65.2319742,-6.68132859x^3 - 37.38277035x^2 - 65.01817946x + 47.87153589
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Ponatinib (AP24534),3,0.113457744,0.287963613,0.863879547,1,1,66.99765195,-1.46760663x^3 - 19.64612158x^2 - 63.7832184x + 46.02573834
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Velcade,1,0.033166199,0.137296358,0.827526892,4.448735606,10,278.4913724,1.92381451x^3 - 0.87245399x^2 - 34.45032137x + 47.17453427
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Vargetef,1,0.216008889,1.384775524,10,10,10,699.0334098,3.03474427x^3 + 3.2192689x^2 - 18.02139592x + 77.47493069
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,CYT387,1,1.132012326,3.571806356,10,10,10,701.7263067,-5.41985004x^3 - 17.91871161x^2 - 17.35207123x + 90.9872388
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Trametinib (GSK1120212),1,0.005328315,0.014143931,10,10,10,722.9168143,-2.99081606x^3 + 1.46369103x^2 + 8.91795483x + 67.56751315
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Imatinib,1,0.005295242,3.069124068,10,10,10,718.1279653,5.93096262x^3 - 4.97474928x^2 - 39.88771292x + 94.9207238
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Canertinib (CI-1033),1,0.913306326,2.416432959,10,10,10,690.5519748,4.98100748x^3 - 2.40741979x^2 - 35.33429624x + 88.61244886
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,H-89,1,0.082127842,10,10,10,10,986.5506854,2.93246681x^3 + 12.63903401x^2 + 7.52430019x + 87.02562161
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,STO609,1,10,10,10,10,10,973.7884741,2.20724436x^3 - 0.05744013x^2 - 10.39478127x + 102.58051607
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,AKT Inhibitor IV,1,0.020645593,0.057886161,2.071253794,25,25,1019.63667,-2.74852672x^3 + 1.53521335x^2 - 11.26890042x + 53.49699566
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Cediranib (AZD2171),1,1.094515829,2.144438409,4.659511706,8.336533107,10,519.2932523,-6.50404052x^3 - 29.52293482x^2 - 39.60600228x + 91.59923809
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,GDC-0879,1,10,10,10,10,10,1283.366818,3.45614593x^3 + 8.79337503x^2 + 8.60201227x + 117.87028584
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,KN93,1,1.69041098,5.113081057,10,10,10,793.0174641,3.91367996x^3 - 3.25596633x^2 - 30.95669285x + 97.18075287
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Selumetinib (AZD6244),1,0.059585252,10,10,10,10,855.9325588,-0.45724321x^3 + 1.95296706x^2 - 0.79513917x + 85.25580886
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,PD153035,1,0.391923767,1,1,1,1,90.32009373,1.26775695x^3 + 2.99727187x^2 - 9.68775317x + 85.64837831
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Rapamycin,1,0.00459825,0.007114852,0.020833763,10,10,419.9960119,-6.95379104x^3 - 3.94836393x^2 + 8.14713263x + 41.81251154
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Lestaurtinib (CEP-701),1,0.006858513,0.021720542,1,1,1,80.79623597,10.74213552x^3 + 62.37326351x^2 + 90.07128069x + 101.69191938
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,AT7519,1,0.075454089,0.125969645,0.278546573,0.657474753,1.320263412,129.439042,17.83017775x^3 + 36.87058012x^2 - 47.73376214x + 15.19146369
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,JNK Inhibitor II,1,0.03102799,0.074452368,50,50,50,3524.428049,-2.27962058x^3 + 10.3286874x^2 - 0.26488172x + 58.283413
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,R406,1,0.257328705,0.6109579,10,10,10,814.6978292,16.45047642x^3 + 35.41447578x^2 - 20.03417029x + 69.25243817
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Sunitinib,1,0.676226495,1,1,1,1,92.85875425,-2.68894066x^3 - 15.58520119x^2 - 26.59299656x + 85.91837668
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Sunitinib,2,0.000507,0.000681,0.001365084,1,1,52.0665222,-17.16612618x^3 - 79.20640184x^2 - 91.68780668x + 33.7797401
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Sunitinib,3,0.098857965,0.287029541,1,1,1,70.13203251,1.87205706x^3 - 1.38738904x^2 - 38.01046538x + 55.10140322
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Sorafenib,1,0.0073253,0.035776017,9.43785104,10,10,613.0234792,-6.01408786x^3 - 11.9944161x^2 - 6.16344438x + 72.97983838
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Sorafenib,2,4.199477647,10,10,10,10,899.0008759,-0.87441917x^3 - 2.58969823x^2 - 6.01468439x + 94.96572733
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Sorafenib,3,0.0122754,10,10,10,10,927.2275777,-2.0479947x^3 + 0.04726903x^2 + 7.23043023x + 89.35268955
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Neratinib (HKI-272),1,0.078795419,0.267990866,10,10,10,575.7024561,5.85796705x^3 + 12.51865057x^2 - 19.98812627x + 60.57063062
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,GS-1101 (CAL-101),1,1.707575098,10,10,10,10,875.6793701,4.12635805x^3 + 3.8976664x^2 - 16.53004447x + 93.57899318
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,Vatalanib (PTK787),1,3.161555869,10,10,10,10,891.8630324,1.95712127x^3 - 0.7957705x^2 - 14.94545997x + 97.42561738
516,11-00499,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123,Standard,JNJ-7706621,1,0.013733378,2.771273742,5.805462343,9.815303954,10,585.2420596,-10.75182447x^3 - 34.21453738x^2 - 24.54739371x + 93.50419818
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Barasertib (AZD1152-HQPA),1,7.475174637,10,10,10,10,945.0854242,-2.82259364x^3 - 8.82086839x^2 - 4.49340361x + 102.53973903
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GSK-1838705A,1,0.325755144,10,10,10,10,1290.137552,11.856214x^3 + 37.45097201x^2 + 22.32664158x + 93.35965149
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Trametinib (GSK1120212),1,0.004700801,0.006459208,0.012895281,0.056370304,10,354.7708616,-10.1937396x^3 - 7.29674105x^2 + 14.42872712x + 34.54325887
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,KI20227,1,0.06608031,0.281088336,10,10,10,607.5802228,4.31653559x^3 + 10.0903809x^2 - 16.51677974x + 63.55416674
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,STO609,1,3.224409053,10,10,10,10,900.2265826,3.49343828x^3 + 1.18133415x^2 - 16.74344575x + 97.7486108
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,INK-128,1,0.002681254,0.004071455,0.010373877,0.121165112,5,109.1402361,-6.10246856x^3 - 6.41504319x^2 - 1.7808639x + 24.05774409
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,R406,1,0.056131851,0.194151911,1.32602214,10,10,431.503815,4.98248976x^3 + 7.61839134x^2 - 27.63674893x + 53.26331619
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Quizartinib (AC220),1,0.009890463,0.036147969,0.207023566,1.425183375,10,189.5019582,3.1352198x^3 + 8.15422384x^2 - 26.72662288x + 28.90796251
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Quizartinib (AC220),2,0.007807397,0.03117314,0.242145593,10,10,315.9754565,2.71544473x^3 + 9.38451758x^2 - 17.87507903x + 36.06467841
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sunitinib,1,0.020386954,0.055245112,0.398387553,1,1,52.67966745,5.50289047x^3 + 22.69178458x^2 - 3.87776933x + 45.17631887
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sunitinib,2,0.018224951,0.069502165,0.487584784,1,1,53.48815386,2.17233394x^3 + 4.34711372x^2 - 27.06812771x + 41.19901689
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sunitinib,3,0.031223036,0.079957506,1,1,1,60.17590131,7.57709247x^3 + 32.26380151x^2 + 8.43116886x + 55.42033672
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Roscovitine (CYC-202),1,2.993927611,10,10,10,10,880.8284483,-1.26128039x^3 - 3.98714928x^2 - 5.09833633x + 93.46858305
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,NF-kB Activation Inhibitor,1,10,10,10,10,10,1070.243382,-0.95951618x^3 - 12.42286395x^2 - 12.40911686x + 120.72287783
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Alisertib (MLN8237),1,5.874624773,8.614688879,10,10,10,969.6798583,-8.3715536x^3 - 32.55838958x^2 - 16.44039069x + 125.70182504
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,TG100-115,1,1.000900326,2.103880317,8.192294708,10,10,643.5684169,6.60187683x^3 - 3.62259085x^2 - 46.01096034x + 90.01798305
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,KN92,1,10,10,10,10,10,1010.401744,3.65455021x^3 + 8.3785409x^2 - 1.64181934x + 96.51248428
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,BI-2536,1,0.093945932,0.175892583,0.463123807,1.396929011,10,179.6126444,12.34114387x^3 + 19.78261339x^2 - 49.43904301x + 31.72259068
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,MLN120B,1,5,5,5,5,5,511.6738217,-0.03947561x^3 + 1.27639111x^2 + 5.46392434x + 100.60312139
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Velcade,1,0.024621969,0.049810765,0.132735539,0.356617878,0.738933615,72.23247023,11.9243031x^3 + 31.89947304x^2 - 32.23065135x + 5.24138754
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Vargetef,1,0.076361588,0.473251948,10,10,10,725.7920796,4.32495963x^3 + 11.54904953x^2 - 9.70386354x + 70.77630749
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PD98059,1,5.212189677,10,10,10,10,925.3018481,-1.64388911x^3 - 13.1372898x^2 - 16.1714194x + 108.95534326
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GDC-0879,1,10,10,10,10,10,1322.999268,-4.25229046x^3 - 15.07955901x^2 + 4.70101635x + 138.79280628
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PHA-665752,1,0.012646196,10,10,10,10,860.2971054,-5.13768457x^3 - 9.21419105x^2 + 1.80444313x + 91.48910677
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,NVP-TAE684,1,0.232899365,0.894150888,4.725304596,10,10,529.4553686,0.72363647x^3 - 6.80533656x^2 - 30.625327x + 73.52809002
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,CYT387,1,0.598280345,1.81392173,6.293057579,10,10,590.9784614,-1.48276938x^3 - 13.57422307x^2 - 30.56919819x + 83.8393017
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Tandutinib (MLN518),1,0.118648223,0.503882537,6.984606002,10,10,555.6900165,3.31228577x^3 + 2.37934093x^2 - 25.0167022x + 67.42979737
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PLX-4720,1,1.235272242,7.475711525,10,10,10,806.7583697,-1.13595074x^3 - 6.11793507x^2 - 12.31027171x + 91.18201668
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,A-674563,1,0.320892739,0.625301084,1.874282466,7.635009251,10,382.0185822,8.28866491x^3 + 2.65092742x^2 - 53.12206073x + 64.12788829
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AKT Inhibitor IV,1,0.269572728,0.449797522,1.016180138,2.54773298,6.048640509,384.8888244,16.52638232x^3 + 9.53291856x^2 - 69.33996898x + 50.48287945
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Crizotinib (PF-2341066),1,0.173684001,0.572298782,2.139306272,5.728440946,9.472427992,341.1420432,-0.86192651x^3 - 14.05159445x^2 - 42.34594028x + 65.54952238
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Lestaurtinib (CEP-701),1,0.015829704,0.058581474,0.402008258,1,1,51.29577447,2.92618935x^3 + 7.54652869x^2 - 23.93008593x + 39.52868702
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SB-202190,1,0.021929496,0.094845925,10,10,10,934.9234446,5.74829062x^3 + 26.3514038x^2 + 15.49663966x + 69.43004968
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Bosutinib (SKI-606),1,2.365753677,3.452796159,5.761936389,8.79117397,10,630.8197189,-7.49526456x^3 - 41.93793191x^2 - 48.37036888x + 114.3462066
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,JNJ-28312141,1,0.00726974,0.01742608,10,10,10,606.9313482,-1.62922101x^3 + 6.75299487x^2 + 5.42960627x + 54.79602738
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sorafenib,1,0.251014215,0.645136518,2.138895882,5.736001783,9.780109018,346.1343378,1.03750937x^3 - 11.81437513x^2 - 46.46059212x + 66.59152172
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sorafenib,2,0.157729014,0.401884302,1.458244662,4.965128211,10,308.7239787,3.92830257x^3 - 3.94633114x^2 - 46.04661557x + 57.63248251
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sorafenib,3,0.210346862,0.451809318,1.581402468,10,10,385.9048409,8.14524478x^3 + 5.824735x^2 - 45.83112274x + 58.82734311
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PP2,1,0.83872901,2.142545288,5.171768338,9.535749677,10,544.3769039,-7.84799334x^3 - 28.47254552x^2 - 28.87251431x + 87.95736751
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PI-103,1,0.022127581,0.056910445,0.227076118,1.241426057,10,227.2761443,6.1413027x^3 + 16.7825153x^2 - 26.88649016x + 27.37207349
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AMPK Inhibitor,1,1.614839123,10,10,10,10,845.9203065,-1.90946673x^3 - 5.4302489x^2 - 6.16393121x + 91.53533602
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GDC-0941,1,0.010272369,0.028656983,0.140074446,0.978537784,10,201.2073094,3.35969313x^3 + 12.42925236x^2 - 21.36148648x + 24.79762284
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GDC-0941,2,0.004807518,0.00707081,0.017521338,8.16396689,10,303.4641305,-8.91605942x^3 - 9.04928468x^2 + 3.62847545x + 35.9773314
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Selumetinib (AZD6244),1,0.00721958,0.033091964,0.826797568,10,10,417.8543276,-0.02268168x^3 + 2.24676948x^2 - 14.32277093x + 48.80158528
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AST-487,1,0.16134324,2.427743176,10,10,10,702.8299093,-0.63328966x^3 - 5.18820379x^2 - 14.55302034x + 81.41189182
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Nilotinib,1,0.123648203,0.244394462,0.892624686,10,10,527.7900638,15.44685826x^3 + 31.52173615x^2 - 29.88256695x + 48.45100432
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Nilotinib,2,0.386023457,0.767522587,2.283785344,7.710072922,10,401.6301116,6.73076814x^3 - 2.14313629x^2 - 52.94606362x + 68.9545399
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Nilotinib,3,0.34194227,0.781088602,2.840103021,10,10,453.7426044,4.72543624x^3 - 2.45693351x^2 - 44.5378855x + 70.25522314
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,JNK Inhibitor II,1,0.65396504,20.42498005,50,50,50,3680.036585,-3.71725322x^3 - 2.74028647x^2 - 1.34237028x + 89.82230555
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,TG101348,1,0.144278248,0.362169078,1.27637204,4.189084067,8.91225832,275.9989375,4.1392076x^3 - 3.76318222x^2 - 47.61773769x + 55.08373672
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AZD1480,1,4.539669245,9.665082792,10,10,10,898.6872168,-3.42997924x^3 - 15.12001286x^2 - 13.84576241x + 106.5968476
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,KW-2449,1,0.710094469,2.448024797,10,10,10,675.9498527,0.54649527x^3 - 8.16673093x^2 - 26.00900625x + 86.31521764
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Axitinib (AG-013736),1,0.038604431,0.120279258,0.75652149,10,10,443.6141148,6.34903384x^3 + 14.87716856x^2 - 21.98912974x + 47.12822221
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Tozasertib (VX-680),1,1.364819027,3.645930038,10,10,10,720.2168274,-1.75247235x^3 - 13.23332307x^2 - 25.210587x + 93.65108631
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GW-2580,1,0.088918278,0.328752923,10,10,10,587.3943853,5.40992724x^3 + 10.35788024x^2 - 20.50935878x + 63.28369828
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Staurosporine,1,0.220444039,0.267468482,0.372187787,0.530231563,0.670181608,-23.28454014,51.4870836x^3 + 104.73227427x^2 - 108.32292876x - 11.72086292
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Imatinib,1,0.269504003,1.352054682,6.848112664,10,10,588.7059229,-1.02823176x^3 - 9.60361369x^2 - 25.35170349x + 78.48803197
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GS-1101 (CAL-101),1,0.014554855,0.137704264,1.731807677,7.500078118,10,363.448015,-2.20338492x^3 - 8.96871078x^2 - 27.01356497x + 56.98277698
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,YM-155,1,0.18158757,0.337453671,0.676973358,1,1,64.82657194,-9.29895523x^3 - 60.00673655x^2 - 118.08075882x + 31.67108961
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Go6976,1,0.473907538,10,10,10,10,795.2432008,4.89057574x^3 + 7.29918445x^2 - 17.08105095x + 83.8596288
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Dasatinib,1,0.002596255,0.006633071,0.026231248,1,1,33.18157676,8.29704128x^3 + 47.62125632x^2 + 48.4720167x + 40.38309791
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Dasatinib,2,0.001351056,0.003690611,0.018051963,1,1,30.85452356,4.53853158x^3 + 30.2967573x^2 + 30.35811444x + 34.88801515
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Dasatinib,3,0.003016877,0.008784346,0.049761769,1,1,41.63465564,5.95247113x^3 + 34.28053057x^2 + 30.74271829x + 45.02134793
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,JNJ-7706621,1,0.64658712,1.557973435,3.914467398,7.59191874,10,461.3866518,-5.44846494x^3 - 26.43013859x^2 - 38.99093147x + 83.52701066
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,JAK Inhibitor I,1,0.352291767,2.234711008,10,10,10,730.7755528,3.33648444x^3 + 3.17962588x^2 - 18.92945909x + 81.08069937
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AT7519,1,0.081406157,0.139297222,0.322603601,0.837851987,2.54156272,196.5750869,17.44360505x^3 + 35.40604083x^2 - 45.1699537x + 21.32837129
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Rapamycin,1,0.01295835,0.053436115,0.670067852,10,10,424.7247915,1.91657887x^3 + 7.33206034x^2 - 15.74398986x + 47.05080931
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Flavopiridol,1,0.015489863,0.036700475,0.124025074,0.454690472,1.532391171,132.3103887,7.30235188x^3 + 22.31144915x^2 - 25.56986838x + 13.9267
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Ponatinib (AP24534),1,0.009266659,0.023990969,0.084061143,0.267125814,0.548420704,18.37452919,4.32881646x^3 + 10.44314716x^2 - 41.66904955x - 1.50479153
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Ponatinib (AP24534),2,0.023289155,0.055666891,0.183206753,0.53570048,1,32.89985328,3.14398862x^3 + 1.69646286x^2 - 54.5072297x + 10.1622568
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Ponatinib (AP24534),3,0.001267686,0.058313644,0.232441676,0.590196537,0.933058971,34.7841882,-2.1124332x^3 - 24.47271201x^2 - 81.6235547x + 7.56597477
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Midostaurin (PKC412),1,0.826571924,2.661919028,10,10,10,698.724014,2.23324661x^3 - 5.28619066x^2 - 28.06264051x + 87.71611136
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Dovitinib (CHIR-258),1,0.074915465,0.197027159,0.811291824,5.025370287,10,302.6801884,6.16677721x^3 + 7.06125686x^2 - 38.56578935x + 46.44371628
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,BEZ235,1,0.036512038,0.114529218,0.746504059,10,10,441.7362524,5.86411823x^3 + 14.31517194x^2 - 21.40752943x + 47.06316291
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Crenolanib,1,1.049812608,1.986669265,4.843409308,10,10,552.1791035,-0.38377864x^3 - 15.34595537x^2 - 49.21323049x + 91.04582253
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Crenolanib,2,1.886448653,3.119363236,5.637347508,8.832589345,10,590.7384269,-12.31908521x^3 - 41.41758384x^2 - 31.17435447x + 101.9979746
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Vatalanib (PTK787),1,0.442304984,1.901691605,7.676011435,10,10,619.320197,-2.20357525x^3 - 12.39390535x^2 - 24.38192989x + 82.81962572
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SGX-523,1,10,10,10,10,10,1065.717491,0.53814505x^3 - 2.09409339x^2 - 4.49334222x + 110.04005064
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,H-89,1,10,10,10,10,10,1045.437279,-1.57129285x^3 - 2.70392967x^2 + 4.33224974x + 104.04718386
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PP242,1,0.008149454,0.022079387,0.150921863,2.439055687,10,235.9625777,0.33161274x^3 + 5.2257104x^2 - 18.58715139x + 31.39454868
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Vandetanib (ZD6474),1,2.459411938,3.944483603,7.043909426,10,10,686.5841685,-10.61941331x^3 - 37.76621062x^2 - 27.97779762x + 107.33732218
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,KN93,1,10,10,10,10,10,1112.700192,5.07544417x^3 - 5.44204535x^2 - 25.0431281x + 126.5094984
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AKT Inhibitor X,1,50,50,50,50,50,5111.563863,-2.25978631x^3 - 0.7662994x^2 + 6.3327445x + 101.45980515
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GSK690693,1,0.099687791,0.211578233,10,10,10,1411.948311,27.70744835x^3 + 83.74973608x^2 + 35.35533145x + 69.24646961
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Afatinib (BIBW-2992),1,0.168821625,0.323844303,0.963804909,10,10,341.4356653,11.98259727x^3 + 15.63323241x^2 - 47.84602982x + 49.22998527
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Gefitinib,1,2.566191832,4.767960061,10,10,10,766.3369307,-5.11478742x^3 - 23.06195566x^2 - 26.04003397x + 104.8718714
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,LY294002,1,0.300871235,1.122007107,5.077288602,16.87106052,32.09592323,1078.588737,0.77592648x^3 - 9.86945008x^2 - 31.08893197x + 76.57888237
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,RAF265 (CHIR-265),1,0.346326054,1.277572781,4.557084528,10,10,515.6840086,-2.60097118x^3 - 16.0104218x^2 - 31.67581954x + 78.55418885
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Masitinib (AB-1010),1,0.167231327,0.653522404,5.680079506,10,10,549.5811871,2.61281613x^3 - 0.29573755x^2 - 27.66482545x + 69.91578018
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SB-431542,1,0.133242629,1.311861706,10,10,10,658.0336408,0.18904133x^3 - 2.87162758x^2 - 17.40515648x + 77.09145904
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,BMS-345541,1,1.934495031,3.13449823,5.625972755,8.828395614,10,594.3441295,-11.12998908x^3 - 40.84883777x^2 - 34.35436199x + 103.46131958
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Pazopanib (GW786034),1,0.581563881,3.925215439,10,10,10,752.3649531,1.28066977x^3 - 2.4511303x^2 - 17.55324176x + 86.02045549
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Canertinib (CI-1033),1,1.465209411,2.411370872,4.713319657,8.183128008,10,539.2753016,-2.84786341x^3 - 29.16560537x^2 - 52.66485695x + 99.55280382
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,p38 MAP Kinase Inhibitor,1,0.805067576,5.020506345,10,10,10,782.3210528,5.30521505x^3 + 4.41510348x^2 - 23.85012594x + 87.71936826
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Cediranib (AZD2171),1,0.889089111,1.855216118,4.605905965,9.378149931,10,525.4571874,-2.15231631x^3 - 20.98912989x^2 - 42.262886x + 87.89670416
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Ibrutinib (PCI-32765),1,0.552361119,2.964445312,10,10,10,720.9780969,0.71944996x^3 - 4.09626385x^2 - 19.79906205x + 85.18077498
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,CI-1040 (PD184352),1,0.110147054,0.301053693,1.689635258,10,10,447.1510396,5.84721477x^3 + 8.14441176x^2 - 32.17863098x + 56.83834054
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Doramapimod (BIRB 796),1,0.008737352,0.016826885,10,10,10,625.2393274,-5.07371245x^3 + 1.56756071x^2 + 9.30510942x + 58.24810151
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Lapatinib,1,3.068567877,5.021356436,9.066100438,10,10,768.0154923,-11.12965033x^3 - 34.14393465x^2 - 17.673064x + 107.98637242
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SB-203580,1,0.147446937,0.370666543,10,10,10,766.6968532,13.18440124x^3 + 31.47538211x^2 - 14.01986122x + 64.16556237
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Motesanib (AMG-706),1,0.035346148,0.133050599,1.261103757,10,10,459.0486922,3.9368841x^3 + 9.06388598x^2 - 21.2823506x + 52.048183
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,R547,1,0.564133489,1.13595601,2.888141039,6.294660633,9.59289736,394.1512437,0.95540183x^3 - 17.65986502x^2 - 52.8071295x + 77.97744617
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Linifanib (ABT-869),1,0.027000147,0.09434639,0.652419202,10,10,346.7608283,2.86193047x^3 + 6.3906666x^2 - 25.68256127x + 45.03499055
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,VX-745,1,0.034901229,0.098169243,0.518365261,10,10,421.8756266,6.86343865x^3 + 17.85684208x^2 - 21.00579317x + 42.7110624
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Neratinib (HKI-272),1,0.129241011,0.627444537,10,10,10,688.3892084,4.9237005x^3 + 9.7930861x^2 - 16.15101799x + 71.37019638
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PD173955,1,0.175655312,0.46224538,10,10,10,648.3353008,10.16097358x^3 + 19.41789829x^2 - 24.03225248x + 65.14774319
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Pelitinib (EKB-569),1,0.004629175,0.520501811,0.92713741,2.129326138,10,343.6548262,33.78521085x^3 + 49.41769581x^2 - 87.14280354x + 47.08469663
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Foretinib (XL880),1,0.007482179,0.016268794,0.118539472,6.646174171,10,284.7638454,-2.46835839x^3 + 0.95469064x^2 - 12.29048492x + 35.83765754
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Tofacitinib (CP-690550),1,0.238004354,1.139972971,4.578241497,10,10,515.8397196,-2.35424329x^3 - 14.85122256x^2 - 29.62321951x + 76.73390671
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SYK Inhibitor,1,0.585637526,5.106906277,10,10,10,768.7750233,-0.42788908x^3 - 4.43581452x^2 - 13.67069575x + 87.05747425
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Erlotinib,1,2.844185005,7.436241586,10,10,10,839.0060278,-2.1324423x^3 - 11.91692539x^2 - 17.24146526x + 100.48220247
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PD153035,1,1,1,1,1,1,100.6898927,-4.45073121x^3 - 23.92496852x^2 - 33.28118782x + 93.12990388
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SNS-032 (BMS-387032),1,0.111450332,0.159094652,0.282694605,0.520777376,0.802316377,81.99659612,28.58630116x^3 + 58.09140772x^2 - 61.23215709x + 3.63637532
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SU14813,1,0.009603875,3.276048019,6.82568827,10,10,636.7028933,-11.56802573x^3 - 33.150812x^2 - 17.58892154x + 94.45215602
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,LY-333531,1,0.112336436,0.345974915,10,10,10,947.7392958,14.20143484x^3 + 38.84805244x^2 + 2.05212823x + 69.08245209
513,11-00503,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,MEK1/2 Inhibitor,1,1.042099423,5.692170293,10,10,10,782.0547048,-1.15661731x^3 - 6.89202678x^2 - 14.33797611x + 90.25899822
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,H-89,1,2.447962398,6.961359331,10,10,10,821.3702385,-3.41462305x^3 - 12.39587575x^2 - 13.72239712x + 97.40990221
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,AMPK Inhibitor,1,0.319282033,0.956150029,4.581579406,10,10,530.1888575,2.25114317x^3 - 4.86532357x^2 - 34.57246414x + 74.32859903
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,CI-1040 (PD184352),1,0.028993632,0.08068309,0.324969462,1.500598794,10,185.6018016,5.90529318x^3 + 11.20548893x^2 - 35.2143451x + 30.8265568
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Crenolanib,1,0.242462842,0.571145492,10,10,10,699.0515657,12.41477315x^3 + 25.41330564x^2 - 25.78544266x + 67.40254359
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Crenolanib,2,0.006607071,0.007986454,0.012374853,9.826163693,10,902.8266859,-46.12358142x^3 - 99.20740714x^2 + 26.52759697x + 141.45422531
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,TG100-115,1,0.65897023,1.58437075,4.026063343,7.902842838,10,472.7226935,-5.01883134x^3 - 25.309607x^2 - 38.71369914x + 83.78819635
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,AKT Inhibitor IV,1,0.093267942,0.17663512,0.429407015,1.03263823,1.900310667,27.66680358,14.47653047x^3 + 14.9674952x^2 - 62.19682928x + 25.86458254
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,NVP-TAE684,1,0.024250634,0.06235821,0.207120069,0.67052551,1.58115605,45.67242805,7.77334178x^3 + 15.01761172x^2 - 40.91682503x + 17.48561769
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,KW-2449,1,1.434692876,2.590300965,5.019415198,8.196068354,10,538.5505525,-10.86785317x^3 - 38.69507074x^2 - 33.57019172x + 96.25515986
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Imatinib,1,0.004735751,0.66783357,1.275258764,2.929375123,10,280.5060069,23.12067951x^3 + 21.61238529x^2 - 88.02351498x + 59.02690997
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Erlotinib,1,1.80501049,3.042051649,5.76069282,9.443102894,10,603.8076137,-8.23989168x^3 - 35.22266347x^2 - 36.6315193x + 101.8512753
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,NF-kB Activation Inhibitor,1,0.069740905,0.202258759,10,10,10,561.6720558,8.02781403x^3 + 18.31406022x^2 - 19.59499526x + 55.26060628
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,GSK690693,1,0.033243195,10,10,10,10,1052.663693,5.29722108x^3 + 24.30346094x^2 + 18.18109958x + 80.87847715
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Canertinib (CI-1033),1,0.61163199,1.217837523,2.796981716,5.312361372,7.395973568,341.4610325,-3.35110566x^3 - 27.83554307x^2 - 53.5952528x + 79.79319431
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,YM-155,1,0.0013944,0.953648787,1,1,1,82.25628208,-5.03669822x^3 - 24.31279378x^2 - 33.84958173x + 74.31259286
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Axitinib (AG-013736),1,0.087390407,0.224450433,0.951574555,5.596869338,10,313.6488343,4.64550484x^3 + 4.91145352x^2 - 38.58220482x + 49.16604062
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,STO609,1,2.329849255,5.949337314,10,10,10,798.3238135,-4.8578903x^3 - 16.23057962x^2 - 13.35904083x + 97.33790886
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,SGX-523,1,10,10,10,10,10,1028.284088,-0.50460607x^3 - 3.80457283x^2 - 3.50722732x + 106.96278483
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,BEZ235,1,0.017729677,0.036826453,0.111404543,0.364177216,0.949660568,87.07665217,7.14165985x^3 + 23.5996835x^2 - 26.60154805x + 9.39149066
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Pelitinib (EKB-569),1,0.119913458,0.178666633,0.338198819,0.669142214,1.10176963,70.65251807,24.35039524x^3 + 44.12765955x^2 - 64.02444644x + 12.61484605
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Roscovitine (CYC-202),1,0.011143601,4.523147551,7.243496195,10,10,720.6846467,-16.12322668x^3 - 48.46926052x^2 - 20.85747201x + 114.03331948
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Doramapimod (BIRB 796),1,0.007871787,0.023262502,0.680712781,10,10,515.7400113,0.06615743x^3 + 7.91268964x^2 - 3.00017538x + 49.27839834
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,KN92,1,10,10,10,10,10,960.8381725,7.30064264x^3 + 14.53212017x^2 - 9.48771932x + 91.62623024
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Linifanib (ABT-869),1,0.063494323,0.09725124,0.193135656,0.405452547,0.706409384,147.8199641,20.01139826x^3 + 52.51973116x^2 - 38.40837595x + 3.07471772
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,p38 MAP Kinase Inhibitor,1,0.925666402,10,10,10,10,832.9818216,6.6878489x^3 + 8.02848179x^2 - 21.7033708x + 89.26316759
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,MEK1/2 Inhibitor,1,0.290648602,1.040246717,4.459902021,10,10,517.4967218,-0.21453319x^3 - 10.47673329x^2 - 32.46989477x + 75.55949323
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Lapatinib,1,0.023503239,8.289159982,10,10,10,883.5911489,-9.28943564x^3 - 23.63235088x^2 - 4.09007504x + 105.89297889
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Vargetef,1,0.018712307,0.037114923,0.09620548,0.245753415,0.469184806,18.33377086,11.55310954x^3 + 34.16696923x^2 - 29.21045152x - 2.88059831
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PP2,1,0.455665766,1.114128856,2.869660641,5.683486872,8.006188147,357.4579649,-4.80265765x^3 - 27.00822951x^2 - 46.08948082x + 77.22322318
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,JNJ-28312141,1,0.005003709,0.006568241,0.011425005,0.025808981,0.067211808,78.60743803,-11.10859588x^3 - 7.34542128x^2 + 7.61649434x + 11.12139736
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,R406,1,0.013897334,0.043988283,0.211956129,1.239865135,10,187.8359094,4.29472688x^3 + 11.09074514x^2 - 27.86904874x + 27.5020628
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,AST-487,1,3.416819651,10,10,10,10,876.2830883,-1.83860734x^3 - 7.70487735x^2 - 8.09647835x + 96.79381928
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Neratinib (HKI-272),1,0.042420285,0.076343381,0.178730804,0.420424082,0.765690397,17.01846049,14.80336683x^3 + 33.68592169x^2 - 43.97032374x + 4.47199435
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,SYK Inhibitor,1,0.012413396,3.522520907,8.944441741,10,10,688.6490389,-7.44171079x^3 - 22.51116452x^2 - 15.20739375x + 91.26514236
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Vandetanib (ZD6474),1,0.099603488,0.392821046,1.56507461,4.230262245,6.973791217,257.872923,-1.21234773x^3 - 15.24005907x^2 - 44.71299864x + 59.28391353
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Cediranib (AZD2171),1,0.056169695,0.191887397,0.863365716,3.156608678,6.675251427,213.7827291,2.01505005x^3 - 4.47043781x^2 - 42.90264064x + 47.28131142
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PD98059,1,3.10807887,7.390497373,10,10,10,844.8361872,-2.4181294x^3 - 13.6808635x^2 - 17.80670173x + 102.37678344
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Motesanib (AMG-706),1,0.013553145,0.036108728,0.137732806,0.563754444,2.065410018,115.546766,5.86769065x^3 + 16.77869695x^2 - 28.19441065x + 17.03307304
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Nilotinib,1,0.00514153,1.226343653,3.296121001,7.020703244,10,423.9680789,-1.63952393x^3 - 21.25283372x^2 - 44.80164512x + 79.13799236
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Nilotinib,2,0.402315843,0.719175006,1.839088867,5.2325682,10,341.3152356,9.02968017x^3 - 0.32674026x^2 - 61.74489684x + 66.19345963
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Nilotinib,3,0.307209929,0.620696639,1.720733755,4.482355869,8.013426715,294.7909126,4.75975417x^3 - 7.5132301x^2 - 56.47596862x + 63.66726442
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,GDC-0879,1,10,10,10,10,10,2214.456427,-5.69822406x^3 - 26.95905233x^2 + 20.97219359x + 225.25526751
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Masitinib (AB-1010),1,0.175584588,0.29195025,0.669812305,1.781329033,10,198.7566573,15.62458934x^3 + 20.48350373x^2 - 61.19728392x + 38.81068826
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,GW-2580,1,0.037485527,0.08117345,0.240649828,0.764898475,2.232360816,132.4732259,10.31630516x^3 + 22.10807019x^2 - 38.35995715x + 20.25179298
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,SB-431542,1,10,10,10,10,10,1180.798322,0.7792042x^3 - 1.21540539x^2 + 1.46627815x + 117.64504367
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Selumetinib (AZD6244),1,0.006157942,0.01103053,0.044456677,1.227505198,9.068443088,172.7995266,-4.00367962x^3 - 1.18978962x^2 - 11.9819249x + 26.07892493
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Lestaurtinib (CEP-701),1,0.004250904,0.008525333,0.022920535,0.063042631,0.13516207,5.949430293,11.29339581x^3 + 56.95275293x^2 + 35.99139401x + 5.67371329
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,BMS-345541,1,0.884724964,1.60543762,3.255609632,5.577872904,7.34930572,367.1554534,-7.08443422x^3 - 36.74985795x^2 - 52.12037867x + 87.33053985
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Sunitinib,1,0.010252206,0.021934561,0.071186199,0.353390379,1,28.64547941,9.68391105x^3 + 42.29794191x^2 + 11.97209042x + 22.66918743
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Sunitinib,2,0.007397843,0.02139663,0.082474699,0.280160977,0.594008909,19.47487647,3.63574046x^3 + 8.072202x^2 - 41.42203564x + 0.25907576
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Sunitinib,3,0.01161656,0.022150444,0.058721566,0.166427178,0.386286107,14.44691754,10.5365902x^3 + 42.93517889x^2 - 1.4239564x + 2.82788188
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,KN93,1,1.834513095,4.057156111,9.372154264,10,10,717.9603716,-6.79574234x^3 - 23.10170067x^2 - 19.30214449x + 96.81513364
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,AT7519,1,0.119358706,0.191449939,0.404449504,0.908446751,1.700974491,86.92780273,18.06536256x^3 + 29.44864737x^2 - 61.45121916x + 22.38755273
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,SB-203580,1,0.060250079,10,10,10,10,1033.978161,5.78376498x^3 + 24.38130605x^2 + 13.93267126x + 81.21032485
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,AZD1480,1,1.37023823,3.372881596,8.770905662,10,10,686.6592401,-4.73046811x^3 - 19.54659132x^2 - 23.59956712x + 93.60621638
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Tofacitinib (CP-690550),1,0.090261627,0.425469003,3.669599139,10,10,498.0450694,1.26000721x^3 - 1.68720577x^2 - 26.70126897x + 65.38710748
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Sorafenib,1,0.098497161,0.157992697,0.330741118,0.728006219,1.322980963,79.654419,19.15275479x^3 + 34.6619365x^2 - 57.58230219x + 16.45279802
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Sorafenib,2,0.094928002,0.206409148,0.649480931,2.353317786,10,218.062751,8.67326236x^3 + 9.55256922x^2 - 47.37227603x + 40.84236096
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Sorafenib,3,2.761811879,4.069017722,6.780709431,10,10,697.3490044,-9.95956735x^3 - 41.73765459x^2 - 36.9593096x + 115.28587834
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,RAF265 (CHIR-265),1,0.083224792,0.160722212,0.461109743,2.651318472,10,323.4359392,13.77480118x^3 + 27.56570365x^2 - 37.38108242x + 34.84039072
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,GDC-0941,1,0.008121967,0.017251423,0.062373229,0.283007363,1.157382499,97.38975443,2.81343742x^3 + 15.42870249x^2 - 17.80291997x + 11.06718762
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,GDC-0941,2,0.011119871,0.024404625,0.078446208,0.267711957,0.697385688,71.37124131,6.2450959x^3 + 22.85933913x^2 - 22.17148846x + 5.99344453
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Velcade,1,0.008685988,0.020754215,0.070690481,0.247831786,0.646832237,64.89716568,6.21190907x^3 + 22.36900678x^2 - 21.43277201x + 5.18601192
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Dovitinib (CHIR-258),1,0.119857638,0.180630931,0.349353759,0.70628214,1.172835698,31.3525476,20.58502027x^3 + 37.08385615x^2 - 65.42170144x + 14.34500944
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Staurosporine,1,0.191272602,0.234092397,0.329547785,0.473625037,0.600946085,-21.7129405,51.12631603x^3 + 104.85326253x^2 - 99.40146829x - 16.55975587
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,A-674563,1,0.148936409,0.366156105,1.215856769,3.512631991,6.492913981,229.9180391,2.97471917x^3 - 6.98781918x^2 - 50.89823113x + 54.36889301
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Rapamycin,1,0.114109627,0.264338626,0.984270063,10,10,340.1260177,8.04218795x^3 + 9.42801311x^2 - 40.99124883x + 49.71730119
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PD173955,1,0.038043206,0.087215835,0.288802027,1.2121286,10,230.537829,9.49532977x^3 + 21.33891482x^2 - 32.8054131x + 27.58635803
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,INK-128,1,0.002608982,0.003799882,0.008398315,0.031304069,2.777085328,52.26701807,-5.9969969x^3 - 4.50080265x^2 - 1.72421242x + 12.17392319
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,TG101348,1,0.100945973,0.164353962,0.350430744,0.780725225,1.414779853,57.04444789,17.70203638x^3 + 30.00651127x^2 - 59.71227412x + 18.25604175
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Go6976,1,0.034426357,0.156610294,1.610497929,10,10,443.4123444,2.60553432x^3 + 4.23238284x^2 - 23.53486977x + 54.66639999
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,AKT Inhibitor X,1,50,50,50,50,50,4604.099523,3.21093473x^3 - 2.33007036x^2 - 11.90305253x + 103.07370061
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,CYT387,1,0.165208012,0.258981472,0.544293483,1.264366721,2.59894298,132.7533878,16.59864694x^3 + 25.80090428x^2 - 64.99512472x + 31.33593821
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Bosutinib (SKI-606),1,0.114507963,0.178308539,0.357936267,0.749185625,1.285852155,51.30246259,20.6324022x^3 + 34.74112871x^2 - 63.66265985x + 16.5103241
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Gefitinib,1,2.704220627,5.561155988,10,10,10,809.4672755,-0.66296013x^3 - 15.41569797x^2 - 29.05172763x + 105.48253481
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,VX-745,1,0.159708883,0.487157983,3.800783129,10,10,517.793614,4.36256593x^3 + 4.45097613x^2 - 30.31372919x + 65.23083228
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Vatalanib (PTK787),1,0.595063457,1.405088092,3.600362083,7.169714068,10,439.060259,-4.43993984x^3 - 24.70953494x^2 - 41.94544169x + 81.74886943
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,JNK Inhibitor II,1,14.53437661,50,50,50,50,4304.023616,-2.38489767x^3 - 3.27050615x^2 - 0.45508791x + 98.69368337
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Flavopiridol,1,0.011489365,0.023930756,0.073325352,0.242018965,0.619034439,85.80795728,6.47776913x^3 + 25.02874119x^2 - 19.71382607x + 4.86662013
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PD153035,1,0.04456997,1,1,1,1,84.33770388,1.71490003x^3 + 7.82503979x^2 + 2.53451424x + 83.37092897
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,LY294002,1,0.280932836,0.536163204,1.367197127,3.582076586,7.377010332,294.8505888,12.50165164x^3 - 3.14377562x^2 - 62.60655312x + 58.53059192
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PP242,1,0.007611746,0.013947333,0.04202507,0.162911473,0.534468937,70.86248477,1.92844337x^3 + 16.84429628x^2 - 12.96817417x + 5.26357276
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PI-103,1,0.035034792,0.069742316,0.183557201,0.491327949,1.028167029,66.99398074,12.34256476x^3 + 28.37226869x^2 - 39.49109528x + 10.4722569
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Pazopanib (GW786034),1,0.119532594,0.237176661,0.669336356,2.05064316,5.26220092,178.1960062,9.01994275x^3 + 8.74142988x^2 - 53.2777083x + 40.49280484
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Midostaurin (PKC412),1,0.004896486,0.116607185,0.330948237,0.973313199,2.360843494,108.8946436,11.39027223x^3 + 18.20993025x^2 - 47.09636161x + 24.44424628
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,R547,1,0.279169815,0.506887308,1.25120611,3.041626495,5.357097372,202.8886889,7.22814853x^3 - 3.47169103x^2 - 64.88451077x + 56.34135799
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Tozasertib (VX-680),1,0.764076885,1.459963071,3.300857017,6.289043159,8.801345611,408.4763901,-2.66177967x^3 - 25.59475047x^2 - 52.06957177x + 84.2602948
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Tandutinib (MLN518),1,0.005394361,0.865346167,1.622387624,3.373953056,6.282893512,272.5796868,20.08236636x^3 + 8.37686892x^2 - 93.52228304x + 69.09778224
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Trametinib (GSK1120212),1,0.004599867,0.005823513,0.009307506,0.017769682,0.03283119,137.2895746,-13.07147622x^3 - 8.99405834x^2 + 17.4182697x + 12.94851882
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,KI20227,1,0.01011654,0.020844584,0.069710038,0.292434667,10,167.9745271,4.42053473x^3 + 21.47536326x^2 - 13.74296337x + 12.21150755
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,JNJ-7706621,1,1.107937051,1.64164542,3.12118632,6.03181401,9.201023577,430.6381638,10.62980919x^3 - 11.9119907x^2 - 85.3612908x + 93.82253225
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,LY-333531,1,0.005421984,2.287149722,4.138194284,7.206738306,9.938989321,514.8332476,5.8539587x^3 - 24.14548368x^2 - 77.79291188x + 105.7960563
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Dasatinib,1,0.000796,0.001399713,0.003953989,0.014408079,0.045597151,8.87537618,1.92417485x^3 + 24.43773831x^2 + 33.05542339x + 15.02016293
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Dasatinib,2,0.000776,0.001318173,0.003620221,0.013748444,0.053473793,12.54045573,0.96653145x^3 + 20.53331269x^2 + 31.71251046x + 19.10716867
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Dasatinib,3,0.0006,0.000914,0.002259678,0.011758802,1,19.45880164,-4.54745116x^3 - 8.72113783x^2 - 2.8176258x + 19.36271111
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Foretinib (XL880),1,0.005670555,0.007639587,0.014193302,0.037801141,5.766087343,104.1292654,-10.18433751x^3 - 5.66553986x^2 + 4.86254177x + 14.06644121
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Ponatinib (AP24534),1,0.00879379,0.022007478,0.074365242,0.233827591,0.488881327,16.25537661,5.25437855x^3 + 15.0595235x^2 - 36.27633794x - 2.57148483
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Ponatinib (AP24534),2,0.042003115,0.112167008,0.289124955,0.560219079,0.777468297,35.04429289,-6.18598003x^3 - 48.32131025x^2 - 122.19895914x - 2.78908989
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Ponatinib (AP24534),3,0.028359663,0.052233916,0.13474825,0.360503868,0.720550675,25.65281516,8.0367732x^3 + 23.53976739x^2 - 38.34129666x + 4.08894733
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,MLN120B,1,2.897925082,5,5,5,5,464.7283577,1.55725891x^3 - 2.16334474x^2 - 16.34216568x + 97.85978203
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Quizartinib (AC220),1,0.034560481,0.075263996,0.220280044,0.66494453,1.610207213,89.39289061,10.16499372x^3 + 21.48430763x^2 - 40.07170055x + 17.28056799
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Quizartinib (AC220),2,0.010510858,0.028926576,0.113943813,0.452626411,1.279578324,44.42469174,4.78525422x^3 + 13.73894069x^2 - 30.42214396x + 13.09383691
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,JAK Inhibitor I,1,0.146401523,0.323072731,1.137976542,7.650282051,10,340.9209001,7.92804102x^3 + 7.72303293x^2 - 44.07719466x + 52.44846168
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,GSK-1838705A,1,1.537923828,2.636605724,4.870969589,7.704620842,9.727020185,524.1892633,-12.64899177x^3 - 42.95439186x^2 - 34.27694032x + 97.99120703
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,SB-202190,1,0.04336754,10,10,10,10,914.8900289,-2.15954189x^3 + 0.28874689x^2 + 4.21699773x + 89.7445002
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Alisertib (MLN8237),1,0.412555973,1.081032629,3.669841812,9.903038655,10,477.1474371,0.37970719x^3 - 11.92674113x^2 - 40.08872227x + 76.37019654
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Ibrutinib (PCI-32765),1,0.205070534,2.648188713,10,10,10,725.7385318,0.4511522x^3 - 1.49286334x^2 - 14.05964086x + 81.17942813
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PLX-4720,1,0.894391604,2.599635586,10,10,10,676.8504815,0.58142061x^3 - 9.01732227x^2 - 29.15596423x + 88.60799674
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,SNS-032 (BMS-387032),1,0.029104309,0.053538594,0.128486416,0.307757289,0.563415354,17.38887491,13.57556534x^3 + 36.11319205x^2 - 35.76579492x - 0.94393075
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,BI-2536,1,0.041095365,0.083949239,0.226768789,0.622121866,1.332322714,63.35727448,11.80566828x^3 + 23.76582562x^2 - 43.7980734x + 15.06578646
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Afatinib (BIBW-2992),1,0.143724184,0.261819491,0.655433921,1.711038065,3.453947469,121.4108625,10.37982258x^3 + 8.88543953x^2 - 60.90311548x + 38.59104593
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Barasertib (AZD1152-HQPA),1,7.395297501,10,10,10,10,982.2301941,-5.67276531x^3 - 18.45984245x^2 - 6.32499549x + 113.15696747
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,Crizotinib (PF-2341066),1,0.136029393,0.277090446,0.783759198,2.190174636,4.340498151,147.5209062,6.82538848x^3 + 1.47523826x^2 - 56.98455984x + 43.96161341
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,PHA-665752,1,4.823502546,10,10,10,10,911.1522419,1.82950384x^3 + 1.76151652x^2 - 8.92631054x + 94.69347489
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,SU14813,1,0.514891655,1.128250923,2.842577793,5.74860149,8.251431805,364.7295711,-2.74300852x^3 - 24.02278887x^2 - 49.50071589x + 77.6604895
538,12-00016,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123,Standard,GS-1101 (CAL-101),1,0.004572222,0.053435053,0.246460527,1.102758512,4.736364279,144.973362,6.18576882x^3 + 10.78862406x^2 - 34.45419457x + 26.44368542
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Nilotinib,1,0.202521204,0.373430408,1.163041664,10,10,438.2076658,14.22782603x^3 + 22.62944985x^2 - 44.73976168x + 52.83333258
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Nilotinib,2,0.017253477,0.643449049,10,10,10,724.8200164,-0.25172594x^3 + 2.14219363x^2 - 4.48030179x + 74.06177081
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Nilotinib,3,0.029948754,0.105471177,0.663205721,7.253756069,10,315.6737684,2.8614209x^3 + 4.78590316x^2 - 29.09948963x + 44.67405264
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,KN92,1,0.008726912,5.03046373,10,10,10,748.9721872,-5.14953224x^3 - 8.79486843x^2 - 0.44301827x + 81.41862269
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Flavopiridol,1,0.107578068,0.168336414,0.357614826,0.901433825,10,264.1020314,19.46690263x^3 + 44.02880181x^2 - 44.93062762x + 22.88751071
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,TG101348,1,0.025165527,0.073223987,0.313963755,1.785082145,10,229.7270321,6.05242442x^3 + 13.02261075x^2 - 30.99663503x + 31.87934808
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Midostaurin (PKC412),1,0.069202661,0.19425849,10,10,10,699.3186824,10.69613608x^3 + 27.9240292x^2 - 9.83792029x + 57.71285596
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,NVP-TAE684,1,0.006363563,0.012540578,0.091728578,3.496348875,9.666557393,223.3405213,-4.96640573x^3 - 6.53306404x^2 - 15.02579137x + 35.89671374
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Foretinib (XL880),1,0.005195068,0.00731113,0.01569299,8.866109472,10,301.0629048,-9.92332805x^3 - 8.20290923x^2 + 8.13899722x + 33.10149234
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Crizotinib (PF-2341066),1,0.050401508,0.431989875,1.716165519,4.1648002,6.387398674,242.6174138,-3.56222141x^3 - 21.82906823x^2 - 44.20257557x + 61.6150817
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,GSK690693,1,0.00532538,0.049446316,10,10,10,834.0256494,6.72360035x^3 + 26.18334549x^2 + 12.03824419x + 61.04285731
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,JNJ-7706621,1,4.741925803,6.316374346,9.356989411,10,10,892.734392,-15.73294094x^3 - 49.62071106x^2 - 21.42584783x + 132.01452029
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PLX-4720,1,0.007146998,0.033108356,3.988173857,10,10,487.624165,-3.85117329x^3 - 7.82234599x^2 - 12.49057166x + 61.16240434
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,NF-kB Activation Inhibitor,1,0.082708899,10,10,10,10,814.7885732,2.19648071x^3 + 7.31962228x^2 - 4.33781424x + 79.51398049
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,LY-333531,1,0.276152745,0.532697861,2.05619416,10,10,502.2432674,13.05601006x^3 + 18.1925423x^2 - 44.47751792x + 61.7406801
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Tandutinib (MLN518),1,0.004723867,0.451519523,1.40051852,6.458521313,10,346.9109371,9.22440254x^3 + 5.78153455x^2 - 50.5337645x + 57.23992095
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Tozasertib (VX-680),1,0.144098054,0.712525003,3.466447547,10,10,465.4422235,-0.9704449x^3 - 11.13329016x^2 - 31.78698599x + 70.55909788
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Gefitinib,1,0.008313453,8.563031777,10,10,10,1005.510114,-19.75832993x^3 - 48.6577836x^2 + 3.53564161x + 130.05265778
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,AST-487,1,10,10,10,10,10,1619.825562,13.22718722x^3 + 40.38569651x^2 + 31.8166717x + 119.00054709
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Sunitinib,1,0.00267953,0.097714417,0.489072483,1,1,52.11211835,-5.17452698x^3 - 31.70227792x^2 - 70.21062821x + 31.09452881
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Sunitinib,2,0.002391596,0.006889812,0.03588896,1,1,41.9564123,6.74751959x^3 + 40.12300134x^2 + 43.13575756x + 48.91073414
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Sunitinib,3,0.001556183,0.006999907,0.066051778,1,1,35.93449431,1.98354595x^3 + 10.5405076x^2 - 7.51116821x + 29.71646481
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,GDC-0879,1,10,10,10,10,10,1300.698766,-14.53972654x^3 - 46.22600345x^2 - 2.8980305x + 160.18953666
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,STO609,1,3.003380316,10,10,10,10,871.5046604,-2.67731783x^3 - 6.28880766x^2 - 4.76063205x + 93.99996688
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,R406,1,0.008514223,0.024406213,0.264389449,10,10,581.3588891,2.69864645x^3 + 17.28480753x^2 + 3.26571738x + 46.63753669
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,BEZ235,1,0.007137538,0.013231342,0.050198193,0.607804325,10,199.9692852,-1.55841033x^3 + 6.79704639x^2 - 9.63951867x + 22.58201323
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,JNJ-28312141,1,0.004947151,0.006447547,0.011170473,0.026823585,10,285.4773275,-12.88715432x^3 - 10.59404024x^2 + 17.41667369x + 28.51923746
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PHA-665752,1,0.007407863,0.051304916,2.772036679,10,10,464.1859868,-1.73416453x^3 - 3.83470521x^2 - 15.44232507x + 57.74028007
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Rapamycin,1,0.04399707,0.082097872,0.234930445,10,10,1028.842066,25.72053316x^3 + 79.84464162x^2 + 24.10019101x + 39.9671905
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Doramapimod (BIRB 796),1,0.005100122,0.00690191,0.012991715,10,10,223.4560803,-9.59941473x^3 - 3.83645262x^2 + 11.58140995x + 21.06568402
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,GW-2580,1,0.024579365,0.068053124,0.332687608,10,10,402.5381476,6.87020392x^3 + 20.27432301x^2 - 17.68191009x + 37.66720526
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PP242,1,0.005765624,0.009256613,0.025892527,0.199291405,10,225.3337983,-3.39663399x^3 + 6.14552347x^2 - 0.15459814x + 20.70839299
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Neratinib (HKI-272),1,0.018304491,0.067043937,0.42070525,10,10,353.6947321,4.67893028x^3 + 11.89978639x^2 - 22.07401006x + 40.26590684
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,AMPK Inhibitor,1,0.022993502,0.580399402,7.004527095,10,10,568.8868098,-2.06517926x^3 - 7.12399842x^2 - 17.59482726x + 71.2132739
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Staurosporine,1,0.207878483,0.307810278,0.606513166,1.424151,10,249.0382529,23.33978949x^3 + 39.63677514x^2 - 65.78876898x + 34.08314118
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PP2,1,0.008224394,0.395338845,2.628432025,6.090038518,8.888204489,351.1957459,-8.19865803x^3 - 25.52819143x^2 - 28.57219665x + 67.094438
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,RAF265 (CHIR-265),1,0.488313669,0.811148356,3.021814928,10,10,577.9346026,21.04396094x^3 + 29.04008133x^2 - 59.18639803x + 69.39582833
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,AKT Inhibitor IV,1,0.038969596,0.087554378,0.253919008,0.726333311,1.562286663,169.5207344,10.4138243x^3 + 17.89001862x^2 - 46.38954555x + 18.24106878
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Cediranib (AZD2171),1,0.198875884,0.327695646,0.753705472,2.128598867,10,239.3578363,16.25540064x^3 + 21.35681689x^2 - 61.17011272x + 42.19646417
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Roscovitine (CYC-202),1,3.4630706,10,10,10,10,915.1450441,10.28378303x^3 + 3.40922288x^2 - 40.99566516x + 109.50894504
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,SB-203580,1,0.004803861,0.195623293,0.520746016,10,10,382.3751779,17.70064549x^3 + 34.28278733x^2 - 38.65095343x + 36.69716741
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,TG100-115,1,0.170236794,0.718440109,3.042253287,8.455939233,10,430.3493206,-1.55864906x^3 - 13.36567816x^2 - 35.05813097x + 70.23635477
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Ponatinib (AP24534),1,0.027565022,0.066439813,0.211642274,0.570491293,0.992457955,34.64812654,2.13963058x^3 - 4.47658326x^2 - 63.61438727x + 9.79089183
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Ponatinib (AP24534),2,0.000457,0.000804,0.335011619,0.898074624,1,42.70845085,-9.05598652x^3 - 48.77241386x^2 - 81.55452295x + 21.29780618
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Ponatinib (AP24534),3,0.0131631,0.032686767,0.132588839,0.978310124,1,36.22925207,6.12638741x^3 + 22.8728453x^2 - 13.28329595x + 24.87142798
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Crenolanib,1,0.00633112,0.009040548,8.367347576,10,10,787.7024533,-26.19250597x^3 - 58.58883356x^2 + 8.19710359x + 112.8747928
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Crenolanib,2,0.006048116,0.00876121,7.328100688,10,10,718.3989835,-25.79591037x^3 - 60.53302487x^2 + 1.85108036x + 110.38525032
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,MLN120B,1,0.003083617,0.007880927,5,5,5,444.4686368,-5.52449947x^3 - 8.41546052x^2 + 12.81122105x + 87.76770862
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,KI20227,1,0.017731887,0.060144409,0.35853158,10,10,361.1923166,4.97843062x^3 + 13.97672955x^2 - 20.0702063x + 38.7257538
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Pazopanib (GW786034),1,0.037684652,0.110691375,0.821177404,10,10,510.7154,6.51213982x^3 + 18.54240867x^2 - 15.94453973x + 48.50406695
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PI-103,1,0.007041597,0.01505047,0.075683317,10,10,285.0041937,-0.12609844x^3 + 8.88957386x^2 - 8.63955041x + 28.96643138
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Axitinib (AG-013736),1,0.008277471,0.020236692,0.112013304,10,10,296.348382,1.45701279x^3 + 11.30115877x^2 - 11.59830921x + 30.0102398
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,GS-1101 (CAL-101),1,0.013171284,0.055804198,0.851138414,10,10,387.4562403,0.0421531x^3 + 1.67904111x^2 - 18.97495111x + 48.66354426
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PD98059,1,0.008652675,10,10,10,10,971.2758276,-13.06055212x^3 - 29.03711233x^2 + 6.64353516x + 112.62024002
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Vatalanib (PTK787),1,0.025524541,1.165639901,6.846196688,10,10,582.1735045,-0.51887648x^3 - 10.02560064x^2 - 23.07806929x + 76.58075262
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,LY294002,1,0.111491213,0.295313457,1.151963739,5.12376745,50,805.252202,5.85777441x^3 + 1.58713877x^2 - 43.02199007x + 52.6358703
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,SNS-032 (BMS-387032),1,0.057549353,0.100463003,0.235233129,0.588306383,1.247390161,130.1051478,15.45730759x^3 + 35.03778488x^2 - 41.86826572x + 13.68284998
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,CI-1040 (PD184352),1,0.012795255,0.038700967,0.264886159,10,10,373.7394288,2.9853914x^3 + 12.56108873x^2 - 14.32193985x + 38.12931495
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Vandetanib (ZD6474),1,0.005720922,0.016122339,4.001924769,10,10,481.5888314,-5.32067308x^3 - 10.21627631x^2 - 9.31687473x + 60.47934476
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,MEK1/2 Inhibitor,1,0.026859036,2.583668102,10,10,10,693.5898662,-3.57200481x^3 - 8.8284305x^2 - 10.68432091x + 81.15500243
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,R547,1,0.005611183,3.302792646,5.183197953,7.392184142,8.891275512,554.4184673,-18.30915382x^3 - 59.87612611x^2 - 32.81187593x + 110.70422036
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Trametinib (GSK1120212),1,0.004776344,0.006608983,0.013412001,0.061239846,10,327.0108438,-9.80977168x^3 - 6.73194634x^2 + 12.43318134x + 32.47892956
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Selumetinib (AZD6244),1,0.006600579,0.01439508,0.111886119,10,10,412.8757095,-1.5068482x^3 + 5.7044548x^2 - 3.02470601x + 40.66435146
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Dovitinib (CHIR-258),1,0.043043212,0.120454565,0.530521269,10,10,326.7319627,7.30563499x^3 + 13.88077968x^2 - 30.82168767x + 40.61529905
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,SB-431542,1,0.430874714,1.605159776,7.279830445,10,10,604.6578925,-0.079246x^3 - 9.5656719x^2 - 27.7857803x + 81.11520589
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,H-89,1,0.867438256,2.983504584,9.814241237,10,10,681.0227611,-3.38371022x^3 - 14.59328002x^2 - 21.25682495x + 88.74201666
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,AT7519,1,0.0591132,0.134163906,0.434297776,1.624625588,10,194.2591626,8.95421339x^3 + 14.12764128x^2 - 42.38182092x + 33.22078089
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Velcade,1,0.011011253,0.027802794,0.140685757,10,10,284.5155615,2.76165976x^3 + 13.67193668x^2 - 14.93481432x + 29.06708721
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Tofacitinib (CP-690550),1,0.005223933,0.007721337,0.021322509,10,10,585.0081718,-10.1069854x^3 - 9.36973526x^2 + 16.87940597x + 57.20462479
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Sorafenib,1,0.009790591,1.08449181,3.800041376,8.126914652,10,452.6434716,-6.57413471x^3 - 24.06380604x^2 - 28.7565072x + 76.0431326
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Sorafenib,2,0.006801538,0.096418154,1.553147703,10,10,545.3534142,6.35498895x^3 + 15.75569202x^2 - 13.27486661x + 51.91783034
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Sorafenib,3,0.016108575,0.041125151,0.1706167,10,10,482.6621989,8.82016733x^3 + 31.29121383x^2 - 4.59201625x + 32.01322252
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,GSK-1838705A,1,0.006928123,0.014135922,1.856661263,6.264733309,9.818443615,329.267897,-9.64450399x^3 - 20.98729677x^2 - 16.08176471x + 56.02451275
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,CYT387,1,0.006410759,0.020833813,0.191853128,3.720071511,10,256.7847465,0.21865523x^3 + 3.29156726x^2 - 19.02822888x + 34.74446963
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,A-674563,1,0.076255277,0.193758178,0.812246324,10,10,328.3204214,6.39320725x^3 + 9.23604891x^2 - 36.45968561x + 46.63662125
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Go6976,1,0.142673985,0.342304851,3.380146924,10,10,550.6478944,10.21344555x^3 + 18.41416876x^2 - 28.86040982x + 58.60210898
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Dasatinib,1,0.001037746,0.002026179,0.006841534,0.039060388,1,30.51029906,3.70127981x^3 + 34.292581x^2 + 53.51719625x + 42.6942781
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Dasatinib,2,0.001188379,0.002970621,0.016087885,1,1,34.65352843,2.65014801x^3 + 22.40358667x^2 + 25.26060111x + 38.5293645
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Dasatinib,3,0.000698,0.001401623,0.011954834,1,1,44.02469618,-3.2643794x^3 - 7.52537037x^2 - 6.24628513x + 42.61063813
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Erlotinib,1,2.964385092,5.769202682,10,10,10,801.5490208,-7.51770448x^3 - 23.45652105x^2 - 14.21784105x + 102.72437002
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Barasertib (AZD1152-HQPA),1,0.667648768,9.213878246,10,10,10,807.0522637,-0.51855746x^3 - 3.53002813x^2 - 9.96340278x + 88.35776706
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Alisertib (MLN8237),1,0.508187866,1.752887149,5.130823869,10,10,540.9803593,-5.63224633x^3 - 21.87954973x^2 - 28.57608705x + 83.3471006
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,SYK Inhibitor,1,0.005821453,0.016544573,10,10,10,599.3236606,-3.254209x^3 - 1.58300901x^2 + 0.11220095x + 61.82850444
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,BMS-345541,1,0.339369013,0.818578484,2.552578946,6.522379467,10,383.7631136,0.83722519x^3 - 12.87096363x^2 - 46.61176077x + 71.04542412
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,VX-745,1,0.045852695,0.135143548,0.827204591,10,10,424.026559,5.45750259x^3 + 12.64224374x^2 - 24.29440595x + 47.91569627
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,GDC-0941,1,0.005538779,0.011343004,0.081656196,10,10,337.7606718,-2.9980282x^3 + 0.41723328x^2 - 6.65804576x + 38.40075015
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,GDC-0941,2,0.010754558,0.027265899,0.168710535,10,10,312.4110807,1.15757428x^3 + 9.61921418x^2 - 14.02621328x + 33.94846366
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,JAK Inhibitor I,1,0.020875018,0.151048908,10,10,10,606.5655977,2.27884366x^3 + 7.04822101x^2 - 10.93646449x + 62.53356172
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Afatinib (BIBW-2992),1,0.01737766,0.06502719,0.320688875,1.669624245,9.821111061,181.2482056,4.36906474x^3 + 7.21202717x^2 - 33.73550784x + 32.10453178
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,SB-202190,1,0.015910478,0.033576542,0.140308785,10,10,296.2666262,2.22030263x^3 + 15.49666652x^2 - 13.42585196x + 28.65323774
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Quizartinib (AC220),1,0.008782545,0.02138961,0.109524458,1.286398533,10,236.5962563,1.58440392x^3 + 10.67036739x^2 - 15.59993524x + 26.57652846
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Quizartinib (AC220),2,0.006450302,0.011324785,0.036753163,0.329315314,10,291.1166871,-0.59687769x^3 + 13.16762283x^2 + 0.77238815x + 22.24150797
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,SGX-523,1,0.072753598,9.024934481,10,10,10,789.5824078,-0.58791306x^3 - 2.42521519x^2 - 6.94887711x + 84.36595508
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,BI-2536,1,0.011408066,0.032855877,0.139277334,0.68288299,10,164.7100665,5.28828499x^3 + 16.01637129x^2 - 24.61343602x + 20.50722458
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Pelitinib (EKB-569),1,0.086334889,0.15412783,0.40510624,1.65836926,10,315.4951114,14.10771076x^3 + 32.04301023x^2 - 36.94398538x + 31.41994283
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,KN93,1,0.668406214,1.536729961,4.816132116,10,10,543.4912127,0.81911773x^3 - 10.95255236x^2 - 41.38661171x + 83.09867191
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PD153035,1,0.004204787,0.000599,1,1,1,102.8773234,-12.61640214x^3 - 78.31284024x^2 - 121.86054476x + 73.34512857
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Canertinib (CI-1033),1,0.3213656,10,10,10,10,1744.800187,30.30302325x^3 + 91.59615671x^2 + 43.73109854x + 92.9280662
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,AZD1480,1,0.008221502,1.533658825,7.831904979,10,10,608.1091873,-6.42258866x^3 - 16.09136558x^2 - 11.51219606x + 77.73436818
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,p38 MAP Kinase Inhibitor,1,0.004984145,1.25282321,4.870072009,10,10,549.2833039,4.92738026x^3 - 4.61547563x^2 - 41.48127787x + 79.100199
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Linifanib (ABT-869),1,0.005606188,0.009616278,8.354049655,10,10,565.3165058,-9.07129958x^3 - 12.86540143x^2 + 5.15087721x + 63.29314992
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,YM-155,1,0.006660468,0.042972792,0.456703777,1,1,52.07646622,0.89419271x^3 + 0.29739066x^2 - 26.03838165x + 41.13824238
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,INK-128,1,0.002560331,0.003774132,0.009373303,5,5,187.1897869,-8.31865598x^3 - 12.93386431x^2 + 3.09247064x + 40.07703624
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Lestaurtinib (CEP-701),1,0.000872,0.003419368,0.030907767,1,1,45.04175312,3.68776496x^3 + 25.38499157x^2 + 30.21684056x + 50.44533896
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,KW-2449,1,0.010494286,0.649712176,5.209245216,10,10,530.2929221,-3.99579877x^3 - 12.94451757x^2 - 19.14248502x + 71.84277672
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Imatinib,1,0.200902891,0.396018487,1.274592252,10,10,385.5987855,10.96876899x^3 + 12.95628234x^2 - 46.83100884x + 54.77795521
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Vargetef,1,0.008061085,0.016695983,0.08851428,10,10,394.9660217,-0.36047267x^3 + 10.64485223x^2 - 2.16923001x + 35.49215771
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,SU14813,1,0.009221794,5.172127927,9.150247609,10,10,768.9953894,-13.50796776x^3 - 36.71516873x^2 - 10.76649582x + 106.29362097
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Lapatinib,1,0.012251686,10,10,10,10,1018.965856,-1.75822454x^3 + 5.00936285x^2 + 16.38502253x + 90.72992664
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Masitinib (AB-1010),1,0.004901116,0.256439354,0.989980373,10,10,340.8626202,8.02464508x^3 + 8.61257095x^2 - 40.31150352x + 49.82353698
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,JNK Inhibitor II,1,0.031879237,0.092096665,12.39577893,50,50,2327.548062,-3.17185686x^3 + 3.47286445x^2 - 8.33999524x + 59.11173532
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Bosutinib (SKI-606),1,0.009512457,0.036327736,0.321148407,3.29916767,10,242.5508015,0.50684029x^3 + 1.58674119x^2 - 24.88069156x + 37.40122214
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Motesanib (AMG-706),1,0.005041668,0.004572222,10,10,10,594.0375286,-4.08090375x^3 + 0.97657756x^2 + 8.72638139x + 55.40784953
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,Ibrutinib (PCI-32765),1,0.007170681,0.019185188,1.895482217,10,10,454.1415515,-3.36574091x^3 - 2.74691557x^2 - 7.90902849x + 52.48045218
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,AKT Inhibitor X,1,0.786710316,50,50,50,50,4221.818267,5.28091641x^3 + 3.45128671x^2 - 18.45239452x + 88.04604436
559,12-00032,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123,Standard,PD173955,1,0.036353699,0.102040573,10,10,10,943.3293676,11.17478249x^3 + 40.71571618x^2 + 15.42303916x + 61.16652335
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Nilotinib,1,0.315944993,0.793181658,10,10,10,618.608422,9.34847585x^3 + 11.85322835x^2 - 33.30455944x + 71.53815224
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Nilotinib,2,0.006970588,0.014912473,4.506585304,10,10,485.3808906,-9.50917522x^3 - 19.08652027x^2 - 8.0292023x + 66.0677873
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Nilotinib,3,0.082558709,0.187304724,0.592517635,1.90245466,4.505639702,152.4721061,7.17377067x^3 + 5.47855799x^2 - 50.10715558x + 38.4119035
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sunitinib,1,0.010022729,0.027299129,0.111542335,0.47802812,1,29.8597907,4.30179522x^3 + 13.28255141x^2 - 28.30484092x + 14.70388208
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sunitinib,2,0.001014778,0.028617246,0.196516294,0.575850102,0.946167426,32.90548356,-3.49048685x^3 - 26.84384096x^2 - 76.41106739x + 8.17914354
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sunitinib,3,0.009454159,0.022003863,0.091012842,1,1,41.03482721,9.23058271x^3 + 43.94076844x^2 + 26.73929974x + 40.63453198
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Rapamycin,1,0.0777619,0.150098807,0.464839832,10,10,319.5913387,9.27518361x^3 + 23.06732873x^2 - 34.11102042x + 36.43968291
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,BEZ235,1,0.019342301,0.046557929,0.174097949,1.218126416,10,329.1388577,8.02979026x^3 + 26.01850051x^2 - 16.23040761x + 26.19471062
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,YM-155,1,0.000538,0.000751,0.001813954,1,1,93.05606444,-14.14331158x^3 - 57.08169268x^2 - 34.62104276x + 92.68973393
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Ibrutinib (PCI-32765),1,0.00968295,5.807540581,7.511920615,9.434280506,10,924.4338859,-20.67247433x^3 - 83.27850606x^2 - 45.3887816x + 167.50350279
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,KI20227,1,0.007323288,0.009721893,0.022511482,10,10,1201.56039,-25.37480197x^3 - 37.66182204x^2 + 49.36025907x + 120.07223548
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Roscovitine (CYC-202),1,2.928542364,10,10,10,10,875.4702643,-1.23203676x^3 - 5.00549651x^2 - 6.6641925x + 94.32506984
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Ponatinib (AP24534),1,0.025947674,0.067409194,0.198982732,0.450382546,0.684628045,27.70472189,-1.40425719x^3 - 24.07496094x^2 - 94.48992126x - 4.90229646
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Ponatinib (AP24534),2,0.000592,0.002529153,0.373137214,0.742609243,1,42.82921246,-10.84449211x^3 - 63.43066377x^2 - 116.22779533x + 11.01482592
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Ponatinib (AP24534),3,0.001423358,0.000529,0.164286258,0.379954264,0.587838833,22.39225895,0.51966276x^3 - 18.19654634x^2 - 91.16040516x - 10.05930936
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SGX-523,1,7.193936845,10,10,10,10,967.7187929,0.30296755x^3 - 8.51293025x^2 - 17.08745341x + 110.70453089
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Tandutinib (MLN518),1,0.109640148,0.284998271,1.340284745,10,10,412.336153,7.07566473x^3 + 8.80553388x^2 - 35.2290796x + 54.32400904
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,JNJ-7706621,1,2.174583204,3.385770083,6.1199,9.929783592,10,645.8424351,-5.49659223x^3 - 33.70937403x^2 - 45.63365502x + 109.44366413
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,KN92,1,0.017258312,10,10,10,10,854.3508699,-2.31454136x^3 - 2.26394565x^2 + 1.31739913x + 86.67628275
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Dovitinib (CHIR-258),1,0.047529717,0.110492337,0.359799986,1.422186598,10,219.2861551,10.22173578x^3 + 18.94922845x^2 - 37.92906458x + 30.32159052
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,A-674563,1,0.040339145,0.359199296,1.671465611,4.273725103,6.656062157,250.0050064,-4.35670793x^3 - 20.42103752x^2 - 41.31703978x + 60.28250889
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AMPK Inhibitor,1,0.005342472,3.373646517,10,10,10,736.9443855,10.61005396x^3 - 4.85614676x^2 - 58.83489846x + 105.86234966
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,JNJ-28312141,1,0.005853108,0.008751099,0.022263487,8.856245507,10,290.6398464,-7.68578611x^3 - 3.92283279x^2 + 3.46897563x + 31.76643447
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Go6976,1,0.02041608,0.335411448,10,10,10,743.820924,0.56240527x^3 + 5.63701956x^2 - 2.32233488x + 72.68952751
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Masitinib (AB-1010),1,0.005894542,0.00744475,7.989467311,9.174736363,9.915662633,1161.724491,-55.31357484x^3 - 146.52177494x^2 + 1.50022522x + 208.65660495
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Canertinib (CI-1033),1,0.007655765,3.305927903,5.668761102,8.499931446,10,587.465819,-16.74297858x^3 - 49.33575254x^2 - 23.38316246x + 102.79148985
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,TG101348,1,0.073926751,0.183921598,0.654719126,2.478738854,7.817143087,208.3764796,6.36800589x^3 + 5.2008919x^2 - 45.0765027x + 41.57206181
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,MEK1/2 Inhibitor,1,0.061285291,10,10,10,10,894.9871945,4.79096365x^3 + 15.27243923x^2 + 2.28706814x + 78.85844209
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GSK-1838705A,1,0.008185278,5.588519538,7.394711889,9.394721996,10,845.9283894,-28.44843889x^3 - 81.14102459x^2 - 18.57000346x + 146.06308834
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Trametinib (GSK1120212),1,0.004572222,0.005968393,0.011108871,0.034050575,10,337.635545,-11.3774542x^3 - 9.67742974x^2 + 16.09788391x + 33.49696851
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Vargetef,1,0.013409565,0.034213655,0.154241967,1.294060967,10,261.4515894,4.20707563x^3 + 16.18600296x^2 - 18.17877832x + 26.82642373
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Selumetinib (AZD6244),1,0.006625861,0.013419942,0.061087567,10,10,312.763213,-0.19032745x^3 + 10.35476103x^2 - 4.64408778x + 28.75929568
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,KW-2449,1,0.625830353,1.757275403,10,10,10,722.9877675,9.97840106x^3 + 11.47362092x^2 - 34.44164344x + 82.59842623
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Doramapimod (BIRB 796),1,0.006150115,0.011578187,0.061783431,10,10,409.1514964,-3.06811601x^3 + 3.74187197x^2 + 0.56588123x + 39.79003004
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Cediranib (AZD2171),1,0.005617942,0.004913715,3.39246975,5.715291331,8.147825115,470.2444515,20.87087447x^3 - 11.81830018x^2 - 121.36513898x + 114.59609663
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PI-103,1,0.00478457,0.198869593,0.326799474,0.552558088,0.791601228,32.30427374,35.05549413x^3 + 64.8245946x^2 - 76.39947466x + 1.6148424
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GSK690693,1,0.083248041,1.613337465,10,10,10,755.7236003,2.77649607x^3 + 6.23691886x^2 - 8.94725288x + 76.56456192
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SYK Inhibitor,1,0.009264775,0.085463915,10,10,10,574.3999048,-0.97482849x^3 - 0.55350161x^2 - 10.00223558x + 63.75878627
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PHA-665752,1,0.030201777,10,10,10,10,865.2336677,-0.62761994x^3 + 2.29658974x^2 + 1.4999729x + 84.77015664
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Neratinib (HKI-272),1,0.151545539,0.2047346,0.348481251,0.680348687,10,520.891104,37.32496713x^3 + 91.58358264x^2 - 40.52109836x + 15.83438534
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sorafenib,1,0.04500286,0.139888117,0.622262423,2.734906895,8.175297262,214.8495799,3.85191092x^3 + 2.15821875x^2 - 39.93264089x + 41.71489678
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sorafenib,2,0.006051716,0.007164452,0.01061845,10,10,1372.917739,-59.96734873x^3 - 141.15595365x^2 + 35.71910439x + 209.28398093
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Sorafenib,3,0.185042067,0.272691513,0.529069449,1.166702386,2.643999379,191.5929302,21.77153491x^3 + 39.12332004x^2 - 65.95282532x + 29.23425509
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Afatinib (BIBW-2992),1,0.162506668,0.346390536,1.058396171,3.254243413,7.039347213,233.0014073,5.79964444x^3 - 0.14929103x^2 - 52.76993676x + 51.30069096
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SNS-032 (BMS-387032),1,0.010832403,0.023447191,0.073307554,0.239722538,0.587095608,58.64644716,6.57722357x^3 + 24.15996486x^2 - 21.81234887x + 3.74392479
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Bosutinib (SKI-606),1,0.27956611,0.636847072,2.00950265,5.729739885,10,346.8922035,3.37600844x^3 - 7.9988125x^2 - 49.47723259x + 65.63678013
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Velcade,1,0.072074857,0.136027933,0.350187953,0.964554402,2.267015918,115.9680086,12.63815355x^3 + 21.68008292x^2 - 49.31332671x + 24.2218217
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Gefitinib,1,0.006114523,4.855747655,9.870063574,10,10,750.2923854,-9.99552253x^3 - 29.01289516x^2 - 10.98344645x + 99.43146469
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Quizartinib (AC220),1,0.029119174,0.072380451,0.263326559,1.116590755,10,176.672538,6.89641432x^3 + 15.50820027x^2 - 33.74310187x + 26.57976211
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Quizartinib (AC220),2,0.007415042,0.005876138,0.914172785,10,10,426.1922439,25.82863015x^3 + 37.17172233x^2 - 57.86274642x + 47.69006233
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,p38 MAP Kinase Inhibitor,1,0.004865393,0.786829771,1.53402307,10,10,673.0606658,48.91351474x^3 + 77.34586392x^2 - 93.81457562x + 64.44881847
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,STO609,1,2.597392001,10,10,10,10,885.8788808,0.48452748x^3 - 1.14521718x^2 - 7.36004427x + 93.21329484
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,JAK Inhibitor I,1,0.040059673,0.906872149,10,10,10,657.3439389,-0.2571053x^3 - 1.96311819x^2 - 13.38012726x + 74.43547947
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SB-203580,1,0.02885361,0.152629428,10,10,10,734.222581,3.63075326x^3 + 14.67607009x^2 - 1.747269x + 65.76813411
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,NF-kB Activation Inhibitor,1,0.00858458,0.015754571,10,10,10,1374.985002,-21.30427937x^3 - 37.05949241x^2 + 39.2711476x + 141.42454542
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Crenolanib,1,0.006254657,0.009303101,5.152026203,8.690553777,10,505.9802906,-19.31612478x^3 - 41.34389259x^2 - 2.09954073x + 79.42397116
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Crenolanib,2,0.006656344,0.008692698,7.57626931,9.095870591,10,935.1799545,-44.97580616x^3 - 111.47757197x^2 + 4.08604139x + 163.22080772
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,JNK Inhibitor II,1,0.68551576,7.606428634,50,50,50,3198.17054,-1.15428274x^3 - 4.88404869x^2 - 10.08846832x + 88.47191075
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PD173955,1,0.061754429,0.131587359,0.460105003,10,10,429.903546,11.97107134x^3 + 28.67811804x^2 - 25.260649x + 38.68258673
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Dasatinib,1,0.003037634,0.007288933,0.024660997,0.095834219,1,18.15898577,8.57163409x^3 + 45.14149423x^2 + 31.06238995x + 18.86678506
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Dasatinib,2,0.000629,0.001024682,0.002801008,0.013503468,1,16.82949586,-1.72620308x^3 + 5.64410353x^2 + 13.88325952x + 19.94811607
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Dasatinib,3,0.000683,0.00109037,0.002771637,0.010422161,0.046786879,11.26669909,-1.18619924x^3 + 9.70855736x^2 + 19.0381967x + 15.35826108
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Vatalanib (PTK787),1,0.006519944,0.012598447,5.476706858,8.393043661,10,553.7496421,-19.00196624x^3 - 48.90792287x^2 - 13.98701612x + 94.65853457
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Motesanib (AMG-706),1,0.007511314,4.131350481,6.782321379,9.875781184,10,669.9593145,-19.39919992x^3 - 50.56650348x^2 - 12.22265026x + 106.26027181
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Pelitinib (EKB-569),1,0.023409698,0.096095224,0.563232337,2.804105822,7.58682592,208.8710791,1.73277038x^3 - 0.84030198x^2 - 35.95743525x + 41.114447
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PP242,1,0.008308137,0.01855399,0.077772694,0.596812413,10,247.5767765,2.69547305x^3 + 16.16867404x^2 - 10.8117632x + 21.79431892
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SU14813,1,1.587636581,3.855644552,9.915038218,10,10,715.7022849,-4.76683415x^3 - 19.1795033x^2 - 21.44428567x + 95.11648302
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Axitinib (AG-013736),1,0.0115902,0.032302932,0.166976321,10,10,316.8571961,4.10084812x^3 + 16.07789747x^2 - 14.92024749x + 30.6127628
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Crizotinib (PF-2341066),1,0.138575345,0.277375953,0.813187708,2.704955146,8.783711656,225.6209185,8.1857576x^3 + 7.442195x^2 - 51.72049223x + 45.30092733
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AKT Inhibitor IV,1,0.257051657,0.377477516,0.6896745,1.281539755,1.948925338,-55.20221125,25.82128989x^3 + 17.21418495x^2 - 92.50645604x + 34.733836
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SB-431542,1,0.018938595,0.674571656,9.35685179,10,10,599.2962548,-1.7121502x^3 - 6.11676139x^2 - 15.6146084x + 72.50058514
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PP2,1,0.884551365,2.05583453,4.543544944,7.890575018,10,495.4850446,-10.26953478x^3 - 35.09549301x^2 - 30.9753257x + 88.44779255
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Midostaurin (PKC412),1,0.188691467,0.36492713,1.035720903,3.602101385,10,276.8299804,10.04217533x^3 + 7.70463268x^2 - 53.78761766x + 50.81804508
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,H-89,1,10,10,10,10,10,969.6995833,0.45470705x^3 + 1.76131149x^2 - 1.23807826x + 96.6684152
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,CYT387,1,0.009302976,0.103683603,1.615742998,5.645219039,9.71769888,315.0258312,-4.1209171x^3 - 14.53149375x^2 - 28.91056621x + 56.69238696
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Barasertib (AZD1152-HQPA),1,0.008276548,5.806945617,10,10,10,763.875797,-5.66103401x^3 - 10.4789442x^2 - 0.24205219x + 83.82458147
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PD98059,1,1.940555151,6.212130543,10,10,10,800.6313428,-2.85892193x^3 - 11.9076036x^2 - 14.12148385x + 95.12133986
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GDC-0941,1,0.00622032,0.010950901,0.037024002,0.310767113,10,137.4153216,-2.31087888x^3 + 4.88966239x^2 - 10.56630248x + 18.07505929
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GDC-0941,2,0.004578267,0.005920247,0.010032559,0.022388244,0.082147555,161.2443122,-13.43243806x^3 - 14.15177855x^2 + 11.17061569x + 21.62058022
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Linifanib (ABT-869),1,0.007417246,0.015233019,0.084247012,6.353015409,10,272.8912358,-1.98472179x^3 + 3.61800552x^2 - 10.47534822x + 32.10626372
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AST-487,1,0.498275435,1.822186461,10,10,10,713.2715931,6.17250437x^3 + 5.86707793x^2 - 26.88857619x + 81.49931293
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Vandetanib (ZD6474),1,0.245953278,0.384974304,0.862158624,2.703990396,10,284.2699225,13.82916956x^3 + 25.49813465x^2 - 61.98718048x + 45.90513448
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,SB-202190,1,0.011629215,0.199746498,10,10,10,787.5366286,-2.58960927x^3 + 0.78870287x^2 + 4.39293452x + 76.80060055
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Imatinib,1,0.012387834,0.079398253,0.80055914,4.814728165,10,282.3012188,-0.20613486x^3 - 4.13027594x^2 - 29.58051218x + 47.18068921
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GS-1101 (CAL-101),1,0.03658395,0.211912563,1.403925309,6.070470967,10,329.1344732,0.32300547x^3 - 6.17185194x^2 - 33.81480811x + 55.11536843
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Foretinib (XL880),1,0.006342909,0.009910092,0.025885796,0.149524834,10,174.2100122,-4.0441763x^3 + 5.15927715x^2 - 2.14225817x + 17.44481283
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,BMS-345541,1,1.18747361,2.105248856,4.09171751,6.749171723,8.710826702,456.3687347,-9.50368993x^3 - 39.36380033x^2 - 43.37908876x + 93.46027567
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,KN93,1,2.52538968,6.70564147,10,10,10,819.0105064,-3.16995962x^3 - 13.83770827x^2 - 14.63245652x + 98.33337791
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,R547,1,0.405164715,0.753586818,1.931293896,4.821099075,8.526341477,318.8240099,5.52474911x^3 - 6.85550484x^2 - 60.39077444x + 67.69372411
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AKT Inhibitor X,1,2.754738744,50,50,50,50,4301.051779,4.68938026x^3 + 0.29086011x^2 - 19.49306461x + 98.12250567
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,MLN120B,1,5,5,5,5,5,566.9508631,11.10281194x^3 + 34.9432764x^2 + 7.02632674x + 102.47595255
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Staurosporine,1,0.250918765,0.300263505,0.408804852,0.570279685,0.71188434,49.03705952,59.961433x^3 + 118.15328502x^2 - 116.50307408x - 9.57571016
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Tofacitinib (CP-690550),1,0.161079938,0.272323822,0.83882329,10,10,627.9422216,19.12973195x^3 + 47.82099124x^2 - 27.54442562x + 47.62743997
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Lapatinib,1,0.233019912,0.541799813,10,10,10,864.9868193,14.68877673x^3 + 40.63602055x^2 - 13.80351849x + 68.72427419
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,TG100-115,1,3.421199674,4.518715844,6.65332108,9.209475245,10,733.1494939,-14.11983252x^3 - 56.93756598x^2 - 41.39724166x + 130.51268276
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,BI-2536,1,0.072604836,0.13745768,0.350103687,0.914006255,1.847515129,53.66402358,11.67737291x^3 + 17.76832174x^2 - 53.84662817x + 22.87084365
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,LY-333531,1,0.319875483,0.628964707,2.204383284,10,10,463.6675867,10.81639383x^3 + 10.00073328x^2 - 48.28492468x + 64.9594679
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Pazopanib (GW786034),1,0.00798184,0.031472237,0.452409814,5.684503179,10,292.3298857,-0.89388899x^3 - 1.48481955x^2 - 21.75271233x + 42.6465363
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Erlotinib,1,0.008951774,10,10,10,10,893.9489192,-1.15480915x^3 + 1.73851413x^2 + 6.18387429x + 85.45157685
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Tozasertib (VX-680),1,0.200867685,0.880055823,3.80421434,10,10,480.1618437,-1.52513998x^3 - 12.74507672x^2 - 32.16592462x + 73.25410292
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,VX-745,1,0.419743719,0.559795611,0.971507874,10,10,488.4542813,42.83081791x^3 + 70.10530089x^2 - 88.73736709x + 48.87505642
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Alisertib (MLN8237),1,1.218858832,10,10,10,10,847.2043979,5.47891261x^3 + 7.02917673x^2 - 22.1154941x + 91.84549139
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,NVP-TAE684,1,0.007348671,0.00986362,10,10,10,1035.872337,-29.53484717x^3 - 55.77318019x^2 + 31.5043642x + 124.22304876
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Lestaurtinib (CEP-701),1,0.009182503,0.019403691,0.062492838,0.354099146,1,29.48429231,10.32408747x^3 + 47.47280127x^2 + 22.70786214x + 26.53402329
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,R406,1,0.007652267,0.016475328,0.090714995,10,10,330.1124989,-0.38976198x^3 + 8.59069311x^2 - 7.08516639x + 32.84040026
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GW-2580,1,0.050574377,0.132798472,0.566029485,10,10,327.9597052,7.22531118x^3 + 13.74091964x^2 - 31.82244756x + 41.40441395
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,LY294002,1,0.323709233,1.128536951,5.125509566,18.64397558,39.01058976,1226.751839,1.86623305x^3 - 9.16311521x^2 - 32.06910633x + 76.70913497
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,Flavopiridol,1,0.033164335,0.064444285,0.16985318,0.478282662,1.175351286,157.1763043,12.76996135x^3 + 33.48790619x^2 - 31.12311822x + 12.01454771
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AT7519,1,0.140837242,0.191414714,0.318986618,0.552896139,0.811952473,43.82321405,30.16657552x^3 + 61.88244149x^2 - 71.30410977x + 3.06500805
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,AZD1480,1,0.00695562,0.009706022,10,10,10,1585.772062,-56.0879947x^3 - 147.01039266x^2 + 15.20977707x + 243.82063964
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,CI-1040 (PD184352),1,0.014488086,0.058171939,0.440217251,4.641509659,10,279.1699616,1.80838339x^3 + 3.77831616x^2 - 26.21436287x + 40.26103397
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PLX-4720,1,0.100414873,0.959151518,10,10,10,769.0378357,4.65662279x^3 + 10.9499055x^2 - 8.90179212x + 74.83519909
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,INK-128,1,0.002534397,0.00339697,0.006244791,0.016450048,5,82.87046462,-10.34601744x^3 - 15.55318705x^2 + 2.42263754x + 20.08603925
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,RAF265 (CHIR-265),1,0.016864003,0.074522938,0.458570055,2.491085547,7.598566349,199.1357857,2.00550435x^3 + 0.6147416x^2 - 34.32579042x + 38.38485569
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,PD153035,1,0.000954,1,1,1,1,90.29083264,-3.19532897x^3 - 11.90718675x^2 - 6.69571825x + 90.36036325
564,12-00035,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123,Standard,GDC-0879,1,6.737843104,8.720410693,10,10,10,1086.876899,-9.16023575x^3 - 45.00280379x^2 - 32.76742144x + 153.25027913
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Vatalanib (PTK787),1,0.610285948,2.339235091,9.316624035,10,10,654.767823,-1.55278718x^3 - 11.72817792x^2 - 23.73186924x + 85.43443689
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Crizotinib (PF-2341066),1,0.981658617,2.135728639,4.638200299,8.031920287,10,505.5748272,-9.88785176x^3 - 34.41161748x^2 - 32.32134681x + 89.74237101
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,CI-1040 (PD184352),1,0.466757446,1.178638431,3.768313639,9.470253291,10,479.3923853,-0.61313916x^3 - 13.30146733x^2 - 40.68292012x + 77.97196766
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Go6976,1,0.707596408,10,10,10,10,801.9527779,4.99073465x^3 + 5.13127199x^2 - 19.5117845x + 86.97018156
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Afatinib (BIBW-2992),1,0.260050822,0.468224558,1.253643173,4.221635978,10,301.8546482,9.20714804x^3 + 7.92997135x^2 - 57.40547737x + 55.55057994
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Vargetef,1,0.007434463,0.014677285,6.869443736,10,10,622.2435179,-16.10342065x^3 - 36.36068783x^2 - 4.89590705x + 89.00589664
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Linifanib (ABT-869),1,0.042197424,0.121722617,0.7307253,10,10,446.4455482,6.36781231x^3 + 15.83712543x^2 - 21.71373024x + 46.76371572
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Nilotinib,1,0.591077757,10,10,10,10,866.4752119,2.37921636x^3 + 3.86471424x^2 - 7.44146818x + 88.12750197
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Nilotinib,2,0.03110026,0.075327678,0.301248055,10,10,472.2285237,10.42671258x^3 + 30.33618397x^2 - 13.73714872x + 36.08022312
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Nilotinib,3,0.136209932,0.744510212,4.631174823,10,10,522.6425761,0.20086184x^3 - 7.22030947x^2 - 27.68707836x + 71.57143216
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,KW-2449,1,0.175918968,0.77672364,4.723421681,10,10,528.0723661,0.85421451x^3 - 5.87745689x^2 - 28.90562157x + 71.89998738
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,AT7519,1,0.055624204,0.10029085,0.240696625,0.602869509,1.226279913,88.41328503,14.6656879x^3 + 30.86722024x^2 - 45.1320056x + 13.74578084
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,PP242,1,0.041138224,0.078094309,0.211938434,0.655709465,2.274666585,165.6240106,10.42847315x^3 + 27.72573396x^2 - 33.5777748x + 17.97835451
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Canertinib (CI-1033),1,10,10,10,10,10,1326.09169,4.28336084x^3 + 13.21236095x^2 + 14.48239646x + 116.28855019
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,AKT Inhibitor IV,1,0.165573673,0.280843128,0.617975383,1.386209571,2.464455427,73.01020658,17.15822829x^3 + 13.12184069x^2 - 70.95833027x + 34.75103834
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,SYK Inhibitor,1,0.868926882,4.619811583,10,10,10,770.0510848,2.18996706x^3 - 1.45884635x^2 - 20.67751459x + 88.74425376
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Tofacitinib (CP-690550),1,0.690330292,2.383237423,10,10,10,674.2546838,0.55570006x^3 - 7.44859678x^2 - 26.32446762x + 85.95851458
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Roscovitine (CYC-202),1,10,10,10,10,10,981.205133,2.30863939x^3 + 2.13819347x^2 - 11.66756058x + 102.89982796
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,p38 MAP Kinase Inhibitor,1,10,10,10,10,10,986.6559542,4.50910804x^3 + 6.1285294x^2 - 13.28754853x + 101.58210413
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,GS-1101 (CAL-101),1,0.004572222,0.006604757,8.254158966,10,10,652.4693614,-12.37072202x^3 - 29.32530806x^2 - 0.65375634x + 84.76981472
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Motesanib (AMG-706),1,0.034622258,0.083508761,0.358996751,10,10,406.4146071,7.59211492x^3 + 22.41351592x^2 - 19.30441182x + 37.64327066
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Lestaurtinib (CEP-701),1,0.000733,0.00299952,0.041321189,0.862481193,1,31.7944349,-0.07999415x^3 + 0.90301956x^2 - 17.47719569x + 23.87333479
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,GSK-1838705A,1,0.797079226,2.255417826,7.87378464,10,10,636.9496007,-0.40769135x^3 - 12.43761801x^2 - 29.99715141x + 87.16560492
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,JNJ-28312141,1,0.005620108,0.009973092,0.036070267,10,10,349.0564703,-1.73446852x^3 + 9.25034679x^2 + 2.64609067x + 29.35046143
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,PP2,1,10,10,10,10,10,964.5253934,4.36195277x^3 + 6.13592696x^2 - 13.78525946x + 99.69782895
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Pazopanib (GW786034),1,0.059859163,0.482085901,10,10,10,587.8894905,1.08447352x^3 - 0.03207907x^2 - 18.75665326x + 69.09420113
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,PD173955,1,0.048090183,0.37044177,10,10,10,805.2735744,5.34816296x^3 + 16.20160913x^2 - 1.9014248x + 71.59543905
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Lapatinib,1,10,10,10,10,10,1049.88989,4.13201247x^3 + 9.09585079x^2 - 2.20130186x + 100.25186749
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Dovitinib (CHIR-258),1,0.146269253,0.275788066,0.770501077,3.023496837,10,277.4405624,11.82935961x^3 + 15.66100192x^2 - 50.09758827x + 44.14400571
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Selumetinib (AZD6244),1,0.0085533,0.031561971,0.99871279,10,10,454.9558548,-0.37088335x^3 + 3.41185595x^2 - 10.70532131x + 49.9940105
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,PD98059,1,10,10,10,10,10,971.2263179,0.30685931x^3 - 0.50672172x^2 - 3.949076x + 99.55634752
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,AMPK Inhibitor,1,0.935173143,2.496166207,10,10,10,705.218731,6.109136x^3 - 0.20026143x^2 - 36.00474862x + 88.95229506
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,H-89,1,1.250599725,2.575652817,5.404662513,9.182718776,10,562.0279952,-10.44912421x^3 - 34.01448171x^2 - 28.24668829x + 93.07366631
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,KN92,1,10,10,10,10,10,1007.865751,2.27220308x^3 + 5.76969758x^2 - 0.33809738x + 97.31848453
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Pelitinib (EKB-569),1,0.188903219,0.347154966,1.037296432,10,10,391.801471,12.57896009x^3 + 20.31824915x^2 - 46.14384199x + 50.72863106
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,PLX-4720,1,2.074392875,8.449129027,10,10,10,840.6041573,6.85429987x^3 + 2.55124733x^2 - 36.35545964x + 101.04640368
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,GDC-0879,1,10,10,10,10,10,1414.335447,1.80669217x^3 - 0.21371144x^2 + 6.88733098x + 137.07073595
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Flavopiridol,1,0.016807979,0.045437628,0.145403524,0.447664803,1.033917628,59.85814176,9.84880635x^3 + 23.19661171x^2 - 34.65323197x + 10.49708706
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,BMS-345541,1,2.028837849,3.039917499,5.245498939,8.217707692,10,584.8326985,-6.33850814x^3 - 39.16240664x^2 - 51.45521631x + 109.69029057
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Axitinib (AG-013736),1,0.028728424,0.106041237,0.756904895,10,10,390.2850401,4.049702x^3 + 8.67976964x^2 - 24.16294184x + 46.9574555
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,BI-2536,1,0.03231111,0.108226535,0.473227125,1.983899008,5.691321357,170.0181731,4.50344745x^3 + 3.56485368x^2 - 40.50490366x + 36.6168459
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,SB-203580,1,10,10,10,10,10,1197.543448,8.80692626x^3 + 27.61559687x^2 + 13.79271137x + 94.96737634
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,KI20227,1,0.012711295,0.044489208,0.344184843,10,10,412.7390652,3.69765217x^3 + 13.32610255x^2 - 13.8149073x + 41.10904504
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,JAK Inhibitor I,1,0.732210064,2.901644281,10,10,10,709.6534353,0.58404295x^3 - 5.89053106x^2 - 23.25453835x + 86.9615493
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Midostaurin (PKC412),1,0.005083009,0.990298268,3.435022861,10,10,510.7273262,9.9478898x^3 + 3.48982154x^2 - 50.97264036x + 74.78412102
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Trametinib (GSK1120212),1,0.004864426,0.007411551,0.019697843,10,10,412.1092291,-6.08796261x^3 + 0.64950218x^2 + 11.05038758x + 36.75220245
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Velcade,1,0.096103423,0.183116687,0.487072195,1.445664947,4.478940614,165.4817563,11.96128237x^3 + 17.24845745x^2 - 51.1610424x + 32.6982383
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,A-674563,1,0.010313509,0.103750484,1.071621009,4.129172933,7.631896386,248.2696981,-2.48157193x^3 - 12.1033649x^2 - 33.86809362x + 51.0284291
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,GW-2580,1,0.083290368,0.602599864,10,10,10,597.8835488,1.07540788x^3 - 0.40705228x^2 - 19.54260923x + 70.73233582
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,SGX-523,1,10,10,10,10,10,981.5604951,-0.42377918x^3 - 0.11410045x^2 - 0.88345711x + 98.90719579
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Ponatinib (AP24534),1,0.050744711,0.128921544,0.365159552,0.790559237,1,45.50600158,-2.62723246x^3 - 28.17809798x^2 - 89.08318835x + 16.19842111
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Ponatinib (AP24534),2,0.03833613,0.10951534,0.376049929,0.967444086,1,47.7582505,-0.85258478x^3 - 16.26209152x^2 - 67.90104215x + 24.02733933
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Ponatinib (AP24534),3,0.031075452,0.086961957,0.288409549,0.723374969,1,40.91341451,-0.67335262x^3 - 17.0273755x^2 - 73.92961856x + 14.93770068
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,PD153035,1,0.000461,1,1,1,1,99.83328291,10.05673911x^3 + 47.13114035x^2 + 51.04873064x + 109.18226285
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Crenolanib,1,0.006789894,0.011154385,5.967053739,9.142979212,10,582.5519846,-20.34866934x^3 - 47.54253679x^2 - 6.1088x + 92.85010642
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Crenolanib,2,0.013429558,1.505519164,4.656044728,8.826579242,10,495.5847656,-11.92494341x^3 - 29.43005018x^2 - 18.98345803x + 79.36917677
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,SB-431542,1,2.433260925,10,10,10,10,884.7740807,0.59739711x^3 - 0.76915157x^2 - 7.63186476x + 93.02764418
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,STO609,1,3.115136981,5.91060064,10,10,10,810.8055848,-6.76129672x^3 - 23.58597037x^2 - 15.84118004x + 104.37342322
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Sorafenib,1,0.193212005,0.585055989,2.262138032,6.76413342,10,375.6076672,0.81911213x^3 - 10.17639362x^2 - 41.40721538x + 65.92215911
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Sorafenib,2,0.021141111,0.160217782,5.369155103,10,10,526.1670026,1.25344959x^3 + 2.45668814x^2 - 16.96368657x + 60.58563921
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Sorafenib,3,0.155247053,0.469726834,2.269292249,10,10,423.6671037,3.2008646x^3 - 2.09277463x^2 - 36.86553727x + 63.24087519
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,KN93,1,10,10,10,10,10,1012.353668,-1.23608707x^3 - 5.31277631x^2 - 2.04796407x + 105.55787023
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,BEZ235,1,0.02417861,0.048044439,0.133968268,0.5447701,10,577.0091967,16.38360761x^3 + 54.54066869x^2 + 3.56504041x + 22.44600711
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,INK-128,1,0.003013933,0.074493091,0.322440242,1.946843582,5,140.3872676,6.82699836x^3 + 14.21216081x^2 - 30.39122577x + 32.43803649
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,JNJ-7706621,1,0.011657191,4.299796705,6.661404268,9.43988312,10,691.6694299,-18.18442901x^3 - 54.23960954x^2 - 23.35255585x + 116.17863778
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,R406,1,0.136647012,0.417913792,2.763068539,10,10,487.1102467,5.11481902x^3 + 4.42360893x^2 - 31.62826581x + 62.658768
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Neratinib (HKI-272),1,0.079463964,0.525625065,10,10,10,767.1059849,5.24643545x^3 + 14.02404633x^2 - 7.30740001x + 71.97902363
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Tozasertib (VX-680),1,1.684329228,3.390458149,7.412608489,10,10,666.8388666,-6.73263553x^3 - 26.68694407x^2 - 26.12929408x + 97.36275232
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Staurosporine,1,0.22056385,0.310311392,0.55335414,1.07086934,1.832634643,137.6508393,27.3818385x^3 + 43.06120057x^2 - 79.02638028x + 27.31116949
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Ibrutinib (PCI-32765),1,0.010021537,10,10,10,10,867.3953021,-6.36480058x^3 - 14.24033044x^2 + 0.05000798x + 96.16100698
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,TG100-115,1,0.280685168,4.840323986,10,10,10,768.2656906,2.81428174x^3 + 4.40462367x^2 - 13.8290936x + 81.50112412
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Masitinib (AB-1010),1,0.004970956,0.491204385,1.43611047,10,10,397.2899154,13.30985212x^3 + 13.92790593x^2 - 52.49747794x + 57.85614182
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,TG101348,1,0.060662595,0.166847039,0.633605893,2.31563971,5.700096482,179.8904343,4.87996541x^3 + 1.8655285x^2 - 45.2152056x + 41.00392899
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,MEK1/2 Inhibitor,1,1.999851475,10,10,10,10,856.4309014,1.24747013x^3 - 2.06944175x^2 - 14.49747111x + 94.51717789
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,NF-kB Activation Inhibitor,1,2.675087816,4.509604448,8.579618364,10,10,743.3604108,-7.65418703x^3 - 30.73649449x^2 - 26.08401786x + 107.35705345
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,AZD1480,1,0.00898262,7.400695319,10,10,10,805.7563272,-6.88375335x^3 - 14.04957955x^2 + 0.10288948x + 90.04852177
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,PHA-665752,1,10,10,10,10,10,1192.822827,5.35022241x^3 + 20.41520533x^2 + 18.10725433x + 96.88882256
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Foretinib (XL880),1,0.008908128,0.021148246,0.11404146,10,10,299.9424994,1.31035094x^3 + 11.3412187x^2 - 11.38487087x + 30.27954743
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,RAF265 (CHIR-265),1,0.062516267,0.869168809,10,10,10,638.1604707,-0.11123933x^3 - 2.29951178x^2 - 15.8609185x + 74.04263779
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,SNS-032 (BMS-387032),1,0.023928202,0.048252268,0.133175097,0.373360313,0.784502583,18.15585346,9.19596781x^3 + 25.06195014x^2 - 35.35198104x + 6.00602487
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,GSK690693,1,0.126032504,10,10,10,10,1224.703323,12.23553752x^3 + 39.52023097x^2 + 21.38865368x + 86.1677653
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,MLN120B,1,0.399748824,5,5,5,5,423.911651,1.32251854x^3 + 2.19100435x^2 - 8.27335968x + 86.44151887
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Cediranib (AZD2171),1,0.200186448,0.719078519,2.75093401,7.407878247,10,404.3348437,-0.66830775x^3 - 14.2340721x^2 - 38.58578192x + 69.76362254
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,R547,1,0.004642786,0.047143323,2.088971134,5.94467608,9.339542805,331.8605611,-6.07187836x^3 - 20.38578161x^2 - 26.97503106x + 60.91564745
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,LY294002,1,0.351154923,1.497256053,8.898892294,40.47972883,50,1878.638093,0.99893752x^3 - 6.71064034x^2 - 25.84829202x + 79.73193265
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Tandutinib (MLN518),1,0.195033051,0.841809725,5.166693555,10,10,541.3869117,0.74078131x^3 - 5.64433878x^2 - 28.46388786x + 72.90317632
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,VX-745,1,0.503716315,1.975956995,7.645846452,10,10,621.4913559,-2.18431793x^3 - 12.69717127x^2 - 25.10334425x + 83.59232871
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,PI-103,1,0.028950801,0.113274953,0.862685013,10,10,390.2042496,3.51109025x^3 + 6.88797756x^2 - 24.76549761x + 48.38393236
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,YM-155,1,0.00056,0.000805,0.002477358,1,1,69.7913923,-15.6309244x^3 - 71.96955154x^2 - 79.55988676x + 54.7933949
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Dasatinib,1,0.001387325,0.003485319,0.016945675,1,1,37.39247852,4.43530861x^3 + 32.43758431x^2 + 40.76209915x + 45.08954475
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Dasatinib,2,0.001163973,0.003064455,0.018931729,1,1,38.85535503,2.61905269x^3 + 22.13794458x^2 + 26.51065117x + 43.35809565
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Dasatinib,3,0.000709,0.00152301,0.011554931,1,1,37.17653375,-2.05357734x^3 - 2.40655848x^2 - 4.63474104x + 35.12304738
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,SB-202190,1,10,10,10,10,10,1371.645226,9.48570094x^3 + 34.21972146x^2 + 26.7181168x + 101.48076539
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Sunitinib,1,0.022647913,0.074333311,0.366552901,1,1,49.25059439,2.23748481x^3 + 1.37855054x^2 - 38.29748068x + 33.23091206
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Sunitinib,2,0.002961501,0.0096932,0.075790439,1,1,45.36538342,4.64063773x^3 + 27.08523887x^2 + 21.78322508x + 46.93298797
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Sunitinib,3,0.009926975,0.027827024,0.156003308,1,1,44.86399314,6.80321729x^3 + 29.79668105x^2 + 7.56946119x + 40.28262473
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Bosutinib (SKI-606),1,0.128186232,0.233250965,0.669366641,10,10,378.7861431,13.38763276x^3 + 27.04883988x^2 - 40.021614x + 42.27163424
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,JNK Inhibitor II,1,8.341998981,50,50,50,50,4362.374868,5.30639343x^3 - 5.8625235x^2 - 19.58827671x + 108.87268232
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Doramapimod (BIRB 796),1,0.035554724,10,10,10,10,799.6387965,0.08323356x^3 + 3.59996517x^2 - 2.252178x + 79.43007802
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Erlotinib,1,10,10,10,10,10,972.4249376,1.89403794x^3 + 1.27672901x^2 - 6.48249549x + 99.65981963
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Gefitinib,1,10,10,10,10,10,996.2985684,-1.29822209x^3 - 4.11505887x^2 - 1.3090936x + 102.9489662
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,GDC-0941,1,0.005993781,0.010257571,0.035375061,10,10,388.3471372,-2.59912932x^3 + 8.34912711x^2 + 5.48382257x + 32.42794095
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,GDC-0941,2,0.011293531,0.053530764,2.583863354,10,10,461.7654413,-2.11914245x^3 - 2.83254757x^2 - 14.60716493x + 56.65201877
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Barasertib (AZD1152-HQPA),1,4.409474451,10,10,10,10,894.875955,-2.34034944x^3 - 5.52111519x^2 - 2.77177616x + 94.70486392
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,LY-333531,1,0.045823015,0.135491551,0.660678004,10,10,374.4183981,7.34832541x^3 + 13.67969385x^2 - 28.91937113x + 44.39381021
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,NVP-TAE684,1,0.090461165,0.222678935,1.031580914,10,10,434.8458459,8.73892466x^3 + 15.45355136x^2 - 31.31867672x + 50.42006614
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Vandetanib (ZD6474),1,0.761564886,2.306793266,6.315993082,10,10,598.1242989,-6.02190418x^3 - 21.99086111x^2 - 25.16475736x + 87.32093876
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Imatinib,1,0.169673579,0.734897646,5.594826505,10,10,549.617594,1.86766541x^3 - 2.8674167x^2 - 27.48915635x + 71.3784733
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Quizartinib (AC220),1,0.072227182,0.183997902,0.767595481,10,10,333.7611136,7.02693032x^3 + 10.71358544x^2 - 35.67886825x + 45.7709435
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Quizartinib (AC220),2,0.011158007,0.039881795,0.695271639,10,10,406.442286,-0.22522937x^3 + 3.09722209x^2 - 14.81996943x + 47.58268106
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Rapamycin,1,0.005905894,0.011030473,10,10,10,888.5674494,-21.647698x^3 - 54.66874531x^2 + 0.77005235x + 123.61641896
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,Alisertib (MLN8237),1,3.549048238,8.03799209,10,10,10,856.7798425,-4.54545646x^3 - 16.09441012x^2 - 11.46478571x + 101.93416745
652,12-00069,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v2,Standard,CYT387,1,0.95396936,2.560878605,7.620793284,10,10,642.237369,-2.81137895x^3 - 16.16350134x^2 - 28.26012526x + 89.42838613
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Go6976,1,0.195982086,10,10,10,10,779.1545943,3.74679225x^3 + 7.41813907x^2 - 11.53967282x + 79.4447337
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,GW-2580,1,0.17102695,2.186158889,10,10,10,757.1794502,3.24378463x^3 + 6.49204446x^2 - 12.21826315x + 78.27410874
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Foretinib (XL880),1,0.007917073,0.026979054,0.262471967,10,10,318.0472048,0.78709776x^3 + 5.23294524x^2 - 16.97253899x + 38.52873012
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,GDC-0879,1,10,10,10,10,10,1255.246841,6.32051082x^3 - 6.85243746x^2 - 30.5770397x + 144.18900768
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Lapatinib,1,3.405727221,6.953687489,10,10,10,836.2698245,-7.16153145x^3 - 20.63950378x^2 - 9.70041908x + 102.0883227
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,CI-1040 (PD184352),1,0.014485744,0.08037249,10,10,10,570.529992,-0.08428717x^3 + 3.53766519x^2 - 9.22160506x + 60.55178555
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Doramapimod (BIRB 796),1,0.020581069,10,10,10,10,921.1036707,-4.23902169x^3 - 7.57095776x^2 + 2.77471598x + 95.87916036
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Midostaurin (PKC412),1,0.111275785,0.566611846,10,10,10,633.0944733,3.61473851x^3 + 5.51910082x^2 - 18.95272504x + 70.04243683
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,PP242,1,0.00985747,0.030792708,0.172086602,10,10,294.8740843,3.89942893x^3 + 14.17628071x^2 - 16.88296826x + 30.55767717
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Staurosporine,1,0.171670243,0.307068717,0.880520986,10,10,424.9948645,15.93141313x^3 + 27.93448467x^2 - 43.4657157x + 47.51545687
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Afatinib (BIBW-2992),1,0.062738328,0.188497385,0.859789466,4.002492188,10,269.4404433,3.39516591x^3 + 1.01699004x^2 - 39.08666255x + 47.4321882
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,BMS-345541,1,1.240743705,2.725333306,5.995543984,10,10,595.2478572,-9.20339416x^3 - 30.5339932x^2 - 25.53668416x + 92.66787306
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,PD173955,1,2.485600199,4.436310673,10,10,10,766.6888189,0.55657427x^3 - 18.45086598x^2 - 40.84891951x + 109.00361239
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Tandutinib (MLN518),1,0.160583265,1.125189565,7.531406448,10,10,592.1786166,-0.61720646x^3 - 7.42034421x^2 - 22.88840412x + 76.19202891
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,KN93,1,0.689658641,1.435117999,3.513463186,7.04614761,10,437.5763709,-2.37795395x^3 - 22.98137635x^2 - 47.17491605x + 82.9759998
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Bosutinib (SKI-606),1,0.190813884,0.954932709,10,10,10,686.9237531,4.51554886x^3 + 6.55902427x^2 - 19.00200401x + 74.616848
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,GDC-0941,1,0.00888737,0.01837146,0.083231615,1.276374611,10,234.1829144,-0.23189732x^3 + 8.6105849x^2 - 12.45394682x + 26.22341369
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,GDC-0941,2,0.010342943,0.031502379,0.236910474,7.016207728,10,286.7772855,1.09216328x^3 + 6.31508203x^2 - 19.01403795x + 35.90538353
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,LY294002,1,0.143880294,0.576133063,3.432793289,18.10603579,50,1244.523634,1.79123982x^3 - 4.36291444x^2 - 31.34759627x + 67.76777623
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,VX-745,1,2.083444977,10,10,10,10,859.5966654,-0.53539785x^3 - 3.8826028x^2 - 9.11121311x + 93.31639322
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,YM-155,1,0.004415009,0.0138675,0.068812082,0.368826405,1,25.96317828,3.11540647x^3 + 11.9175656x^2 - 21.63369283x + 13.64573973
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,KN92,1,6.103438821,10,10,10,10,931.0727193,-3.63541181x^3 - 11.29401537x^2 - 6.36245677x + 103.73047761
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,JNJ-28312141,1,0.008603676,0.0452582,8.679404645,10,10,551.9617479,-2.30651296x^3 - 2.41966524x^2 - 8.64365322x + 62.14966895
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Vargetef,1,0.044800659,0.124473799,0.676396108,10,10,444.3274091,7.34162191x^3 + 17.6151765x^2 - 22.42819042x + 45.71978459
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,GS-1101 (CAL-101),1,0.008772682,0.14072289,5.87954581,10,10,543.1630009,-5.73562267x^3 - 13.32277918x^2 - 12.72230671x + 70.28525727
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,PHA-665752,1,2.845253567,10,10,10,10,883.0882821,-0.96828108x^3 - 3.0412531x^2 - 4.37661256x + 92.70537757
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,JNJ-7706621,1,0.720780553,1.720247049,4.704861501,10,10,528.0774428,-2.54768379x^3 - 19.53901651x^2 - 37.7724384x + 85.01662805
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,NF-kB Activation Inhibitor,1,0.00516382,0.007172594,0.014591663,0.057532056,10,205.9151808,-9.63417199x^3 - 7.05672217x^2 + 5.55522008x + 24.36821822
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,SB-431542,1,2.629076945,10,10,10,10,886.40403,1.52433771x^3 - 0.37056525x^2 - 10.95331643x + 94.55076831
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,SGX-523,1,10,10,10,10,10,958.6655204,1.98221178x^3 + 6.15086978x^2 - 0.00146409x + 92.11360729
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,AKT Inhibitor IV,1,0.040643367,0.085785597,0.25526753,0.829468103,2.493489089,464.7609086,9.32451906x^3 + 20.23294996x^2 - 38.99514603x + 21.70516857
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,NVP-TAE684,1,0.011292822,0.035243472,0.206280735,10,10,345.6657063,4.14842291x^3 + 15.18075243x^2 - 14.95375804x + 33.9506756
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,SB-203580,1,10,10,10,10,10,1256.263525,0.18781435x^3 + 6.85638994x^2 + 18.68686883x + 111.55437571
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Sunitinib,1,0.031357113,0.178513624,1,1,1,64.12927641,-0.98803317x^3 - 11.22182263x^2 - 41.23117975x + 50.01565446
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Sunitinib,2,0.001618108,0.174426328,1,1,1,64.23350251,-3.74561934x^3 - 22.3143099x^2 - 47.32216146x + 50.31177274
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Sunitinib,3,0.026305781,0.11115059,0.935311905,1,1,60.68804614,1.59022577x^3 + 2.10365957x^2 - 26.45051112x + 49.23004805
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Ponatinib (AP24534),1,0.033286915,0.091500628,0.332497113,0.960801967,1,45.87964853,0.70394546x^3 - 8.35412652x^2 - 58.55522095x + 23.98564636
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Ponatinib (AP24534),2,0.047094473,0.119350976,0.37058389,0.899995172,1,47.21095497,-0.61031379x^3 - 16.88876395x^2 - 72.80252327x + 21.70387557
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Ponatinib (AP24534),3,0.025672132,0.066334629,0.289330146,1,1,46.51716588,4.30521525x^3 + 11.67192121x^2 - 29.0025521x + 31.66573682
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,A-674563,1,0.020721096,0.052154541,0.205717739,1.228087681,10,257.6903444,6.56360594x^3 + 19.43272556x^2 - 23.35265529x + 26.92435877
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,SNS-032 (BMS-387032),1,0.007683148,0.015149848,0.06124979,0.572305648,10,179.7297496,-0.49366453x^3 + 8.17743976x^2 - 12.95857366x + 21.37179931
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Dasatinib,1,0.009055472,1,1,1,1,98.5384152,7.33842911x^3 + 45.04542554x^2 + 74.9825321x + 117.75103949
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Dasatinib,2,0.00787679,1,1,1,1,100.3357101,4.50705382x^3 + 30.75754178x^2 + 56.99519759x + 115.74310362
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Dasatinib,3,0.016070173,1,1,1,1,104.3049876,3.55050225x^3 + 25.54082444x^2 + 50.12980258x + 118.23165885
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,BEZ235,1,0.022205711,0.100448018,1.408914663,10,10,498.2034584,4.06744724x^3 + 10.78273933x^2 - 16.17807194x + 52.1562263
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Tozasertib (VX-680),1,0.067187689,10,10,10,10,765.5779568,1.1372812x^3 + 3.96273005x^2 - 7.00576025x + 78.16870263
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Quizartinib (AC220),1,0.02738636,0.104646572,0.791537937,10,10,376.9082017,3.14319887x^3 + 6.47370189x^2 - 24.81198773x + 47.4174406
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Quizartinib (AC220),2,0.008693215,0.030699351,1.525366578,10,10,448.2801447,-1.74049649x^3 - 0.27013237x^2 - 11.53829153x + 52.13564097
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,MLN120B,1,0.178142736,5,5,5,5,451.364269,1.30367239x^3 + 5.92951643x^2 + 1.53803319x + 88.37211756
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Masitinib (AB-1010),1,0.178964161,0.779637522,10,10,10,637.7618461,3.99270507x^3 + 4.68214523x^2 - 22.0632554x + 72.56512532
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Barasertib (AZD1152-HQPA),1,0.13680009,10,10,10,10,873.298046,2.83999642x^3 + 8.04495223x^2 - 2.45276636x + 83.70786824
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,PLX-4720,1,0.008644416,6.615609898,10,10,10,842.9778458,-9.95041763x^3 - 29.29112054x^2 - 9.3884156x + 107.92437468
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,GSK690693,1,0.058534493,0.339980984,10,10,10,690.5468466,4.01144077x^3 + 10.85922435x^2 - 10.45124616x + 68.13176449
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Roscovitine (CYC-202),1,1.333592535,4.643623923,10,10,10,758.2669596,-2.64819902x^3 - 11.59416663x^2 - 17.06274027x + 92.31963875
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,BI-2536,1,0.012642223,0.042334352,0.21128278,1.259229767,10,186.4541422,4.1670545x^3 + 10.53485247x^2 - 27.8496843x + 27.67814211
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,JNK Inhibitor II,1,4.54877698,33.10403477,50,50,50,3963.951046,-1.52265257x^3 - 2.41223258x^2 - 6.44940669x + 95.72068619
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Rapamycin,1,0.744438652,10,10,10,10,790.5380589,5.8086601x^3 + 5.0639101x^2 - 22.17301024x + 87.08710272
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Trametinib (GSK1120212),1,0.005305134,0.010592708,0.065557031,10,10,481.7323025,-1.77119985x^3 + 7.19680197x^2 + 4.6777727x + 42.52203437
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Velcade,1,0.055790164,0.116558784,0.366598043,2.002945768,10,304.198136,11.14801149x^3 + 25.1288483x^2 - 32.19469544x + 32.11926593
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,LY-333531,1,0.027359898,1.011921017,3.708600753,8.275706169,10,451.8868347,-5.52911218x^3 - 21.76660835x^2 - 30.01167941x + 75.15503589
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,STO609,1,10,10,10,10,10,960.5113112,1.89803795x^3 - 1.47409266x^2 - 12.52345209x + 103.28303428
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,AT7519,1,0.019700398,0.052020914,0.203153432,1.017388991,10,219.3318517,6.80012987x^3 + 18.43797125x^2 - 26.33035513x + 25.19609985
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Vandetanib (ZD6474),1,0.681772707,2.36434841,7.615976343,10,10,632.4848787,-3.91720668x^3 - 16.1874792x^2 - 24.00563616x + 86.43637871
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,INK-128,1,0.003443186,0.007010374,0.036999253,5,5,163.0767881,-1.36206838x^3 + 5.31126956x^2 - 2.24307947x + 31.90177258
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Pazopanib (GW786034),1,0.007663291,7.37218692,10,10,10,914.6044165,-16.01279521x^3 - 42.46480915x^2 - 3.6931883x + 120.62576959
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,R406,1,0.043752118,0.259826959,10,10,10,721.7555004,4.47944821x^3 + 13.5244574x^2 - 6.46271057x + 67.48211364
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,H-89,1,0.84980425,3.008605755,8.808327133,10,10,668.9923657,-5.47786435x^3 - 18.4551749x^2 - 18.70054309x + 88.76848943
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,SYK Inhibitor,1,0.390326865,7.385762307,10,10,10,792.958135,-1.66724426x^3 - 5.13904319x^2 - 8.43947115x + 87.296025
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Gefitinib,1,1.350349005,5.4866098,10,10,10,784.4230405,-0.21143909x^3 - 6.91136992x^2 - 18.48556444x + 92.52944282
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Lestaurtinib (CEP-701),1,0.006179148,0.015959076,0.072304302,1,1,38.91601222,7.79706524x^3 + 38.53939458x^2 + 23.81082214x + 38.58209208
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,TG100-115,1,0.959070223,3.617337395,10,10,10,716.2543616,-3.27140714x^3 - 13.52250591x^2 - 17.72400473x + 89.68275139
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Linifanib (ABT-869),1,0.058773333,0.35956334,2.704005467,10,10,444.721767,0.27070535x^3 - 5.35364314x^2 - 28.64864802x + 63.35376014
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Ibrutinib (PCI-32765),1,2.468223661,8.863049989,10,10,10,839.4593423,-3.03484378x^3 - 10.03683255x^2 - 9.24762696x + 95.35729877
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,RAF265 (CHIR-265),1,0.017388292,0.037655498,0.126003825,0.544403358,10,241.3169496,7.09712685x^3 + 25.54050929x^2 - 17.54020759x + 18.71755922
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Tofacitinib (CP-690550),1,0.732462111,10,10,10,10,841.7910085,3.03976202x^3 + 4.08503053x^2 - 12.58046507x + 88.23176237
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,GSK-1838705A,1,0.065174694,0.173227927,1.077689217,10,10,516.4801701,8.90393476x^3 + 20.20210208x^2 - 21.71675048x + 50.68401859
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Nilotinib,1,10,10,10,10,10,978.7538857,5.7778223x^3 + 10.91316717x^2 - 7.3830877x + 94.58330178
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Nilotinib,2,5.0432788,10,10,10,10,904.8326578,-3.2972898x^3 - 8.97653672x^2 - 4.65630337x + 98.84887954
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Nilotinib,3,0.498210139,1.536977139,10,10,10,673.1411504,5.66713288x^3 + 4.33015701x^2 - 30.55316629x + 80.51553609
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Canertinib (CI-1033),1,0.299547008,1.605083126,10,10,10,676.92304,1.63464361x^3 - 0.45879554x^2 - 21.06233145x + 79.33344621
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,SB-202190,1,10,10,10,10,10,1151.897908,-10.75351103x^3 - 26.03841048x^2 + 7.55175159x + 127.85751354
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Crenolanib,1,0.008692956,8.734009705,10,10,10,899.46686,-9.48288317x^3 - 24.81688644x^2 - 2.50101793x + 107.2457331
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Crenolanib,2,0.008536244,3.069748615,5.417147874,8.28271134,10,567.1702198,-15.17282594x^3 - 46.93465042x^2 - 26.85709625x + 100.97190301
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Erlotinib,1,10,10,10,10,10,987.2048187,-2.33986907x^3 - 7.1375104x^2 - 1.98608491x + 104.31283821
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Neratinib (HKI-272),1,0.039603566,0.077304705,0.213710617,0.706807457,10,250.0092818,12.47704489x^3 + 32.94163402x^2 - 28.23193958x + 20.04007028
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,PD153035,1,0.785178242,1,1,1,1,91.65123773,-0.56308345x^3 - 3.05545756x^2 - 7.72158117x + 89.22204323
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,KW-2449,1,0.118195995,0.369591548,2.273029787,10,10,456.0281887,4.1047638x^3 + 3.03119732x^2 - 32.11725942x + 60.88156564
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Dovitinib (CHIR-258),1,0.044167442,0.137917343,0.629659385,4.253287146,10,286.0565942,5.94124504x^3 + 7.79043934x^2 - 35.30520125x + 42.6411454
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Cediranib (AZD2171),1,1.802247862,3.985725131,9.389618007,10,10,716.8467075,-5.93551399x^3 - 22.15305938x^2 - 21.10622624x + 96.94836409
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,CYT387,1,0.097453466,0.385965196,2.601502555,10,10,452.4524195,1.76605296x^3 - 1.77480756x^2 - 30.46864967x + 62.83088858
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Motesanib (AMG-706),1,0.025829373,10,10,10,10,981.3192218,-0.09424936x^3 + 6.19149181x^2 + 9.77660605x + 89.53567562
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,PI-103,1,0.007895754,0.018921974,0.119895333,1.827191671,10,203.7618,-0.84501879x^3 + 3.04791394x^2 - 18.55198525x + 29.66289844
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,p38 MAP Kinase Inhibitor,1,10,10,10,10,10,1053.748236,-0.5102211x^3 - 2.29029553x^2 - 0.37026288x + 106.96782585
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,AMPK Inhibitor,1,0.095987158,10,10,10,10,821.0110375,3.51422717x^3 + 11.0594983x^2 - 4.36648848x + 77.80452414
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,PP2,1,1.390168919,3.067723522,7.032111334,10,10,643.4313974,-7.32652484x^3 - 25.76316731x^2 - 25.0121845x + 94.12721626
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Vatalanib (PTK787),1,0.257481402,1.6641445,10,10,10,692.1604328,1.97209809x^3 + 0.28915869x^2 - 18.92611764x + 79.1507985
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,PD98059,1,0.580587021,4.396336975,10,10,10,763.4702533,1.59629054x^3 - 0.66621465x^2 - 17.29615812x + 85.97397656
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Sorafenib,1,0.358629494,0.742147391,2.238835043,6.812046695,10,384.6476326,4.89113696x^3 - 4.73699921x^2 - 51.5491616x + 68.41395404
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Sorafenib,2,0.43538063,1.504014442,7.219426628,10,10,601.0763259,0.73907191x^3 - 7.74339288x^2 - 29.35735609x + 80.44281845
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Sorafenib,3,0.471960957,1.474555307,5.700829046,10,10,567.8129625,-0.03473236x^3 - 11.30172173x^2 - 32.09452787x + 80.734759
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Selumetinib (AZD6244),1,0.009984395,0.055822752,10,10,10,606.2377296,-1.85832139x^3 - 0.1747885x^2 - 5.61988708x + 64.57434117
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,TG101348,1,0.033377735,0.081187694,0.286978082,1.341850603,10,240.4498796,8.72346162x^3 + 19.91634257x^2 - 31.16958124x + 28.63751473
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Imatinib,1,0.005573932,0.022939468,10,10,10,779.5494966,-5.92861773x^3 - 10.1282329x^2 + 4.11151693x + 82.83910355
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Pelitinib (EKB-569),1,0.058584121,0.10053814,0.227038443,0.53947511,1.070535658,134.9475803,17.74597659x^3 + 39.58319021x^2 - 42.11008553x + 11.21136228
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,JAK Inhibitor I,1,0.123577903,1.125657982,10,10,10,668.6004334,1.03664875x^3 + 0.01234703x^2 - 16.4322647x + 75.84455103
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,R547,1,0.360018671,0.983892091,3.41265061,9.266350316,10,459.8638833,0.40103027x^3 - 12.24607778x^2 - 39.95448487x + 74.71882901
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Alisertib (MLN8237),1,0.523730454,4.259596174,10,10,10,749.3120689,-1.60434876x^3 - 6.65333095x^2 - 13.68182005x + 86.64627801
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,KI20227,1,0.023360379,0.685395892,10,10,10,718.0409602,0.34514222x^3 + 2.75564868x^2 - 6.29414012x + 73.89474802
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,AZD1480,1,1.875214598,8.641176432,10,10,10,826.5004592,-3.88138235x^3 - 10.26811591x^2 - 5.49947605x + 92.34621199
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Crizotinib (PF-2341066),1,0.004678012,0.485626689,1.790851956,4.667536279,7.601485032,286.2616355,-0.68834555x^3 - 15.84261662x^2 - 45.01409066x + 62.41695534
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,MEK1/2 Inhibitor,1,1.495984851,5.467181645,10,10,10,780.7576526,-2.79905485x^3 - 10.69513798x^2 - 14.91898675x + 92.95198512
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Flavopiridol,1,0.010266523,0.027389706,0.156485252,10,10,325.577923,2.63394789x^3 + 13.30708828x^2 - 12.9736051x + 32.29152855
657,12-00071,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v2,Standard,Axitinib (AG-013736),1,0.129328725,1.12660945,10,10,10,738.9379566,3.62550782x^3 + 7.80141631x^2 - 12.13380039x + 75.60679327
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,GS-1101 (CAL-101),1,0.01409509,2.9114676,10,10,10,714.5283862,-3.27630269x^3 - 6.86959597x^2 - 6.89056287x + 80.00523394
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Pazopanib (GW786034),1,10,10,10,10,10,1095.525925,-0.61518356x^3 - 1.51406478x^2 + 4.48591881x + 108.03722997
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,NF-kB Activation Inhibitor,1,10,10,10,10,10,960.01925,-0.35690145x^3 - 0.68190494x^2 - 0.98472417x + 97.07314889
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Selumetinib (AZD6244),1,0.005505306,0.008510217,0.023450679,5.996871336,10,259.5032254,-6.40977558x^3 - 2.43440424x^2 + 0.32196599x + 29.24031306
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,GW-2580,1,0.145889242,10,10,10,10,872.3016523,4.1052082x^3 + 12.0162934x^2 - 3.01501288x + 81.48022617
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,BEZ235,1,0.035808411,0.092107482,0.590198251,10,10,775.4908613,14.10120239x^3 + 42.79908318x^2 + 3.92782102x + 48.82435747
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,JAK Inhibitor I,1,0.0192677,0.192836478,5.80494018,10,10,534.0654474,-0.52583341x^3 - 1.64789789x^2 - 16.53871092x + 63.82789832
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Midostaurin (PKC412),1,0.208683949,0.959585531,7.007843626,10,10,578.8157206,1.01047011x^3 - 4.28581853x^2 - 26.11219591x + 74.53354736
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Cediranib (AZD2171),1,1.152122063,2.229091812,4.54268011,7.635818925,9.918460765,498.2193727,-9.98275603x^3 - 37.22568437x^2 - 35.62242751x + 92.33383746
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,GSK690693,1,0.086879988,10,10,10,10,1317.33347,6.08817262x^3 + 28.12521532x^2 + 30.61872402x + 98.09629071
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,SB-202190,1,10,10,10,10,10,1082.594174,2.14023752x^3 + 12.00850447x^2 + 12.24729456x + 94.54958585
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,PI-103,1,0.01402085,0.059831747,1.692700967,10,10,524.2565966,2.68365076x^3 + 10.80384137x^2 - 9.88192223x + 51.66227202
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Roscovitine (CYC-202),1,2.995428299,10,10,10,10,867.01419,-0.39444367x^3 - 6.4583472x^2 - 15.06251915x + 98.68546521
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Crizotinib (PF-2341066),1,0.700120262,1.641626542,3.698534821,6.516069505,8.626047993,418.6027383,-9.7289967x^3 - 35.85961727x^2 - 38.00197251x + 84.93975569
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,H-89,1,0.800151683,10,10,10,10,886.7505088,4.20844533x^3 + 7.76505103x^2 - 9.94397095x + 88.96816689
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,SB-431542,1,10,10,10,10,10,1018.721963,-5.2417059x^3 - 11.16038457x^2 + 5.23102185x + 106.4147078
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,TG100-115,1,0.014046536,10,10,10,10,967.3170545,-9.1871556x^3 - 21.83688186x^2 + 1.84842207x + 109.95811096
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,TG101348,1,0.045214605,0.113027547,0.386597592,1.364037758,3.834528304,134.6177527,7.32924406x^3 + 10.04271215x^2 - 43.83942282x + 30.71019001
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,JNJ-28312141,1,0.010779084,10,10,10,10,796.7655453,-2.55926528x^3 - 0.72281535x^2 + 3.02241374x + 79.25447046
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,SNS-032 (BMS-387032),1,0.032003134,0.060857628,0.151605434,0.379226907,0.729091435,38.57558275,13.19171024x^3 + 32.75551624x^2 - 37.90054211x + 4.21669958
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,STO609,1,2.642305231,10,10,10,10,865.3374263,-0.13165098x^3 - 4.93074774x^2 - 12.23716749x + 96.0517855
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Crenolanib,1,1.301596206,2.355897233,4.480755905,7.171040819,9.090264686,484.1776074,-12.99322669x^3 - 43.57284274x^2 - 34.48436205x + 94.53814774
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Crenolanib,2,0.008398773,2.626572587,4.682049718,7.197737122,8.954268259,499.0610319,-15.07794739x^3 - 48.93906412x^2 - 32.57921495x + 98.38337604
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Vatalanib (PTK787),1,0.214751541,10,10,10,10,809.1365501,3.18063846x^3 + 6.52912371x^2 - 9.30100974x + 81.82067391
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Barasertib (AZD1152-HQPA),1,0.015308967,10,10,10,10,887.3433333,-0.77503914x^3 + 1.84717065x^2 + 3.70698113x + 86.00862502
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,R547,1,0.010901327,0.688855781,2.468592647,5.17435282,7.325581201,307.1331661,-8.11062538x^3 - 29.6608763x^2 - 37.31462435x + 69.7026054
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Velcade,1,0.019083775,0.041055866,0.117650486,0.338599089,0.737903369,57.28728541,9.91916534x^3 + 27.88174188x^2 - 30.52666961x + 5.50746297
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,MEK1/2 Inhibitor,1,0.03173875,0.31256755,3.126817688,10,10,464.1359727,-0.77621227x^3 - 6.13475062x^2 - 24.86292407x + 63.90769086
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Flavopiridol,1,0.037425693,0.069015326,0.166028835,0.403192597,0.762327178,51.92613594,14.55955755x^3 + 34.91001709x^2 - 39.48320262x + 4.88547828
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,LY294002,1,0.1578927,1.347427143,9.368541018,33.19210597,50,1768.665186,-1.59917968x^3 - 7.17678279x^2 - 20.04450932x + 77.71970974
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,PP242,1,0.009348351,0.036571287,0.565624283,10,10,384.2116151,0.23174052x^3 + 3.27461326x^2 - 16.07872066x + 45.82393472
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Doramapimod (BIRB 796),1,0.009337478,0.040954335,10,10,10,724.3386832,-2.08405629x^3 + 2.53313117x^2 + 3.76469749x + 69.77694609
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,PP2,1,2.553477472,10,10,10,10,849.3309799,-3.96158158x^3 - 9.55243836x^2 - 4.20731042x + 93.56365594
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,GDC-0941,1,0.017583267,0.101612734,10,10,10,667.926979,1.93979647x^3 + 9.86398607x^2 - 3.85056399x + 63.3484435
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,GDC-0941,2,0.032448007,0.151946193,10,10,10,588.7838653,1.27421653x^3 + 6.92769303x^2 - 11.61829594x + 61.55185613
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,JNJ-7706621,1,1.847031631,2.9513377,5.161036059,7.911426061,9.850589116,552.4617009,-13.43651967x^3 - 46.19783848x^2 - 34.06416598x + 102.61191367
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Go6976,1,0.070451954,0.703715011,10,10,10,665.5182617,1.77397714x^3 + 2.61183012x^2 - 14.30765922x + 72.76208637
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,RAF265 (CHIR-265),1,0.046230494,0.108736933,0.358728815,1.297555167,5.216737089,159.1302244,8.30078262x^3 + 13.96180536x^2 - 41.47081911x + 29.5007281
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,YM-155,1,0.01597236,0.035975878,0.131832603,0.819014477,1,35.50080493,6.66120095x^3 + 25.49610495x^2 - 12.58496006x + 23.72143179
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Vandetanib (ZD6474),1,0.204147878,10,10,10,10,788.3436683,5.55121806x^3 + 10.85567543x^2 - 12.09054492x + 78.31170669
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Trametinib (GSK1120212),1,0.004646318,0.006074111,0.010540896,0.024620833,10,239.9608575,-11.86845216x^3 - 8.69297255x^2 + 15.82927649x + 23.55086784
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,BI-2536,1,0.006740512,0.021562573,0.178198919,1.482350095,4.779638863,130.1308581,-0.71464688x^3 - 1.55817008x^2 - 27.74302192x + 29.79179792
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,AT7519,1,0.004677521,0.221942366,0.601924797,1.675272941,3.552359956,124.1378922,9.69841087x^3 + 7.96725953x^2 - 56.74563291x + 37.20667747
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,SYK Inhibitor,1,0.121878175,2.791214499,10,10,10,707.9225544,-1.81194669x^3 - 6.88962217x^2 - 13.12108357x + 82.37900169
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,AKT Inhibitor IV,1,0.164055316,0.292310671,0.688389708,1.673078712,3.242095516,146.7293418,14.91967112x^3 + 10.2031076x^2 - 66.04315278x + 39.08537843
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,CYT387,1,0.057552551,0.647280932,10,10,10,605.507969,-0.23482909x^3 - 2.49530934x^2 - 17.41272238x + 71.79807596
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Dovitinib (CHIR-258),1,0.095838322,0.365441197,1.812408763,6.94537506,10,361.5481515,1.37024874x^3 - 6.30414303x^2 - 37.27508743x + 60.0233812
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,KN92,1,0.207663439,10,10,10,10,942.3846917,0.35966149x^3 + 3.57001444x^2 + 3.12176704x + 90.58183712
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Bosutinib (SKI-606),1,0.024412146,0.159694169,5.843946125,10,10,527.6481573,2.4672414x^3 + 5.06050848x^2 - 17.34809363x + 59.21414569
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Vargetef,1,0.813920682,10,10,10,10,878.2020614,1.78151445x^3 + 2.79543859x^2 - 6.32142693x + 89.41367376
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Dasatinib,1,0.003956156,0.022743936,1,1,1,73.55688959,5.01315012x^3 + 30.35824433x^2 + 40.80951961x + 82.3313396
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Dasatinib,2,0.007627624,0.050233742,1,1,1,73.35783834,4.47405008x^3 + 25.02907143x^2 + 27.2712841x + 77.99807236
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Dasatinib,3,0.003869171,0.015669785,1,1,1,64.46683654,6.2327708x^3 + 36.03882802x^2 + 43.57767267x + 72.89718477
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,R406,1,0.004572222,0.011161673,10,10,10,595.5555636,-1.35906863x^3 + 4.746844x^2 + 4.31112472x + 55.21197836
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,KW-2449,1,1.179565284,4.005504611,10,10,10,749.1894838,1.03734333x^3 - 7.21079763x^2 - 23.81615305x + 91.74485164
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,NVP-TAE684,1,0.276570114,1.628747692,10,10,10,686.0501339,1.61353876x^3 + 0.25593144x^2 - 19.77500878x + 79.16258207
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Erlotinib,1,1.361023238,5.177206578,10,10,10,776.6005816,-0.83067178x^3 - 8.6633651x^2 - 17.98774512x + 92.56517925
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,AZD1480,1,0.529640836,4.032161885,10,10,10,738.0986154,-2.5079635x^3 - 9.69331499x^2 - 13.12972052x + 87.0617114
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,GDC-0879,1,10,10,10,10,10,1089.13616,4.01352388x^3 - 4.93116518x^2 - 23.44100317x + 123.35468257
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Gefitinib,1,0.701961164,10,10,10,10,1010.327969,5.05073734x^3 + 14.58789074x^2 + 3.15817676x + 90.15914366
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,KN93,1,5.371772916,10,10,10,10,910.3063682,-1.46771811x^3 - 4.95200286x^2 - 5.36643475x + 97.12914505
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Canertinib (CI-1033),1,2.257985023,10,10,10,10,850.8244559,-0.06599691x^3 - 5.4924112x^2 - 12.97672684x + 95.28026509
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Staurosporine,1,0.021703321,0.042752727,0.113769313,0.309571956,0.648369388,72.3333596,10.79606466x^3 + 31.99157106x^2 - 28.6252092x + 3.55247324
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,AMPK Inhibitor,1,0.145207825,10,10,10,10,936.2196473,4.93124335x^3 + 14.65478947x^2 + 1.37596678x + 83.7636349
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Sunitinib,1,0.18164289,0.648415821,1,1,1,80.15137833,-3.42967729x^3 - 22.37572243x^2 - 45.4466336x + 67.21861695
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Sunitinib,2,0.13024477,0.582247916,1,1,1,78.11453217,-4.88453835x^3 - 27.82771599x^2 - 49.12235932x + 64.93361849
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Sunitinib,3,0.050281852,0.501356623,1,1,1,77.16894386,2.42340022x^3 + 8.39723918x^2 - 6.84468198x + 72.25792344
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,LY-333531,1,0.21366533,0.4235325,1.343659782,10,10,366.8242626,9.62162854x^3 + 9.57976119x^2 - 48.55204144x + 56.05072801
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Rapamycin,1,0.054744859,0.342491465,10,10,10,605.7633948,3.05548623x^3 + 5.42533717x^2 - 16.78661101x + 66.32139246
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,MLN120B,1,0.246634421,5,5,5,5,448.2333539,7.27826452x^3 + 21.22897273x^2 + 0.41490094x + 84.0414346
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,JNK Inhibitor II,1,0.34428371,50,50,50,50,4077.737221,0.16252797x^3 + 1.13329415x^2 - 6.14437459x + 86.92775065
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,BMS-345541,1,0.994896474,2.01616701,4.392949894,7.786111153,10,493.5525254,-7.44882497x^3 - 31.74353831x^2 - 38.61799216x + 89.9143433
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Masitinib (AB-1010),1,0.760784922,10,10,10,10,814.5345124,1.17798271x^3 - 0.78522405x^2 - 12.44301244x + 88.53558298
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Quizartinib (AC220),1,0.129208193,0.319422236,2.019786836,10,10,504.1425705,7.7068194x^3 + 14.13442644x^2 - 29.96849122x + 57.61273514
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Quizartinib (AC220),2,0.040431255,0.187987444,10,10,10,600.711145,4.69272013x^3 + 11.71426615x^2 - 13.97872974x + 60.47587318
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Nilotinib,1,10,10,10,10,10,933.8147323,3.84223388x^3 + 4.38621484x^2 - 10.7790169x + 95.98505116
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Nilotinib,2,10,10,10,10,10,1103.6246,-2.33571049x^3 - 6.44579443x^2 + 1.11304811x + 113.85126626
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Nilotinib,3,1.258552301,2.801860922,9.131330148,10,10,678.9523786,2.66248937x^3 - 10.48467674x^2 - 38.09625274x + 93.90664585
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Ponatinib (AP24534),1,0.075839089,0.17030546,0.415688853,0.801322008,1,48.30024068,-4.85003254x^3 - 40.53506765x^2 - 106.13219867x + 15.16159019
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Ponatinib (AP24534),2,0.07816812,0.178419417,0.424633942,0.793468283,1,48.46033107,-6.2114263x^3 - 47.22044061x^2 - 113.2312201x + 14.09396895
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Ponatinib (AP24534),3,0.041995994,0.101097289,0.295220989,0.685262816,1,40.61633582,-0.50776338x^3 - 18.47720515x^2 - 80.98289406x + 12.20282169
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Neratinib (HKI-272),1,0.040626904,0.251558943,10,10,10,881.2855433,7.64813364x^3 + 23.85263655x^2 + 4.60939567x + 70.84075964
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,CI-1040 (PD184352),1,0.013713343,0.030673045,0.121995684,0.743462067,10,208.0964723,3.36584008x^3 + 15.7125321x^2 - 18.73330103x + 22.33501052
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,GSK-1838705A,1,0.039900625,10,10,10,10,968.8074013,0.25915413x^3 + 5.1036496x^2 + 6.88401624x + 90.35134754
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Motesanib (AMG-706),1,0.194270723,10,10,10,10,1081.404674,5.78777001x^3 + 20.8462981x^2 + 11.03605756x + 89.38283861
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Foretinib (XL880),1,0.147137261,0.65418735,10,10,10,615.5994585,4.28096069x^3 + 4.29041044x^2 - 22.55476549x + 70.72427622
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Tozasertib (VX-680),1,0.004572222,0.006040336,8.285405826,10,10,673.5437248,-14.54745443x^3 - 34.5194777x^2 + 1.38628143x + 89.10299677
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Tandutinib (MLN518),1,3.582846809,7.237575122,10,10,10,842.6899638,-7.69773545x^3 - 21.3546888x^2 - 7.21020554x + 101.86607226
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Lestaurtinib (CEP-701),1,0.002347681,0.009209309,0.051551652,0.390552445,1,27.27796074,4.11743533x^3 + 18.43455012x^2 - 6.84037491x + 19.41372461
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,PD173955,1,0.597775007,1.192167,3.556086272,10,10,490.1663378,5.60787317x^3 - 5.6718117x^2 - 51.08497996x + 78.93023605
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,A-674563,1,0.140587854,0.283959523,0.839093046,2.718200725,7.20056776,217.7438042,7.29846934x^3 + 5.61178828x^2 - 52.16124517x + 45.99649315
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,PD98059,1,0.162249598,0.691693986,10,10,10,653.0926,4.66215272x^3 + 7.39240324x^2 - 20.41490914x + 71.56153681
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Alisertib (MLN8237),1,0.113851356,6.968197319,10,10,10,783.3160575,-1.88384032x^3 - 4.27161236x^2 - 7.30658809x + 85.32586767
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Pelitinib (EKB-569),1,0.051339526,1.008236735,4.250588861,10,10,491.7210544,-4.71683602x^3 - 17.91242291x^2 - 26.8128742x + 75.09574886
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,PHA-665752,1,10,10,10,10,10,1022.548764,-2.55589482x^3 - 3.98990305x^2 + 5.55495925x + 102.05613637
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,PD153035,1,0.964103116,1,1,1,1,95.76355294,-3.77237942x^3 - 19.51176633x^2 - 27.05547407x + 89.57535651
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,SB-203580,1,0.026881628,10,10,10,10,975.3011197,2.75661568x^3 + 14.77812142x^2 + 11.65766748x + 82.535935
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,INK-128,1,0.003448787,0.006920788,0.066567246,5,5,204.4700172,-3.92126737x^3 - 3.94707859x^2 - 4.91092972x + 43.29718992
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Ibrutinib (PCI-32765),1,0.011362829,10,10,10,10,902.2867426,-2.29877843x^3 - 2.4512613x^2 + 3.95805596x + 90.06335221
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Axitinib (AG-013736),1,0.018121746,0.290235081,10,10,10,749.834205,1.75066472x^3 + 7.72720484x^2 - 2.29693061x + 71.80708811
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Lapatinib,1,10,10,10,10,10,1028.872399,1.83211111x^3 + 6.77427107x^2 + 0.62935153x + 98.51696706
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Tofacitinib (CP-690550),1,0.028990014,3.512435392,10,10,10,725.2898456,-2.89192162x^3 - 8.11883016x^2 - 9.98194126x + 83.33282224
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Afatinib (BIBW-2992),1,0.023996536,0.54455389,2.181106739,5.066896441,7.555436321,301.8737392,-5.22361961x^3 - 23.60406869x^2 - 39.22462695x + 66.19483267
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,PLX-4720,1,0.004715445,2.00936283,5.223251565,10,10,572.907816,2.7961673x^3 - 14.26887956x^2 - 47.99594824x + 90.77826076
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Linifanib (ABT-869),1,1.154106529,2.533203051,6.679199278,10,10,625.5294637,-1.68934829x^3 - 18.07088131x^2 - 35.18984643x + 92.26084758
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Sorafenib,1,0.795484224,1.518927158,3.573499313,7.208023569,10,449.7696568,-0.56355687x^3 - 20.92400609x^2 - 51.66549888x + 85.07213302
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Sorafenib,2,1.425349571,2.714963406,6.059367802,10,10,612.598962,-3.22927397x^3 - 24.37532927x^2 - 38.37683437x + 96.49628706
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Sorafenib,3,0.261470529,1.117189813,4.666436222,10,10,522.3719094,-1.4348207x^3 - 12.97761705x^2 - 30.26876305x + 76.48696253
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,SGX-523,1,10,10,10,10,10,927.4712793,-3.34458491x^3 - 7.27174129x^2 + 1.23099851x + 96.92939705
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,VX-745,1,0.091289479,0.363232813,10,10,10,640.3302925,5.15972182x^3 + 11.66166958x^2 - 16.69107997x + 65.84218489
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,p38 MAP Kinase Inhibitor,1,7.483106774,10,10,10,10,967.0139467,-7.02495051x^3 - 17.42299293x^2 + 0.03019956x + 107.97647524
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,KI20227,1,4.502824532,9.048977417,10,10,10,883.6825991,-7.12307829x^3 - 19.16155803x^2 - 4.62165849x + 103.19079654
669,12-00085,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v2,Standard,Imatinib,1,10,10,10,10,10,958.4051435,-0.27449812x^3 - 0.37590622x^2 - 0.17144332x + 96.26705866
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Pazopanib (GW786034),1,0.009886025,9.989968958,10,10,10,854.6726998,-7.12038211x^3 - 13.99627296x^2 + 2.40319x + 93.69300788
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PP2,1,8.461312287,10,10,10,10,955.1420637,-3.70841947x^3 - 9.66303745x^2 - 1.27976306x + 102.45677884
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,H-89,1,0.316060229,10,10,10,10,944.7045779,3.20209548x^3 + 9.69187204x^2 + 0.49344991x + 88.22245433
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SGX-523,1,10,10,10,10,10,986.2164943,0.09949139x^3 - 0.94316266x^2 - 2.76564702x + 100.67745373
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Rapamycin,1,0.012716044,1.473367798,9.030617541,10,10,622.7749045,-2.90520622x^3 - 10.82785406x^2 - 16.37576323x + 78.07681454
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,AZD1480,1,0.739192251,10,10,10,10,866.2422902,1.22103511x^3 + 1.52270384x^2 - 6.45260037x + 89.12967627
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,MLN120B,1,5,5,5,5,5,460.6642853,0.11587537x^3 + 1.44110459x^2 + 0.78708039x + 91.59674088
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PHA-665752,1,0.241574545,4.309413805,10,10,10,744.7704142,-2.83150909x^3 - 9.20943531x^2 - 10.71688097x + 86.22866817
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Barasertib (AZD1152-HQPA),1,0.319051941,10,10,10,10,826.0490252,5.62367923x^3 + 10.34118663x^2 - 11.92502687x + 82.22481322
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Imatinib,1,0.192392736,0.817716437,10,10,10,703.0966711,6.13281236x^3 + 10.9124292x^2 - 18.67753441x + 73.28837626
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Crizotinib (PF-2341066),1,0.088579134,1.071546699,4.1773856,9.722610348,10,486.7794321,-4.88644695x^3 - 18.96526823x^2 - 27.98473066x + 75.85706609
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Ibrutinib (PCI-32765),1,0.032868965,6.381484555,10,10,10,777.7970384,-2.68405486x^3 - 6.07719647x^2 - 6.2383739x + 85.35856804
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Motesanib (AMG-706),1,0.162388232,10,10,10,10,927.519412,4.38243766x^3 + 13.52139634x^2 + 0.52190415x + 84.14132023
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GSK-1904529A,1,10,10,10,10,10,940.1808319,0.93098733x^3 + 0.10846294x^2 - 6.28024734x + 97.24465138
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Alisertib (MLN8237),1,2.540436454,10,10,10,10,874.6600411,0.16216685x^3 - 2.91755356x^2 - 9.51096936x + 94.31864045
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,BMS-345541,1,0.10468642,0.420708172,4.461955791,10,10,525.1909386,2.89942322x^3 + 2.3269728x^2 - 25.93877071x + 65.07166574
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Go6976,1,0.079822023,10,10,10,10,788.9224836,3.30814602x^3 + 9.26892106x^2 - 6.07271261x + 76.53845712
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Flavopiridol,1,0.02338108,0.269326157,10,10,10,688.1874376,1.07245151x^3 + 5.26257954x^2 - 6.74799576x + 69.64569998
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PP242,1,0.017527107,0.079159262,1.686201934,10,10,534.0340068,4.20940059x^3 + 13.13600612x^2 - 11.60281204x + 51.9072642
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SB-203580,1,0.008967434,0.03047768,10,10,10,754.7725493,-1.16323908x^3 + 7.1994883x^2 + 8.58211852x + 67.41093302
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Erlotinib,1,0.014897382,9.384774116,10,10,10,911.7766031,-9.03163097x^3 - 22.95992837x^2 - 2.33803692x + 107.28952912
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PLX-4720,1,0.950592494,10,10,10,10,817.9054089,0.22224122x^3 - 2.80498573x^2 - 11.59714514x + 89.74615832
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GDC-0941,1,0.0104935,0.06682096,1.738567966,10,10,415.9590127,-1.36902731x^3 - 3.54207827x^2 - 19.3928621x + 54.88132453
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GDC-0941,2,0.154840063,0.656261173,10,10,10,602.1401925,3.40702035x^3 + 3.38397202x^2 - 23.41052535x + 70.62529247
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PD173955,1,0.227311583,1.321614221,10,10,10,750.0382576,5.42105159x^3 + 10.72807992x^2 - 15.9191925x + 76.76091864
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Axitinib (AG-013736),1,0.04935817,0.546543223,10,10,10,809.688665,4.35672144x^3 + 13.80044783x^2 - 1.94284849x + 73.6189008
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,KW-2449,1,0.006635233,2.903664634,10,10,10,673.8347416,-7.4407816x^3 - 17.46953952x^2 - 6.25011415x + 82.37579233
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Gefitinib,1,0.176735057,10,10,10,10,818.015303,-0.82431145x^3 - 2.89922031x^2 - 5.83395978x + 86.89989235
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Lapatinib,1,0.012764691,7.713773286,10,10,10,883.6635077,-10.21946134x^3 - 27.98880715x^2 - 6.039344x + 109.53072271
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Staurosporine,1,0.134921456,0.36912553,10,10,10,693.3950815,10.34962212x^3 + 23.39575536x^2 - 17.50685958x + 63.87885468
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Linifanib (ABT-869),1,1.509710516,10,10,10,10,876.5618042,2.45335715x^3 + 2.65368628x^2 - 11.32867133x + 91.92765614
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,AT7519,1,0.00921597,0.025175218,0.308241162,10,10,616.3599514,2.51477127x^3 + 17.89720766x^2 + 5.64366688x + 48.54496216
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,MGCD-265,1,0.049452831,3.540229642,10,10,10,750.3969368,0.3830977x^3 + 0.73658314x^2 - 8.02357915x + 79.11976311
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,NF-kB Activation Inhibitor,1,0.008578016,0.049330194,1.586268238,10,10,484.8325253,1.31983014x^3 + 5.58085105x^2 - 12.37265423x + 52.24449674
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Nilotinib,1,1.546316528,10,10,10,10,900.4169997,5.57914888x^3 + 7.4030187x^2 - 14.01327795x + 92.34956713
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Nilotinib,2,10,10,10,10,10,1400.899472,11.62532939x^3 + 37.2484319x^2 + 23.9574969x + 103.69852272
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Nilotinib,3,0.204018264,0.497848985,10,10,10,715.5873105,12.74836475x^3 + 26.69753292x^2 - 22.1106346x + 66.20743464
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,MEK1/2 Inhibitor,1,10,10,10,10,10,913.1543749,2.03567375x^3 + 2.77587077x^2 - 8.31228077x + 93.9612169
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Crenolanib,1,0.006983571,0.027645784,4.707688069,9.713545664,10,498.2313029,-10.09441131x^3 - 25.78898962x^2 - 15.54253098x + 75.20539417
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Crenolanib,2,0.006750773,0.025323906,2.5844905,7.439957956,10,383.4415017,-7.33433996x^3 - 19.3089285x^2 - 20.19671455x + 62.12648717
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Pelitinib (EKB-569),1,0.071486851,0.158757501,0.570187593,10,10,375.9832205,10.79469387x^3 + 21.70807479x^2 - 32.01868597x + 41.05256353
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Afatinib (BIBW-2992),1,0.055391012,0.269129015,2.276233052,10,10,447.9106786,2.08066708x^3 - 0.11041084x^2 - 27.50268478x + 59.74366643
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GDC-0879,1,10,10,10,10,10,1481.269553,-6.1472804x^3 - 14.5014425x^2 + 20.44600505x + 146.06344629
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Dasatinib,1,0.001290737,0.015766708,1,1,1,75.92359987,0.83357385x^3 + 9.73869068x^2 + 17.88157166x + 80.47434604
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Dasatinib,2,0.0007,0.002434592,1,1,1,68.96872663,-6.03229872x^3 - 27.77483382x^2 - 36.93261315x + 60.50441878
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Dasatinib,3,0.001145335,1,1,1,1,82.28200693,-3.50386031x^3 - 14.79148917x^2 - 16.99778573x + 78.81517007
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Canertinib (CI-1033),1,0.659323388,1.426531025,10,10,10,701.642319,14.43837832x^3 + 18.02296429x^2 - 44.68513354x + 81.41205967
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Trametinib (GSK1120212),1,0.006417036,0.025364746,10,10,10,678.9974977,-0.77654353x^3 + 5.27907102x^2 + 3.29743461x + 63.66333681
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Quizartinib (AC220),1,0.031035908,0.084469456,0.413419952,10,10,373.3299121,6.21562858x^3 + 16.8713999x^2 - 22.30203322x + 39.31290212
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Quizartinib (AC220),2,0.027972374,0.070682278,0.293766948,10,10,319.276079,6.87423892x^3 + 19.16208359x^2 - 23.41981831x + 33.1524841
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Cediranib (AZD2171),1,1.387748562,10,10,10,10,867.663415,1.9333228x^3 + 1.25085749x^2 - 10.51464118x + 91.46544195
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,LY-333531,1,0.086916942,0.653655975,10,10,10,615.4003081,1.17626093x^3 + 0.15725599x^2 - 18.51704477x + 71.58285728
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,CI-1040 (PD184352),1,0.026848723,1.036734147,10,10,10,674.6806625,-1.59518226x^3 - 2.84833252x^2 - 9.98515948x + 75.15714683
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GSK690693,1,0.01099611,10,10,10,10,905.2429746,-5.93436893x^3 - 13.72373659x^2 + 0.59736284x + 99.22620512
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sorafenib,1,1.883508033,4.970995406,10,10,10,778.14749,-1.08378432x^3 - 11.19595601x^2 - 23.89819448x + 97.44025148
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sorafenib,2,0.465200457,1.957159765,7.817534965,10,10,623.3347323,-2.20855552x^3 - 12.42084905x^2 - 24.32721252x + 83.20557233
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sorafenib,3,0.276620771,0.935628205,10,10,10,644.1170058,5.3309609x^3 + 6.46808069x^2 - 26.29782131x + 74.23480755
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,MK-2206,1,0.475941665,2.994830563,10,10,10,734.9605744,1.93842546x^3 - 0.74899396x^2 - 19.00612032x + 84.01440762
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sunitinib,1,0.053634668,0.52577549,1,1,1,77.26070366,1.64829203x^3 + 3.40310476x^2 - 13.23088694x + 71.07653438
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sunitinib,2,0.000982,0.476881097,1,1,1,74.41118188,-7.44383844x^3 - 38.68323253x^2 - 59.06291593x + 59.75901193
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sunitinib,3,0.01298641,0.035409764,1,1,1,76.49284318,11.75923515x^3 + 64.15634057x^2 + 80.89194286x + 93.22692213
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Foretinib (XL880),1,0.006738888,0.019092575,10,10,10,577.2170613,-4.48522863x^3 - 5.27759329x^2 - 2.55140746x + 63.42286971
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SB-431542,1,1.851928018,10,10,10,10,884.7117557,1.67636448x^3 + 1.44363723x^2 - 8.89707912x + 92.2455432
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Vatalanib (PTK787),1,0.387516732,4.390131671,10,10,10,749.8365819,-2.11030427x^3 - 7.53280704x^2 - 11.82005535x + 86.26314577
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,KN92,1,2.373676824,10,10,10,10,899.0600872,0.4361944x^3 + 1.63838522x^2 - 4.05861555x + 91.26969554
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Masitinib (AB-1010),1,0.045933449,0.857347356,10,10,10,736.0492348,1.65501442x^3 + 5.40573549x^2 - 7.32566676x + 74.48667048
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,RAF265 (CHIR-265),1,0.016032715,0.076648478,10,10,10,622.1347446,3.92698242x^3 + 14.50430137x^2 - 5.26279146x + 56.53204461
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,NVP-TAE684,1,0.072705676,0.42007662,10,10,10,668.0926296,3.44797725x^3 + 8.42914384x^2 - 13.35663178x + 68.95726794
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Midostaurin (PKC412),1,0.017847678,2.222956242,10,10,10,727.2241206,-2.19715641x^3 - 1.78573679x^2 - 4.01306524x + 76.69893616
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,BEZ235,1,0.010157115,0.109270204,10,10,10,642.5879286,0.42692902x^3 + 3.76620029x^2 - 6.31963569x + 65.82139946
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Ponatinib (AP24534),1,0.018365097,0.057696639,1,1,1,58.23507637,5.03134113x^3 + 22.30962792x^2 + 2.49084702x + 53.41232548
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Ponatinib (AP24534),2,0.010244456,0.055501719,0.463275989,1,1,52.41788738,1.2395535x^3 + 0.39679512x^2 - 29.11087026x + 40.27425007
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Ponatinib (AP24534),3,0.011368481,0.04403173,0.445453846,1,1,52.55568809,2.96508496x^3 + 11.22486898x^2 - 12.94090329x + 44.19915689
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GS-1101 (CAL-101),1,0.013997376,10,10,10,10,873.7643322,-4.53902835x^3 - 8.72854673x^2 + 0.9619518x + 92.86061372
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Doramapimod (BIRB 796),1,0.008239766,0.050184483,10,10,10,670.9260047,-2.29443444x^3 - 0.73892434x^2 - 1.56337253x + 69.18194326
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PD98059,1,7.94436273,10,10,10,10,922.0506213,-0.40336667x^3 - 1.9273206x^2 - 4.52479293x + 95.9280277
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Roscovitine (CYC-202),1,0.962706222,3.596911485,10,10,10,712.1479519,-3.84099875x^3 - 14.69005871x^2 - 17.12674937x + 89.7212872
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,KN93,1,1.256864821,4.222472955,10,10,10,750.2478227,-1.0572894x^3 - 9.3835927x^2 - 21.21043542x + 92.19949422
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,TG100-115,1,4.263827235,10,10,10,10,891.5024157,-2.70050695x^3 - 10.0694477x^2 - 8.78935597x + 100.20416396
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,KI20227,1,10,10,10,10,10,952.2680966,0.18140729x^3 + 0.40002559x^2 - 3.48045664x + 96.97934732
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,CHIR-99021,1,10,10,10,10,10,1462.483024,-6.73054333x^3 - 7.76621007x^2 + 31.97096006x + 134.4465322
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,JNJ-28312141,1,0.009226114,0.055936404,10,10,10,708.1081168,1.81875646x^3 + 10.94626637x^2 + 1.79949874x + 63.65878235
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PI-103,1,0.040821956,0.316545324,10,10,10,576.9604895,0.97089317x^3 + 1.42183847x^2 - 16.9667246x + 66.29023794
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,R406,1,0.026934733,10,10,10,10,811.3982088,0.95295732x^3 + 4.51957818x^2 - 1.86626168x + 79.62032119
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,VX-745,1,0.053325492,0.214668938,10,10,10,621.221297,4.90770917x^3 + 13.14955825x^2 - 13.59333997x + 61.50920309
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Dovitinib (CHIR-258),1,0.009120785,0.03611589,10,10,10,637.8923116,-3.50502988x^3 - 2.52600835x^2 - 1.70384203x + 67.28100523
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,YM-155,1,0.089222523,0.357077654,1,1,1,71.97449847,-2.58420834x^3 - 19.08006331x^2 - 48.88694558x + 56.72117539
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Selumetinib (AZD6244),1,0.013833173,10,10,10,10,825.7202841,-2.2993099x^3 - 2.6061039x^2 + 0.20333895x + 84.61142483
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,INK-128,1,0.003113471,0.010706469,5,5,5,324.9304827,-2.08362545x^3 - 0.29069835x^2 + 2.20818969x + 64.54081435
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,LY294002,1,0.359728824,1.17517284,12.52881937,50,50,2546.66707,5.04028717x^3 - 0.5023431x^2 - 30.22514979x + 77.11956803
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Lestaurtinib (CEP-701),1,0.002080002,0.007986845,1,1,1,61.99637072,1.30118738x^3 + 14.17012019x^2 + 19.65121431x + 65.88137835
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,JNJ-7706621,1,0.177865861,0.480549872,10,10,10,804.6686248,13.69149762x^3 + 31.12130531x^2 - 13.86198516x + 67.87734435
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,AMPK Inhibitor,1,0.111051401,10,10,10,10,872.5275906,6.47183896x^3 + 18.92688426x^2 - 1.91062186x + 76.56109791
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,R547,1,0.098972994,0.224905934,1.222915557,10,10,573.9653157,13.19037311x^3 + 28.04624684x^2 - 23.16492733x + 51.80150644
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,BI-2536,1,0.012725017,0.106397813,3.282400713,10,10,459.2648161,-3.96938751x^3 - 9.55362535x^2 - 18.32936026x + 62.55301553
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Velcade,1,0.033185846,0.406375959,10,10,10,672.5897162,0.42741301x^3 + 3.04188533x^2 - 9.34598144x + 70.90539403
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SB-202190,1,0.007424298,0.023622415,10,10,10,803.2771845,-6.19149313x^3 - 7.36866116x^2 + 8.38429413x + 81.48648014
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PD153035,1,0.021129483,1,1,1,1,84.5769542,1.47136951x^3 + 7.84600625x^2 + 6.03060044x + 85.00201607
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SNS-032 (BMS-387032),1,0.006948429,0.016181419,0.382046731,10,10,469.8631391,-2.42278455x^3 + 2.43554916x^2 - 2.81944946x + 48.21968753
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GW-2580,1,0.028030286,0.160387168,10,10,10,726.7087428,3.99750248x^3 + 14.51049244x^2 - 2.83308634x + 65.58839512
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Vargetef,1,0.198836227,0.717963522,10,10,10,686.4131577,7.13202413x^3 + 12.35292476x^2 - 20.83483488x + 71.76738141
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,CYT387,1,0.21612918,0.715590722,10,10,10,679.9695058,7.56754625x^3 + 13.13848078x^2 - 22.43950662x + 71.48446305
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,STO609,1,10,10,10,10,10,1061.940719,0.48024186x^3 - 6.77045125x^2 - 11.44678537x + 115.98935783
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Neratinib (HKI-272),1,0.008620245,0.033959288,0.803081463,10,10,538.0672159,2.38367203x^3 + 12.20130781x^2 - 4.61068976x + 49.45226051
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,A-674563,1,0.023844891,0.10471235,5.074566084,10,10,519.9001967,1.64694788x^3 + 6.77979955x^2 - 14.23422446x + 56.08918706
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Tofacitinib (CP-690550),1,0.031175067,10,10,10,10,871.9035981,-1.00291227x^3 - 0.86768998x^2 - 0.25264747x + 88.16099571
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SYK Inhibitor,1,0.008190158,10,10,10,10,1040.387258,-10.50404324x^3 - 25.755784x^2 + 5.29328295x + 117.7528061
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GSK-1838705A,1,0.627484276,10,10,10,10,842.1631239,-1.16138574x^3 - 3.44042614x^2 - 4.85164519x + 89.14934734
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Bosutinib (SKI-606),1,0.095067695,0.394957149,10,10,10,621.347952,4.70876327x^3 + 9.36095703x^2 - 18.53413574x + 66.30792767
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,p38 MAP Kinase Inhibitor,1,1.387413272,10,10,10,10,924.5404595,7.15222034x^3 + 12.37335996x^2 - 14.0550288x + 91.72791889
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,JAK Inhibitor I,1,0.010028087,10,10,10,10,915.3236572,-8.23273616x^3 - 11.64011911x^2 + 11.51923985x + 93.78660323
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Tandutinib (MLN518),1,0.025622698,10,10,10,10,820.2958689,2.02676695x^3 + 7.79678866x^2 - 0.46353216x + 77.68528435
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,JNK Inhibitor II,1,25.29072902,50,50,50,50,4569.155376,-3.37264246x^3 - 5.69267878x^2 + 1.60237107x + 108.2702202
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,AKT Inhibitor IV,1,0.081371952,0.180407408,0.554675246,2.01713933,25,581.429255,11.33238732x^3 + 14.23229837x^2 - 46.19242072x + 37.43412604
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,TG101348,1,0.013332444,0.080669023,1.654806627,10,10,468.3457609,1.65499715x^3 + 4.61381345x^2 - 16.68089182x + 53.41080352
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Tozasertib (VX-680),1,0.115832553,0.419721697,10,10,10,624.4309827,4.96078578x^3 + 10.75172537x^2 - 19.51203508x + 66.38065884
685,12-00109,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Vandetanib (ZD6474),1,0.050524993,1.091339413,10,10,10,673.3192709,-0.1276638x^3 - 1.49912827x^2 - 12.91876898x + 75.49256155
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,LY294002,1,0.026159962,1.707186567,10.81349832,41.32006923,50,1956.795856,0.08262141x^3 - 8.73356915x^2 - 20.23808193x + 80.17110111
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Selumetinib (AZD6244),1,0.006037322,0.009841457,0.036751211,10,10,442.7746452,-6.54630372x^3 - 2.64648333x^2 + 5.89359998x + 44.57009223
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,SGX-523,1,0.049332029,10,10,10,10,802.2135248,1.15585224x^3 + 4.98554792x^2 - 3.59010428x + 79.37320617
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,TG101348,1,0.038539525,0.104004034,0.38638847,1.640177219,10,197.5297614,7.63460788x^3 + 12.39304533x^2 - 38.33959234x + 32.59077811
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Tozasertib (VX-680),1,0.06846159,0.294449311,1.914273889,10,10,406.5555384,1.9378817x^3 - 2.1516173x^2 - 31.69659055x + 59.0662175
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,RAF265 (CHIR-265),1,0.066748876,0.140099721,0.434831506,1.825185015,10,248.6739525,10.30269146x^3 + 19.4217733x^2 - 39.25740984x + 33.7482636
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,SB-431542,1,0.010560679,10,10,10,10,1008.175133,-2.60107678x^3 - 2.7136022x^2 + 8.89272309x + 98.0956843
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Erlotinib,1,7.771145354,10,10,10,10,1019.800539,-6.75802811x^3 - 23.62160839x^2 - 8.69487913x + 121.24572892
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Vandetanib (ZD6474),1,0.008663892,4.083979862,10,10,10,739.6845735,-3.58249296x^3 - 4.18829946x^2 + 0.37049414x + 77.15510408
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,PD98059,1,0.009980287,0.083065427,10,10,10,546.2486484,1.24855528x^3 + 4.43589642x^2 - 11.78636501x + 58.65966189
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,GSK690693,1,0.007336729,0.01934366,10,10,10,591.2517021,-2.04433585x^3 + 3.84798526x^2 + 1.97363411x + 56.79994351
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Quizartinib (AC220),1,0.094492702,0.249876326,1.238300567,10,10,427.0502607,7.58033286x^3 + 11.22726048x^2 - 32.63746125x + 52.92680247
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Quizartinib (AC220),2,0.004572222,0.098713255,3.172486327,10,10,500.9930008,1.90213481x^3 + 3.09033704x^2 - 16.47345628x + 57.24310162
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Motesanib (AMG-706),1,10,10,10,10,10,1202.427904,3.0184709x^3 + 11.00468508x^2 + 12.66535728x + 106.50285794
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Sorafenib,1,0.00478081,0.454326853,1.424298728,10,10,386.6746511,11.21415048x^3 + 10.84476579x^2 - 49.32049541x + 57.27917836
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Sorafenib,2,0.56919957,0.984165725,2.410123198,6.348177962,10,392.4109144,7.5217885x^3 - 2.88705717x^2 - 64.26746296x + 74.55465434
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Sorafenib,3,0.202786614,0.370456241,0.979978994,3.080984923,10,253.7826895,10.50215869x^3 + 9.1857446x^2 - 57.12613158x + 49.49754634
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,BEZ235,1,0.00575753,0.021644289,0.07884481,0.399136463,10,587.1503786,12.69450819x^3 + 47.33867603x^2 + 12.55726129x + 23.28267822
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Lapatinib,1,0.006435639,10,10,10,10,1233.223374,-8.66327786x^3 - 18.68502772x^2 + 17.13671021x + 126.11404114
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Masitinib (AB-1010),1,0.007903827,10,10,10,10,818.6264111,-3.53209614x^3 - 4.42526105x^2 + 3.22976599x + 83.53320548
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,AKT Inhibitor IV,1,0.020462727,0.072910838,0.322623873,1.424537677,5.018414698,245.0753255,5.19757995x^3 + 7.62249268x^2 - 37.17237837x + 30.51355289
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,STO609,1,0.310923332,0.685977487,10,10,10,804.6161492,15.70821389x^3 + 37.23929245x^2 - 24.42802112x + 70.07246315
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Foretinib (XL880),1,0.005437119,0.01045013,0.056103273,10,10,308.2606343,-3.16994348x^3 + 0.93635257x^2 - 5.97167327x + 34.85760345
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Axitinib (AG-013736),1,0.027529088,0.077202084,10,10,10,676.5245094,8.29054767x^3 + 29.26393162x^2 - 0.11236745x + 50.07594076
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,R547,1,0.007483924,0.004795646,3.697676121,5.67401893,7.154420103,414.7952546,-3.09233398x^3 - 44.01317361x^2 - 72.17970795x + 105.7555484
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Cediranib (AZD2171),1,0.37456216,0.836095893,2.674048645,7.74411819,10,415.4098455,2.1541254x^3 - 7.44902372x^2 - 47.24513428x + 71.3730135
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Velcade,1,0.02561794,0.055772431,0.166132443,0.528631262,1.516011361,140.9716204,10.15918064x^3 + 26.54619321x^2 - 30.83319668x + 14.64486679
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,PI-103,1,0.004625827,0.054278659,0.233737782,1.061632729,10,167.9369997,6.77116811x^3 + 13.74178324x^2 - 32.31156131x + 25.8298804
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,PP242,1,0.00509806,0.008391021,0.028071982,6.672704863,10,270.6688672,-5.26431597x^3 - 1.95211104x^2 - 2.4226328x + 31.27188713
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,INK-128,1,0.002286444,0.003425624,0.010026581,5,5,210.8190582,-5.19932378x^3 - 3.36666516x^2 + 9.36316222x + 40.64396791
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,H-89,1,0.008063104,0.020806812,10,10,10,916.6642744,-12.0786913x^3 - 21.27720785x^2 + 12.86681326x + 99.36405414
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,R406,1,0.008504403,0.025852254,10,10,10,875.6344957,-1.78304164x^3 + 8.26972757x^2 + 17.18088125x + 74.30010715
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,NF-kB Activation Inhibitor,1,5.906881908,10,10,10,10,918.8361084,-1.3046823x^3 - 6.24688124x^2 - 5.97847405x + 98.92718811
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Tofacitinib (CP-690550),1,1.737683151,10,10,10,10,847.7740755,-0.22437073x^3 - 4.24608405x^2 - 9.8023717x + 92.59989599
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Vargetef,1,0.004647922,4.132723515,10,10,10,747.767046,0.29431501x^3 - 12.92580828x^2 - 28.56397146x + 97.44182373
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,VX-745,1,0.037400752,0.118004878,10,10,10,578.7210732,5.0359177x^3 + 17.01522769x^2 - 11.24875277x + 53.92953092
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,BI-2536,1,0.009777356,0.03304218,0.162356812,0.834035367,3.425288589,117.9288942,3.6710493x^3 + 9.32505552x^2 - 29.61814722x + 22.60950107
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,AT7519,1,0.0540507,0.098878166,0.237232629,0.583760694,1.146354815,71.66249742,15.25856269x^3 + 30.83055246x^2 - 46.47748683x + 12.64533086
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,GDC-0941,1,0.051041863,0.104385373,0.286554858,0.844885958,2.393999682,148.1564033,12.95841777x^3 + 24.84581046x^2 - 42.33519503x + 21.77292919
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,GDC-0941,2,0.051716321,0.106183433,0.317927801,1.165111154,10,208.7710288,10.00324325x^3 + 21.90839204x^2 - 37.06524215x + 27.3604998
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Vatalanib (PTK787),1,0.00914368,10,10,10,10,794.8312934,-2.60106856x^3 - 4.40183359x^2 - 1.3828818x + 83.43320001
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,GDC-0879,1,3.031466463,10,10,10,10,942.1309607,23.05832111x^3 + 18.47251264x^2 - 72.91510824x + 118.25783847
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,CHIR-99021,1,0.005175534,10,10,10,10,1650.473964,11.80982266x^3 + 29.23224647x^2 + 23.80427626x + 132.74034204
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Roscovitine (CYC-202),1,7.312332031,10,10,10,10,984.4343105,-6.16420204x^3 - 20.36847089x^2 - 5.86766118x + 114.25344984
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Nilotinib,1,10,10,10,10,10,1140.072759,4.59311923x^3 + 2.9552858x^2 - 10.69361502x + 117.03351677
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Nilotinib,2,9.327270251,10,10,10,10,1427.629852,-26.74370198x^3 - 80.66013202x^2 - 6.57259695x + 196.61825368
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Nilotinib,3,0.060028639,0.295389384,1.955033614,8.196050515,10,383.3033432,-0.42960561x^3 - 6.43402105x^2 - 31.90312569x + 59.84475023
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,KW-2449,1,1.044869166,5.549910692,10,10,10,778.7702957,-1.00729227x^3 - 8.24432885x^2 - 13.817313x + 90.26638703
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,GW-2580,1,0.022267629,0.179344593,10,10,10,597.9762911,0.90817712x^3 + 3.63695525x^2 - 11.93753638x + 64.44267369
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Doramapimod (BIRB 796),1,0.004600341,0.007402078,10,10,10,706.292634,-11.62788953x^3 - 20.18926701x^2 + 11.38911019x + 78.44888703
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,PD173955,1,3.573062297,5.166679224,9.698552125,10,10,870.0062112,10.39421398x^3 - 18.25074682x^2 - 83.10610073x + 139.78493148
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,JNJ-28312141,1,0.004905922,0.007992931,0.050482347,10,10,501.1000732,-9.2084635x^3 - 13.47821419x^2 + 4.05782277x + 57.84595214
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,NVP-TAE684,1,0.00785727,0.012560719,10,10,10,730.3777963,-14.39517902x^3 - 21.28291148x^2 + 14.50992062x + 80.60392986
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,TG100-115,1,0.012111494,1.513290271,7.332659963,10,10,599.4922384,-4.57929362x^3 - 14.53186895x^2 - 17.00024877x + 78.55582052
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Tandutinib (MLN518),1,0.087212119,0.16704274,10,10,10,999.5217953,22.27808446x^3 + 65.22161934x^2 + 9.83843138x + 53.71004923
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Pelitinib (EKB-569),1,0.056011249,0.12107545,0.373524209,1.362812749,10,199.311459,10.0524547x^3 + 18.46433355x^2 - 40.5025296x + 30.08687392
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,CI-1040 (PD184352),1,0.009067929,0.026065384,0.196037245,2.619587541,10,228.7084219,0.01081506x^3 + 3.17948633x^2 - 21.28844347x + 33.34658476
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,KN93,1,10,10,10,10,10,1160.576143,7.42726031x^3 + 16.83480208x^2 - 2.62067364x + 106.50643783
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Afatinib (BIBW-2992),1,0.187469993,0.27284737,0.518391772,1.102953068,2.207606278,169.3415448,21.91393557x^3 + 39.84780025x^2 - 68.12637557x + 27.825399
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,A-674563,1,0.293064643,0.492068123,1.161263634,3.22262073,10,263.1713702,13.15433513x^3 + 9.55203559x^2 - 65.75961153x + 54.22595339
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Alisertib (MLN8237),1,0.203766554,10,10,10,10,781.2141151,2.55912571x^3 + 4.35168842x^2 - 10.88866817x + 81.24419729
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,PD153035,1,0.001124396,1,1,1,1,103.8937711,-8.13697911x^3 - 35.24989049x^2 - 29.6668954x + 100.380601
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,SB-202190,1,0.006881326,0.015053006,10,10,10,1201.683138,-9.10004139x^3 - 7.55703462x^2 + 34.39333168x + 107.69952423
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Dovitinib (CHIR-258),1,0.008643089,3.023626871,10,10,10,697.2079649,-5.55128991x^3 - 12.39852785x^2 - 6.10948495x + 81.41464817
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,KI20227,1,0.13687434,0.323555662,10,10,10,602.7934451,10.18909412x^3 + 22.51315284x^2 - 24.0301439x + 59.01658195
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,GS-1101 (CAL-101),1,0.367555312,0.905991739,4.175469339,10,10,526.4148613,5.29094357x^3 - 0.17912067x^2 - 39.47825729x + 73.30808594
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Pazopanib (GW786034),1,0.009686629,10,10,10,10,1538.861606,-16.78450447x^3 - 39.11936807x^2 + 26.34387328x + 164.62027577
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Imatinib,1,0.024419753,0.777051086,10,10,10,705.6129282,1.83479685x^3 + 3.11734797x^2 - 9.72991831x + 73.89908336
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,JAK Inhibitor I,1,0.010493225,7.271073585,10,10,10,787.3583627,-7.09157806x^3 - 11.15839241x^2 + 3.19849105x + 85.06348044
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Go6976,1,0.115916574,0.268015274,1.437495089,10,10,501.8911918,9.08681006x^3 + 18.60993473x^2 - 28.94183668x + 54.06357735
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Dasatinib,1,0.01103493,0.026026753,1,1,1,70.10579367,14.08522674x^3 + 74.88068364x^2 + 91.95372341x + 88.73164953
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Dasatinib,2,0.000822,0.002064461,1,1,1,59.56349578,-0.63944175x^3 + 7.32064287x^2 + 20.75195502x + 65.55905213
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Dasatinib,3,0.00146479,0.005032967,1,1,1,71.19151674,3.64076791x^3 + 30.14879075x^2 + 54.56403236x + 85.35542753
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,AZD1480,1,0.015436424,10,10,10,10,954.3497392,-2.39675291x^3 + 0.12394861x^2 + 8.78771685x + 91.26543291
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,SB-203580,1,0.00760968,0.012575631,10,10,10,995.9266938,-9.94244993x^3 - 4.62720094x^2 + 33.21703808x + 86.59454808
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Sunitinib,1,0.000759,0.251465975,1,1,1,68.6136731,1.47263323x^3 - 3.25541371x^2 - 35.67472319x + 55.09966726
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Sunitinib,2,0.000505,0.002136353,1,1,1,81.16301807,-1.88889633x^3 - 2.79230658x^2 + 10.01582473x + 85.68970548
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Sunitinib,3,0.001628243,0.012660139,0.239141739,1,1,42.77922444,-2.35884186x^3 - 13.78734559x^2 - 42.13275617x + 28.57806365
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,MGCD-265,1,0.025583127,0.364866482,10,10,10,610.3294111,-0.17268198x^3 - 0.59317848x^2 - 13.6091697x + 69.14023825
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Trametinib (GSK1120212),1,0.004572222,0.0060868,0.011882445,0.049830082,10,330.8166798,-11.34196754x^3 - 11.47029453x^2 + 12.53792736x + 35.72760948
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,AMPK Inhibitor,1,0.017923527,0.11145942,10,10,10,693.3153046,0.55932741x^3 + 7.34822148x^2 - 2.20774566x + 66.70812367
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Bosutinib (SKI-606),1,0.016815902,1.500888321,10,10,10,709.2300222,-0.11658388x^3 - 1.02788623x^2 - 8.9981605x + 76.61941636
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,BMS-345541,1,0.451990323,1.45879931,4.001577003,7.894294855,10,465.2097078,-6.94765286x^3 - 26.18204973x^2 - 33.59273198x + 81.24385593
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Midostaurin (PKC412),1,0.007581717,9.616849977,10,10,10,1229.227205,-23.03204467x^3 - 69.00923571x^2 - 5.52059934x + 168.9937103
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Staurosporine,1,0.182906643,0.248369801,0.420039038,0.76624163,1.23260567,171.7820122,30.48723399x^3 + 61.65721392x^2 - 71.46308869x + 15.95912161
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Ponatinib (AP24534),1,0.032650678,0.093717867,0.287400088,0.646895162,0.972069606,38.8202028,-2.80226768x^3 - 28.26897938x^2 - 90.39928058x + 8.89212399
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Ponatinib (AP24534),2,0.206320524,0.291324443,0.469592194,0.700643735,0.868192803,53.4211561,-7.19868299x^3 - 68.4416587x^2 - 175.59270842x - 0.52232963
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Ponatinib (AP24534),3,0.03963646,0.105125051,0.293070502,0.614023839,0.889691786,37.91530451,-3.7175983x^3 - 34.69596356x^2 - 102.03021951x + 4.90981538
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,CYT387,1,0.118739846,0.248794649,10,10,10,692.3025373,12.41469283x^3 + 35.08975065x^2 - 15.12542773x + 55.79151956
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Gefitinib,1,0.007725783,0.066889532,10,10,10,1152.985361,8.64758592x^3 + 36.3973547x^2 + 31.66499643x + 75.99014867
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,GSK-1904529A,1,0.012797456,10,10,10,10,988.8892695,-2.82785631x^3 + 0.86612413x^2 + 12.91117842x + 92.15704132
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,SNS-032 (BMS-387032),1,0.02598732,0.049671314,0.123834073,0.309427717,0.595071342,66.60864806,13.47829801x^3 + 36.86399178x^2 - 31.45564345x + 1.18993846
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Flavopiridol,1,0.13211677,0.193988761,0.369376307,0.776468593,1.501215433,199.8202628,24.13348104x^3 + 50.03748914x^2 - 56.29474836x + 18.24247495
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Crenolanib,1,3.792199661,4.65976702,6.251152981,8.04060843,9.215913047,729.2111521,-24.14592335x^3 - 80.95830055x^2 - 38.45244107x + 144.0743133
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Crenolanib,2,0.00580955,0.007868495,7.211460264,10,10,761.1572465,-31.98230301x^3 - 77.28914894x^2 + 2.65110588x + 124.82843827
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,p38 MAP Kinase Inhibitor,1,0.077743719,0.201902979,10,10,10,708.0489565,8.44874162x^3 + 27.06156802x^2 - 8.35492156x + 58.96299186
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Rapamycin,1,0.00717043,0.023636573,4.421859321,10,10,496.1127673,-4.77569622x^3 - 8.49107961x^2 - 9.72280847x + 61.1013243
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,LY-333531,1,0.024788707,0.09312719,1.111332008,10,10,417.1593582,0.84395947x^3 + 3.9287291x^2 - 20.20638227x + 50.91799966
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,PLX-4720,1,0.110683661,0.716205048,6.822828368,10,10,567.8040972,0.40217771x^3 - 3.82667284x^2 - 23.14112335x + 71.72704153
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,KN92,1,0.007876268,0.025402339,10,10,10,655.820557,-3.98532194x^3 - 2.85759769x^2 + 1.0854233x + 67.82717687
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,YM-155,1,0.008405733,0.032878297,0.468590883,1,1,52.56271106,1.24551425x^3 + 6.93680529x^2 - 12.5770744x + 45.1521993
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Crizotinib (PF-2341066),1,0.00550332,0.041913446,1.523322132,4.461413188,7.048111852,252.523077,-6.50736033x^3 - 22.07217401x^2 - 31.46506792x + 56.52879285
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,JNJ-7706621,1,0.600535316,1.475440489,10,10,10,698.9536116,10.17616224x^3 + 13.86973744x^2 - 38.10385461x + 80.99175107
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,MLN120B,1,0.032599978,5,5,5,5,420.5443965,3.15254333x^3 + 11.8894962x^2 + 3.98472665x + 80.00346532
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Neratinib (HKI-272),1,0.004615017,0.137468663,0.826389909,10,10,516.2339751,9.62135552x^3 + 21.83438551x^2 - 19.36656093x + 48.25187575
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,MEK1/2 Inhibitor,1,0.017609556,0.254452833,3.749792729,10,10,494.6246972,-0.04510816x^3 - 3.71546028x^2 - 21.45711475x + 63.54925681
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,PP2,1,0.012263427,10,10,10,10,1255.078596,-4.82779808x^3 - 1.70807226x^2 + 26.45868148x + 113.10021618
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Lestaurtinib (CEP-701),1,0.000894,0.003680001,0.056875374,1,1,38.89808876,0.50952187x^3 + 5.30430767x^2 - 6.86200988x + 34.21691338
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,MK-2206,1,0.045689121,0.085165691,0.245549675,1.075389168,10,291.137806,9.08716521x^3 + 28.9475774x^2 - 25.44931065x + 25.77419533
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,SYK Inhibitor,1,0.006056404,0.007718434,0.015747406,10,10,1297.92334,-36.90375187x^3 - 77.65033398x^2 + 40.41568345x + 159.00354007
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,PHA-665752,1,0.032916582,0.135791189,10,10,10,906.3472857,9.54316432x^3 + 31.71542896x^2 + 9.72936876x + 65.81159172
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,GSK-1838705A,1,0.0117677,0.075017834,10,10,10,778.281562,-1.09503507x^3 + 5.2386316x^2 + 5.19165371x + 72.65309442
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Ibrutinib (PCI-32765),1,0.014877356,4.833582177,10,10,10,749.8334933,-5.03919405x^3 - 9.98578872x^2 - 4.50050687x + 84.36966009
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,JNK Inhibitor II,1,0.035524578,0.127212464,45.60506432,50,50,3028.147277,-6.4109957x^3 + 1.16441104x^2 + 2.58595831x + 71.77854195
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Canertinib (CI-1033),1,3.202815237,4.178645685,6.014129806,8.139336699,9.564847437,669.3674059,-19.43081115x^3 - 66.11424944x^2 - 36.82352329x + 128.02215061
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Linifanib (ABT-869),1,0.491893579,2.223601512,6.924290916,10,10,611.1688473,-5.92068423x^3 - 18.98447153x^2 - 21.51311929x + 85.00042897
603,12-00111,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MarcTest 384 123v3,Standard,Barasertib (AZD1152-HQPA),1,0.005743776,10,10,10,10,906.4868067,-7.98969929x^3 - 18.82472304x^2 + 2.97562805x + 101.29424916
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Vandetanib (ZD6474),1,0.007733611,0.018192764,5.076518362,10,10,512.8177261
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Crizotinib (PF-2341066),1,0.007493979,0.457006817,2.083620376,5.993879281,10,345.2871488
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,A-674563,1,0.255648653,1.534858532,6.316334314,10,10,580.4737907
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Sorafenib,1,0.007159816,0.01343671,10,10,10,1663.021829
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Sorafenib,2,0.006274953,0.009601844,10,10,10,1242.467524
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Sorafenib,3,0.011239216,10,10,10,10,1806.88428
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,PP242,1,0.005417531,0.010502311,0.038569111,0.344480808,10,328.4076867
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,LY-333531,1,0.314757862,1.407842335,6.071568324,10,10,573.1340654
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,R547,1,0.3436251,2.381347431,10,10,10,684.6431024
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Velcade,1,0.129252906,0.396737834,10,10,10,609.2910012
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,RAF265 (CHIR-265),1,0.030557354,10,10,10,10,1062.514468
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Doramapimod (BIRB 796),1,0.006234959,0.004572222,0.032292822,10,10,655.6995014
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Staurosporine,1,2.585244593,10,10,10,10,928.6007136
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,PLX-4720,1,0.009244026,3.701236479,8.143005715,10,10,680.1596509
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,SB-203580,1,0.007350506,0.019601753,10,10,10,740.918226
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Quizartinib (AC220),1,0.007525442,0.017489923,0.252840565,10,10,435.5208728
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Quizartinib (AC220),2,0.005560076,0.010577778,0.046006443,10,10,519.3274764
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,JNK Inhibitor II,1,0.045461272,0.099005259,50,50,50,5106.551073
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Roscovitine (CYC-202),1,6.759675411,10,10,10,10,956.3967171
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Dasatinib,1,0.000532,0.003087245,0.022899399,1,1,60.52082526
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Dasatinib,2,0.000919,0.435515641,1,1,1,72.72193641
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Dasatinib,3,0.199717251,0.499828549,1,1,1,78.101802
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,JNJ-28312141,1,0.005633523,0.009624615,0.040792205,10,10,528.426187
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Neratinib (HKI-272),1,0.004698911,0.066520919,0.524448332,10,10,540.9880474
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Trametinib (GSK1120212),1,0.005999596,0.009315617,0.028312832,10,10,779.7755509
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Crenolanib,1,0.006364792,0.00776603,0.012314802,10,10,1399.30925
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Crenolanib,2,0.006369032,0.007799495,0.012505027,10,10,1267.964906
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,GS-1101 (CAL-101),1,0.321320113,5.849359161,10,10,10,775.8854174
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,KN93,1,10,10,10,10,10,1628.212671
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Nilotinib,1,10,10,10,10,10,1280.120203
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Nilotinib,2,10,10,10,10,10,1208.527974
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Nilotinib,3,0.056310971,10,10,10,10,824.0989025
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Barasertib (AZD1152-HQPA),1,0.007027745,0.244945191,10,10,10,759.3353179
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Axitinib (AG-013736),1,10,10,10,10,10,1150.581899
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,R406,1,0.116578455,1.078883194,10,10,10,795.2048883
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,JAK Inhibitor I,1,0.025969679,0.08747297,10,10,10,813.2737396
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Tozasertib (VX-680),1,0.024127931,0.067397072,0.328147054,10,10,426.4630224
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,GW-2580,1,0.02776836,0.271526823,10,10,10,884.1643525
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,NF-kB Activation Inhibitor,1,10,10,10,10,10,1295.090874
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Midostaurin (PKC412),1,0.00715002,0.016331765,0.200352201,10,10,706.9826515
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,AZD1480,1,0.004987955,0.007945998,0.041291811,10,10,817.6158294
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,STO609,1,2.255878217,8.557063144,10,10,10,838.374023
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Pelitinib (EKB-569),1,0.008766399,0.021092904,0.249724019,10,10,514.6449235
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Tofacitinib (CP-690550),1,0.025488156,0.409228517,10,10,10,747.1059315
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,p38 MAP Kinase Inhibitor,1,0.006538533,0.004572222,10,10,10,699.3671227
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Cediranib (AZD2171),1,10,10,10,10,10,1148.184908
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Flavopiridol,1,0.277752441,0.587178091,10,10,10,776.2597294
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Imatinib,1,0.357815422,10,10,10,10,802.7790025
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,BI-2536,1,0.016897109,0.234141305,10,10,10,668.5942958
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,KW-2449,1,0.006061044,0.010286052,10,10,10,584.7935172
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Vatalanib (PTK787),1,0.00926627,0.347156413,10,10,10,613.0062167
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,TG100-115,1,0.006326611,0.021428692,10,10,10,613.7904632
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Rapamycin,1,0.007704645,0.042000371,10,10,10,708.3367402
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Go6976,1,0.024261877,0.09565407,1.025841668,10,10,471.1439964
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Erlotinib,1,0.006392748,0.014689335,10,10,10,855.4152432
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,VX-745,1,0.282757206,0.635694995,10,10,10,753.832215
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Sunitinib,1,0.000457,0.001800964,0.011001692,1,1,59.53431636
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Sunitinib,2,0.000597,0.001077038,1,1,1,58.08116461
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Sunitinib,3,0.001770142,0.009842545,1,1,1,55.84460538
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Selumetinib (AZD6244),1,0.4044088,10,10,10,10,852.9037824
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,PHA-665752,1,0.005894113,0.013473523,10,10,10,913.8650132
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,MEK1/2 Inhibitor,1,0.069589182,1.593347442,7.492667843,10,10,605.3814844
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Dovitinib (CHIR-258),1,8.902684836,0.009411154,0.036465656,10,10,655.9678326
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,GSK690693,1,0.010442827,10,10,10,10,915.1795553
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Afatinib (BIBW-2992),1,0.012046594,0.521078888,10,10,10,619.0303919
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,INK-128,1,0.003274203,0.002286444,5,5,5,335.6004397
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,NVP-TAE684,1,0.005781488,0.00836639,0.022095724,10,10,498.9780113
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Alisertib (MLN8237),1,0.14286764,0.296369547,10,10,10,716.6189511
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,CYT387,1,0.012059424,0.041708571,0.205105905,10,10,442.0079154
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,SB-431542,1,10,10,10,10,10,1555.286703
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,LY294002,1,0.047950589,0.111961524,6.427839149,50,50,2172.241708
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,BEZ235,1,0.005226525,0.009636316,0.107956192,10,10,904.8264265
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,GSK-1904529A,1,10,10,10,10,10,1032.400333
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,PI-103,1,0.005921801,0.004572222,0.017099909,10,10,441.2942846
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Ibrutinib (PCI-32765),1,0.009928149,10,10,10,10,823.4984786
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,PP2,1,0.013726004,6.726832154,10,10,10,785.6160587
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Tandutinib (MLN518),1,0.027489969,0.111654923,10,10,10,768.3321107
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,GSK-1838705A,1,0.013922139,0.040005531,0.223952369,10,10,497.364515
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Masitinib (AB-1010),1,0.02804807,0.181454363,10,10,10,930.9384906
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,GDC-0879,1,10,10,10,10,10,2672.35766
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,GDC-0941,1,0.00532762,0.010946218,3.412989473,10,10,453.4735853
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,GDC-0941,2,0.029363014,0.195815737,10,10,10,631.9902001
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,CI-1040 (PD184352),1,0.012212728,0.063323466,10,10,10,638.8896836
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,JNJ-7706621,1,0.296415602,0.808513094,10,10,10,878.0843918
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Ponatinib (AP24534),1,0.001295072,0.004182527,0.202798141,1,1,45.2863842
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Ponatinib (AP24534),2,0.001032415,0.004008949,0.035456942,1,1,57.18758435
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Ponatinib (AP24534),3,0.015749996,0.028573311,0.084158919,1,1,43.7889926
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Linifanib (ABT-869),1,0.028646553,10,10,10,10,828.7378729
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Vargetef,1,0.089745578,0.587462884,10,10,10,748.3734385
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,KN92,1,0.035069085,0.177711045,10,10,10,1072.548521
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,AT7519,1,0.005457717,0.065869854,10,10,10,676.3490945
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,MLN120B,1,0.002983536,0.014647962,5,5,5,418.4876674
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,PD98059,1,0.019044041,10,10,10,10,1047.554229
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Canertinib (CI-1033),1,0.009216165,5.504574446,10,10,10,781.7447006
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,PD153035,1,0.000554,0.001242685,1,1,1,82.88727569
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Gefitinib,1,0.015975892,0.178984131,10,10,10,870.9564185
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,PD173955,1,10,10,10,10,10,1338.916518
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,H-89,1,0.138038294,10,10,10,10,1042.320791
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Bosutinib (SKI-606),1,0.024311525,10,10,10,10,1010.776449
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,SGX-523,1,5.634148317,10,10,10,10,903.6467118
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Foretinib (XL880),1,0.004572222,0.007571756,0.041009176,10,10,485.570193
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,MK-2206,1,0.19360758,10,10,10,10,821.9679853
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Pazopanib (GW786034),1,0.005430732,0.008683823,10,10,10,1121.778999
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Lestaurtinib (CEP-701),1,0.000692,0.001562135,1,1,1,55.68147119
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,AKT Inhibitor IV,1,0.16277735,0.299918133,0.821700461,25,25,1028.323804
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,BMS-345541,1,0.027398754,1.780623367,10,10,10,644.5563076
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,AMPK Inhibitor,1,0.01915032,0.065288045,10,10,10,631.0145772
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,SYK Inhibitor,1,5.229181513,0.021938598,10,10,10,863.6673585
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,SB-202190,1,0.006204997,0.009285549,10,10,10,942.6220487
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,MGCD-265,1,0.004572222,0.103637063,10,10,10,602.5026032
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Motesanib (AMG-706),1,10,10,10,10,10,1168.587917
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,KI20227,1,0.163343891,10,10,10,10,942.1344428
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,CHIR-99021,1,0.00655126,0.013643288,10,10,10,3569.672852
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,Lapatinib,1,0.007369053,10,10,10,10,924.976669
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,YM-155,1,1,1,1,1,1,120.3915749
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,SNS-032 (BMS-387032),1,0.015171562,0.079767938,10,10,10,565.924264
694,12-00116,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",MarcTest 384 123v3,Standard,TG101348,1,0.014934071,0.046530523,0.257047299,10,10,567.041544
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,CI-1040 (PD184352),1,0.021854628,0.146072135,4.767770875,10,10,519.1332722,0.54484339x^3 + 1.70262925x^2 - 16.56999152x + 60.28623421
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Afatinib (BIBW-2992),1,0.029988855,0.191450792,1.160066019,4.835006283,10,290.5959909,1.0952932x^3 - 6.00692369x^2 - 36.39561518x + 52.37157097
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,MGCD-265,1,0.005315067,0.056746744,0.163460988,10,10,704.2524751,20.76874409x^3 + 62.68810574x^2 + 7.55955312x + 27.26763389
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GDC-0941,1,0.01197133,0.056110594,0.266851797,1.259066674,5.456347505,152.0817737,5.27148805x^3 + 8.95162362x^2 - 34.34933356x + 28.34172447
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GDC-0941,2,0.035134783,0.08932196,0.348836609,2.555571802,10,284.4288654,7.74387406x^3 + 17.6739019x^2 - 29.48700983x + 33.55694905
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Doramapimod (BIRB 796),1,0.005425771,0.007960715,0.019076363,10,10,331.6803439,-7.80716742x^3 - 3.13128729x^2 + 7.83481214x + 33.03822051
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,CHIR-99021,1,0.006156014,0.009908993,10,10,10,1386.865313,-19.34255532x^3 - 34.17957275x^2 + 41.28548175x + 139.33269029
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Staurosporine,1,0.116542394,0.208001545,0.543972329,3.012331378,10,334.0849343,16.27889259x^3 + 30.21932323x^2 - 42.92434664x + 36.83785374
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SYK Inhibitor,1,0.005515388,0.019101273,10,10,10,616.9353081,1.03847319x^3 + 10.98705044x^2 + 3.49865934x + 53.82445726
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Erlotinib,1,0.004572222,0.009196922,10,10,10,772.3852264,-14.17730383x^3 - 23.72086975x^2 + 15.57291324x + 85.35960831
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Selumetinib (AZD6244),1,0.004646397,0.871347278,10,10,10,738.5103442,18.68375898x^3 + 30.94535138x^2 - 36.91348551x + 72.68555476
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,MEK1/2 Inhibitor,1,0.006834464,1.740184912,6.833055988,10,10,593.6478788,-5.60925679x^3 - 18.06541009x^2 - 17.30366774x + 80.28704072
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,JAK Inhibitor I,1,0.004717129,4.425412801,6.851729148,9.761036873,10,713.6972107,-15.11266794x^3 - 52.81234021x^2 - 28.40836706x + 119.46006523
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PHA-665752,1,0.020896146,0.052327193,0.231186628,10,10,330.0637727,5.53328728x^3 + 18.83203594x^2 - 18.47021819x + 32.05761691
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,BI-2536,1,0.008972844,0.028473723,0.164533294,1.163224279,9.420838831,162.3207587,2.08342929x^3 + 6.81664944x^2 - 25.71881327x + 26.65880509
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Pelitinib (EKB-569),1,0.00653252,0.017388084,0.109758411,1.615217327,10,223.1368968,0.71149739x^3 + 6.78405313x^2 - 16.85463383x + 28.20907515
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,CYT387,1,0.006631927,0.02445449,0.442689788,5.634074199,10,290.9201451,-1.63120637x^3 - 3.14685049x^2 - 20.6906214x + 42.99940553
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sunitinib,1,0.0018908,0.378272066,0.529625611,0.703874918,0.820275414,59.63129749,-19.06114748x^3 - 132.44432455x^2 - 256.44475948x - 11.0962498
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sunitinib,2,0.000603,0.001883931,0.019009183,0.260149502,1,21.30802485,-0.8630328x^3 - 2.98623913x^2 - 25.16774975x + 11.13108241
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sunitinib,3,0.027542463,0.036561522,0.06123994,0.120533507,1,34.4261818,33.63088348x^3 + 171.3448938x^2 + 164.90826468x + 57.94912861
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Foretinib (XL880),1,0.005361919,0.007752058,0.018457455,6.502843655,10,281.3202977,-10.24148587x^3 - 11.70635197x^2 + 2.5262526x + 36.19094106
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Barasertib (AZD1152-HQPA),1,0.010919577,0.042570224,0.259589731,10,10,461.0130806,6.75880149x^3 + 21.79300599x^2 - 9.64723473x + 38.23127772
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Imatinib,1,0.180154578,0.263738406,0.497593017,1.021573934,1.853565007,138.1860095,24.20948722x^3 + 39.23855172x^2 - 70.65482088x + 25.65156525
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PP2,1,0.009073579,0.964547782,3.201290803,6.76807763,9.685313937,400.5670755,-6.34641948x^3 - 25.78341071x^2 - 33.78783369x + 74.47664505
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,MLN120B,1,0.114053185,0.155224345,0.277256516,0.740995409,5,264.2067682,32.82277587x^3 + 109.03849952x^2 + 3.26095073x + 23.64895982
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,AZD1480,1,0.005293055,0.008697507,0.040214633,10,10,485.8078557,-7.64211358x^3 - 7.52943807x^2 + 5.69331322x + 51.83752087
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GS-1101 (CAL-101),1,0.024814145,0.088775344,0.628923982,5.495398971,10,297.1647905,1.37725545x^3 + 2.2945691x^2 - 28.39679797x + 44.19900994
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Nilotinib,1,0.035817333,0.163405071,10,10,10,618.678193,5.52110121x^3 + 14.38718923x^2 - 11.87484068x + 59.44118779
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Nilotinib,2,0.006113762,0.010485342,10,10,10,820.0518545,-14.70016209x^3 - 28.20819715x^2 + 11.73955213x + 94.7520968
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Nilotinib,3,0.091106199,0.385352969,2.548456023,10,10,444.5838948,1.50841623x^3 - 2.92713737x^2 - 30.74916833x + 62.87468561
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Tozasertib (VX-680),1,0.006565966,2.553621474,4.505447653,7.13289024,9.085823531,508.4528574,-6.55260089x^3 - 41.05306513x^2 - 52.20261424x + 103.50254617
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GSK-1838705A,1,2.157418795,0.004641338,0.106794635,10,10,1548.001599,27.25957042x^3 + 99.35501318x^2 + 74.0606751x + 53.17420461
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SB-431542,1,0.018405354,0.058686135,1.271870791,10,10,519.516429,1.73404925x^3 + 10.98211512x^2 - 8.76237086x + 50.79339601
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,JNK Inhibitor II,1,0.037659819,0.102720846,50,50,50,3168.792839,-4.00873244x^3 + 6.45603257x^2 - 1.15769722x + 63.67927403
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,R406,1,0.01426486,0.040623448,0.160262609,0.713903181,10,171.9439719,6.61943644x^3 + 18.18088435x^2 - 26.51202521x + 20.75097463
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PI-103,1,0.005968832,0.010021124,0.029050906,0.151289035,10,150.1503842,-1.43198472x^3 + 10.04812245x^2 - 5.05036935x + 13.30808695
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,AT7519,1,0.005435712,0.010417742,0.036242385,0.203643251,10,171.1993301,0.97407771x^3 + 13.9402498x^2 - 7.08662835x + 13.76507792
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GSK690693,1,0.007086858,0.004654349,2.820050665,10,10,478.2729206,9.42770968x^3 + 2.95290933x^2 - 46.7158293x + 69.57490558
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Canertinib (CI-1033),1,0.02224622,0.729743364,5.904959761,10,10,552.044952,-2.86119981x^3 - 10.18966497x^2 - 19.61401822x + 72.49966219
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SNS-032 (BMS-387032),1,0.006004735,0.008909,0.020606148,0.086215277,6.395136026,112.2715873,-5.57385105x^3 + 2.08311193x^2 - 2.32795991x + 13.44009969
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Lestaurtinib (CEP-701),1,0.000621,0.001028546,0.003927729,0.792844189,1,30.3155309,-6.64048914x^3 - 25.36145951x^2 - 34.30434287x + 21.79265255
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Vargetef,1,0.060487218,0.123660092,0.378856221,2.103654764,10,313.7610323,11.9385826x^3 + 26.5051499x^2 - 32.70876351x + 32.39706271
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,NF-kB Activation Inhibitor,1,0.032671911,0.124775749,1.042257367,10,10,430.7264195,3.92733785x^3 + 8.42056336x^2 - 22.80581956x + 50.40719052
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SGX-523,1,0.007652039,0.010339607,0.026195331,10,10,1117.709601,-22.93857663x^3 - 31.54202877x^2 + 45.41900592x + 109.97898167
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Quizartinib (AC220),1,0.007748475,0.016515728,0.065942516,0.411741128,10,163.8469055,1.68280163x^3 + 12.90182691x^2 - 14.58358522x + 17.56004519
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Quizartinib (AC220),2,0.00517337,0.007692401,0.018518125,0.123131089,6.531695643,130.002438,-7.05530848x^3 - 4.37652618x^2 - 3.8176534x + 19.83837891
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Crenolanib,1,0.005658063,0.007725706,0.016648075,7.513802595,10,374.0558891,-17.50591747x^3 - 30.83543048x^2 + 4.28327395x + 56.66544926
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Crenolanib,2,0.007283079,0.012599299,3.454289456,9.557444253,10,432.2318959,-11.48040245x^3 - 20.45303484x^2 - 5.08130885x + 60.45478922
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Lapatinib,1,0.005488076,0.008797988,7.625445034,10,10,669.4423813,-17.86044038x^3 - 40.75325068x^2 + 0.6536852x + 93.41089823
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Dasatinib,1,0.000768,0.001381894,0.004606885,0.034399967,1,23.91114166,-0.18566863x^3 + 12.49863951x^2 + 20.90953376x + 28.25010064
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Dasatinib,2,0.000591,0.000908,0.002279673,0.012004961,1,18.4604452,-4.31014446x^3 - 7.89860771x^2 - 2.83003862x + 18.16413589
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Dasatinib,3,0.000874,0.002144145,0.016192549,1,1,40.45200839,0.4139154x^3 + 11.00714664x^2 + 14.36049735x + 42.79680663
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Linifanib (ABT-869),1,0.005350625,0.008831527,0.02612725,10,10,468.1785928,-1.3332469x^3 + 15.14003845x^2 + 15.29025843x + 30.98046773
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,LY294002,1,0.05037196,0.286023797,2.425221671,13.88410573,35.67553527,999.7753536,0.24156003x^3 - 3.83296493x^2 - 27.59498969x + 61.17086156
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,YM-155,1,0.000881,0.128221323,0.416223406,0.835732511,1,47.03173895,-8.63085191x^3 - 53.04030142x^2 - 105.34431749x + 17.10828798
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GDC-0879,1,0.005598083,0.005133646,10,10,10,1302.782952,48.42666259x^3 + 55.61415843x^2 - 97.76941634x + 140.84278382
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,KN93,1,0.011466953,1.001306388,10,10,10,672.3570834,-3.41755856x^3 - 5.89305262x^2 - 6.29405075x + 75.00357054
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,AMPK Inhibitor,1,0.011933467,0.051932621,3.555989393,10,10,508.6514461,0.35452886x^3 + 4.92950878x^2 - 10.44554365x + 54.19939822
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sorafenib,1,0.013847267,1.670321779,3.533338808,6.124496179,8.086619367,400.8552249,-7.70140268x^3 - 37.30482528x^2 - 44.43331105x + 86.83673184
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sorafenib,2,0.02480835,0.055314497,0.188807195,0.753146637,10,144.7826944,6.06189015x^3 + 17.41310235x^2 - 30.66585107x + 20.97176082
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sorafenib,3,0.051594869,0.153216577,0.775503767,10,10,366.5088445,6.19706099x^3 + 10.51241455x^2 - 30.51836157x + 46.5104598
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,JNJ-28312141,1,0.004572222,0.021791435,0.22641018,2.936341691,10,246.2292385,2.02661523x^3 + 4.72621406x^2 - 22.30097801x + 34.19076844
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,VX-745,1,0.007877634,0.024377522,0.273447275,10,10,375.1237786,0.37443976x^3 + 5.99272835x^2 - 12.20422861x + 41.29397967
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Dovitinib (CHIR-258),1,0.00818287,0.035374358,0.158637953,0.704428464,2.789509139,120.8577161,5.82657971x^3 + 13.80606925x^2 - 30.04325036x + 20.12939321
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Alisertib (MLN8237),1,0.007486726,8.704002643,10,10,10,965.4381103,-17.84170284x^3 - 41.23111201x^2 + 6.94269469x + 119.69159886
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SB-202190,1,0.051021407,0.106496202,0.415741859,10,10,424.7902862,7.17514139x^3 + 24.11210916x^2 - 20.11317766x + 39.22733934
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Pazopanib (GW786034),1,0.006240917,0.014489535,0.116723181,3.021935376,10,226.8727293,-2.33830923x^3 - 1.08982646x^2 - 16.65791843x + 33.51100517
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,NVP-TAE684,1,0.005938569,6.871294723,10,10,10,832.6074401,-11.67499758x^3 - 28.31204587x^2 + 0.06047418x + 101.63263875
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,JNJ-7706621,1,1.682635918,2.354554201,3.862539135,5.985474767,7.628036722,455.3314098,0.15487337x^3 - 37.59550707x^2 - 80.36112077x + 110.07909549
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Motesanib (AMG-706),1,0.114835266,0.163508922,0.296345547,0.579516818,0.984307162,185.4513898,25.15687361x^3 + 58.99797543x^2 - 52.2695578x + 9.63816603
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GW-2580,1,0.017267746,0.046214406,0.206234906,10,10,324.7729727,6.05252862x^3 + 19.7422554x^2 - 17.76659748x + 30.48856743
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Trametinib (GSK1120212),1,0.009716289,0.021614248,0.123819357,10,10,371.9985133,0.39111014x^3 + 11.03824213x^2 - 6.58120935x + 35.23664617
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Velcade,1,0.008165068,0.015812694,0.053549137,0.260857496,10,141.2143166,1.79576386x^3 + 15.46656486x^2 - 12.51355188x + 12.78638517
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PD98059,1,0.007382227,5.323360336,10,10,10,770.9123019,-7.71441629x^3 - 21.7660452x^2 - 8.65869629x + 95.7203023
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Go6976,1,0.016675471,0.056000142,0.580434348,10,10,426.9237458,1.98825781x^3 + 9.01958239x^2 - 15.00983468x + 45.97678313
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,H-89,1,0.413960665,0.712621797,10,10,10,629.9586705,21.11416682x^3 + 34.11961784x^2 - 50.24168135x + 66.93595171
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,KN92,1,0.015710899,0.11703862,10,10,10,718.2621065,0.57369787x^3 + 7.21480524x^2 - 0.79216247x + 68.46338816
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,AKT Inhibitor IV,1,0.02159158,0.058043409,0.214993961,0.787480537,2.043075312,65.0356243,5.58101449x^3 + 10.86973918x^2 - 38.89057455x + 20.85391637
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Cediranib (AZD2171),1,0.006871993,0.012380777,5.961118817,9.196692535,10,585.0348376,-19.12491223x^3 - 46.21744332x^2 - 8.84931187x + 93.55760329
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,TG100-115,1,0.005399289,0.057435543,2.039546283,8.867484811,10,390.3476904,-3.0912587x^3 - 10.47759652x^2 - 22.01469436x + 57.90983274
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Tandutinib (MLN518),1,0.006116258,0.008202734,6.895479693,8.666896312,9.79889971,773.9397505,-36.86807313x^3 - 91.84608139x^2 - 1.25739026x + 137.37969966
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Flavopiridol,1,0.013175232,0.028809732,0.096224338,0.366614678,1.294602452,130.1589848,5.82019146x^3 + 21.67272715x^2 - 21.25556776x + 12.10279112
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Midostaurin (PKC412),1,0.00802151,0.029007324,0.257723864,5.18695412,10,279.2570488,1.01193244x^3 + 4.6150752x^2 - 20.19922862x + 36.7121638
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PD153035,1,0.000505,0.000893,1,1,1,64.53035612,-9.90924718x^3 - 46.79493603x^2 - 58.04541593x + 52.17274688
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Neratinib (HKI-272),1,0.004572222,5.349301915,10,10,10,763.0804897,-1.12355276x^3 - 5.27514161x^2 - 7.24540221x + 83.50885808
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Tofacitinib (CP-690550),1,0.005740729,0.010961606,1.908653629,10,10,416.8564868,-6.95660447x^3 - 10.52190857x^2 - 5.37873339x + 52.49306813
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Crizotinib (PF-2341066),1,0.018989394,0.069328215,0.388179852,2.360515249,10,212.6137284,2.93369538x^3 + 4.509202x^2 - 32.17159353x + 36.22058701
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,KI20227,1,0.005054609,10,10,10,10,1786.615215,1.80768528x^3 - 1.44205104x^2 + 20.72614283x + 167.08619594
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Gefitinib,1,0.013244789,0.136086453,10,10,10,625.5818887,3.17450647x^3 + 8.82043937x^2 - 9.3621539x + 62.33591551
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Vandetanib (ZD6474),1,0.005540934,0.010038528,1.529976856,7.749857781,10,357.4260703,-8.72260262x^3 - 16.38399488x^2 - 9.25629813x + 52.32327809
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Ibrutinib (PCI-32765),1,0.015159314,0.456084232,10,10,10,722.8902913,0.0832106x^3 + 2.89688385x^2 - 4.22498398x + 73.22600544
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Ponatinib (AP24534),1,0.001207214,0.006646076,0.055507326,0.311470497,0.786312565,21.68423436,0.16207303x^3 - 3.10423404x^2 - 39.24547073x + 5.93660679
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Ponatinib (AP24534),2,0.000548,0.00217553,0.027143396,0.212659739,0.553290444,15.42083494,-1.51333279x^3 - 10.00746573x^2 - 44.37625863x - 0.77125487
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Ponatinib (AP24534),3,0.000931,0.082861572,0.396817248,0.894906667,1,46.46364541,-7.33557688x^3 - 44.16420857x^2 - 89.30059038x + 20.79560028
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Roscovitine (CYC-202),1,0.006787287,0.010190861,9.528722215,10,10,1115.093615,-37.15363738x^3 - 93.86142787x^2 + 7.08440602x + 167.89660473
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Vatalanib (PTK787),1,1.52588173,2.446158131,4.395193454,6.942766674,8.795926975,487.7640088,-9.97754041x^3 - 42.39971755x^2 - 46.37763478x + 100.00095358
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,STO609,1,0.011008872,6.620279346,10,10,10,768.0430706,-3.57695849x^3 - 5.1827073x^2 - 0.91488417x + 81.22186169
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Axitinib (AG-013736),1,0.012507757,0.039056498,0.24264313,10,10,297.2372891,2.90135481x^3 + 10.47323901x^2 - 19.68886038x + 34.60405253
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GSK-1904529A,1,0.005605159,10,10,10,10,1371.027838,14.57264831x^3 + 48.67432822x^2 + 34.73994538x + 87.79504643
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,BMS-345541,1,0.434750353,0.554818999,0.881963942,1.76457004,10,438.9648768,41.44848021x^3 + 84.61177637x^2 - 101.34469966x + 44.22668673
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,RAF265 (CHIR-265),1,0.004952889,0.006502468,0.011597035,0.032716636,10,307.6774185,-13.93909527x^3 - 15.47412104x^2 + 14.60943694x + 35.16442811
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Rapamycin,1,0.00526195,0.010545657,0.094959305,10,10,368.0932772,-3.99976049x^3 - 2.41674012x^2 - 5.54312683x + 42.58349851
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PD173955,1,0.321395287,0.454351376,0.878826095,10,10,456.5541497,30.70959963x^3 + 56.01635784x^2 - 69.21420183x + 45.94643148
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Bosutinib (SKI-606),1,0.004768101,0.008667134,0.040022838,10,10,439.5971045,-3.02636351x^3 + 4.33377504x^2 + 4.8719059x + 40.07986705
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,p38 MAP Kinase Inhibitor,1,0.129457906,0.372027193,10,10,10,580.5403479,8.42980887x^3 + 14.3626502x^2 - 25.21327916x + 62.19176451
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,MK-2206,1,0.006225089,0.009844089,0.03125738,10,10,320.1751479,-7.23600329x^3 - 4.92607316x^2 + 0.26535439x + 36.88887971
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,BEZ235,1,0.009314944,0.024337594,0.102161772,0.590382346,10,238.5275659,5.15258929x^3 + 19.87926928x^2 - 15.06626205x + 20.57232973
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,A-674563,1,0.029556603,0.10171655,0.503687981,2.563327797,9.879641906,214.6572314,3.5895756x^3 + 3.59612156x^2 - 36.25886956x + 38.97655074
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,TG101348,1,0.025406643,0.083207569,0.390451328,2.145220941,10,216.8169904,4.82046279x^3 + 8.01891831x^2 - 33.85213714x + 35.16440673
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,R547,1,0.004735485,2.141342885,3.974176171,6.476520813,8.351857023,449.390668,-6.90559579x^3 - 39.53659574x^2 - 51.7189959x + 96.67593683
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SB-203580,1,0.004785916,0.461802562,0.683638874,1.097727218,1.656615316,324.2595315,55.73343274x^3 + 92.62113018x^2 - 111.2465663x + 29.34928568
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,LY-333531,1,0.007240297,0.127944813,2.386442933,8.673679298,10,400.3865147,-3.4363833x^3 - 12.16233371x^2 - 23.8687225x + 60.93718285
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PLX-4720,1,0.008345229,0.019113956,5.304520778,10,10,518.2834554,-9.96609451x^3 - 19.40406077x^2 - 7.26095598x + 69.2432325
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PP242,1,0.008275063,0.01930312,0.091839349,0.966593884,10,238.4813174,1.7515018x^3 + 12.16945619x^2 - 13.56832913x + 24.79714219
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,KW-2449,1,0.048225994,0.188594705,1.344148838,10,10,393.0246709,2.68263583x^3 + 2.37446125x^2 - 29.09853744x + 53.69276967
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Masitinib (AB-1010),1,0.006692566,2.476881359,4.78983491,8.188218025,10,541.4176667,-3.27787779x^3 - 32.13627152x^2 - 49.8600858x + 99.82679342
706,12-00123,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,INK-128,1,0.002595206,0.003453196,0.006241184,0.015846934,5,90.49609612,-10.77412339x^3 - 16.05181857x^2 + 3.9786736x + 21.33246459
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,PI-103,1,0.194078403,0.914419866,6.579925388,10,10,571.6992112,-0.39236639x^3 - 4.47369659x^2 - 25.43151323x + 74.01860589
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Ponatinib (AP24534),1,0.043603268,0.179436533,1,1,1,66.76904684,1.52878121x^3 + 2.45941242x^2 - 24.46586522x + 56.01217223
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Ponatinib (AP24534),2,0.087690661,0.327087893,0.976100748,1,1,68.71927976,-5.17766055x^3 - 33.27905711x^2 - 67.90494849x + 49.29030121
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Ponatinib (AP24534),3,0.280425196,0.592814001,1,1,1,81.96952955,-1.41798585x^3 - 18.79188762x^2 - 60.10002458x + 62.30481226
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Sunitinib,1,0.958865663,1,1,1,1,101.3435016,-2.60504038x^3 - 21.26058155x^2 - 43.5487408x + 89.21263298
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Sunitinib,2,0.017883511,1,1,1,1,82.56956262,0.57867439x^3 + 2.84008229x^2 - 1.97063305x + 80.97114891
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Sunitinib,3,0.928535459,1,1,1,1,103.1180159,-2.12474945x^3 - 19.91894867x^2 - 48.78154921x + 88.44974437
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,LY294002,1,1.925495113,6.827619199,24.36670558,50,50,2659.974811,-2.31733281x^3 - 10.48785614x^2 - 13.20174405x + 94.65898533
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Tofacitinib (CP-690550),1,0.558314955,1.110957777,10,10,10,595.1643296,12.18411672x^3 + 11.174091x^2 - 48.5451123x + 77.19389568
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Selumetinib (AZD6244),1,0.339137256,10,10,10,10,996.7774756,10.669415x^3 + 27.54101076x^2 - 2.8318406x + 83.70108409
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Rapamycin,1,0.188038622,0.659585385,10,10,10,715.5449964,8.10084449x^3 + 16.06923424x^2 - 18.54925209x + 71.17056432
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,AT7519,1,0.091778289,0.161953897,0.393956254,1.086607109,10,176.6099832,14.84411562x^3 + 26.90671353x^2 - 49.05519095x + 26.73383689
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,GW-2580,1,0.019096185,10,10,10,10,884.752009,-1.35946744x^3 + 0.27216784x^2 + 2.87004096x + 87.22329405
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,TG100-115,1,5.073954237,10,10,10,10,920.7107466,-1.76165951x^3 - 12.93446795x^2 - 15.98896101x + 108.33103493
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,YM-155,1,0.18889401,0.340007499,0.676271957,1,1,65.24992205,-8.0993519x^3 - 56.08315647x^2 - 116.86156218x + 31.72650156
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Pelitinib (EKB-569),1,0.170167636,0.267403619,0.601212419,10,10,416.1148454,22.40469099x^3 + 44.80723043x^2 - 46.76445126x + 37.72022785
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Lestaurtinib (CEP-701),1,0.025277823,0.101622435,1,1,1,79.23528302,9.20389999x^3 + 47.7025738x^2 + 51.58309649x + 88.19674183
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,SB-431542,1,10,10,10,10,10,953.7775494,-0.40349135x^3 - 1.318535x^2 - 1.80411272x + 97.25135848
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,NVP-TAE684,1,10,10,10,10,10,945.3743661,6.27867101x^3 + 6.06720716x^2 - 19.85369371x + 100.59172224
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,PD153035,1,0.009896395,1,1,1,1,94.32041801,2.23453247x^3 + 17.86567374x^2 + 33.44601934x + 103.25484482
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,JNK Inhibitor II,1,4.272595246,40.82962727,50,50,50,4053.306248,-3.67371404x^3 - 0.72131988x^2 + 1.0433425x + 90.55052383
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Tandutinib (MLN518),1,0.62526839,10,10,10,10,876.2928187,1.76460461x^3 + 3.40974587x^2 - 5.88811776x + 88.67237412
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Vargetef,1,10,10,10,10,10,1151.341737,7.81187799x^3 + 24.67011978x^2 + 4.54809624x + 97.4234746
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Velcade,1,0.032500402,0.082293854,0.314669111,1.58562311,10,225.0157375,6.82645684x^3 + 15.16611048x^2 - 32.324292x + 30.80868845
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Alisertib (MLN8237),1,0.017185304,0.292042301,10,10,10,773.5380193,0.18372643x^3 + 6.0334235x^2 + 0.88289912x + 73.77598119
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,NF-kB Activation Inhibitor,1,0.008817771,10,10,10,10,815.6566499,-2.91627765x^3 - 2.01351301x^2 + 3.97815554x + 81.37870308
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,MGCD-265,1,0.135945411,10,10,10,10,860.5066128,3.58950641x^3 + 9.81790393x^2 - 3.54451973x + 81.8907713
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Midostaurin (PKC412),1,0.228341947,10,10,10,10,843.9889617,0.73992128x^3 + 2.53167716x^2 - 5.1734326x + 85.83537788
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,MEK1/2 Inhibitor,1,0.34868715,10,10,10,10,841.0280296,1.10786794x^3 + 2.42906703x^2 - 6.8979761x + 86.44130413
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,PP242,1,0.016537456,0.142171509,3.271615531,10,10,469.9973617,-2.41460988x^3 - 6.10686141x^2 - 19.06627053x + 61.76215093
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Afatinib (BIBW-2992),1,0.517165107,1.146279396,2.898720628,5.860389337,8.405799066,370.9955068,-2.76942702x^3 - 24.26625051x^2 - 48.71564271x + 77.97425602
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,GS-1101 (CAL-101),1,4.768235652,10,10,10,10,895.8285349,-3.94753069x^3 - 10.42361369x^2 - 2.11842743x + 97.46593586
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,KI20227,1,10,10,10,10,10,1172.975021,-5.69627839x^3 - 14.73801237x^2 + 3.462961x + 124.81580869
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Linifanib (ABT-869),1,0.874489972,7.234753022,10,10,10,797.8471756,-0.57669363x^3 - 4.85887734x^2 - 12.05389706x + 89.31428855
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,KW-2449,1,10,10,10,10,10,1028.486209,1.01343255x^3 - 7.39004505x^2 - 13.96036174x + 114.19565669
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,SNS-032 (BMS-387032),1,0.015984007,0.041491264,0.156373791,0.640232012,2.420224263,120.2292805,5.86090057x^3 + 16.10296842x^2 - 29.68357711x + 18.69002547
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Neratinib (HKI-272),1,10,10,10,10,10,972.5695322,2.74891623x^3 - 2.97563375x^2 - 16.25410679x + 107.06810792
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,H-89,1,0.028903585,8.702131285,10,10,10,852.738722,-6.60666679x^3 - 15.51051974x^2 - 3.42106097x + 97.3895355
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Canertinib (CI-1033),1,0.318823908,0.99757252,10,10,10,641.6527447,5.00389685x^3 + 6.80557685x^2 - 28.12904487x + 74.97030158
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Staurosporine,1,0.119566525,0.178304074,0.341254968,0.693753987,1.192247288,106.5909777,23.20700069x^3 + 44.68281868x^2 - 60.54210335x + 14.35246162
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Bosutinib (SKI-606),1,0.496009439,1.605555942,10,10,10,707.7176826,6.90519753x^3 + 8.57062621x^2 - 29.05633859x + 80.55230548
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Tozasertib (VX-680),1,0.145129973,0.559570113,10,10,10,684.179446,5.24769911x^3 + 12.51768558x^2 - 17.07396292x + 69.98316051
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,SGX-523,1,10,10,10,10,10,1181.689242,6.17468676x^3 + 13.74645868x^2 + 1.70341445x + 108.16228659
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Dasatinib,1,0.010990277,1,1,1,1,99.61908751,2.67583777x^3 + 19.76029962x^2 + 38.85478254x + 110.3998538
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Dasatinib,2,0.001443767,1,1,1,1,83.29137159,-2.21235171x^3 - 8.80709499x^2 - 10.29677577x + 81.10791579
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Dasatinib,3,1,1,1,1,1,101.1056071,1.92565864x^3 + 5.61003193x^2 - 4.2762271x + 98.11858134
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Pazopanib (GW786034),1,0.20215227,1.089249333,10,10,10,788.106212,6.68941664x^3 + 16.44203152x^2 - 12.7632708x + 75.45085917
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Trametinib (GSK1120212),1,0.185375759,0.804846395,10,10,10,822.0610736,9.52841207x^3 + 22.38754042x^2 - 10.87326378x + 73.78375339
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,GSK690693,1,10,10,10,10,10,1220.37722,2.51473382x^3 + 14.69254812x^2 + 15.64303826x + 104.9215359
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Foretinib (XL880),1,0.00863832,5.162422009,8.387021085,10,10,772.8130228,-15.86398159x^3 - 44.67729201x^2 - 13.46989378x + 113.05190665
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,PLX-4720,1,9.80086859,10,10,10,10,1006.704731,3.57794829x^3 - 6.16946159x^2 - 23.60995025x + 115.98085343
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,JNJ-28312141,1,4.333838059,9.738845397,10,10,10,888.4782356,-3.97162931x^3 - 14.89059955x^2 - 10.46287153x + 103.72919646
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,AZD1480,1,2.402187526,10,10,10,10,913.8507645,15.0144379x^3 + 14.62693634x^2 - 44.16406055x + 103.86243882
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Crenolanib,1,0.009898373,4.231991441,6.913597032,10,10,688.9082734,-17.0043698x^3 - 48.38374113x^2 - 18.72933833x + 109.9105278
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Crenolanib,2,1.475915303,2.446065812,4.591837427,7.510375817,9.688465158,513.8773742,-8.22359056x^3 - 36.70315333x^2 - 45.88696501x + 98.84649425
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,KN93,1,1.263314908,10,10,10,10,827.9512927,-1.72889841x^3 - 5.25485418x^2 - 8.51623171x + 90.9204542
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,JAK Inhibitor I,1,0.063098803,10,10,10,10,771.9365452,0.83617815x^3 + 3.30979548x^2 - 6.45834254x + 78.92902721
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,AKT Inhibitor IV,1,0.063545322,0.186438705,0.786377486,4.668454135,25,616.3138303,6.81800086x^3 + 6.61017611x^2 - 38.70346266x + 45.89630849
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,A-674563,1,0.769128762,1.581226195,3.676924062,6.958902454,9.637933426,441.4941625,-4.55277916x^3 - 26.90002843x^2 - 45.50161013x + 85.1556266
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,LY-333531,1,0.331069375,0.952658859,6.245298283,10,10,569.0354545,4.79098551x^3 + 0.20772285x^2 - 33.72911583x + 74.28953008
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,CYT387,1,0.180812878,4.058035056,10,10,10,743.2694257,-1.69692432x^3 - 6.58366765x^2 - 11.18996851x + 84.62529636
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Imatinib,1,0.022727329,10,10,10,10,875.7393987,-2.60845183x^3 - 4.62601719x^2 - 0.02573558x + 90.87373401
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,MLN120B,1,5,5,5,5,5,552.6395411,-0.38049144x^3 - 7.19251542x^2 - 9.83745897x + 115.03390606
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Nilotinib,1,0.505993058,10,10,10,10,927.5833401,5.67965313x^3 + 12.91913075x^2 - 5.46833966x + 87.39842706
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Nilotinib,2,10,10,10,10,10,953.3944298,-1.10699933x^3 - 0.06281796x^2 + 2.41756933x + 94.42872467
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Nilotinib,3,2.08515635,4.760189328,10,10,10,770.5795769,-1.76961335x^3 - 14.78836215x^2 - 25.72670942x + 99.77409308
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Flavopiridol,1,0.046611944,0.082197604,0.189776114,0.446760369,0.827796944,49.29903951,15.38611904x^3 + 35.31186042x^2 - 43.17642916x + 6.22687232
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Erlotinib,1,3.287834992,10,10,10,10,877.4225252,-1.54539144x^3 - 6.06133413x^2 - 8.94719684x + 96.45790334
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,PHA-665752,1,10,10,10,10,10,1071.050204,4.0635018x^3 + 6.2833044x^2 - 10.11172992x + 108.30083745
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Cediranib (AZD2171),1,3.615700329,6.133910241,10,10,10,842.7249022,-4.55812893x^3 - 24.02647534x^2 - 26.75579357x + 113.21377543
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Gefitinib,1,0.551970997,10,10,10,10,941.322914,5.26238816x^3 + 12.68909244x^2 - 4.01378156x + 88.20938481
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Doramapimod (BIRB 796),1,0.04884258,0.510164095,10,10,10,703.5042173,2.24392156x^3 + 6.35077963x^2 - 9.4477262x + 71.75198748
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,GDC-0941,1,0.15448247,1.284289385,7.047073209,10,10,589.4416343,-1.41625488x^3 - 10.34487152x^2 - 22.75134518x + 77.59619247
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,GDC-0941,2,0.137283449,1.69679219,10,10,10,683.4660759,-0.00476795x^3 - 2.97845408x^2 - 15.61790504x + 78.74342814
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,BEZ235,1,0.205061688,0.611930234,10,10,10,598.0621588,6.95840705x^3 + 9.12728455x^2 - 27.99635206x + 68.68070194
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Crizotinib (PF-2341066),1,2.363527672,3.365989286,5.356338368,7.796285274,9.498108858,587.3077779,-13.32088841x^3 - 52.10450097x^2 - 42.57453857x + 113.86964277
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,CHIR-99021,1,10,10,10,10,10,1477.481232,-0.62074139x^3 + 6.39448647x^2 + 29.96422917x + 127.80414742
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,PD173955,1,2.518093558,6.573665562,10,10,10,828.8540537,1.29080438x^3 - 8.55358108x^2 - 27.06257073x + 102.14667567
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Ibrutinib (PCI-32765),1,8.371994138,10,10,10,10,1197.09912,-20.38797824x^3 - 58.25779686x^2 - 1.85494376x + 157.34768034
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,STO609,1,10,10,10,10,10,962.4629647,6.971771x^3 + 11.98397245x^2 - 11.2875553x + 94.21164348
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Lapatinib,1,10,10,10,10,10,958.0340693,1.26651913x^3 - 3.35562626x^2 - 10.50100181x + 103.05844222
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,p38 MAP Kinase Inhibitor,1,10,10,10,10,10,932.0747926,0.26060512x^3 - 1.54502982x^2 - 5.39929653x + 97.00273569
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,KN92,1,0.292402537,10,10,10,10,845.422072,1.20210693x^3 + 4.55772564x^2 - 6.37786518x + 85.47741324
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,R406,1,0.4016118,10,10,10,10,800.9499654,3.99550111x^3 + 5.56774641x^2 - 13.95701075x + 83.84483833
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Axitinib (AG-013736),1,2.859497094,10,10,10,10,890.9362019,2.71709269x^3 + 0.82199581x^2 - 16.20000151x + 96.96263066
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Masitinib (AB-1010),1,10,10,10,10,10,942.335717,4.03937854x^3 + 5.47029013x^2 - 11.76721694x + 96.78172801
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,MK-2206,1,0.006957087,3.33241935,6.374285471,10,10,617.3935735,-15.31822963x^3 - 40.79536953x^2 - 14.07210729x + 95.69313226
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,PP2,1,1.056801238,10,10,10,10,842.3944762,-0.48174057x^3 - 2.90468399x^2 - 7.52599741x + 90.18225243
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,RAF265 (CHIR-265),1,0.007856048,5.954853727,10,10,10,809.0118329,-16.62949452x^3 - 39.44390039x^2 - 1.13197206x + 107.297153
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,TG101348,1,0.206015993,0.576154272,2.030586892,5.559703658,9.487530324,335.4119524,0.38705876x^3 - 11.9500282x^2 - 44.91271462x + 64.93569621
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,CI-1040 (PD184352),1,2.431381665,10,10,10,10,869.6428188,0.41382858x^3 - 2.63784343x^2 - 11.99754035x + 94.99824455
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Vatalanib (PTK787),1,10,10,10,10,10,936.1907347,-1.24284261x^3 - 1.92826958x^2 - 2.71792451x + 96.61040689
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,SB-202190,1,0.012539971,10,10,10,10,845.8780575,-2.99548587x^3 - 6.14987536x^2 - 1.15970987x + 89.43410324
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,GDC-0879,1,10,10,10,10,10,1444.675557,3.85264855x^3 + 7.193825x^2 + 11.74010355x + 132.89870944
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,INK-128,1,0.003237148,0.006680085,0.692003761,5,5,223.8532256,-4.91688199x^3 - 8.58526878x^2 - 7.35210546x + 49.0238469
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,SB-203580,1,0.233752369,1.199653418,10,10,10,727.3948307,5.3630124x^3 + 9.29922675x^2 - 17.88579987x + 76.35320788
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,GSK-1904529A,1,0.01291528,10,10,10,10,829.8706272,-2.7793979x^3 - 5.02986585x^2 - 1.09151259x + 87.15284421
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,AMPK Inhibitor,1,10,10,10,10,10,1021.568272,3.98530555x^3 + 12.12679926x^2 + 3.58512516x + 92.67138716
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Go6976,1,0.060043046,1.741216376,10,10,10,764.3148927,1.77966995x^3 + 6.44994529x^2 - 6.16700131x + 76.08631224
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,BI-2536,1,0.045393173,0.389474279,2.695212266,9.256752866,10,421.5875508,-1.97479643x^3 - 10.32880268x^2 - 29.19110693x + 64.64221266
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,SYK Inhibitor,1,10,10,10,10,10,1088.676282,-2.46294343x^3 - 12.48769046x^2 - 4.72836897x + 118.76622189
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,PD98059,1,0.119416426,10,10,10,10,885.130108,0.5024474x^3 + 3.72661234x^2 - 0.48646384x + 86.77166408
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,VX-745,1,0.149456302,5.737262553,10,10,10,766.322269,1.33889823x^3 + 2.26781308x^2 - 10.16163434x + 80.81950805
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,BMS-345541,1,1.710462311,3.108809726,7.675903882,10,10,683.6916758,2.93301285x^3 - 13.74392924x^2 - 49.04158495x + 102.14197238
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Dovitinib (CHIR-258),1,0.216883619,0.903325039,10,10,10,620.996601,3.53595419x^3 + 1.83528329x^2 - 24.57769567x + 73.91147454
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,GSK-1838705A,1,10,10,10,10,10,1071.404768,5.80932529x^3 + 4.96807612x^2 - 12.71384627x + 109.86925843
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Roscovitine (CYC-202),1,3.645111552,10,10,10,10,882.1688951,-2.99543032x^3 - 6.43368145x^2 - 1.88915254x + 93.62198799
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Quizartinib (AC220),1,0.09815742,0.360594409,2.696233678,10,10,474.1204117,3.15948205x^3 + 1.78599214x^2 - 29.19420377x + 61.99169768
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Quizartinib (AC220),2,0.052196253,0.130484082,0.560678704,10,10,392.5923894,8.54142315x^3 + 18.91930668x^2 - 27.11660174x + 42.12685657
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,JNJ-7706621,1,1.023520536,2.170507033,4.657375887,8.023869352,10,507.4664474,-9.87569363x^3 - 34.73161986x^2 - 32.75357888x + 90.33424923
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Vandetanib (ZD6474),1,0.244530163,10,10,10,10,786.1796641,3.73044075x^3 + 8.94703809x^2 - 12.44482091x + 79.89418928
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Motesanib (AMG-706),1,0.293183839,1.231574172,10,10,10,784.1143403,8.53272594x^3 + 18.29054093x^2 - 18.0542434x + 76.47720724
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Sorafenib,1,0.02186004,2.676213429,8.538869745,10,10,652.846855,-5.4172708x^3 - 18.00435524x^2 - 17.30174992x + 86.1108886
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Sorafenib,2,0.144766568,1.203361745,8.230723391,10,10,604.9409924,-2.02312931x^3 - 7.45046261x^2 - 20.66178451x + 76.71033672
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Sorafenib,3,1.602676528,4.661237275,10,10,10,774.5767478,1.7653205x^3 - 6.688461x^2 - 27.614999x + 95.92230458
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,R547,1,1.06185164,1.694455433,3.247396842,5.635280098,7.592306709,389.4824414,-0.68214255x^3 - 29.5304103x^2 - 66.33054401x + 91.74890163
144,12-00125,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,MarcTest 384 123v3,Standard,Barasertib (AZD1152-HQPA),1,0.010226948,10,10,10,10,844.2562009,-2.31258912x^3 - 3.15629504x^2 + 1.01386555x + 86.28871852
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SNS-032 (BMS-387032),1,0.00720691,0.014744192,0.058564004,0.439565194,10,198.5874445,0.99477099x^3 + 12.33997055x^2 - 11.02132003x + 19.53838637
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Cediranib (AZD2171),1,10,10,10,10,10,1282.570261,13.25192022x^3 + 37.66696485x^2 + 14.13100477x + 96.65653285
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,H-89,1,0.007890047,0.025747571,7.794516428,10,10,532.5522964,-2.78050947x^3 - 1.39992288x^2 - 5.75935797x + 58.22149331
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Pelitinib (EKB-569),1,0.010026895,0.025959147,0.148335479,10,10,408.4521749,3.2258853x^3 + 17.0414243x^2 - 6.44756629x + 34.78813557
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,TG101348,1,0.011638464,0.038573676,0.287285334,10,10,463.5249744,4.37716812x^3 + 17.13649207x^2 - 8.54480432x + 41.03885568
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,AZD1480,1,0.005490951,0.010948429,9.107622882,10,10,662.7244281,-11.45329767x^3 - 24.47062563x^2 - 0.03645097x + 82.67347149
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Doramapimod (BIRB 796),1,10,10,10,10,10,1271.757426,2.09491501x^3 + 1.11149009x^2 - 0.11885942x + 126.01067543
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,AMPK Inhibitor,1,0.211039974,10,10,10,10,805.9615224,5.60218719x^3 + 13.80267832x^2 - 11.03714609x + 77.97003078
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,BMS-345541,1,0.046264094,0.451013221,3.57393296,10,10,470.7787415,-3.00820689x^3 - 10.08800758x^2 - 25.01365987x + 67.4319823
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Neratinib (HKI-272),1,0.010608752,0.026865343,0.209549363,10,10,394.4252825,0.55400219x^3 + 9.40086576x^2 - 9.08931164x + 39.67363963
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,VX-745,1,0.169786598,0.538194698,10,10,10,649.586268,7.30062866x^3 + 13.57255007x^2 - 22.20481224x + 68.18519807
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Flavopiridol,1,0.035239983,0.078880362,0.259338745,1.176949323,10,268.1840909,9.9271657x^3 + 24.84739867x^2 - 28.30085784x + 26.8745861
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Canertinib (CI-1033),1,0.019077627,0.100246276,1.624883752,10,10,467.0233272,2.11899374x^3 + 5.39243086x^2 - 18.17792776x + 53.57278484
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sunitinib,1,0.000907,0.00362266,1,1,1,74.44404554,1.66983137x^3 + 18.7985975x^2 + 40.33860384x + 85.74315746
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sunitinib,2,0.000597,0.001279725,0.022386306,1,1,58.46521346,-1.90510977x^3 + 1.21364237x^2 + 15.6225389x + 63.91498732
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sunitinib,3,0.008977127,0.046179111,1,1,1,59.87986506,2.7188616x^3 + 12.25536786x^2 - 3.30840077x + 55.1984519
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Vatalanib (PTK787),1,0.013597442,0.127101862,5.108226752,10,10,521.3903427,-0.90267403x^3 - 1.90548098x^2 - 15.33780216x + 62.13990711
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Linifanib (ABT-869),1,0.008732135,2.549364318,6.552674192,10,10,599.9842269,-11.37299617x^3 - 28.59945159x^2 - 12.77174913x + 85.6786522
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GS-1101 (CAL-101),1,0.006007336,0.011640361,7.430918016,10,10,561.0014991,-8.50522554x^3 - 13.93133515x^2 + 0.21729937x + 66.00150944
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,JNJ-7706621,1,0.016613056,0.069623352,0.614978573,10,10,334.1765753,1.60738649x^3 + 3.58061303x^2 - 24.14151486x + 44.75826582
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Pazopanib (GW786034),1,0.007209062,0.020974219,9.73689472,10,10,642.0269848,-8.45678838x^3 - 16.61355315x^2 - 2.78251209x + 77.14771882
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Rapamycin,1,0.006408013,0.071754398,6.257559982,10,10,545.8221502,-3.88926107x^3 - 9.40949957x^2 - 12.14077782x + 67.60163167
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Crizotinib (PF-2341066),1,0.082296728,0.318193148,2.131249669,10,10,425.8475728,1.58264761x^3 - 1.36207176x^2 - 30.80184616x + 60.2134761
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SYK Inhibitor,1,10,10,10,10,10,1260.001727,10.0842522x^3 + 22.3332736x^2 + 2.72657207x + 109.71754657
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,A-674563,1,0.095189625,0.210150033,0.825387091,10,10,375.6390689,7.49419717x^3 + 14.99141407x^2 - 34.5875747x + 47.01759982
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PI-103,1,0.005597556,0.016894313,0.222815292,10,10,376.2231788,-0.23511583x^3 + 4.49411589x^2 - 10.31206027x + 41.29999744
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,JNK Inhibitor II,1,50,50,50,50,50,5680.788497,4.28105719x^3 - 1.96850387x^2 - 6.98361903x + 114.98097202
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,INK-128,1,0.003301065,0.006115163,0.026645611,5,5,185.4151972,-2.15040135x^3 + 5.16434364x^2 + 3.81329259x + 34.81135088
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,JNJ-28312141,1,0.006905795,0.014198053,0.083408749,10,10,703.7068157,1.22959387x^3 + 20.49803177x^2 + 19.39808189x + 48.61486295
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Ibrutinib (PCI-32765),1,1.440427359,2.865959337,6.442337943,10,10,626.519504,-4.94309879x^3 - 25.02838027x^2 - 33.27688547x + 95.92247917
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,MGCD-265,1,0.00539267,0.010731788,0.073667883,10,10,430.1396297,-2.7333309x^3 + 3.20522777x^2 + 0.26494852x + 42.21513506
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Alisertib (MLN8237),1,0.025709286,0.207314411,10,10,10,624.0745139,3.03844549x^3 + 7.5004051x^2 - 11.89674197x + 64.33712532
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,MEK1/2 Inhibitor,1,1.955485361,4.288674078,10,10,10,740.4048497,-4.43189445x^3 - 19.16966373x^2 - 23.31058848x + 98.52496147
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PD173955,1,2.012315323,10,10,10,10,844.5142445,9.01399588x^3 + 4.52495851x^2 - 38.94503667x + 101.15762597
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,KN92,1,10,10,10,10,10,1266.407656,9.20358858x^3 + 17.94552448x^2 - 1.7663082x + 115.43039005
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,BI-2536,1,0.006968196,0.012435642,2.453778847,10,10,447.7568641,-7.46097039x^3 - 8.26175753x^2 - 0.73553352x + 51.9843072
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Selumetinib (AZD6244),1,0.006663453,0.009905,10,10,10,981.9926202,-17.94792134x^3 - 28.63039954x^2 + 28.55957386x + 102.75631829
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,TG100-115,1,0.88112766,10,10,10,10,826.5710623,4.97595393x^3 + 6.40760334x^2 - 19.69769313x + 88.89886232
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Tandutinib (MLN518),1,0.005696839,0.015093021,0.113076801,10,10,385.209241,1.04119379x^3 + 10.50826476x^2 - 5.68082182x + 36.08912683
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Ponatinib (AP24534),1,0.000716,0.001752312,0.022890204,0.375233048,0.985585765,23.51275859,-3.66262406x^3 - 16.88248091x^2 - 42.38553834x + 9.73340502
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Ponatinib (AP24534),2,0.000707,0.004130706,0.351220993,1,1,46.99772674,-3.9249753x^3 - 21.05727325x^2 - 45.35572106x + 33.36943529
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Ponatinib (AP24534),3,0.017408469,0.060275021,0.220615483,0.559573332,0.891074473,33.62339188,-2.02595931x^3 - 22.37680046x^2 - 80.83992757x + 6.00693165
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Dasatinib,1,1,1,1,1,1,120.7101751,10.29015069x^3 + 61.6991492x^2 + 106.01230153x + 148.56217733
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Dasatinib,2,0.000782,0.002509455,1,1,1,83.17859558,-1.29030082x^3 + 4.35261467x^2 + 26.81420089x + 92.6056714
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Dasatinib,3,0.420050853,0.85195019,1,1,1,88.38971351,-3.96042926x^3 - 28.95985737x^2 - 61.08140008x + 70.88849663
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PLX-4720,1,0.612209763,10,10,10,10,854.3483084,4.86839067x^3 + 8.24637526x^2 - 12.89140195x + 86.92547747
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Trametinib (GSK1120212),1,0.006137116,0.009203779,10,10,10,855.8814663,-20.29725719x^3 - 41.0709985x^2 + 15.17302019x + 104.83609593
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,CYT387,1,10,10,10,10,10,1080.833197,14.86539035x^3 + 23.31078627x^2 - 26.34308175x + 106.12393386
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Axitinib (AG-013736),1,0.085971318,0.787020704,10,10,10,781.8569724,4.69951066x^3 + 12.51758061x^2 - 6.86567824x + 74.15573665
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,YM-155,1,0.007887542,0.017527979,0.067580997,1,1,38.56834341,8.90032866x^3 + 45.40573661x^2 + 32.29034423x + 39.8721099
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,RAF265 (CHIR-265),1,0.010282668,0.02350753,0.081396671,0.364614228,10,322.0838036,7.60030165x^3 + 30.6737387x^2 - 5.64004959x + 17.27903913
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,R406,1,0.032826199,0.067279114,0.202416925,0.742250234,10,217.9411126,9.49766489x^3 + 26.58398x^2 - 28.0016586x + 20.95032395
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Nilotinib,1,0.023196575,10,10,10,10,1056.764103,1.32424457x^3 + 9.37922042x^2 + 13.53490672x + 92.84747303
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Nilotinib,2,10,10,10,10,10,1482.068444,-9.8270579x^3 - 21.8173787x^2 + 21.74774044x + 150.38207458
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Nilotinib,3,0.396340102,0.964198639,10,10,10,655.2896622,10.22707469x^3 + 14.2329085x^2 - 34.62399819x + 74.44825383
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PD98059,1,0.046514112,10,10,10,10,918.443795,-0.89325629x^3 + 1.11961789x^2 + 3.0175224x + 89.91992364
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,LY-333531,1,0.104862446,0.252560371,1.084341151,10,10,378.8015076,6.45831x^3 + 9.74711666x^2 - 36.20341167x + 51.26079242
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,AKT Inhibitor IV,1,0.146375739,0.267686081,0.700689441,2.735003179,25,965.3565021,16.69016379x^3 + 22.22872461x^2 - 51.00790262x + 41.65167587
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,JAK Inhibitor I,1,10,10,10,10,10,1051.996849,2.75547236x^3 + 7.74534047x^2 + 2.03336291x + 99.22203973
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Imatinib,1,0.006476881,0.016285427,2.343754066,10,10,458.6480815,-3.97703363x^3 - 4.23159568x^2 - 6.95512825x + 53.35312076
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SB-203580,1,10,10,10,10,10,1190.313307,4.43829082x^3 + 8.98727599x^2 + 0.30161755x + 112.82916188
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PHA-665752,1,0.00844256,3.100941562,8.270507812,10,10,657.3029251,-9.30361982x^3 - 23.84564507x^2 - 10.805598x + 87.17577895
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,MLN120B,1,5,5,5,5,5,487.483135,1.87460751x^3 + 4.38845803x^2 - 0.13276331x + 96.42531204
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,R547,1,0.078805598,0.607581254,10,10,10,645.1435539,2.18139609x^3 + 3.07051531x^2 - 16.13651022x + 71.38645087
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,LY294002,1,0.030541909,0.060682384,0.360692931,7.545564835,25.59773844,642.4197734,-4.35336236x^3 + 2.97588416x^2 - 17.71019227x + 41.19504951
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sorafenib,1,0.512005075,1.838329967,10,10,10,755.1381507,9.10924369x^3 + 13.40467611x^2 - 27.37376218x + 81.13259763
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sorafenib,2,0.00633448,0.024355533,1.137991085,10,10,403.5422687,-2.06217377x^3 - 3.01088604x^2 - 14.47522102x + 50.82247628
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Sorafenib,3,0.063121036,0.323590427,1.951149081,8.082429453,10,381.8682852,0.59982284x^3 - 6.48015482x^2 - 33.44259547x + 60.23946637
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,KW-2449,1,0.006668792,0.013516605,10,10,10,806.7065238,-9.36496221x^3 - 13.29713747x^2 + 12.47097266x + 83.61133212
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Velcade,1,0.009403699,0.017213311,0.049710207,0.198910699,10,419.4243546,6.08988191x^3 + 34.96438748x^2 + 9.67504237x + 16.6880803
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,BEZ235,1,0.007206847,0.014332692,7.922944368,10,10,753.8168633,-21.41813881x^3 - 52.59682507x^2 - 4.19478322x + 111.82466532
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GSK-1904529A,1,0.00741675,0.028127729,10,10,10,915.8380692,2.18931171x^3 + 18.67043263x^2 + 20.38137548x + 69.86934161
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SB-431542,1,0.010762363,10,10,10,10,935.3769644,0.22156247x^3 + 3.15967717x^2 + 4.91319389x + 89.11997681
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,NVP-TAE684,1,0.009503852,0.058109272,10,10,10,687.2378442,-1.42680481x^3 + 2.15618992x^2 - 0.47279011x + 68.4305186
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,CI-1040 (PD184352),1,0.004572222,0.65553652,3.128380231,7.341382914,10,407.7876358,-5.75696972x^3 - 22.43338253x^2 - 28.75346924x + 70.44559414
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Roscovitine (CYC-202),1,0.007949886,0.139162565,3.670197363,10,10,468.148483,-4.44766172x^3 - 12.710015x^2 - 18.77004925x + 65.45301085
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Vandetanib (ZD6474),1,0.018788226,0.151547979,10,10,10,626.9154452,1.89059267x^3 + 6.61282445x^2 - 9.28746047x + 63.98920874
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,MK-2206,1,0.009625682,3.717330462,10,10,10,714.4730187,-6.25622356x^3 - 13.99238736x^2 - 5.75494581x + 83.99148341
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Staurosporine,1,0.004728975,0.455622228,0.732624904,10,10,1478.292689,89.34777945x^3 + 198.44427315x^2 - 42.80128643x + 40.81418019
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SGX-523,1,10,10,10,10,10,1034.039713,-3.28460823x^3 - 11.54138499x^2 - 8.01258034x + 114.97079184
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,STO609,1,10,10,10,10,10,1060.271322,5.00440339x^3 + 1.88260403x^2 - 18.96984822x + 114.14311449
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,AT7519,1,0.028544272,0.090107109,0.671112664,10,10,583.7902124,8.8452055x^3 + 25.44292562x^2 - 9.1980456x + 47.6895339
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Tozasertib (VX-680),1,10,10,10,10,10,1150.497723,7.00183936x^3 + 16.38582393x^2 + 0.0989837x + 104.3303607
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Midostaurin (PKC412),1,0.006478605,0.011706531,10,10,10,768.9535995,-3.88130516x^3 + 7.56629228x^2 + 22.27429578x + 61.82364291
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GDC-0941,1,0.008510214,0.022138541,0.736920199,7.292134215,10,330.683576,-4.64452512x^3 - 7.74650291x^2 - 16.44933795x + 47.94449365
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GDC-0941,2,0.041239703,0.256228125,10,10,10,661.1751748,3.19483588x^3 + 9.28623892x^2 - 10.41701275x + 66.25279771
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,KI20227,1,0.02139684,10,10,10,10,943.6118722,-6.43221631x^3 - 10.8392855x^2 + 5.29376467x + 99.11676564
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Lapatinib,1,0.005995422,0.025903229,10,10,10,973.5707963,-7.66628533x^3 - 12.08085243x^2 + 14.57005635x + 97.90900482
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Gefitinib,1,0.2147685,10,10,10,10,829.2256872,0.60814206x^3 + 1.40761144x^2 - 6.08412664x + 85.48875661
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Crenolanib,1,0.005625938,0.007671546,0.019575082,10,10,767.3160208,-22.35288925x^3 - 43.57379594x^2 + 17.94622425x + 96.38241593
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Crenolanib,2,0.00543313,0.00769925,10,10,10,674.716591,-20.40479045x^3 - 42.30594436x^2 + 9.19327987x + 90.76462228
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Erlotinib,1,0.006423381,0.017895958,10,10,10,739.3137672,-9.7217137x^3 - 19.90656927x^2 + 1.50838391x + 86.55096079
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Bosutinib (SKI-606),1,0.591300649,10,10,10,10,846.9248148,3.64009481x^3 + 6.29578236x^2 - 11.8578594x + 87.00955777
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,p38 MAP Kinase Inhibitor,1,10,10,10,10,10,1192.179397,-4.22745819x^3 - 15.38037109x^2 - 2.17893106x + 129.75075668
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Tofacitinib (CP-690550),1,0.0102515,10,10,10,10,890.4815778,-1.3946109x^3 + 1.92675905x^2 + 6.72894175x + 84.78384639
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Vargetef,1,0.030154638,0.110314474,1.244214779,10,10,488.3790589,4.02401926x^3 + 11.36713243x^2 - 17.3133679x + 51.53715701
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,SB-202190,1,10,10,10,10,10,1236.664236,-0.27989893x^3 - 7.92413979x^2 - 6.30571381x + 131.40097297
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Barasertib (AZD1152-HQPA),1,0.006969457,0.026028273,10,10,10,714.021612,-2.90538389x^3 - 0.12175392x^2 + 4.07145457x + 70.19801265
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Dovitinib (CHIR-258),1,0.004572222,0.006914533,0.020276651,0.187932453,10,362.2442441,-1.69538236x^3 + 11.51735731x^2 + 9.84432983x + 25.42772764
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PD153035,1,0.001073951,0.009747773,1,1,1,86.66288534,0.62527425x^3 + 11.99237922x^2 + 32.29021861x + 96.52139144
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,NF-kB Activation Inhibitor,1,0.00540255,0.00970759,0.034256064,0.277367359,2.761473752,84.45595838,-2.40303749x^3 + 2.75467197x^2 - 14.08713947x + 15.88463671
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GDC-0879,1,10,10,10,10,10,1353.63267,-1.38083092x^3 - 5.12485503x^2 + 9.56800723x + 133.06784891
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GSK690693,1,0.007696197,10,10,10,10,1168.503014,-5.15799x^3 - 5.91250304x^2 + 20.13495001x + 110.26497666
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GSK-1838705A,1,0.040829052,10,10,10,10,1000.92343,4.57664701x^3 + 17.00219986x^2 + 10.47585383x + 84.01256608
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Go6976,1,10,10,10,10,10,1013.445579,8.88898238x^3 + 10.87490803x^2 - 21.52997295x + 105.01521216
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Quizartinib (AC220),1,0.006126725,0.011022242,0.044228303,0.884631281,6.245752191,140.3683562,-3.97572576x^3 - 1.71499569x^2 - 14.03908624x + 24.25685207
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Quizartinib (AC220),2,0.00608296,0.010905926,0.038151709,10,10,338.1170732,-0.72688373x^3 + 12.47570341x^2 + 2.49465637x + 26.36161318
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Foretinib (XL880),1,0.006764182,0.010488742,0.032433816,10,10,579.8980252,-6.95420426x^3 + 1.54630154x^2 + 17.52793739x + 49.71282918
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,GW-2580,1,0.006734787,0.014269006,0.08806196,10,10,451.3860392,-0.53144975x^3 + 10.17758185x^2 + 1.3305552x + 39.4471427
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Afatinib (BIBW-2992),1,0.019851935,0.134283224,6.712086024,10,10,534.7708912,0.18540377x^3 + 1.64918301x^2 - 14.77560215x + 60.98497031
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Lestaurtinib (CEP-701),1,0.006986441,0.018294542,1,1,1,64.39701811,10.81216049x^3 + 59.86236517x^2 + 73.79346877x + 79.20436659
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,CHIR-99021,1,0.005584502,10,10,10,10,1639.146824,-6.13048037x^3 + 1.0827454x^2 + 53.60639431x + 135.16879081
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PP2,1,0.006236234,0.012741984,8.655030117,10,10,656.643788,-12.12250459x^3 - 25.76474454x^2 - 0.85494828x + 83.41617398
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,KN93,1,3.495453053,7.35903709,10,10,10,886.9391617,6.68714281x^3 - 6.67459874x^2 - 47.13105175x + 116.51392775
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Motesanib (AMG-706),1,0.54438218,10,10,10,10,989.9419018,14.7854091x^3 + 32.0546598x^2 - 12.43641966x + 84.75222667
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,Masitinib (AB-1010),1,0.047502024,10,10,10,10,904.8545304,5.85112948x^3 + 20.06440096x^2 + 5.25206812x + 75.37363087
707,12-00127,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,MarcTest 384 123v3,Standard,PP242,1,0.007804899,0.024139757,0.650940211,10,10,596.9509964,1.96650405x^3 + 14.51918381x^2 + 2.91111561x + 50.05076416
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,JNJ-28312141,1,0.005340099,0.014057403,10,10,10,632.2749839,-2.06352567x^3 + 3.47317638x^2 + 5.06070332x + 59.34911445
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,KN93,1,2.959236365,10,10,10,10,902.1492818,6.43474735x^3 + 4.61317168x^2 - 27.24312912x + 101.13911888
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Lapatinib,1,10,10,10,10,10,955.6190536,3.13185995x^3 + 3.88850083x^2 - 9.53493086x + 97.95949282
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Doramapimod (BIRB 796),1,4.651214013,10,10,10,10,902.1750576,-1.06069657x^3 - 3.04379096x^2 - 4.92181833x + 94.95764429
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,STO609,1,10,10,10,10,10,1039.452149,2.55771543x^3 + 2.18373399x^2 - 6.14305675x + 105.48381936
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Sunitinib,1,0.003585184,0.015470318,1,1,1,76.80963542,6.35484281x^3 + 40.40653418x^2 + 61.37562202x + 91.38536319
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Sunitinib,2,0.006437521,1,1,1,1,86.55324861,2.15600901x^3 + 14.75294907x^2 + 22.90656071x + 92.04060257
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Sunitinib,3,0.006453178,0.02775472,1,1,1,72.32216046,6.87255308x^3 + 38.60997508x^2 + 47.93826483x + 81.98803378
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Vargetef,1,0.023624833,0.095520834,10,10,10,667.2667368,1.09674567x^3 + 10.57285489x^2 - 2.60356053x + 62.51028087
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,SB-202190,1,10,10,10,10,10,995.5591446,0.34749859x^3 - 2.05791121x^2 - 7.37180861x + 104.70183538
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,SYK Inhibitor,1,10,10,10,10,10,1137.256678,10.65929341x^3 + 27.25694297x^2 + 3.51047745x + 94.30490729
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,BEZ235,1,0.039317428,0.072446487,0.205630024,10,10,539.3995954,13.82026651x^3 + 46.52580112x^2 - 5.48499786x + 28.75850385
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Vandetanib (ZD6474),1,0.450659129,10,10,10,10,869.2727211,1.49154157x^3 + 3.59076579x^2 - 5.47187225x + 87.73751557
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,AZD1480,1,0.009889481,5.74728408,10,10,10,766.1318018,-4.36427476x^3 - 8.97576398x^2 - 3.19074748x + 84.51207768
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,AT7519,1,0.008408373,0.033254147,1.663096008,10,10,526.0995889,1.39225202x^3 + 9.17157353x^2 - 5.83837355x + 50.82717321
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,MK-2206,1,0.006677302,0.012913223,3.164009815,10,10,451.6965938,-7.52227685x^3 - 11.14887406x^2 - 4.33125491x + 55.89815508
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,H-89,1,0.007444318,0.026413722,10,10,10,664.5557032,-0.00009387x^3 + 8.37960487x^2 + 3.78619115x + 60.10445935
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,SB-431542,1,0.004765099,10,10,10,10,1021.731243,3.18198842x^3 - 9.387819x^2 - 25.81733013x + 120.50020281
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Motesanib (AMG-706),1,0.076899884,0.471880284,10,10,10,671.1543463,4.14967035x^3 + 8.25189759x^2 - 14.25283277x + 69.61728794
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Dasatinib,1,0.001383,1,1,1,1,83.19049325,-3.24538339x^3 - 14.35281807x^2 - 18.31467884x + 79.11197444
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Dasatinib,2,0.023130348,0.271581878,1,1,1,74.59922014,1.94538131x^3 + 8.93875211x^2 - 1.97055902x + 71.37280619
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Dasatinib,3,0.000957,0.002533819,1,1,1,70.32350205,-8.63649182x^3 - 38.6673627x^2 - 47.9925794x + 59.89860503
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Afatinib (BIBW-2992),1,0.09758395,0.325936137,1.994839772,10,10,436.3641161,3.93310609x^3 + 2.31738539x^2 - 32.05377917x + 59.29865236
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Alisertib (MLN8237),1,10,10,10,10,10,1117.901242,11.94261775x^3 + 19.75249759x^2 - 15.79546963x + 106.66452868
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Masitinib (AB-1010),1,0.005782689,0.009221398,10,10,10,704.6570733,-13.78895114x^3 - 24.40509532x^2 + 10.67471777x + 81.57267129
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,PI-103,1,0.009739293,0.037908585,0.576524571,10,10,385.387331,0.26340627x^3 + 3.37399023x^2 - 16.18352111x + 45.93977478
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Dovitinib (CHIR-258),1,0.004792725,0.010064289,0.066394264,10,10,443.6736544,-1.2657494x^3 + 7.09884661x^2 + 1.80997753x + 40.21472268
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,INK-128,1,0.003019049,0.004955168,0.019404358,5,5,210.4395799,-6.7696176x^3 - 10.17545633x^2 - 0.52114694x + 44.96052484
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Ibrutinib (PCI-32765),1,0.008490136,4.354760284,10,10,10,725.7274221,-8.79936607x^3 - 18.38823573x^2 - 2.17725431x + 86.19417041
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,GSK-1838705A,1,0.008722134,3.219941102,6.934382961,10,10,636.0408576,-11.53443723x^3 - 32.05304238x^2 - 15.74462706x + 92.77342784
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,KN92,1,10,10,10,10,10,1010.749537,5.8821722x^3 + 10.07805713x^2 - 10.13180426x + 99.72912665
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Ponatinib (AP24534),1,0.000585,0.001149742,0.40830189,1,1,48.4038952,-6.00875844x^3 - 24.8877307x^2 - 32.94289805x + 40.59724671
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Ponatinib (AP24534),2,0.00814058,0.177283909,1,1,1,72.80365015,1.12998221x^3 + 5.33635817x^2 - 3.39627055x + 69.91516847
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Ponatinib (AP24534),3,0.001319917,0.011322745,0.405577005,1,1,50.46440069,-0.40044588x^3 - 2.09575674x^2 - 19.10261949x + 42.8109879
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Crizotinib (PF-2341066),1,0.826899413,2.230562737,5.547575155,10,10,565.0774452,-7.32113834x^3 - 26.93125579x^2 - 26.91767887x + 87.95741102
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,GSK-1904529A,1,10,10,10,10,10,1101.155702,2.33496903x^3 + 5.23427431x^2 + 0.69316548x + 106.31546543
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Flavopiridol,1,0.010535029,0.034428321,0.391657847,10,10,435.2689373,1.53290087x^3 + 9.39572835x^2 - 10.55117065x + 44.25100273
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Go6976,1,0.974282171,10,10,10,10,855.7434354,2.69146798x^3 + 3.58517369x^2 - 12.33118504x + 89.8600145
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,MLN120B,1,0.027105167,5,5,5,5,404.924483,1.78947233x^3 + 8.83231315x^2 + 1.93291715x + 78.22733224
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Barasertib (AZD1152-HQPA),1,0.008570505,0.030161724,10,10,10,767.0904209,0.9027577x^3 + 13.00317499x^2 + 10.4179116x + 63.95056987
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Foretinib (XL880),1,0.005688273,0.007929124,5.367696189,8.208257588,10,525.5866456,-23.4261368x^3 - 52.7211987x^2 - 1.1652728x + 88.03443262
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Tandutinib (MLN518),1,0.006292298,0.016534737,0.177943918,10,10,493.8483794,0.55247334x^3 + 10.55263135x^2 - 0.31748284x + 44.06341454
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,PD173955,1,0.321560111,0.985949506,10,10,10,731.2454099,9.80050481x^3 + 17.44544457x^2 - 24.53289349x + 74.84858081
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,SB-203580,1,1.261689975,10,10,10,10,919.5530425,11.41676423x^3 + 17.78346246x^2 - 23.09384199x + 92.13839938
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,p38 MAP Kinase Inhibitor,1,10,10,10,10,10,956.3420323,0.69505245x^3 - 2.33168273x^2 - 9.52189982x + 102.01530413
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,LY294002,1,0.053937398,0.170579799,2.026749026,13.58324464,30.15192041,876.8647632,-3.31569968x^3 - 1.45503094x^2 - 22.44292532x + 57.11819597
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,PD98059,1,0.016994446,10,10,10,10,938.0834161,-2.68278855x^3 - 2.21425258x^2 + 5.92145847x + 92.5448414
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Rapamycin,1,0.391132787,10,10,10,10,825.5165076,5.43673788x^3 + 10.28048179x^2 - 13.49537367x + 83.15802074
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,CI-1040 (PD184352),1,0.03855878,0.387087092,3.762457855,10,10,486.501189,-1.64769486x^3 - 7.25703511x^2 - 23.69257882x + 66.35171596
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,PP242,1,0.007203296,0.016552166,0.125308456,3.669173964,10,246.6989293,-2.10038216x^3 + 0.40622078x^2 - 15.60048918x + 34.05602566
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Linifanib (ABT-869),1,0.006441174,0.013354364,1.752617118,10,10,457.5938625,-4.8005394x^3 - 3.7383256x^2 - 2.94123126x + 51.00820278
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,GDC-0879,1,10,10,10,10,10,1705.768204,2.99984419x^3 + 14.00304671x^2 + 36.6344964x + 141.75534881
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Cediranib (AZD2171),1,1.35939556,3.238866557,10,10,10,708.1458094,1.55844489x^3 - 10.55030376x^2 - 33.53092915x + 94.65511118
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Staurosporine,1,5.007634198,6.514691137,9.457581853,10,10,932.4210192,-13.2162262x^3 - 50.93738459x^2 - 31.43348195x + 141.451045
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Nilotinib,1,0.057026201,0.287466416,10,10,10,744.513428,6.17627855x^3 + 16.99397348x^2 - 6.53882658x + 67.4585824
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Nilotinib,2,0.005113194,0.017377982,10,10,10,887.6480949,-9.62916208x^3 - 20.78414568x^2 + 6.77759749x + 98.8135003
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Nilotinib,3,0.170551571,0.373605342,1.64315771,10,10,472.3570682,9.98526093x^3 + 15.05255119x^2 - 37.04365358x + 57.18915895
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Pazopanib (GW786034),1,0.007901528,0.027334774,10,10,10,565.2018967,-3.53034387x^3 - 3.54114105x^2 - 4.97657428x + 62.38675753
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,KW-2449,1,0.011534267,10,10,10,10,920.0573213,-3.80979764x^3 - 3.72549985x^2 + 7.58201497x + 90.9552795
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,R406,1,0.006285152,0.023135341,10,10,10,621.4160522,0.67556676x^3 + 9.37728336x^2 + 1.96558518x + 56.0819982
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,A-674563,1,0.02049705,0.06993697,10,10,10,646.9318642,5.05130878x^3 + 20.16265429x^2 - 1.79992138x + 53.79840045
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Quizartinib (AC220),1,0.05016468,0.187125169,4.021555862,10,10,527.8932293,4.70573742x^3 + 10.62041538x^2 - 19.5956231x + 56.92498889
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Quizartinib (AC220),2,0.009080128,0.032319561,10,10,10,569.7733237,0.692454x^3 + 8.80573242x^2 - 2.63208482x + 53.80621932
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,YM-155,1,0.001173498,0.109366897,0.5143636,1,1,53.21203026,-4.77560742x^3 - 31.15489755x^2 - 69.98509312x + 32.2754958
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,GSK690693,1,0.010250505,10,10,10,10,1074.490367,-6.30451577x^3 - 5.68421567x^2 + 19.44020923x + 101.53717226
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,R547,1,0.545966561,2.266201283,10,10,10,702.6643691,3.24001264x^3 - 1.30973487x^2 - 24.4758084x + 83.7162341
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Trametinib (GSK1120212),1,0.006661251,0.01537974,10,10,10,675.106437,-0.03989457x^3 + 13.3907819x^2 + 12.62240026x + 53.62973102
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,CHIR-99021,1,10,10,10,10,10,2676.049987,-3.59173065x^3 + 14.34233631x^2 + 95.07937443x + 207.7986
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,JNJ-7706621,1,1.064406457,3.402534723,10,10,10,772.1467465,8.81443039x^3 + 8.16293782x^2 - 36.90965325x + 90.99435461
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,TG101348,1,0.005954539,0.012562841,0.064108206,10,10,422.7968639,0.48676474x^3 + 13.19183691x^2 + 1.94034101x + 34.3636818
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Erlotinib,1,0.009133237,0.045150567,10,10,10,741.0425712,-6.7773086x^3 - 10.3696167x^2 + 2.33737515x + 80.41032643
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,GDC-0941,1,0.007779576,0.016768187,0.079536154,10,10,279.4176254,0.62527771x^3 + 11.03577015x^2 - 9.19822332x + 27.37853341
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,GDC-0941,2,0.007973281,0.28874866,7.989154906,10,10,583.0912524,-4.04087012x^3 - 9.5832141x^2 - 11.35840965x + 71.02699579
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,GW-2580,1,0.011425311,0.053939412,10,10,10,579.904935,2.86082925x^3 + 12.15483978x^2 - 5.67090415x + 54.09675383
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Velcade,1,0.007171353,0.013212707,0.046460671,0.483254333,10,294.0252028,0.17827509x^3 + 14.19082507x^2 - 1.59252334x + 23.08719535
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,KI20227,1,0.990437848,10,10,10,10,854.6906927,14.69768122x^3 + 20.69942947x^2 - 35.11547094x + 89.85311179
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,TG100-115,1,0.008004905,7.590133302,10,10,10,846.0236171,-11.58056599x^3 - 24.98587556x^2 + 3.07603317x + 99.55089808
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,CYT387,1,1.151614494,10,10,10,10,853.3643914,3.94804708x^3 + 3.51455922x^2 - 15.33854761x + 90.92624278
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Sorafenib,1,0.116042069,1.254754508,10,10,10,656.2026402,-0.4278921x^3 - 2.88462329x^2 - 16.58240179x + 76.66277143
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Sorafenib,2,0.012676935,0.650093573,10,10,10,639.0513886,-1.95738913x^3 - 4.72216247x^2 - 10.80647533x + 73.13129557
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Sorafenib,3,0.008712104,0.032575682,3.308603445,10,10,451.5221744,-5.86106803x^3 - 12.42053156x^2 - 14.45924042x + 61.69001692
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Selumetinib (AZD6244),1,0.569214664,5.969224873,10,10,10,779.8597583,-0.42808215x^3 - 3.84977006x^2 - 12.44958194x + 87.17757728
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,JAK Inhibitor I,1,0.171076877,10,10,10,10,841.4934495,1.80910948x^3 + 4.94918261x^2 - 5.13325615x + 83.96936865
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Canertinib (CI-1033),1,0.485385284,10,10,10,10,846.4066875,6.47982612x^3 + 12.18767179x^2 - 14.45064157x + 84.46320106
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Lestaurtinib (CEP-701),1,0.000954,0.003700139,1,1,1,68.92291102,0.14387438x^3 + 9.20520237x^2 + 21.49800477x + 74.9118973
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Vatalanib (PTK787),1,0.039769527,0.135547345,0.80542037,10,10,359.7922879,4.43567492x^3 + 7.31298416x^2 - 29.01054515x + 47.21275976
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,PP2,1,10,10,10,10,10,1090.29591,-4.16231903x^3 - 18.25847593x^2 - 11.63500127x + 126.35307991
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,LY-333531,1,0.300259392,0.523177006,1.514058083,10,10,449.2400167,15.77499186x^3 + 21.26660651x^2 - 52.98064644x + 58.76171979
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Tozasertib (VX-680),1,10,10,10,10,10,1058.460502,5.4900659x^3 + 14.02111051x^2 - 0.12814964x + 96.97218946
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,GS-1101 (CAL-101),1,0.007423573,0.02514128,6.624465602,10,10,552.8437942,-6.27456168x^3 - 12.14942914x^2 - 7.74100235x + 68.02293298
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,JNK Inhibitor II,1,4.718715557,50,50,50,50,4412.459964,1.05155587x^3 + 0.61020042x^2 - 8.29762915x + 94.99237044
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,MGCD-265,1,0.010075445,0.043751245,10,10,10,783.9299881,0.98922456x^3 + 12.14211935x^2 + 8.76945299x + 66.97532319
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,NVP-TAE684,1,0.008001061,0.014732734,10,10,10,922.0864275,-6.20279577x^3 + 3.15568118x^2 + 27.73039039x + 77.08548894
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Gefitinib,1,0.260719073,1.87961436,10,10,10,794.7657575,7.23692836x^3 + 14.99591101x^2 - 14.69188535x + 77.75120695
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,VX-745,1,0.009702526,0.111987729,10,10,10,648.3060754,-4.47418983x^3 - 7.30816524x^2 - 5.0400554x + 72.96879289
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Tofacitinib (CP-690550),1,10,10,10,10,10,971.6538316,4.04871911x^3 + 7.12191663x^2 - 6.46290213x + 95.86834388
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Midostaurin (PKC412),1,0.005465903,0.011475883,10,10,10,766.6044117,-4.29599843x^3 + 1.149018x^2 + 15.27950961x + 68.94300953
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,AMPK Inhibitor,1,0.015033949,0.286562746,10,10,10,768.532799,-0.13377901x^3 + 5.03371453x^2 + 0.80722361x + 73.93376786
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,RAF265 (CHIR-265),1,0.006556484,0.015281444,0.087178839,10,10,294.1675677,0.44010066x^3 + 9.13103631x^2 - 9.59440103x + 30.10575993
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,AKT Inhibitor IV,1,0.185626445,0.904468869,6.977795357,25,25,1145.800944,0.88220024x^3 - 4.101373x^2 - 25.49024853x + 73.8963346
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Neratinib (HKI-272),1,0.049092444,0.17285303,10,10,10,640.5473654,8.54382616x^3 + 20.98849844x^2 - 12.09569801x + 57.36702292
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Pelitinib (EKB-569),1,0.018480602,0.056680944,0.408754314,10,10,490.6556004,5.14243073x^3 + 18.57233558x^2 - 10.0269323x + 43.60207685
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Imatinib,1,0.00745162,0.077930596,5.06458549,10,10,518.2182231,-3.27808314x^3 - 7.97251686x^2 - 13.91540789x + 64.90785167
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Roscovitine (CYC-202),1,0.008730837,2.730444753,10,10,10,670.6671703,-5.60619181x^3 - 15.58734464x^2 - 11.50780866x + 83.45175364
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,BMS-345541,1,0.308550894,1.437793174,10,10,10,627.7908759,0.54212969x^3 - 5.02776205x^2 - 24.32855916x + 78.95943179
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Axitinib (AG-013736),1,0.036842115,0.408041873,10,10,10,617.6827627,1.22585698x^3 + 1.56301704x^2 - 14.90309422x + 69.03374259
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Crenolanib,1,0.005500304,0.00726976,0.01833314,9.763499168,10,755.9412804,-31.03746572x^3 - 72.59940242x^2 + 7.25800447x + 118.99504932
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Crenolanib,2,0.006106696,0.009435369,8.216180774,10,10,855.2947573,-28.24943194x^3 - 71.26869844x^2 - 0.48064723x + 131.68191381
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,PHA-665752,1,0.016344123,7.480352885,10,10,10,769.1323413,-0.83465857x^3 - 1.05060677x^2 - 4.59828104x + 80.37802169
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,MEK1/2 Inhibitor,1,2.660611738,7.68815884,10,10,10,830.5175187,-4.89313572x^3 - 13.65304925x^2 - 8.08737059x + 96.27842585
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,NF-kB Activation Inhibitor,1,0.005984332,0.011636498,0.082496493,7.531799213,10,302.1844218,-4.47420687x^3 - 3.65967907x^2 - 9.06603625x + 38.78103515
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,SGX-523,1,10,10,10,10,10,1020.133059,1.35519094x^3 + 6.33300703x^2 + 6.21341196x + 94.86407392
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,BI-2536,1,0.013282109,0.053978027,0.389632184,2.399395993,7.103838247,189.9578602,0.67150962x^3 - 0.67347742x^2 - 31.79248383x + 37.14481002
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,SNS-032 (BMS-387032),1,0.00764449,0.019458642,0.157165987,10,10,376.7193899,0.1877595x^3 + 8.03733756x^2 - 8.27482131x + 38.25663179
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,PLX-4720,1,2.954638869,5.312913762,10,10,10,782.6091812,-8.74411485x^3 - 28.52332987x^2 - 15.23369948x + 104.39262395
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,Bosutinib (SKI-606),1,0.118042966,0.919128761,8.149888627,10,10,591.2562907,0.32949534x^3 - 5.17451753x^2 - 22.115292x + 74.19701414
718,12-00145,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,MarcTest 384 123v3,Standard,PD153035,1,0.000651,0.001125616,1,1,1,65.47829472,-10.21256358x^3 - 44.88011876x^2 - 50.08303219x + 55.71560975
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Vandetanib (ZD6474),1,0.072273661,0.21327516,1.061730784,10,10,352.5349362,4.61930255x^3 + 4.86864459x^2 - 34.72635045x + 50.90000932
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,LY294002,1,0.086576087,1.669985508,15.35763208,47.87375909,50,2179.229061,-3.86186999x^3 - 5.00904032x^2 - 12.23918447x + 78.01693615
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,AKT Inhibitor IV,1,0.16568358,0.331690919,0.893386189,2.468961729,5.329156651,194.4113206,11.15078173x^3 + 3.19939911x^2 - 59.25790728x + 47.09232676
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,SB-202190,1,0.043313313,10,10,10,10,845.0989184,4.25517402x^3 + 14.41879355x^2 + 0.93255886x + 75.25343385
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,GS-1101 (CAL-101),1,1.16825039,4.43488811,10,10,10,742.2523201,-5.03131682x^3 - 15.49651022x^2 - 12.47208937x + 90.91454522
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Imatinib,1,1.334490983,7.572832863,10,10,10,809.3307259,-1.62762156x^3 - 7.04025944x^2 - 11.35974277x + 91.53731688
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Midostaurin (PKC412),1,0.007345421,0.01297188,0.041387664,10,10,462.0043911,1.37793884x^3 + 22.25095382x^2 + 12.00832246x + 27.68797213
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Pazopanib (GW786034),1,0.29578874,0.984353827,5.991676345,10,10,564.9822815,2.49209526x^3 - 3.00960363x^2 - 31.04563163x + 74.78751771
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,A-674563,1,0.007538187,0.024548396,0.346655552,10,10,326.3321982,-0.85609411x^3 + 0.92880453x^2 - 16.78439213x + 41.9974641
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,MEK1/2 Inhibitor,1,0.008598769,5.467017737,10,10,10,769.6564945,-8.33707959x^3 - 20.02431223x^2 - 4.53572056x + 92.59264666
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,GDC-0879,1,10,10,10,10,10,1449.397059,4.0588253x^3 + 5.57475177x^2 + 7.10625565x + 136.74584934
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,BMS-345541,1,0.606801269,1.575721928,3.851256746,7.156443234,9.721136533,445.1910347,-7.64316883x^3 - 30.83385493x^2 - 36.4641154x + 83.46224518
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,KW-2449,1,0.007438642,0.01403045,0.053786859,0.898121273,10,268.5198214,-0.52755729x^3 + 10.72396086x^2 - 5.45224002x + 24.72216476
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Lestaurtinib (CEP-701),1,0.000585,0.000885,0.002389512,0.713356872,1,28.31597513,-8.07285525x^3 - 30.52624387x^2 - 35.84411921x + 20.37332046
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Trametinib (GSK1120212),1,0.006814476,0.012852578,0.056579796,10,10,463.68213,-0.89432072x^3 + 12.22136608x^2 + 6.21410322x + 37.00084691
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,PD98059,1,0.24748514,10,10,10,10,896.5815359,1.88721439x^3 + 5.99389082x^2 - 1.87662827x + 87.07839632
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,TG100-115,1,10,10,10,10,10,967.7538912,1.27841083x^3 - 2.59875309x^2 - 11.33989715x + 104.12016108
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,AZD1480,1,1.02639111,3.00034443,8.617026129,10,10,669.2234561,-4.43024788x^3 - 17.89467491x^2 - 22.42415906x + 90.25597846
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Go6976,1,0.007443946,0.01304698,0.042863612,0.339785136,10,184.3608035,-1.66156645x^3 + 8.36124483x^2 - 7.90817753x + 19.2839497
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Canertinib (CI-1033),1,0.157716857,0.560636492,4.070943921,10,10,516.1521918,2.98898747x^3 + 0.04956508x^2 - 29.89518621x + 67.53109779
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,PHA-665752,1,0.169599838,0.468935115,2.405464624,10,10,457.8037226,5.24650589x^3 + 2.68628581x^2 - 36.01963582x + 63.04967701
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,BI-2536,1,0.007912414,0.142413062,1.606973116,4.886237812,7.991714694,282.9922004,-4.70396182x^3 - 18.01393778x^2 - 32.54111323x + 57.50937925
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Dasatinib,1,0.000739,0.002033801,0.317387492,1,1,43.66810907,-7.16944802x^3 - 36.69625645x^2 - 65.11985464x + 25.77175797
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Dasatinib,2,0.001660973,0.007648398,1,1,1,55.19202757,0.64340985x^3 + 7.76151073x^2 + 3.74517034x + 54.26002528
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Dasatinib,3,0.001857189,0.008465817,1,1,1,57.92254084,0.37940407x^3 + 7.06290109x^2 + 4.55146962x + 57.47672466
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,CHIR-99021,1,10,10,10,10,10,1230.022577,5.55778727x^3 + 17.59030618x^2 + 12.67054965x + 105.04945379
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Motesanib (AMG-706),1,0.308052127,1.039158689,6.075894599,10,10,567.8616871,2.05219821x^3 - 3.82968993x^2 - 30.82023794x + 75.51519552
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Sunitinib,1,0.001036245,0.002502082,0.00996707,0.057568554,1,25.57430387,5.15176769x^3 + 36.58027616x^2 + 44.40163968x + 33.63886347
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Sunitinib,2,0.001658715,0.004567506,0.018540869,0.146958114,1,32.02937813,7.94766264x^3 + 47.79328364x^2 + 53.95433823x + 41.37632002
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Sunitinib,3,0.002084135,0.004869058,0.016823065,0.075317948,1,25.34132436,8.38263295x^3 + 50.41893374x^2 + 54.01130505x + 33.93900852
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Linifanib (ABT-869),1,0.00544252,0.008709298,4.149999088,10,10,464.168099,-11.01092631x^3 - 18.5589262x^2 + 0.81723537x + 59.18361369
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,TG101348,1,0.010741762,0.034611089,0.172918251,1.259113804,10,233.1214711,4.61176798x^3 + 14.14027025x^2 - 22.00596318x + 27.05581907
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,KN93,1,0.257211689,1.234963928,7.953066749,10,10,600.6364241,0.66549505x^3 - 6.23481827x^2 - 25.32101263x + 77.37264223
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,BEZ235,1,0.056775696,0.163051408,1.011654876,10,10,478.8643286,7.67678141x^3 + 16.53316063x^2 - 23.33059749x + 50.11698874
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,SGX-523,1,10,10,10,10,10,1165.39995,1.61231052x^3 + 4.35720399x^2 + 5.72653011x + 110.58238606
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,GDC-0941,1,0.01322451,0.059480489,2.459208803,10,10,488.4625193,-0.03861498x^3 + 3.2021557x^2 - 12.74760541x + 54.49497369
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,GDC-0941,2,0.042033648,0.181221986,1.705638077,10,10,452.4543365,3.41850484x^3 + 5.18024478x^2 - 24.51130713x + 55.3626759
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,YM-155,1,0.040473927,0.803820662,1,1,1,79.36452296,-0.52543744x^3 - 4.40465925x^2 - 17.01558134x + 73.42539879
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,PI-103,1,0.021338884,2.266528459,10,10,10,656.1696926,-5.02273534x^3 - 13.28172435x^2 - 13.20088274x + 81.59371626
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,AMPK Inhibitor,1,0.007471153,0.013201884,0.042952332,0.305989184,10,206.9901781,-0.84523693x^3 + 11.08926668x^2 - 6.05833332x + 18.83616701
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Tandutinib (MLN518),1,0.071933804,0.173878865,0.648234334,3.908002919,10,288.0830805,7.77509235x^3 + 11.42677848x^2 - 38.78852573x + 42.34422696
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,LY-333531,1,0.065943658,0.159442332,0.573271127,2.503399742,10,233.1671476,7.09321792x^3 + 9.50309928x^2 - 41.40074146x + 39.54112356
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Masitinib (AB-1010),1,0.122694452,0.77041086,10,10,10,655.2234789,2.46072709x^3 + 3.42151742x^2 - 17.62278065x + 72.96340616
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Selumetinib (AZD6244),1,0.048111328,0.612158401,10,10,10,662.8196928,1.12520517x^3 + 2.00544285x^2 - 12.83029188x + 72.1851936
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,PD153035,1,0.269756044,1,1,1,1,86.37302067,-3.0362462x^3 - 16.23169222x^2 - 27.00831932x + 79.32778696
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Crenolanib,1,0.006243931,0.009961078,0.029802335,6.295449681,10,261.9555543,-5.54019527x^3 - 0.20070136x^2 - 1.21951962x + 28.92880535
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Crenolanib,2,0.00527321,0.007796654,0.019924389,6.697767314,10,285.2854568,-9.39994193x^3 - 10.4994556x^2 + 1.31605292x + 36.3714312
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,PP2,1,1.346638559,3.814872372,9.955888295,10,10,708.8803251,-6.35708007x^3 - 20.02975486x^2 - 16.19984123x + 92.44218666
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,KI20227,1,1.203434875,5.55045436,10,10,10,784.8461671,0.58876883x^3 - 5.21593405x^2 - 18.65695923x + 91.53387037
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Lapatinib,1,0.476489351,10,10,10,10,919.8810735,3.87398773x^3 + 9.16824448x^2 - 3.51940061x + 88.04592787
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,R406,1,0.00820918,0.016928953,0.092658597,10,10,376.0753324,-0.89768612x^3 + 8.77476126x^2 - 3.83730153x + 35.68025539
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,SB-431542,1,10,10,10,10,10,1136.001898,-2.29525643x^3 - 4.98854554x^2 + 6.0637664x + 113.53189545
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Vargetef,1,0.023510064,0.060591786,0.230873214,1.197558256,10,242.8008521,7.51267925x^3 + 19.5642414x^2 - 26.76191559x + 26.97182638
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,JNJ-28312141,1,0.015062422,0.035897451,0.13103854,0.802776577,10,359.1531491,8.33922333x^3 + 29.61550312x^2 - 10.06839122x + 23.77709836
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Crizotinib (PF-2341066),1,0.111316092,0.455853065,1.925012004,5.327365874,8.828698736,318.383222,-1.81398105x^3 - 14.32318644x^2 - 40.59193953x + 62.74622713
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,SYK Inhibitor,1,0.0109421,0.028006914,0.109197063,0.533515912,10,220.7601734,6.07894842x^3 + 21.64572946x^2 - 17.23420566x + 18.80959313
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,JAK Inhibitor I,1,0.014391021,0.26698552,3.896321824,10,10,477.2368135,-4.89805546x^3 - 12.90424657x^2 - 19.59272386x + 67.08379243
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,CI-1040 (PD184352),1,0.047954525,0.412665856,4.353596317,10,10,512.1391299,-0.07894573x^3 - 4.36655813x^2 - 23.29641155x + 66.68556333
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Sorafenib,1,0.005173625,0.007107831,0.013842263,0.041317932,6.326819744,114.0971256,-9.12431427x^3 - 5.06819488x^2 + 3.39624881x + 15.22468714
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Sorafenib,2,0.005444755,0.008004654,0.0187228,0.147015541,10,306.613463,-6.49253282x^3 + 1.26132737x^2 + 8.51501372x + 27.46761671
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Sorafenib,3,0.004572222,0.007642685,0.019800481,10,10,279.8921975,-6.05025731x^3 - 0.57866914x^2 + 3.79675637x + 28.2463764
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Ibrutinib (PCI-32765),1,0.039431789,0.131957311,0.695247584,5.577264069,10,303.0212668,4.25592308x^3 + 5.53981693x^2 - 32.88251493x + 44.68783973
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,MK-2206,1,0.128297037,0.643168378,5.55050147,10,10,545.9039368,1.38346224x^3 - 2.76038463x^2 - 25.80357008x + 70.16524989
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Barasertib (AZD1152-HQPA),1,0.062271826,0.404079706,5.061689374,10,10,530.4124125,0.63416482x^3 - 1.68549528x^2 - 22.48545019x + 66.45091348
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Vatalanib (PTK787),1,2.855594974,6.662102021,10,10,10,824.8174406,-4.02396697x^3 - 16.00659626x^2 - 15.21748127x + 100.6392615
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,INK-128,1,0.006103195,0.020946101,0.323843364,5,5,187.8872764,-0.72217869x^3 + 0.88554343x^2 - 16.29915794x + 41.72175506
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,JNJ-7706621,1,0.540608174,1.353297657,3.560142425,7.141242464,10,434.9957312,-4.79394868x^3 - 24.72767029x^2 - 40.73971667x + 80.79070526
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Staurosporine,1,0.014718358,0.06201974,0.411919031,10,10,384.8592375,5.30682668x^3 + 13.75826121x^2 - 19.48385378x + 40.75702553
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,CYT387,1,0.037010719,0.11086344,0.480347473,2.317323155,10,213.6488408,5.019332x^3 + 6.59143183x^2 - 37.48117138x + 37.55799751
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,RAF265 (CHIR-265),1,0.042527216,0.096153536,0.350541773,10,10,376.9050384,9.78986279x^3 + 25.47577638x^2 - 23.68214563x + 34.86205683
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,GW-2580,1,10,10,10,10,10,945.419879,2.25196114x^3 + 6.91579158x^2 - 0.16706632x + 90.40199414
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Nilotinib,1,10,10,10,10,10,1113.644628,9.75513255x^3 + 17.73737638x^2 - 10.35204407x + 104.9304341
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Nilotinib,2,10,10,10,10,10,1011.0193,2.48691614x^3 - 0.34824958x^2 - 11.1596665x + 106.78877368
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Nilotinib,3,0.936056067,3.036165648,10,10,10,706.8751871,0.78567953x^3 - 8.36577291x^2 - 25.73045926x + 89.26849223
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,GSK690693,1,2.057965466,8.73082955,10,10,10,831.3144735,-2.28472504x^3 - 8.81814857x^2 - 9.91591204x + 94.0447037
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Foretinib (XL880),1,0.004774941,0.006311031,0.011376964,0.031351766,9.980881423,214.657623,-12.96854761x^3 - 14.49536792x^2 + 9.47980605x + 27.93559611
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,AT7519,1,0.138304351,0.330005824,1.332170393,10,10,378.572493,6.80101266x^3 + 6.70921042x^2 - 40.13114793x + 54.88148915
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Quizartinib (AC220),1,0.004742885,0.00658884,0.013215736,0.043763531,10,195.9909938,-8.42966137x^3 - 3.56786792x^2 + 7.2210378x + 20.24846206
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Quizartinib (AC220),2,0.004872265,0.006697617,0.01315929,0.042976897,10,237.8327693,-9.19940949x^3 - 4.54566043x^2 + 9.97350579x + 23.63519132
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,SNS-032 (BMS-387032),1,0.073425389,0.167208666,0.574686682,2.502068916,10,239.1789568,7.56423809x^3 + 11.06092745x^2 - 41.78933345x + 39.41196748
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Cediranib (AZD2171),1,1.183009697,2.306911631,5.114205651,9.390736326,10,554.8919086,-4.87364797x^3 - 26.80656105x^2 - 39.23094856x + 93.00810184
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Neratinib (HKI-272),1,0.054318704,0.109443244,0.3259506,10,10,354.2131233,13.54973048x^3 + 32.33154741x^2 - 27.9999479x + 30.26856233
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Doramapimod (BIRB 796),1,0.006341204,0.012664226,10,10,10,707.8698791,-7.95490631x^3 - 10.15359713x^2 + 8.72489396x + 73.76901012
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Velcade,1,0.007229995,0.01143616,0.03414949,10,10,315.8711157,-5.95735981x^3 + 0.61309145x^2 + 1.7096205x + 32.39532702
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Rapamycin,1,0.0084591,8.298636676,10,10,10,814.2405358,-6.43053429x^3 - 12.43238188x^2 + 1.45088105x + 89.15786888
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Pelitinib (EKB-569),1,0.021423271,0.096188757,0.661756042,7.314343154,10,315.997235,3.05108074x^3 + 4.14407234x^2 - 28.70039079x + 44.73831907
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Roscovitine (CYC-202),1,2.501911975,6.257779081,10,10,10,803.8229882,-6.50177973x^3 - 17.83980775x^2 - 9.14372286x + 96.88219456
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Afatinib (BIBW-2992),1,0.013811894,0.071861078,0.500889363,3.159918505,10,234.9817878,1.95163696x^3 + 0.86556637x^2 - 31.79560386x + 40.42790476
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,GSK-1838705A,1,0.25961495,1.501831807,5.906000495,10,10,568.1677395,-3.54904606x^3 - 15.19415404x^2 - 24.93171269x + 79.89700858
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,GSK-1904529A,1,10,10,10,10,10,954.4182986,-1.92232569x^3 - 5.02227649x^2 - 0.8636195x + 99.18192831
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,NVP-TAE684,1,0.008867759,0.019828904,0.102575134,10,10,318.2900366,0.85170961x^3 + 11.46467695x^2 - 8.90405881x + 30.80517989
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,MLN120B,1,5,5,5,5,5,500.6150607,-4.61102203x^3 - 15.48453437x^2 - 5.78254661x + 105.73297454
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Flavopiridol,1,0.016134658,0.045152279,0.187383325,1.033392481,10,228.9189295,6.32206928x^3 + 17.96720009x^2 - 24.18276591x + 25.34129969
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Bosutinib (SKI-606),1,0.237517922,0.607195186,2.417265704,9.9870731,10,422.2062919,3.52796038x^3 - 3.21760343x^2 - 41.52171634x + 66.19036197
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,PD173955,1,0.291197027,0.737515713,3.769395038,10,10,515.1330955,5.23566618x^3 + 2.17203599x^2 - 37.68156747x + 69.99154222
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Ponatinib (AP24534),1,0.000646,0.001120278,0.003506285,0.021718524,1,16.1462424,-1.2815918x^3 + 5.60879069x^2 + 8.03585203x + 16.9542958
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Ponatinib (AP24534),2,0.000701,0.00144077,0.006413371,1,1,31.12170105,0.45685223x^3 + 13.51013703x^2 + 20.73133288x + 35.31123387
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Ponatinib (AP24534),3,0.000569,0.000828,0.001894615,0.012051534,1,20.8655085,-7.59674189x^3 - 25.64779396x^2 - 26.18737945x + 15.51156065
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Axitinib (AG-013736),1,0.14891085,0.990530395,10,10,10,631.62815,1.41522643x^3 - 1.35738416x^2 - 20.32851221x + 74.91602194
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,R547,1,0.242708156,0.619115414,1.854781994,4.319796103,6.695384915,265.9727074,-0.70302166x^3 - 18.03050212x^2 - 51.33875263x + 65.08525285
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,STO609,1,1.031095356,6.334011506,10,10,10,791.8632166,0.3992452x^3 - 4.33473661x^2 - 15.75456146x + 90.21028294
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,SB-203580,1,0.00819393,0.045267753,10,10,10,689.121478,-2.36804648x^3 - 0.27294118x^2 + 0.08589443x + 69.85698638
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,MGCD-265,1,0.017955746,0.03906849,0.126587261,0.58112991,10,367.931217,9.86536203x^3 + 34.62090446x^2 - 9.11803648x + 21.05607405
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,JNK Inhibitor II,1,0.041593784,0.094415276,19.05508647,50,50,2303.986394,-8.66725064x^3 + 1.99909303x^2 + 0.57887458x + 64.16067167
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,NF-kB Activation Inhibitor,1,0.007698621,0.022968197,9.132560365,10,10,581.9831059,-5.66225616x^3 - 8.65819418x^2 - 3.9710136x + 66.82265529
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Dovitinib (CHIR-258),1,0.005174134,0.006862604,0.012390088,0.032638085,10,203.894376,-11.81644261x^3 - 9.54771709x^2 + 10.73283664x + 23.24720831
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,VX-745,1,0.096832187,1.035962971,10,10,10,632.4619486,-0.52697674x^3 - 3.59182761x^2 - 17.62585326x + 75.27130277
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Gefitinib,1,0.24715672,0.800703739,3.916796241,10,10,502.5558954,1.81407852x^3 - 5.53061374x^2 - 34.06574093x + 71.76486139
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,H-89,1,0.220936517,0.929627107,8.821689085,10,10,593.6870134,2.03772494x^3 - 1.49103356x^2 - 25.98242724x + 74.17814751
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,KN92,1,0.010714589,3.975900983,10,10,10,734.7671071,-4.00071038x^3 - 7.39585717x^2 - 3.73464216x + 80.75789575
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Alisertib (MLN8237),1,0.141706558,0.396461649,10,10,10,722.5153486,10.57731614x^3 + 24.41637458x^2 - 15.97208984x + 65.32671994
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Tofacitinib (CP-690550),1,1.493406281,10,10,10,10,839.2006895,-3.08708826x^3 - 6.91179452x^2 - 4.32743304x + 90.97974612
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,p38 MAP Kinase Inhibitor,1,0.547166596,4.536295103,10,10,10,749.2030658,-3.46812631x^3 - 10.79213348x^2 - 10.93149946x + 87.8151055
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,PLX-4720,1,1.853298776,6.658327776,10,10,10,813.9954483,1.79834751x^3 - 5.14249943x^2 - 23.1395504x + 96.53474654
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Tozasertib (VX-680),1,0.024484454,0.069353249,0.309273676,10,10,360.7907101,7.77518117x^3 + 20.65981354x^2 - 21.08678612x + 34.91588439
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,PP242,1,0.026626192,0.091020071,0.564021219,10,10,363.8230164,4.58439227x^3 + 10.52119046x^2 - 24.42858759x + 43.34424504
724,12-00154,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,,MarcTest 384 123v3,Standard,Erlotinib,1,0.215457515,0.852061939,5.456614415,10,10,549.6771176,1.51392537x^3 - 4.18974708x^2 - 28.9556626x + 73.00750973
